













This thesis has been submitted in fulfilment of the requirements for a postgraduate degree 
(e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following 
terms and conditions of use: 
 
This work is protected by copyright and other intellectual property rights, which are 
retained by the thesis author, unless otherwise stated. 
A copy can be downloaded for personal non-commercial research or study, without 
prior permission or charge. 
This thesis cannot be reproduced or quoted extensively from without first obtaining 
permission in writing from the author. 
The content must not be changed in any way or sold commercially in any format or 
medium without the formal permission of the author. 
When referring to this work, full bibliographic details including the author, title, 




Characterisation of proteins secreted in the outer 
membrane vesicles of Bacteroides fragilis 
 












Thesis presented for the degree of Doctor of Philosophy 






All methods and analyses described in this study were performed by the author unless 




























There are many people without whom I would never have completed this PhD. Most 
importantly, I would like to thank my supervisor Dr Garry Blakely for introducing me to the 
fascinating organism known as Bacteroides fragilis and for having faith in me from day one. I 
would also like to thank my second supervisor, Dr Maurice Gallagher, for his support and 
advice, especially over the last, and most trying, year of my PhD. Many of the techniques I 
have learned and used in the course of my PhD were taught to me by third parties, and I 
would like to thank Dr Sarah Martin, Dr Thierry Le Bihan, John Hopkins, Dr Martin Wear, Dr 
Liz Blackburn and Dr Jo Stevens for their significant contributions to my work. I am 
especially grateful to Prof. Sheila Patrick of Queen's University Belfast for her unending 
support and encouragement and for the opportunity to spend two months conducting 
research in her lab.  
 
I am grateful to my former lab mates Aparna, David, Kelly, Harriet and Eleana for all the help 
and company they provided over the years. I give extra special thanks for and to Adam, 
Alex, Liz, Helen, Matt, Sam, Stephen, Christian, Vic and Rachel for getting me through my 
undergraduate degree with pub quizzes, and to Alex, Claire, Tom and Steven for getting me 
through my postgraduate degree with board games and even more pub quizzes. I'm happy 
to have had the EUBDS and all its members to provide a much-needed distraction, and I 
have been very lucky to have Caroline Fonseca force her way into my life; I’m not sure I can 
imagine it without her. I am especially grateful to Dr Job Thijssen, who put up with me, and 
helped me for much longer than I thought anyone would. 
 
Finally, I would like to thank my wonderful Mum and step father, Tracey and Kevin Cardew 
for their moral (and financial) support, as well as my father and sister, Anthony and Anna 
Kowal, who have always believed in me. 
4 
 
I would like to consider this work a dedication to my grandmothers, Theresa Margaret Ella 
Cave and Adela Mauvina Kowal, both of whom passed away during my PhD. I would have 
liked for both of them to have had the chance to read it, even if they wouldn't have 






















Declaration ............................................................................................................................................ 2 
Acknowledgements .............................................................................................................................. 3 
Lay Summary ...................................................................................................................................... 16 
Abstract ................................................................................................................................................ 17 
1. Introduction ..................................................................................................................................... 19 
1.1 An overview of Bacteroides fragilis ....................................................................................... 21 
1.1.1 Bacteroides fragilis ........................................................................................................... 21 
1.1.2 Key features of B. fragilis ................................................................................................ 21 
1.1.3 B. fragilis as a symbiote of the gastro-intestinal tract ................................................. 25 
1.1.4 B. fragilis as a pathogen .................................................................................................. 27 
1.2 Outer membrane vesicles of Gram-negative bacteria ....................................................... 30 
1.2.1 Discovery of OMV ............................................................................................................ 30 
1.2.2 Structure and contents .................................................................................................... 32 
1.2.3 Biogenesis of OMV .......................................................................................................... 33 
1.2.4 Structural variations in OMV ........................................................................................... 38 
1.2.5 Biological functions of OMV ............................................................................................ 39 
1.2.6 Biotechnological applications of OMV ........................................................................... 42 
1.3 Ubiquitin .................................................................................................................................... 44 
1.3.1 Characteristics of ubiquitin .............................................................................................. 44 
1.3.2 Ubiquitylation ..................................................................................................................... 45 
1.3.3 Roles of ubiquitin in the eukaryotic cell ......................................................................... 49 
1.3.4 Eukaryotic ubiquitin-like proteins ................................................................................... 50 
1.3.5 Bacterial ubiquitin-like proteins ...................................................................................... 51 
1.4 B. fragilis, outer membrane vesicles, and ubiquitin ............................................................ 55 
2. Materials and Methods .................................................................................................................. 57 
2.1 Bacterial culture ....................................................................................................................... 57 
2.1.1 Bacterial strains ................................................................................................................ 57 
2.1.2 Culture conditions ............................................................................................................. 58 
2.2 DNA ........................................................................................................................................... 58 
2.2.1 Primers ............................................................................................................................... 58 
2.2.2 Plasmids ............................................................................................................................ 60 
2.3 Bacterial techniques ................................................................................................................ 60 
2.3.1 Preparation of competent cells ....................................................................................... 60 
6 
 
2.3.2 Transformation of competent cells ................................................................................ 61 
2.4 DNA techniques ....................................................................................................................... 61 
2.4.1 Plasmid purification .......................................................................................................... 61 
2.4.2 Polymerase chain reaction (PCR) ................................................................................. 62 
2.4.3 Agarose gel electrophoresis ........................................................................................... 63 
2.4.4 DNA purification ................................................................................................................ 63 
2.4.5 Gel extraction .................................................................................................................... 64 
2.4.6 DNA quantification ........................................................................................................... 64 
2.4.7 Restriction enzyme digestion .......................................................................................... 65 
2.4.8 Dephosphorylation ........................................................................................................... 65 
2.4.9 Ligation ............................................................................................................................... 65 
2.4.10 Single colony preparations ........................................................................................... 65 
2.4.11 Genomic DNA purification ............................................................................................ 66 
2.4.12 Quantitative PCR (qPCR) ............................................................................................. 66 
2.5 Protein techniques ................................................................................................................... 67 
2.5.1 Proteins .............................................................................................................................. 67 
2.5.2 Expression ......................................................................................................................... 67 
2.5.3 Affinity purification ............................................................................................................ 68 
2.5.4 Gel filtration ....................................................................................................................... 68 
2.5.5 Quantification .................................................................................................................... 68 
2.5.6 Bradford assay .................................................................................................................. 69 
2.5.7 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) ......... 69 
2.5.8 Coomassie staining .......................................................................................................... 69 
2.5.9 Silver staining .................................................................................................................... 70 
2.5.10 Western blotting ............................................................................................................. 70 
2.5.11 Ubiquitin transfer assay ................................................................................................. 71 
2.5.12 Pull down with His-tagged rBfUbb ............................................................................... 71 
2.6 Tissue culture techniques ....................................................................................................... 72 
2.6.1 Culture and passage ........................................................................................................ 72 
2.6.2 Transfection ....................................................................................................................... 72 
2.6.3 Preparation of cell lysate ................................................................................................. 73 
2.7 Preparation of periplasmic extract and concentrated supernatants ................................ 73 
2.7.1 Preparation of periplasmic extract ................................................................................. 73 
2.7.2 Preparation of concentrated supernatant ..................................................................... 74 
7 
 
2.8 Isolation of OMV ...................................................................................................................... 74 
2.8.1 Tangential flow filtration ................................................................................................... 74 
2.8.2 Centrifugal filtration .......................................................................................................... 74 
2.8.3 Density centrifugation ...................................................................................................... 74 
2.8.4 Alkaline phosphatase and β-galactosidase assays .................................................... 75 
2.8.5 Dynamic light scattering (DLS) ....................................................................................... 75 
2.9 Proteomic techniques ............................................................................................................. 75 
2.9.1 Sample preparation .......................................................................................................... 75 
2.9.2 LTQ-Orbitrap mass spectrometry .................................................................................. 76 
2.9.3 Analysis .............................................................................................................................. 76 
2.10 OMV antibacterial assays .................................................................................................... 76 
2.10.1 Bacterial culture and inoculation .................................................................................. 76 
2.10.2 T-test analysis ................................................................................................................. 77 
3. Characterisation of B. fragilis ubiquitin (BfUbb) ........................................................................ 78 
3.1 Background............................................................................................................................... 78 
3.1.1 BfUbb ................................................................................................................................. 78 
3.1.2 Aims .................................................................................................................................... 83 
3.2 Results ...................................................................................................................................... 85 
3.2.1 Purification of rBfUbb ....................................................................................................... 85 
3.2.2 BfUbb forms multimers in vitro ....................................................................................... 87 
3.2.3 BfUbb interacts with E2 conjugating enzymes in vitro ................................................ 90 
3.2.4 No binding partners of BfUbb could be identified in vitro ......................................... 100 
3.2.5 Generation of a recombinant BfUbb protein with a cleavable affinity tag .............. 103 
3.2.6 Generation of BfUbb constructs for expression in mammalian cells ...................... 109 
3.2.7 The presence of the ubb gene does not appear to correlate with any particular 
disease ....................................................................................................................................... 115 
3.3 Discussion............................................................................................................................... 119 
3.3.1 Protein purification ......................................................................................................... 119 
3.3.2 BfUbb multimers ............................................................................................................. 119 
3.3.3 BfUbb and E2 conjugating enzymes ........................................................................... 121 
3.3.4 Binding partners of BfUbb ............................................................................................. 124 
3.3.5 10xH-BfUbb and 10xH-YFP-BfUbb: production and uses ....................................... 124 
3.3.6 Expression of 6xHBfUbb and YFP-BfUbb in mammalian cells ............................... 126 
3.3.7 Characterisation of BfUbb by qPCR ............................................................................ 128 
8 
 
3.3.8 Future work and considerations ................................................................................... 128 
4. The proteome of the outer membrane vesicles of B. fragilis................................................. 130 
4.1 Background............................................................................................................................. 130 
4.1.1 B. fragilis OMV ................................................................................................................ 130 
4.1.2 Proteomic studies of OMV ............................................................................................ 132 
4.1.3 Aims .................................................................................................................................. 140 
4.2 Results .................................................................................................................................... 141 
4.2.1 Dynamic light scattering of B. fragilis OMV ................................................................ 141 
4.2.2 Proteome of the OMV of B. fragilis .............................................................................. 142 
4.2.3 Potential proteases in the OMV of B. fragilis ............................................................. 149 
4.2.4 A B. fragilis α-2 macroglobulin is present in the OMV .............................................. 151 
4.2.5 A known fibrinogen-binding protein was detected in the OMV of B. fragilis .......... 152 
4.2.6 BfUbb in the OMV of B. fragilis .................................................................................... 153 
4.3 Discussion............................................................................................................................... 154 
4.3.1 OMV isolation procedure and LTQ-Oribtrap LC-MS ................................................. 154 
4.3.2 Dynamic light scattering of OMV .................................................................................. 156 
4.3.3 The contents of B. fragilis OMV ................................................................................... 157 
4.3.4 B. fragilis proteases in the OMV .................................................................................. 159 
4.3.5 B. fragilis α-2 macroglobulin in the OMV .................................................................... 160 
4.3.6 B. fragilis fibrinogen-binding protein in the OMV ....................................................... 161 
4.3.7 BfUbb in the OMV .......................................................................................................... 162 
4.3.8 Future work and considerations ................................................................................... 163 
5. Anti-bacterial potential of B. fragilis OMV and BfUbb ............................................................ 166 
5.1 Introduction ............................................................................................................................. 166 
5.1.1 Antibiotic potential of OMV............................................................................................ 166 
5.1.2 Antibiotic potential of ubiquitin ...................................................................................... 167 
5.1.3 Aims .................................................................................................................................. 169 
5.2 Results .................................................................................................................................... 170 
5.2.1 Wild-type B. fragilis concentrated supernatant restricts growth of S. enterica 
Typhimurium ............................................................................................................................. 170 
5.2.2 Antibiotic activity of B. fragilis OMV is partially dependent on BfUbb .................... 173 
5.3 Discussion............................................................................................................................... 178 
5.3.1 OMV-associated BfUbb demonstrates antibacterial activity .................................... 178 
5.3.2 Additional antibacterial activity of B. fragilis concentrated supernatants is due to 
sample-associated gentamicin ............................................................................................... 180 
9 
 
5.3.3 Future work and considerations ................................................................................... 181 
6. General Discussion ..................................................................................................................... 183 
6.1 Biochemical characterisation of ubiquitin and BfUbb ................................................... 183 
6.2 Ubiquitin homologues lacking a C-terminal double glycine motif ............................... 184 
6.3 Potential roles of BfUbb in the host eukaryotic cell ...................................................... 186 
6.4 Characterisation of outer membrane vesicles ............................................................... 190 
6.5 Potential roles of B. fragilis OMV .................................................................................... 193 
6.6 Biotechnological potential of BfUbb and the OMV of B. fragilis.................................. 196 
7. Conclusions .................................................................................................................................. 197 





















List of Figures 
 
Figure 1 Micrographs of B. fragilis cultures enriched for LC, SC and MC via Percoll density 
centrifugation ...................................................................................................................... 23 
Figure 2 Electron micrographs showing the first documented outer membrane vesicles. .... 31 
Figure 3 Examples of potential OMV biogenesis mechanisms ............................................ 37 
Figure 4 The basic ubiquitylation cycle. ............................................................................... 46 
Figure 5 Diagrams from showing the different types of ubiquitin chain conformation ........... 48 
Figure 6 A comparison of pupylation and ubiquitylation, highlighting the similarities and 
differences between the two systems .................................................................................. 53 
Figure 7 Comparisons of human ubiquitin Ubc52 and B. fragilis ubiquitin BfUbb. ................ 79 
Figure 8 Detecting expression of BfUbb .............................................................................. 81 
Figure 9 In vitro activity of BfUbb......................................................................................... 83 
Figure 10 Coomassie stained gels showing the expression and purification of rBfUbb from E. 
coli DH5α pTRC99A-6xHBfUbb .......................................................................................... 87 
Figure 11 Multimerisation of rBfUbb. ................................................................................... 88 
Figure 12 Possible structures of BfUbb dimers (A) and hexamers (B) ................................. 89 
Figure 13 Western blots showing samples of BfUbb (U) incubated with E1 activating enzyme 
(E1AE) and randomly selected E2 enzymes ....................................................................... 92 
Figure 14 Western blots of reactions containing rBfUbb and 22 E2 conjugating enzymes in 4 
different conditions ............................................................................................................ 100 
Figure 15 SDS-PAGE gels imaged with Coomassie (A and B) and Western blotting (C and 
D), showing Ni column fractions of Caco-2 cell extract incubated in 4 conditions .............. 102 
Figure 16 DNA gels showing the construction of plasmid expression a form of BfUbb with a 
cleavable affinity tag (pET19b-10xH-BfUbb) and an N-terminal YFP-fusion of BfUbb 
(pET19b-10xH-YFP-BfUbb). ............................................................................................. 106 
11 
 
Figure 17 Coomassie stained gels showing the expression, purification and attempted 
cleavage of 10xH-BfUbb ................................................................................................... 109 
Figure 18 DNA gels showing the construction of constructs for expression of 6xH-BfUbb 
(pcDNA4/TO-6xHBfUbb) and an N-terminal YFP-fusion of BfUbb (pcDNA4/TO-YFP-BfUbb) 
in mammalian cells ........................................................................................................... 112 
Figure 19 Electron micrographs of thin sections of B. fragilis cells, showing OMV budding 
from the cell surface. ......................................................................................................... 131 
Figure 20 A flow chart showing the different combinations of techniques used to isolate OMV 
in 9 independent proteomics studies ................................................................................. 136 
Figure 21 A flow chart showing the different combinations of proteomic techniques used in 9 
independent OMV proteomics studies ............................................................................... 138 
Figure 22 Dynamic light scattering of WT B. fragilis concentrated supernatant grown in BHI-
S (A) and a BHI-S control (B). ........................................................................................... 142 
Figure 23 Venn diagram showing the proportion of proteins which were significantly enriched 
in the OMV or periplasm by abundance ............................................................................ 144 
Figure 24 Pie charts showing the subcellular origin (A) and predicted function (B) of OMV 
proteins. ............................................................................................................................ 147 
Figure 25 Comparison of WT, pGB920 and Δ1705 concentrated supernatant .................. 152 
Figure 26 Comparison of WT, pGB920 and Δubb concentrated supernatant. ................... 153 
Figure 27 Graph showing the log10 mean cfu/ml against time (with standard deviations) in 
cultures of S. enterica Typhimurium incubated with either PBS, WT concentrated 
supernatant (WT OMV) or Δubb concentrated supernatant (ubb OMV) ............................ 172 
Figure 28 Graphs showing the log10 mean cfu/ml against time (with standard deviations) in 
cultures of S. enterica Typhimurium incubated with either PBS or the concentrated 
supernatants of WT B. fragilis (WT), WT B. fragilis grown in gentamicin (WTg), B. fragilis 
pGB920 grown in tetracycline (pGB), or B. fragilis Δubb grown in erythromycin (ubb), at 




List of Tables 
 
Table 1 Bacterial strains used in this study. ........................................................................ 57 
Table 2 Primers used in this study ...................................................................................... 59 
Table 3 Plasmids used and generated in this study. ........................................................... 60 
Table 4 All E1 activating and E2conjugating enzymes used in this study ............................ 94 
Table 5 A table of the samples in which gyrB was detected by qPCR. .............................. 118 
Table 6 The results of the alkaline phosphatase and β-galactosidase assays. .................. 143 
Table 7 The 20 most abundant proteins in the OMV. ........................................................ 146 
Table 8 The 20 OMV proteins with the largest fold increase in abundance over the 
periplasm. ......................................................................................................................... 148 



















ADP Adenosine diphosphate 
amp Ampicillin 
AMP Adenosine monophosphate 
ANOVA Analysis of variance 
APS Ammonium persulphate 
ATP Adenosine triphosphate 
BHI-S Brain-heart infusion, with supplements 
BLAST Basic local alignment search tool 
Cfu Colony-forming units 
CPS Capsular polysaccharide 
DC Dendritic cell 
DLS Dynamic light scattering 
DM Defined medium 
DNA Deoxyribonucleic acid 
DOMV Detergent-extracted outer membrane vesicles 
DTT Dithiothreitol 
DUB Deubiquitylating enzyme 
EDL Electron dense layer 
EDTA Ethylenediaminetetraacetic acid 
EPEC Enteropathogenic Escherichia coli 
ery Erythromycin 
ETBF Enterotoxigentic Bacteroides Fragilis 
ETEC Enterotoxigenic Escherichia coli 
FITC Fluorescein isothiocyanate 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
gent Gentamicin 
GF Germ free (mice) 
GG Double glycine 
GI Gastro-intestinal 
HGT Horizontal gene transfer 
HPLC High performance liquid chromatography 
IBD Inflammatory bowel disease 
14 
 
IM Inner membrane 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
ITC Isothermal titration calorimetry 
iTRAQ Isobaric tag for relative and absolute quantification 
LB Luria-Bertani Broth 
LC Large capsule 
LC-MS Liquid chromatography-mass spectrometry 
LPS Lipopolysaccharide 
LT Labile toxin 
LTQ Linear ion trap 
MC Microcapsule 
MIC Minimum inhibitory concentration 
MS Mass spectrometry 
NCBI National Centre for Biotechnological Information 
NOMV Native outer membrane vesicles 
OM Outer membrane 
OMV Outer membrane vesicles 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction 
PG Peptidoglycan 
PP Periplasm 
PSA Polysaccharide A 
PTAG Phospho-tag 
PVDF Polyvinylidene fluoride 
qPCR Quantitative polymerase chain reaction 
R/M Restriction/modification 
RNA Ribonucleic acid 
SC Small capsule 
SCF Skp, cullin, F-box complex 
SDS Sodium dodecyl sulphate 
SDS-
PAGE 
Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
SOMV Spontaneous outer membrane vesicles 
SPR Surface plasmon resonance 





TFF Tangential flow filtration 
TMT Tandem mass tag 
TNFα Tumour necrosis factor α 
TRITC Tetramethylrhodamine 
UBD Ubiquitin-binding domain 
UBL Ubiquitin-like protein 
UbVME Ubiquitin vinyl methylester 
UDP Ubiquitin domain protein 
ULD Ubiquitin-like domain 
ULF Ultra-low flow 
WT Wild type 
YFP Yellow fluorescent protein 




















Bacteroides fragilis is a bacterial species, found in the gut of most humans, which is known 
to promote host health and immune development. B. fragilis, like many bacteria, produces 
outer membrane vesicles (OMV), small globules, containing cellular proteins, which protrude 
from the bacterial surface and are released into the surrounding environment. OMV from 
various bacteria are proposed to have a range of functions, and B. fragilis OMV are thought 
to be able to deliver their contents to cells of the human host. One of the proteins believed to 
be packaged into these OMV is BfUbb, which is similar to a human protein named ubiquitin. 
Ubiquitin plays an important role in many cell processes and the similarity of BfUbb to this 
protein suggests that BfUbb may interfere with these processes. 
This study demonstrates that BfUbb is able to interact with several important ubiquitin-
related enzymes and shows particular preference for enzymes which are known targets for 
anti-cancer therapies. This suggests BfUbb may play a role in preventing colon cancer. 
BfUbb was also found to inhibit the growth of a known gut pathogen, Salmonella enterica 
Typhimurium, suggesting that B. fragilis strains which produce BfUbb-containing OMV may 
be able to protect against infection in the gut. In addition, this work describes the creation of 
several DNA constructs which will facilitate the continued study of BfUbb. 
Proteomics is the term given to the large scale identification and characterisation of proteins. 
A proteomic study of the OMV of B. fragilis was performed using highly sensitive techniques, 
and a list of proteins believed to be present in the OMV was produced. From this list, 
potential functions of the OMV could be inferred. For example, a large number of proteins on 
this list are known to be involved in the breakdown of complex nutrients, suggesting that 
OMV may play a role in scavenging for "food" for the bacteria. 
 
Overall, the results of this study provide further evidence that the presence of B. fragilis in 





Bacteroides fragilis is an important, anaerobic commensal of the human gastro-intestinal 
tract. As a Gram-negative bacterium, B. fragilis produces a large number of outer membrane 
vesicles (OMV), spherical globules consisting of outer membrane and periplasmic material, 
which have a range of potential functions and which are known to be able to deliver their 
cargo to host dendritic cells (DCs). One of the proteins believed to be packaged into the 
OMV of B. fragilis is BfUbb (encoded by the ubb gene) which shares 63% homology with 
human ubiquitin. Ubiquitin is a small, common, eukaryotic protein modifier, which is 
conjugated to target proteins via a series of activating, conjugating and ligating enzymes, 
and which has known roles in a wide range of eukaryotic cell processes.  
 
Due to key differences between the two proteins, BfUbb has the potential to act as a suicide 
substrate mimic of ubiquitin. BfUbb was therefore assayed for its ability to interact with 
ubiquitin E2 conjugating enzymes of the ubiquitylation cascade in vitro, and was found to 
covalently bind the majority of available enzymes in a DTT-sensitive manner. BfUbb showed 
a preference for three specific E2 enzymes, all of which are involved in the degradation of 
mitotic check point proteins, suggesting a role for BfUbb in the inhibition of cell cycle 
progression and, consequently, tumorigenesis. No binding partners of BfUbb were identified 
outside of the ubiquitylation cascade, however BfUbb was found to form spontaneous 
multimers in vitro, the biological function of which is unknown. This study also describes the 
construction of two sets of plasmids. The first set will allow the expression of untagged and 
fluorescently tagged forms of BfUbb for purification and use in biochemical assays. The 
second set will allow the expression of his-tagged and fluorescently tagged forms of BfUbb 





The proteome of the OMV of B. fragilis was solved using LTQ-Orbitrap mass spectrometry. 
The identified proteins indicated several putative roles for B. fragilis OMV, including nutrient 
acquisition and protease inhibition. The suitability of techniques used during the isolation and 
proteomic analysis of OMV in different studies is discussed.  
 
BfUbb-carrying B. fragilis OMV were able to inhibit growth of Salmonella enterica 
Typhimurium, thus indicating a role for BfUbb in the inhibition of competing, pathogenic 
bacteria in the gastro-intestinal tract. 
 
The conclusions of this study are that the putative roles of both BfUbb and the OMV of B. 



















The human gastro-intestinal (GI) tract is host to ~1014 residential bacteria, made up of up to 
1,000 distinct species (Backhed et al., 2005). The stable colonisation of the gut by 
microbiota is very important for the general health of an animal. GI bacteria contribute 
significantly to the digestion of complex carbohydrates and plant polysaccharides, providing 
energy from otherwise inaccessible sources. They are also essential to proper 
immunological development, impacting IgA production, T-cell-dependent immune responses 
and allergy formation. Various studies have also indicated that the indigenous gut 
microbiome can protect the host against pathogenic bacteria, such as Clostridium difficile, 
and parasitic infections, such as Plasmodium sp. and Toxoplama gondii (Backhed et al., 
2005; Berg., 1996; Denny et al., 2016; Wexler., 2007). Changes to the composition and 
structure of the bacterial communities in the gut can therefore drastically impact the health of 
the host and leave the GI tract vulnerable to infection and disease (Fujimura et al., 2010).  
 
Many residential bacteria interact with the cells of their host, via a myriad of mechanisms, to 
mediate host cell processes and to promote both bacterial growth and host health (Backhed 
et al., 2005). One of these mechanisms is the production of outer membrane vesicles 
(OMV), which are formed from the surface of most Gram-negative bacteria and are capable 
of delivering their contents to other cells, either of the host or of other bacteria (Kulkarni & 
Jagannadham, 2014). One bacterial resident of the GI tract, Bacteroides fragilis, is an 
important and ubiquitous commensal, believed to promote host immune development and 
quell inflammatory responses in the gut. As it is Gram-negative, B. fragilis produces a large 
number of OMV, which have already been shown to interact with host dendritic cells (DCs) 





Recently, B. fragilis was also found to encode and express a unique bacterial homologue of 
eukaryotic ubiquitin, an essential protein modifier with a large number of roles in eukaryotic 
cells (Patrick et al., 2011). The key differences between native ubiquitin and this homologue 
suggest that this protein may provide B. fragilis with a mechanism for interfering with host 























1.1 An overview of Bacteroides fragilis 
 
1.1.1 Bacteroides fragilis  
 
The human body is host to vast numbers of bacterial cells which outnumber eukaryotic cells 
10 to 1 (Fujimura et al., 2010; Karlsson et al., 2011). The gut is the largest reservoir for 
bacteria, containing ~1012 microorganisms per gram of intestinal material. The intestinal 
microbiome is mostly made up of species from the phyla Firmicutes and Bacteroidetes, the 
latter of which contains Bacteroides fragilis (Karlsson et al., 2011; Troy & Kasper, 2010; 
Wexler, 2007; Wick & Sears, 2010). B. fragilis was originally identified in the late 19th 
century as Bacillus fragilis and later reclassified (Patrick et al., 2010). It makes up 4-13% of 
total Bacteroidetes species (<1% of total microbiota) and colonises the mucus layer of the 
lower GI tract of most known mammalian species (Gibson et al., 1998; Huang et al., 2011b; 
Patrick et al., 2010; Troy & Kasper, 2010; Wexler, 2007). B. fragilis is Gram-negative, non-
sporulating and a strict anaerobe, however it is aerotolerant owing to an oxidative stress 
response system (Patrick et al., 2010; Sherwood et al., 2011; Troy & Kasper, 2010; Wexler, 
2007). The complete genome sequence of B. fragilis NCTC9343 identified a singular 
~5.2Mbp, circular chromosome, encoding >4,000 putative proteins, as well as a single 
plasmid, pBF9343 (Cerdeno-Tarraga et al., 2005).  
 
1.1.2 Key features of B. fragilis 
 
A large part of the B. fragilis genome is devoted to carbohydrate metabolism, i.e. the 
degradation of dietary polysaccharides and the production of capsular polysaccharides 
(CPS) (Cerdeno-Tarraga et al., 2005; Troy & Kasper, 2010), which reflects the fact that this 
organism has the most complex bacterial CPS system yet discovered (Wexler, 2007; Wick & 
Sears, 2010). Patrick et al (1986) described 3 distinct surface capsules produced by B. 
fragilis: a thin electron dense layer (EDL), also known as the microcapsule (MC), a small 
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fibrous capsule (SC) and a large fibrous capsule (LC). The three types can be separated 
from a mixed population by discontinuous Percoll density centrifugation, and the LC and SC 
can be distinguished by light microscopy, while the MC can only be seen by electron 
microscopy (Figure 1). There are 8 polysaccharide types (A-H) that can be differentially 
expressed within the MC, as distinuished by immunofluorescence microscopy (Figure 1 c 
and d), and epitopes of the MC and the LC can be detected simultaneously, suggesting the 
two are co-expressed. The SC, meanwhile, is antigenically distinct from both the MC and the 
LC. There is wide, within-strain and within-population variation of CPS, and cultures enriched 
for one capsular type will revert to a mixed population over time (Lutton et al., 1991; Patrick 
et al., 1986; Patrick et al., 2009; Patrick et al., 2010). 
 
Variable expression occurs via the inversion of certain DNA segments in the promoter 
regions of 7 of the polysaccharide biosynthesis loci of the B. fragilis NCTC 3943 genome. 
Invertible regions, designated fin (fragilis invertible) regions, are flanked by inverted repeats, 
referred to as fix (fragilis inversion crossover) regions. Two recombinases, the 
chromosomally encoded FinA and the plasmid encoded FinB, are responsible for the 
inversion of the fin regions, switching the promoter of the biosynthesis loci between an "ON" 
position, in which the promoter is active, and an "OFF" position, in which it is inactivate 
(Cerdeno-Tarraga et al., 2005; Patrick et al., 2003). Between 3 of the sequenced strains of 
B. fragilis (NCTC 9343, YCH46 and 638R) there are a total of 30 biosynthesis loci, only 2 of 
which are shared between strains, allowing for the expression of 28 different known CPS 
types (Patrick et al., 2003). This level of variable polysaccharide expression has not been 
documented before in other bacterial strains; although there are a large number of 
Escherichia coli O-antigen serotypes available, usually no more than one serotype will be 
expressed by a single strain (Patrick et al., 2009). The ability to express so many CPS 
variations is believed to confer multiple advantages to B. fragilis, including improved 
colonisation of the gastro-intestinal tract (Mazmanian et al., 2005) and evasion of the host 






Figure 1 Micrographs of B. fragilis cultures enriched for large capsule (LC), small capsule (SC) and 
microcapsule (MC) via Percoll density centrifugation. a) Light micrographs of negative capsule stain: 
the LC and SC are clearly visible whilst the MC is not. b) Transmission electron micrographs: here the 
MC can be seen. c and d) Immunofluorescence micrographs. Green: primary labelling with rabbit 
anti-B. fragilis polyclonal antibody and secondary labelling with anti-rabbit FITC-conjugated antibody. 
Orange/red: primary labelling with mouse monoclonal anti-QUBf4 (c) or anti-QUBf5 (d) and 











Inverted repeat elements have also been found to be associated with several other genes, 
including outer membrane proteins and signal transduction proteins, but most notably a type 
I restriction modification (R/M) system. The presence of 4 invertible regions in the R/M locus 
allows for the production of 8 different DNA-binding proteins from a single locus, each 
specific for a different DNA sequence (Cerdeno-Tarraga et al., 2005). This broad range R/M 
system provides defence against invading bacteriophage and also makes genetic 
manipulation of B. fragilis very difficult (Patrick et al., 2009), however it does not seem to 
prevent a large amount of horizontal gene transfer (HGT) from foreign species into B. fragilis 
(Patrick et al., 2010). 
 
B. fragilis has a rare bacterial O-glycosylation system which is essential to its growth and 
survival in vivo. This glycosylation occurs in extra-cytoplasmic proteins such as proteases, 
surface lipoproteins and proteins involved in protein-protein interactions and protein folding 
(Fletcher et al., 2009). Computational analysis of the predicted proteome of B. fragilis 
suggests that more than half of the proteins exported from the cytoplasm are glycosylated. 
So far, 20 of these have been confirmed experimentally as glycoproteins (Fletcher et al., 
2011).  
 
B. fragilis, and many other anaerobic gut bacteria, have exhibited increasing resistance to 
antibacterials commonly used in treating anaerobic infections, including some which were 
presumed to be universally effective, such as metronidazole and the carbapenems (Liu et 
al., 2008; Seifert et al., 2010; Sherwood et al., 2011). In studies over the last decade 100% 
of clinically isolated strains were resistant to penicillins, while up to 40% were resistant to 
ampicillin, cefmetazole and clindamycin. There is also emerging resistance to 
chloramphenicol and metronidazole (Liu et al., 2008; Seifert et al., 2010). The mechanisms 
of antibiotic resistance in B. fragilis are varied, for example, CepA, a β-lactamase, confers 
resistance to penicillins and most cephalosporins, the ribosomal tetQ mutation prevents the 
action of tetracycline, and efflux pumps MsrSA and BexA remove erythromycin and 
25 
 
fluoroquinolones respectively (the latter also confers some resistance to moxifloxacin) (Eitel 
et al., 2013; Meggersee & Abratt, 2015; Seifert et al., 2010; Sherwood et al., 2011; Wexler, 
2007). Antibiotics that still remain largely active against B. fragilis include metronidazole, 
ertapenem, moxifloxacin and linezolid. This increasing level of antibiotic resistance is a 
serious concern for the treatment of B. fragilis-related infections which have the potential to 
be fatal (Seifert et al., 2010; Sherwood et al., 2011). Interestingly, clinical isolates of B. 
fragilis were found to produce a form of bacteriocin, a broad range antibiotic of bacterial 
origin, and were resistant to bacteriocin produced by other B. fragilis strains (Avelar et al., 
1999). 
The rapid spread of antibiotic genes amongst B. fragilis is due to the presence of these 
genes on mobile genetic elements, such as conjugative plasmids and transposons (Eitel et 
al., 2013). These antibiotic genetic elements are surprisingly stable, even in the absence of 
antibiotic selective pressure. Due to increasing rates of resistance amongst both 
commensals and pathogens, it has been hypothesised that B. fragilis and other residential 
gut bacteria may act as resevoirs for antibiotic resistance genes which can then be conferred 
to other pathogens and commensals in the gut (Salyers et al., 2004; Wexler, 2007).  
 
1.1.3 B. fragilis as a symbiote of the gastro-intestinal tract 
 
The majority of host-bacterial interactions are not pathogenic; in fact, many gut bacteria have 
a symbiotic relationship with the host (Mazmanian et al., 2005; Mazmanian et al., 2008; Troy 
& Kasper, 2010; Wexler, 2007). This relationship is usually described as a commensalism, in 
which one organism benefits from the other without affecting it, since most residential gastro-
intestinal bacteria are provided with a stable, protected and nutrient-rich environment in 
which to flourish, and do not cause disease in the host (Huang et al., 2011b; Karlsson et al., 
2011; Wexler, 2007). However, some have argued that many gut bacteria have a mutualistic 
relationship with their host. Mutualism is a coevolutionary process in which the fitness of the 
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two participants becomes inter-dependent (Backhed et al., 2005). For example, some 
bacteria, such as B. thetaiotaomicron, metabolise complex carbohydrates in the host diet 
and secrete molecules (e.g. simple carbohydrates, amino acids, vitamins) that can be 
utilised by the host (Huang et al., 2011b; Karlsson et al., 2011; Wexler, 2007). Other species 
are known to promote development of the host immune system, aid host health and 
homeostasis, and protect against colonisation by pathogenic bacteria (Huang et al., 2011b; 
Mazmanian et al., 2005; Mazmanian et al., 2008; Wexler, 2007).  
 
B. fragilis contributes significantly to host immune development. B. fragilis polysaccharide A 
(PSA), one of the many possible CPS, is able to correct immune deficiencies in germ free 
(GF) mice. GF mice are born sterile and remain uncolonised by the normal gut microbiota, 
and consequently they develop several immune deficiencies, including a lack of helper T cell 
differentiation. Helper T cells 1 (TH1) and TH2 (also known as CD4+T cells) are important 
players in the adaptive immune system. They have different functions and cytokine profiles 
and both are necessary for a proper immune response. GF mice are biased towards 
producing TH2 cells, creating a cytokine imbalance. However, when colonised with B. fragilis, 
or treated with purified PSA, the proper levels of TH1 and TH2 cells are produced and 
cytokine balance in the GF mice is restored (Mazmanian et al., 2005). PSA has a zwitterionic 
structure, meaning it contains both positive and negative charges in each repeating unit. 
Such structures are already known to mediate CD4+T cell proliferation (Tzianabos & Kasper, 
2002). PSA is taken up by DCs in vitro and, in addition to promoting TH1 differentiation, it 
has been shown to stimulate production of the anti-inflammatory cytokine IL-10. IL-10 
suppresses T-cell response to antigen-sensing and thus inhibits inflammation in the gut by 
this pathway. Furthermore, either colonisation with B. fragilis or treatment with purified PSA 
is able to protect against experimentally-induced colitis in immunocompromised mice. This 
suggests that B. fragilis PSA may be sufficient to alleviate or even prevent inflammatory 




1.1.4 B. fragilis as a pathogen 
 
As well as benefiting the host, B. fragilis can cause serious, sometimes fatal, disease. 
Enterotoxigenic B. fragilis (ETBF) strains are able to cause disease in the gastro-intestinal 
tract. These strains have a single, enterotoxigenic virulence factor: B. fragilis enterotoxin 
(Bft), a 20kDa, chromosomally encoded metalloprotease, specifially a matrixin (Moncrief et 
al., 1995; Sears et al., 2008; Sears, 2009; Wick & Sears, 2010). Bft has multiple 
mechanisms of action, including cleaving E-cadherin, a structurally important linkage in the 
zonula adherens tight junctions between epithelial cells. As a result, the junctions become 
leaky, allowing immune response cells into the gut lumen and exposing the sub-mucosa to 
antigens of other bacterial species (Moncrief et al., 1995; Sears, 2009; Wexler, 2007; Wick & 
Sears, 2010; Wu et al., 2007). Additionally, the cleavage of E-cadherin promotes T-cell 
proliferation (Wu et al., 2007), and Bft uptake by the cell stimulates the production of the pro-
inflammatory cytokine IL-8 (Sears et al., 2008; Sears, 2009). All of these factors contribute to 
an inflammatory response in the gut stronger than that caused by enterotoxigenic E. coli 
(ETEC) or Vibrio cholerae, resulting in intestinal colitis (Sears et al., 2008). Colonisation with 
ETBF can be asymptomatic (~4-20% of cases) (Sears, 2009) but when colitis does occur it 
is usually associated with self-limiting watery diarrhoea, abdominal pain and tenesmus. 
Other, rarely seen, symptoms can include recurring diarrhoea (for up to several years), a 
high fever, and faecal blood. ETBF has been implicated in the development of IBD and 
colorectal carcinomas, however direct causality has yet to be established (Sears et al., 2008; 
Sears, 2009; Wick & Sears, 2010). B. fragilis may also contribute to disease in the gut by 
secreting enzymes that digest molecules associated with the mucosal layer, such as 
neuramidase and hylauronidase (Huang et al., 2011b; Vieira et al., 2005). The destruction of 
such an important barrier between the lumen and the epithelial layer exposes host cells to 




Upon perforation of the gut, gastro-intestinal bacterial species are able to escape into the 
peritoneal cavity and eventually the bloodstream. Despite making up only 4-13% of the 
Bacteroides species in the gut, B. fragilis has been isolated from 63-80% of extra-intestinal 
Bacteroides infections (Patrick et al., 2010; Wexler, 2007). Meanwhile, B. thetaiotaomicron 
makes up 15-29% of Bacteroides species in the gut and is only isolated from 13-17% of 
extra-intestinal infections (Cerdeno-Tarraga et al., 2005). The transmission of B. fragilis 
outside the gastro-intestinal tract is associated with intra-abdominal and gynaecological 
sepsis, soft tissue infections, bacteraemia and abscesses in the abdomen, brain, liver and 
lungs (Gibson et al., 1998; Meggersee & Abratt, 2015; Patrick et al., 2010; Sherwood et al., 
2011; Wexler, 2007). B. fragilis that escape the gut usually end up in the peritoneal cavity 
where they adhere to the peritoneal wall, stimulating the formation of abscesses. When 
pathogens invade an epithelial layer, the immune response recruits polymorphonuclear 
leukocytes, neutrophils and fibroblasts, and a fibrous network is formed over the infection 
site, trapping the dead epithelial cells and invading bacteria (Gibson et al., 1998; Wexler, 
2007). Untreated abscesses can expand, causing obstructions, or rupture, allowing 
dissemination of the bacteria into the bloodstream, i.e. bacteraemia (Wexler, 2007). B. 
fragilis-associated bacteraemia is fatal in 19.3% of treated cases and up to 45% of untreated 
cases (Redondo et al., 1995; Vieira et al., 2005). The major virulence determinant of extra-
intestinal B. fragilis infections appears to be the CPS. Firstly, the ability to express a variety 
of surface antigens provides a means for escaping detection and clearance by the immune 
system (Liu et al., 2008; Wexler, 2007). Encapsulated B. fragilis are able to resist both 
phagocytosis and complement-mediated killing (Patrick et al., 2009; Reid & Patrick, 1984). 
Secondly, the CPS is directly responsible for the induction of peritoneal abscess formation 
by stimulating the TNFα (tumour necrosis factor α) pathway, which recruits the appropriate 
immune response cells (Gibson et al., 1998; Wexler, 2007). In addition to the CPS, B. fragilis 
expresses 2 hemolysins, HlyA and HlyB, which lyse erythocytes (potentially causing 
hemolytic anaemia) (Vieira et al., 2005; Wexler, 2007), and is also capable of evading killing 
by macrophages via an unknown mechanism (Vieira et al., 2005). 
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Due to the severity of disease caused by B. fragilis, the increase in antibiotic resistance 
amongst clinically isolated strains is a major concern. In 2009 7% of tested ETBF strains 
were found to be metronidazole resistant (Sears, 2009) and in a particularly serious case of 
extra-intestinal B. fragilis infection the responsible strain was resistant to all antibiotics tested 
except moxifloxacin and linezolid (Sherwood et al., 2011). It has therefore been stated that 
periodic monitoring of antibiotic susceptibility in clinical isolates and species identification 
and susceptibility testing prior to prescription of antibiotics for treatment of infection are 




















1.2 Outer membrane vesicles of Gram-negative bacteria 
1.2.1 Discovery of OMV 
 
In 1959, De noted that the cell-free supernatant of a V. cholerae culture was capable of  
enterotoxicity and supposed that the enterotoxigenic OM components of the bacteria were 
being released into the medium (De, 1959). Later, a lipid-dense material, designated 
'extracellular lipoglycopeptide', was identified in the cell-free filtrate of a lysine-requiring 
strain of E. coli. This material could not 'be said to originate from any one cellular fraction' 
(Bishop & Work, 1965) and was later visualised in E. coli and V. cholerae by electron 
microscopy as globules of roughly 40-100nm in diameter which appeared to bud from the 
cell surface (Figure 2) (Chatterj.Sn & Das, 1967; Work et al., 1966). These globules are 
complex proteoliposomes, now known as outer membrane vesicles, which are produced by 













Figure 2 Electron micrographs showing the first documented outer membrane vesicles. A) Cell-free 
supernatant of V. cholerae was centrifuged at 144,000xg for 1 hour, negatively stained with 
phosphostungstate and observed under an electron microscope (magnification 63,000x). Globules of 
varying sizes can be clearly distinguished. B) Lysine limited V. cholerae cells were grown for 18 
hours, negatively stained and observed using an electron microscope (magnification 88,000x). Work 
et al (1966) noted the area of low electron density between the outer and cytoplasmic membranes 
(arrow) that we now know as the periplasm, as well areas of low electron density in the cytoplasm (e). 






1.2.2 Structure and contents 
 
Outer membrane vesicles of Gram-negative bacteria have been studied extensively in recent 
years and are now known to be stable structures, produced in all growth phases 
(Kadurugamuwa & Beveridge, 1999; Post et al., 2005), at sizes ranging from 20 to 250nm in 
diameter. The basic structure consists of a spherical, outer membrane-derived lipid bilayer 
enclosing a mainly periplasmic lumen (Bomberger et al., 2009; Grenier & Mayrand, 1987; 
Kulkarni & Jagannadham, 2014; Kulp & Kuehn, 2010; Patrick et al., 1996; Perez-Cruz et al., 
2013) (Figure 3). Consequently, the majority of OMV contents are expected to be of OM and 
periplasmic origin, i.e. outer membrane lipids and proteins, lipopolysaccharide (LPS) and 
periplasmic proteins. Interestingly, the majority of OMV have also been found to contain 
inner membrane and cytoplasmic proteins, nucleic acids, small signalling molecules, 
metabolites, and ions. More than 200 proteins have been consistently identified in OMV 
proteomic studies, across a range of bacterial species, and these include porins, nutrient 
binding outer membrane proteins, virulence factors, toxins, murein hydrolases, efflux pumps 
and transporters (Aguilera et al., 2014; Altindis et al., 2014; Elhenawy et al., 2014; Jang et 
al., 2014; Kulkarni & Jagannadham, 2014; Kulp & Kuehn, 2010; Lee et al., 2008; Perez-Cruz 
et al., 2013; van de Waterbeemd et al., 2013). The variety of proteins and other molecules 
from all subcellular compartments may be indicative of protein sorting and diverse functions 
of OMV, however some studies have observed alternative mechanisms of vesicle formation 
that may explain the presence of proteins from the cytoplasm and inner membrane (McCaig 
et al., 2013; Perez-Cruz et al., 2013) (Section 1.2.4). Whilst the protein complement of the 
OMV reflects that of the parent cell under any one environmental condition (Altindis et al., 
2014), the protein profile of the OMV is distinct from that of any other subcellular fraction 
(Kulkarni & Jagannadham, 2014). In multiple proteomics studies, OMV have been found to 
contain low abundance periplasmic or OM proteins and yet do not contain some high 
abundance proteins from those fractions, e.g. Lpp, a common OM protein, is virtually absent 
from the OMV (Kulkarni & Jagannadham, 2014; Kulp & Kuehn, 2010). The same is true of 
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other molecules found in OMV. LPS is commonly found on the outer surface of OMV, 
however the relative abundance of LPS chain types differs from OM to OMV (Li et al., 1996), 
for example OMV of Pseudomonas aeruginosa contain mostly Band B LPS while containing 
very little Band A LPS (Kadurugamuwa & Beveridge, 1995). Phospholipids have also been 
observed at different levels of relative abundance in OM and OMV (Kulkarni & 
Jagannadham, 2014). DNA and RNA have been found in OMV from various bacterial 
species (Kulkarni & Jagannadham, 2014; Kulp & Kuehn, 2010; Lee et al., 2008; Perez-Cruz 
et al., 2013). Due to a certain level of DNase sensitivity some of the DNA is thought to be 
bound to the OMV surface, however as some of the DNA was protected there is still 
evidence that nucleic acids are carried in the lumen of the vesicles (Renelli et al., 2004). The 
DNA in these OMV can be of chromosomal, plasmid or phage origin, either linear or circular 
and may be packaged into the OMV during biogenesis or taken up from the environment. 
The phenomenon of RNA-carrying OMV has not been studied in detail (Kulkarni & 
Jagannadham, 2014). The consistent population of enriched and excluded proteins in OMV 
points to an active sorting and biogenesis mechanism.   
 
1.2.3 Biogenesis of OMV 
 
The mechanism behind OMV biogenesis remains unknown, although there is a general 
understanding of the process based on observations of vesiculation in other circumstances 
(Kulp & Kuehn, 2010). There is evidence to support both a stochastic mechanism, in which 
OMV are produced as a side effect of regular cell processes and stress responses, and 
active biogenesis, in which specific proteins and other components are packaged into OMV 
that are released for a purpose using specific machinery (Schwechheimer et al., 2013). The 
simplest and most passive model of vesiculation suggests that OMV are formed during 
routine cell wall turnover. The OM is tethered to the peptigolycan (PG) layer by various 
proteins. As PG is recycled and OM biogenesis occurs areas of excess OM begin to bleb 
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and pinch off, forming OMV (Figure 3 a). Deletion of genes involved in peptidoglycan 
turnover, and others that might result in excess OM, causes hypervesiculation in some 
Gram-negative bacteria (Kulkarni & Jagannadham, 2014; Schwechheimer et al., 2013) and 
this may also explain why more OMV are produced during exponential growth than during 
stationary phase (Kulp & Kuehn, 2010). Many authors have noted that physical and chemical 
stress also lead to membrane disruption and an increase in ruffling and OMV release 
(Kulkarni & Jagannadham, 2014; Lee et al., 2008; McBroom & Kuehn, 2007; 
Schwechheimer et al., 2013). McBroom and Keuhn (2007) noted that cells under 
temperature stress demonstrated hypervesiculation and hypothesised that OMV biogenesis 
was required to deal with an accumulation of misfolded and potentially toxic proteins in the 
periplasm (McBroom & Kuehn, 2007). Similarly, the mutation of V. cholerae degP, which 
encodes a protein responsible for regulation of waste proteins, causes hypervesiculation. It 
is thought that in the absence of the usual mechanism the excess waste proteins are 
removed via OMV (Schwechheimer et al., 2013). In support of the stress response model, it 
was found that SOS response genes are upregulated during times of hypervesiculation 
(Kulkarni & Jagannadham, 2014; Kulp & Kuehn, 2010) and that hypervesiculation mutants 
were better able to resist damage caused by temperature stress (McBroom & Kuehn, 2007). 
Tashiro et al (2012) suggested that the OMV were involved in the removal of phospholipids 
which would increase fluidity of the membrane. Whilst increased fluidity and 
hypervesiculation both correlate with growth at higher temperatures (Kulkarni & 
Jagannadham, 2014), this does not seem like a complete model for OMV biogenesis. In fact, 
neither the passive nor stress-response models can account for the fact that while OMV 
production does not cause envelope stress, it is a resource-depleting process that occurs in 
non-stressful environments and in every growth phase and therefore likely has a purpose 





Although there is no direct evidence of active OMV biogenesis, there are a large number of 
experimental observations which suggest that the process is more than a passive result of 
growth and stress. The higher membrane curvature that leads to blebbing and budding prior 
to vesicle formation requires the rearranging or breaking of linkages between the OM and 
the IM, such as those formed by Tol-Pal (a multi-protein structure anchored in the IM) and 
lipoprotein (an OM protein), allowing the OM to ruffle (Kulkarni & Jagannadham, 2014; Kulp 
& Kuehn, 2010; Schwechheimer et al., 2013) (Figure 3 a). An accumulation of periplasmic 
proteins at the OM might exert enough pressure on the membrane to cause blebbing and 
may be the mechanism by which misfolded proteins are released in OMV during the stress 
response (Figure 3 b) (Kulp & Kuehn, 2010; Schwechheimer et al., 2013). Alternatively, a 
localised increase in the concentration of phospholipids and fatty acyl chains would increase 
the curvature of the OM, causing it to bulge outwards from the cell (Figure 3 c). This 
rearranging of OM components is consistent with the finding that OMV are not produced 
uniformly across the whole cell surface but originate from certain 'hot spots' (Kulp & Kuehn, 
2010). A more direct mechanism for vesiculation was observed in P. aeruginosa, where the 
quorum sensing molecule PQS inserts itself into the OM, forcing an increase in curvature 
that leads to budding of a vesicle (Kulp & Kuehn, 2010; Mashburn-Warren et al., 2009). As 
both PQS and OMV are known to stimulate biofilm formation, this is an attractive model, 
however due to the P. aeruginosa-specific nature of PQS, this model for biogenesis cannot 
be extrapolated to all Gram-negative bacteria. A similar model, again focused on P. 
aeruginosa, theorises that repulsion between highly concentrated electronegative Band B 
LPS molecules could also cause a localised shape change in the OM, resulting in 







Several proteins have been implicated in OMV biogenesis. As mentioned above, OM 
tethering proteins such as Lpp are lacking at biogenesis sites, as are lipoproteins (Kulkarni & 
Jagannadham, 2014). P. aeruginosa has fewer lipoproteins than E. coli and also produces 
more OMV than the latter (Martin et al., 1972), suggesting that lipoproteins inhibit 
vesiculation. Salmonella enterica outer membrane proteins OmpX and PagC are both found 
in OMV and both accelerate OMV biogenesis when overexpressed, whilst NlpA, an IM 
protein found in E. coli is known to play a role in OMV formation via an unknown mechanism 
(Kulkarni & Jagannadham, 2014). It is of course possible that several of the hypothesised 
and observed mechanisms for OMV biogenesis act together or at different times during the 
cell cycle (Kulp & Kuehn, 2010). It has also been suggested that the initial membrane 
bulging occurs at random but triggers a response within the cell that leads to the severing of 
tethers and the rearrangement of localised proteins and components, which in turn prevents 
resorption into the membrane (Schwechheimer et al., 2013). The final step in OMV 
production is fission, in which the vesicle pinches off from the membrane. In other, similar 
cases, such as viral budding, fission is an active, energy dependent process. However, as 
there is no energy source in the periplasm (PP), the fission of OMV must involve an 
alternative active mechanism, possibly conformational changes in OM proteins which cause 









Figure 3 Examples of potential OMV biogenesis mechanisms. A) Rearrangement or severing of OM-
peptidoglycan links (Step 1-2), allowing natural bulging of the membrane (Step 3) and release of a 
vesicle which is representative of the OM and periplasm at time of biogenesis (Step 4). B) The 
accumulation of periplasmic proteins at the OM (Step 1-2) exerts pressure on the membrane, causing 
bulging (Step 3) and eventual release of a vesicle which is enriched with periplasmic proteins (Step 
4). C) The localised enrichment of curvature inducing proteins in the membranes (Step 1-2) causes 




In further support of active biogenesis, it has become apparent from proteomic studies that 
proteins and other molecules are actively sorted into OMV. The presence of IM and 
cytoplasmic proteins in the OMV, discrepancies between SDS-PAGE gels of OMV, OM and 
periplasmic extracts and significant differences in the proteomes of the same, as determined 
by mass spectrometry, all point to an active secretion system (Elhenawy et al., 2014; 
Kulkarni & Jagannadham, 2014; Lee et al., 2008). Several hypotheses have been put 
forward to explain the presence of DNA in the periplasmic lumen of the OMV. One suggests 
that DNA-containing OMV are formed during cell lysis. When a cell is lysed the membranes 
naturally reform into spherical structures, potentially encapsulating the spilled cytoplasmic 
and periplasmic components. This is important to note as cell lysis is a significant risk during 
experimental purification of OMV, and detection of DNA in these studies could therefore be 
considered an artefact. A second theory supposes that DNA is passed through the inner 
membrane into the periplasm, via transport proteins for packaging into the OMV and would 
therefore be encompassed in the active sorting hypothesis. Finally, a model based on 
observations of OMV biogenesis in Shewanella vesiculosa involves a localised weakening of 
peptidoglycan, allowing the formation of a dual bilayer, encompassing OM, periplasm, IM 
and cytoplasm, known as complex outer membrane vesicles (Perez-Cruz et al., 2013). The 
biological reason for exportation of DNA via OMV is unknown (discussed in section 1.2.5). 
Additionally, as no true vesiculation mutants have yet been identified, the correct model for 
OMV biogenesis also remains unsolved (Kulkarni & Jagannadham, 2014; Kulp & Kuehn, 
2010).  
 
1.2.4 Structural variations in OMV 
 
Until recently, proposed models of vesiculation have not allowed for the inclusion of the inner 
membrane or cytoplasmic components, assuming a single lipid bilayer with a periplasmic 
lumen. Not only are OMV now thought to contain proteins from all subcellular fractions, but 
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new types of vesicles have been observed that require an entirely different model. 
Shewanella vesiculosa M7T is a hypervesiculating strain that produces 2 distinct types of 
OMV: simple OMV, of the kind described in the previous sections, and complex OMV. 
Complex OMV are 100-250nm in diameter, consisting of two lipid bilayers, derived from the 
outer and inner membranes. The innermost lumen has a high electron density, similar to that 
of the cytoplasm when post-stained with aqueous uranyl acetate and lead citrate. These 
OMV are rare, making up only 0.1% of all OMV produced by S. vesiculosa M7T, presumably 
as complex vesicle biogenesis appears to require localised weakening of peptidoglycan. 
Producing large amounts of these structures would therefore compromise cell stability and 
viability (Perez-Cruz et al., 2013).  
 
Another unusual form of vesiculation is associated with Delftia spp. Cs1-4 and Francisella 
novidica. These bacteria have been observed with long membranous tubes protruding from 
the cell surface from which OMV are pinched off and released into the environment. The 
OMV themselves are not structurally different from those previously described (McCaig et 
al., 2013; Shetty et al., 2011), however this type of biogenesis is rare and may be an 
improved method of long distance delivery in sparse environments (Sanchez, 2011). 
 
1.2.5 Biological functions of OMV 
 
OMV have been associated with a wide range of biological functions but they should 
primarily be considered as a type of secretion system (Bomberger et al., 2009; Kulp & 
Kuehn, 2010; Lee et al., 2008; Shen et al., 2012). Gram-negative bacteria can posses a 
range of secretion systems, most of which span both the inner and outer membranes (Types 
I, II, III, IV and VI) and some of which operate entirely in the outer membrane (Type V, curli 
and pili). These systems allow long range interaction between bacteria and their 
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environment; transporting substrates either into the extracellular medium or directly into a 
target cell (Costa et al., 2015; Kulp & Kuehn, 2010).  
 
Vesicles hold distinct advantages over several of the other bacterial secretion systems. 
Firstly, the lipid bilayer provides a protective environment for their contents, which would 
usually be susceptible to proteases and other environmental forces, allowing them to travel 
long extracellular distances to their target (Kesty & Kuehn, 2004; Kulp & Kuehn, 2010). The 
OMV structure also allows transport of insoluble membrane proteins and co-transport of 
proteins that work together as part of a system (Altindis et al., 2014; Kulkarni & 
Jagannadham, 2014; Kulp & Kuehn, 2010). Thirdly, although OMV secretion may not be as 
efficient as the Type 3 Secretion System (T3SS), which injects substrates directly into host 
epithelial cells (Costa et al., 2015), vesicles do allow for delivery of proteins at high local 
concentrations. For example, OMV may undergo autolysis near target cells, be taken up by 
the target cell via endocytosis, or fuse with the target cell membrane, thus "emptying" their 
contents in the target cell cytoplasm (Kesty & Kuehn, 2004; Kulp & Kuehn, 2010). This 
allows for delivery of effectors without the need to be directly adjacent to the host target cell 
(Bomberger et al., 2009) and the small size of OMV may allow them to pass anatomical 
barriers that prevent the movement of whole bacterial cells (Grenier & Mayrand, 1987). Due 
to these factors, the efficiency of OMV as a secretion system justifies the supposed energy 
expenditure of vesiculation (Kulkarni & Jagannadham, 2014). 
 
As with other secretion systems, OMV can deliver virulence factors (Altindis et al., 2014; 
Kuehn & Kesty, 2005). For example, ETEC vesicles were able to deliver labile toxin (LT) to 
host epithelial cells (Horstman & Kuehn, 2000; Kesty & Kuehn, 2004) while Helicobacter 
pylori vesicles were found to contain the vacuolating cytotoxin VacA (Fiocca et al., 1999), 
and those of Actinobacillus actinomycetemcomitaus exhibit leukotoxic activity (Kato et al., 
2002). The enrichment of such proteins in OMV suggests that this secretion system could be 
important in virulence and disease, however OMV from commensal bacteria may also 
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benefit the host by boosting the native immune system (Kulp & Kuehn, 2010; Shen et al., 
2012). 
 
OMV are thought to assist with biofilm formation, an important factor in the virulence of many 
species (Kolodziejek et al., 2013), by promoting coaggregation of cells (Inagaki et al., 2006; 
Schooling & Beveridge, 2006). Vesicles of Porphyromonas gingivalis are inherently 
aggregative and are able to promote aggregation between cells of different species, causing 
them to flocculate (Grenier & Mayrand, 1987), and thus have the potential to initiate biofilm 
formation and cooperation or communication between species. The exact mechanism 
behind the aggregative properties of OMV remains unclear (Kulkarni & Jagannadham, 
2014).  
 
OMV can interact with bacteria in other ways. For example, the  DNA transfer via OMV 
allows for the exchange of genetic material within and between species of bacteria (Kuehn & 
Kesty, 2005; Kulkarni & Jagannadham, 2014; Kulp & Kuehn, 2010; Perez-Cruz et al., 2013; 
Yaron et al., 2000), thus providing a mechanism of HGT for species that lack the machinery 
for conjugation. OMV can also be bactericidal; Bacteroides uniformis vesicles contain a 
bacteriocin (Austinprather & Booth, 1984), whilst other OMV carry autolysins capable of 
breaking down peptidoglycan (PG), so that by fusing with other bacterial membranes they 
can cause lysis (Kadurugamuwa & Beveridge, 1996; Li et al., 1996; Perez-Cruz et al., 2013). 
These antibacterial properties confer an advantage when competing against other bacterial 
species for nutrients. 
 
Most OMV contain a large number of nutrient- and metal-binding proteins, proteases and 
other degradative proteins, and in some species vesiculation increases when nutrients are 
sparse. It has therefore been hypothesised that they can be used by bacteria to scavenge 
important resources and break down complex molecules in the environment (Grenier & 
Mayrand, 1987; Kulkarni & Jagannadham, 2014; Kulp & Kuehn, 2010; Lee et al., 2007).  
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It is thought that OMV biogensis is primarily a stress response mechanism. OMV are able to 
relieve pressure from unstable membranes, remove misfolded proteins after heat shock and 
dispose of antibiotics and toxins present in the periplasm. Some have also suggested that 
OMV in the extracellular environment may act as decoys for molecules and predators that 
attack the cell, such as antibiotics, antibodies and bacteriophage (Kulkarni & Jagannadham, 
2014; Kulp & Kuehn, 2010; Lee et al., 2008; Manning & Kuehn, 2011; McBroom & Kuehn, 
2007; Schwechheimer et al., 2013). Interestingly, OMV of one species can protect the cells 
of another from antibiotic attack (Mashburn & Whiteley, 2005; Schaar et al., 2014). 
 
1.2.6 Biotechnological applications of OMV 
 
OMV have drawn great interest due to their potential for biotechnological application and in 
particular they have been investigated and developed as novel vaccines. The advantage to 
using OMV in this case is that they share the same antigens as the strain from which they 
are derived but can be more easily altered so that they have less potential to cause disease 
(Altindis et al., 2014; Kolodziejek et al., 2013; van de Waterbeemd et al., 2013). One 
successful case is that of Neissera meningitidis sergroup B, in which individuals were 
protected against meningitis using a vaccine consisting of OMV extracted with detergent to 
strip endotoxin and reduce their inflammatory effects. The vaccine depended on the PorA 
antigen, which is particular to each strain. Later a recombinant PorA was used to create a 
broad-range vaccine and a mutant was identified which produces attenuated endotoxin, 
abolishing the need for detergent extraction (van de Waterbeemd et al., 2013). This case 
demonstrates that, in principle, OMV-based vaccines could be applied to other disease 
causing organisms, particularly those for which no vaccine has yet been developed, e.g. 





OMV have also been investigated for their potential to act as parcels for the delivery of 
known antibiotics. For example, Pseudomonas aeruginosa OMV are capable of packaging 
and delivering gentamicin to both Gram-positive and Gram-negative bacteria 
(Kadurugamuwa & Beveridge, 1996). Many established and novel antibiotics would be more 
effective and less detrimental to the health of the patient if they were delivered only to 
bacteria and not the host cells. Similarly, gene therapy, a novel treatment for diseases such 
as cancer, requires a non-toxic, durable, targeted method for delivery to a particular organ or 























Ubiquitin is an important, ubiquitous protein modifier, previously thought to be exclusive to 
eukaryotes. Recently, ubiquitin homologues have been identified in several bacteria, 
including B. fragilis, which are distinct from previously described bacterial ubiquitin 
analogues such as Pup (Patrick et al., 2011; van den Ent & Lowe, 2005). The function of 
these homologues is unknown; however, they might play a role in the disruption of 
eukaryotic host cells. This chapter describes the known roles and mechanism of action of 
eukaryotic ubiquitin and its known homologues.  
 
1.3.1 Characteristics of ubiquitin 
 
Ubiquitin is a 76aa, 8kDa protein modifier (Grabbe & Dikic, 2009; Komander & Rape, 2012; 
Wickliffe et al., 2011), originally believed to be present in all living organisms. It was later 
found to be exclusive to and ubiquitous in eukaryotes and is incredibly well conserved 
across all species, with yeast ubiquitin differing by only 3 residues from human ubiquitin 
(Grabbe & Dikic, 2009; Komander & Rape, 2012). The highly thermodynamically stable 3D 
structure consists of a β-grasp fold (4-5 β sheets surrounding a single α helix) with a 6aa, 
flexible C-terminal tail (Vijaykumar et al., 1987). Ubiquitin has multiple hydrophobic surface 
patches as well as 7 conserved lysines, all pointing in different directions, all of which are 
functionally vital. The ubiquitin C-terminus consists of a double glycine residue that is 
essential for ubiquitylation. Each eukaryotic cell contains a high abundance of ubiquitin, with 








Ubiquitin has low affinity for itself and for its substrates (Komander & Rape, 2012) and 
therefore ubiquitylation requires a series of enzymatic reactions (Figure 4). Firstly, an E1 
activating enzyme catalyses the adenylation of the C-terminal glycine of a ubiquitin 
molecule. A thioester bond is then formed between the ubiquitin C-terminal carboxyl group 
and the sulfhydryl group of the active site cysteine of the E1 via an ATP-dependent reaction. 
The E1 transfers the ubiquitin onto the active site cysteine residue of an E2 conjugating 
enzyme, which works with an E3 ligase to form an isopeptide bond between the C-terminus 
of the ubiquitin and the ε-group of a lysine residue in the target substrate (Corn & Vucic, 
2014; Dye & Schulman, 2007; Herrmann et al., 2007; Wickliffe et al., 2011).  
 
The hydrophobic patches on the surface of ubiquitin contribute to the stability of its 
interactions with the E2 and E3 enzymes and with the substrate, essentially holding the C-
terminal tail in place for nucleophilic attack by the substrate lysine (Wickliffe et al., 2011). 
There are only a few E1 activating enzyme molecules per cell, whilst there are nearly 50 
varieties of E2 conjugating enzymes and a wide range of substrate-specific E3 ligases (Corn 
& Vucic, 2014; Herrmann et al., 2007). The latter come in 2 main types: the HECT types, 
which "manually" transfer the ubiquitin molecule from the E2 to the substrate, and the RING 
types, which bind both the E2 and the substrate to bring the ubiquitin close to the target 
lysine (Ashida et al., 2014; Dye & Schulman, 2007; Herrmann et al., 2007). Novel E3 ligases 
have been identified which do not fall into either category. Additionally, ubiquitin can be 
conjugated to cysteine residues via a thioester bond or to serine/threonine residues, via an 








Figure 4 The basic ubiquitylation cycle. Ubiquitin (or ubiquitin-like molecules, see section 1.3.4) are 
expressed as precursors and require processing by hydrolases to expose the C-terminal double 
glycine residue. An E1 activating enzyme adenylates the C-terminal glycine of a free ubiquitin 
monomer and then forms a thioester bond with the C-terminal carboxyl group of the ubiquitin via an 
ATP-dependent reaction. The E1 then transfers the ubiquitin to the active site cysteine of an E2 
conjugating enzyme. The E2 interacts with a substrate-specific E3 ligase to transfer the ubiquitin onto 
a lysine residue in the target protein. De-conjugating enzymes (deubiquitylases) can also remove the 








More than one ubiquitin can be conjugated to a substrate, either by monomeric ubiquitylation 
at multiple lysines or by forming a ubiquitin chain. A second ubiquitin can be added to the 
first at any of its 7 lysines (K6, K11, K27, K29, K33 K48 or K63) or at its N-terminal 
methionine (M1) (Ashida et al., 2014; Komander & Rape, 2012; Valkevich et al., 2014). 
During chain elongation, a free "donor" ubiquitin C-terminus is brought close to the lysine or 
M1 of a substrate-bound "acceptor" ubiquitin. Nucleophillic attack of the donor by the 
acceptor results in the formation of an isopeptide bond between the two (Wickliffe et al., 
2011). These chains can extend up to 10 molecules and be linear or branched, loose or 
compact, using different lysine residues (or M1) to create different conformations (Figure 5) 
(Corn & Vucic, 2014; Komander & Rape, 2012). The rate of formation and the specific 
linkages of a chain seem to depend on the specific E2 and E3 enzymes involved in 
elongation (Valkevich et al., 2014). All 8 chain linkages have been detected in vivo (Xu et al., 
2009), indicating that each is biologically viable and in some way useful to the cell.  
 
Ubiquitin molecules are removed from substrate proteins by deubiquitinases which, like E3 
ligases, are usually specific to a substrate. Deubiquitinases (DUBs) can either remove all 
ubiquitin molecules or merely trim back the chain to allow for chain "editing" (Grabbe & Dikic, 






Figure 5 Diagrams showing the different types of ubiquitin chain conformation. A) Monoubiquitylation, 
a single ubiquitin monomer attached to a single lysine. B) Multiple ubiquitin monomers attached to 
different lysines. C) Homogeneous ubiquitin chain in which each ubiquitin monomer is connected to 
the previous monomer via the same lysine. D) Mixed ubiquitin chain in which different lysine linkages 
are used between different ubiquitin monomers. E) Branched ubiquitin chain in which one or more 
ubiquitin monomers has multiple other ubiquitin residues attached via different lysines. F) Unanchored 
ubiquitin chains which exist freely in the cytoplasm. Note that K48 forms a more compact chain than 









1.3.3 Roles of ubiquitin in the eukaryotic cell 
 
Ubiquitin is known to play roles in a very large number of eukaryotic cell pathways. The best 
studied of these is the 26S proteasome pathway, which degrades malfunctioning proteins or 
those which are no longer needed to maintain homeostasis, thus triggering protein cascades 
in response to environmental triggers (Finley, 2009; Herrmann et al., 2007). Ubiquitin 
contains a proteasomal targeting motif common to all proteasome-recruited proteins (Grabbe 
& Dikic, 2009). Consequently, certain ubiquitylated proteins are brought to the proteasome 
where ubiquitin is cleaved off and returned to the cytosol before the target is degraded 
(Finley, 2009; Herrmann et al., 2007). Ubiquitin also plays roles in antigen processing, 
activating immune and inflammatory responses, DNA repair and cell cycle progression, 
amongst others (Ashida et al., 2014; Corn & Vucic, 2014; Valkevich et al., 2014). Usually 
these roles involve modification of protein function, promotion or inhibition of protein-protein 
interactions and relocalisation of ubiquitylated proteins (Komander & Rape, 2012).  
 
Interestingly, specific ubiquitin chain conformations have been associated with specific cell 
functions. Chains formed via the K48 linkage are known to mark a protein for degradation by 
the 26S proteasome pathway (Corn & Vucic, 2014; Herrmann et al., 2007; Komander & 
Rape, 2012; Valkevich et al., 2014; Wickliffe et al., 2011) and K63 linkages have been 
implicated in DNA damage repair, cytokine signalling, lysosomal degradation and the 
assembly of protein complexes (Komander & Rape, 2012; Valkevich et al., 2014; Wickliffe et 
al., 2011). Inhibition of K11 linkages halts mitotic progression whilst untimely assembly of 
K11 linked chains results in rapid cell cycle progression (Jin et al., 2008). K11, K63 and M1 
linkages all appear to be involved in inflammatory signalling complexes, and several 
inflammatory pathways, e.g. tumour necrosis factor receptor (TNFR) and toll-like receptor 
(TLR) pathways, are known to heavily rely on ubiquitylation (Corn & Vucic, 2014). 
According to Komander and Rape (2012), the complex chains formed via ubiquitylation can 
be seen as a sort of code that stores and transmits information in the cell. The proteins that 
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read and respond to this code will have appropriately spaced and numbered ubiquitin-
binding domains and will be able to distinguish between structurally similar chains based on 
flexibility and linkage (Komander & Rape, 2012). 
  
1.3.4 Eukaryotic ubiquitin-like proteins 
 
The "ubiquitin superfamily" is a term used to refer to the large number of proteins that are 
structurally or functionally related to ubiquitin and the ubiquitylation cycle. Ubiquitin-like 
proteins (UBLs) are small protein modifiers with >10% identity to mammalian ubiquitin 
(Larsen & Wang, 2002) and which resemble ubiquitin in tertiary or higher order structures. 
They are attached to a substrate lysine, using machinery similar to the E1/E2/E3 enzymes, 
in a way that alters protein conformation, function or localisation. Due to the similarities 
between ubiquitin and UBLs, the different systems compete for substrate lysines and 
experience cross talk. The best known examples of UBLs are SUMO, Nedd8 (Dye & 
Schulman, 2007; Grabbe & Dikic, 2009) and ISG15, which is actually comprised of two UBLs 
connected by a hinge region, and is active exclusively in the interferon-induced inflammatory 
pathway (Bade et al., 2012). As they are all conjugated to a substrate lysine, UBLs require a 
C-terminal double glycine in order to function. Only one characterised UBL, the Yeast protein 
Hub1, does not possess a GG motif. If this UBL is covalently conjugated to other proteins, it 
must use hitherto undocumented machinery (Dittmar et al., 2002).  
 
Ubiquitin-like domains (ULD) are domains of 45-80 amino acids that exist within another 
protein, most frequently as an N-terminal fusion. These domains strongly resemble the 
ubiquitin tertiary structure and can appear more than once in the same protein; in fact, some 
proteins contain both a ULD and different UBL domain, e.g. a SUMO-like domain. Whilst 
ULDs are commonly associated with proteasomal shuttles and signal transduction proteins 
(Grabbe & Dikic, 2009) they may have other functions, such as providing a thermostable 
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nucleation or folding template for large proteins. They are also known to serve as nuclei for 
ubiquitin chain formation (Larsen & Wang, 2002).  
 
Ubiquitin-binding domains (UBD) vary in size (20-150 amino acids) and structure, although 
most are α-helical. They bind ubiquitin with a low affinity (Kd = 2-500µM), however they have 
strict patterns of recognition and where multiple UBDs are present on the same substrate the 
affinity of each interaction increases with the number of ubiquitin molecules that are bound. 
Certain proteins contain both a ULD and a UBD in the same peptide (Grabbe and Dikic., 
2009). Such proteins are deemed to be integral players in 26S proteasomal degradation 
system, as shuttle factors capable of binding a polyubiquitin chain via their UBD and the 
proteasome via their ULD (Ng et al., 2002), and in cell cycle progression (Masutani et al., 
1994; Grabbe and Dikic., 2009).  
 
1.3.5 Bacterial ubiquitin-like proteins 
 
The best characterised bacterial ubiquitin-like system is the Pup system, found exclusively in 
Actinobacteria. Possibly the result of horizontal gene transfer from eukaryotes, Pup is a 
small protein modifier which bears no sequential or structural similarity to ubiquitin. When 
unbound it has a largely disordered structure with a weak α-helix near the C-terminus and no 
β-grasp fold. There is also far less sequence conservation of Pup between species, with 
large variation towards the N-terminus, however it does contain a C-terminal GGQ or GGE 
motif via which it forms an isopeptide bond with substrate lysines. (Striebel et al., 2014). 
Pupylation requires the deamidation of this glutamine (Q) or glutamic acid (E) to a glutamate 
by Dop, after which PafA, a Pup ligase, utilises ATP to conjugate Pup to the substrate lysine 
(Striebel et al., 2009) (Figure 6). Dop also acts as a depupylase, cleaving the isopeptide 
bond between Pup and the substrate via a mechanism that requires nucleotide binding 
(Imkamp et al., 2010).  
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So far the only known role of Pup is as a marker for degradation by the 20S proteasome. 
Pup, conjugated to a target substrate, associates with the proteasomal ATPase Mpa via its 
central region, while its N-terminal region begins feeding the tagged protein into the 
proteasome. The Pup proteasomal system is non-essential and Actinobacteria can survive 
without it. However, given the multifaceted roles of ubiquitin, it is believed that Pup may play 















Figure 6 A comparison of pupylation and ubiquitylation, highlighting the similarities and differences 
between the two systems. Both Pup and ubiquitin require C-terminal processing prior to conjugation 
and both require ATP for the activation of the carboxyl group prior to ligation. However, whilst E1 
adenylates ubiquitin, PafA phosphorylates Pup (although nucleophillic attack by the ε-group of the 
lysine remains the same). Additionally, ubiquitylation depends on a large hierarchy of E1, E2 and E3 









Many pathogenic bacteria use proteins, acquired by HGT, that interfere with the ubiquitin 
system, during infection of a host cell (Ashida et al., 2014; Munro et al., 2007). E3 ligases 
can be found in a range of gastrointestinal pathogens, for example, Salmonella enterica 
serovar Typhimurium SopA is a HECT-like E3, the target of which is unknown, but which has 
been shown to be essential for polymorphonuclear transepithelial migration of the bacterium 
into the host cell (Zhang et al., 2006). LubX, a RING-type E3 of Legionalla pneumophila, 
ubiquitylates host cell kinase CLK1 and is essential for bacterial growth in macrophages 
(Kubori et al., 2008). Shigella flexneri possesses a novel E3, IpaH0722, which poly-
ubiquitylates TRAF2 (TNF receptor-associated factor), thus targeting it for degradation and 
inhibiting the NFκB inflammatory pathway (Ashida et al., 2013). There are several 
documented cases of bacterial deubiquitylases contributing to virulence, for example YopJ of 
Yersinia enterolitica and TssM of Burkholderia pseudomallei both cleave ubiquitin from 
inflammatory response proteins, thus reducing the overall inflammatory response of the host 
cell (Ashida et al., 2014; Haase et al., 2005; Tan et al., 2010). Some bacterial proteins also 
modify host cell SUMO. Listeria monocytogenes LLO causes the degradation of UBC9, a 
SUMO-ylating protein, which results in a general decrease of SUMO-ylated proteins in the 
cell. This, in turn, affects signalling pathways which rely on SUMO-ylation, such as the TGFβ 
(transforming growth factor β) pathway, a major player in host cell proliferation and response 










1.4 B. fragilis, outer membrane vesicles, and ubiquitin 
 
B. fragilis produces a protein designated BfUbb which, unlike Pup, is a true homologue of 
eukaryotic ubiquitin and the result of an ancestral HGT (Patrick et al., 2011). As seen above, 
many bacteria use HGT-acquired proteins to interfere with ubiquitin-dependent pathways in 
the host cell (Ashida et al., 2014). This requires delivery of these proteins, usually via a 
secretion system. The only secretion system B. fragilis has that is capable of long-distance 
delivery of effector proteins to host cells is its OMV, which already have established roles in 
the delivery of other molecules (Shen et al., 2012). Importantly, BfUbb is expressed with a 
periplasmic signal sequence and can be detected in concentrated supernatants of B. fragilis 
(Patrick et al., 2011), suggesting that it can indeed be delivered to host cells via OMV. 
 
The following chapters describe the methods and results of experiments designed to 
characterise both BfUbb and the OMV of B. fragilis. As BfUbb is able to form covalent bonds 
with E1 activating enzyme, assays were performed to determine whether BfUbb forms 
covalent bonds with other enzymes of the ubiquitin cycle, as well as other proteins within the 
eukaryotic cell. Constructs were created which would allow the purification of native 
(untagged) BfUbb and fluorescently tagged BfUbb for use in in vitro experiments, such as X-
ray crystallography and ligand-binding assays. It has been hypothesised that BfUbb acts on 
the epithelial cells of the host gastro-intestinal tract, possibly to alter their response to 
bacterial stimulus. A set of constructs was therefore created for the expression of affinity 
tagged BfUbb and fluorescently tagged BfUbb in mammalian cells, thus allowing further 
studies to determine the effect of the presence of BfUbb on the cell, which proteins it forms 
covalent bonds with in vivo and its intracellular location. Clinical samples from patients with 
gastro-intestinal diseases or abscesses were screened for the presence of B. fragilis and the 
ubb gene, to determine whether any correlation exists between the expression of BfUbb by 
B. fragilis and the presence or absence of any of these diseases. OMV of Gram-negative 
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bacteria have a range of proposed functions, including delivery of proteins to other cells, 
eukaryotic or bacterial. The proteome of the OMV of B. fragilis was determined by LTQ-
Orbitrap mass spectrometry with the intention of identifying any proteins that may elucidate 
the mechanism of biogenesis or function of the OMV, as well as proteins that have 
previously been identified in the concentrated supernatant of B. fragilis, such as BfUbb and a 
fibrinogen-binding protein. Finally, OMV of both WT B. fraglis and the Δubb mutant were 
tested for their ability to kill or inhibit growth of other gastro-intestinal bacteria, to determine 



















2. Materials and Methods 
2.1 Bacterial culture  
2.1.1 Bacterial strains 
 
All bacterial strains used in this study are shown in Table 1. 
Species Strain Plasmid Antibiotic Source 
Bacteroides 
fragilis 
NCTC 9343 pBF9343 Gentamicin 
(40µg/ml) 































SL1344 None None Gallagher lab, 
University of Edinburgh 




(Patrick et al., 2011) 
Escherichia coli JM109 None None French lab, University 
of Edinburgh 
Escherichia coli DH5α None None New England Biolabs 
(NEB), UK 
Escherichia coli BL21 DE3 None None NEB, UK 
 
Table 1 Bacterial strains used in this study, showing strain, mutations, plasmids, selection antibiotics, 
and source.  
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2.1.2 Culture conditions 
 
B. fragilis solid cultures were grown on Brain-Heart Infusion (BD, USA) agar, supplemented 
with 5% cysteine, 10% sodium bicarbonate, 50 μg/ml haemin and 0.5 μg/ml menadione 
(BHI-S agar), and liquid cultures in either BHI-S solution or defined medium (Van Tassell & 
Wilkins, 1978), with the appropriate antibiotics (Table 1). All B. fragilis cultures were grown in 
a Minimacs anaerobic work station (Don Whitley Scientific, UK) at 37ºC in an anaerobic gas 
mix (10% Hydrogen, 10% Carbon dioxide, 80% Nitrogen). 
 
Solid cultures of E. coli and S. enterica Typhimurium were grown on Luria-Bertani Broth (LB) 
agar, and liquid cultures were grown in LB, with shaking (200rpm), all at 37ºC and with 





All primers used in this study (Table 2) were synthesised by Eurofins MWG Operon 
(Germany), suspended in TE buffer (1M Tris-HCl, 0.5M EDTA, pH8.0) to a concentration of 
100pg/µl and stored at -20ºC. Primers were diluted 1:10 in dH2O before use (final 








Primer Sequence 5' - 3' Length Tm (ºC) 




Bfx CGAGCTGTACAAGATGCAAGTTTTTATAAAAAACAG 36 64.9 
Brbamhi TACTGTTGGATCCCTTAGTGTTAACAGTCGAC 32 66.9 
Yfndei ATACTTGCATATGGTGAGCAAGGGCGAGC 29 68.1 
Yfhindiii AGTAGCTAAGCTTATGGTGAGCAAGGGCGAG 31 69.5 
Yrx CTTGCATCTTGTACAGCTCGTCCATGC 27 66.5 
Yrbamhi GTCATCAGGATCCTTACTTGTACAGCTCG 29 66.7 
6TRtetf GTAAAGTGATTAACAGCGC 19 46.8 
6TRtetr TAAGATCTGAATTCCCGG 18 45.8 
 
Table 2 Primers used in this study, showing sequence, length and melting temperature. Restriction 
















All plasmids used and generated in this study are shown in Table 3. 
Plasmid Size (bp) Selection Antibiotic Source 
pET19b 5717 Ampicillin Gallagher lab 
pET19b 10xHBfUbb 5952 Ampicillin This study 
pET19b YFPBfUbb 6689 Ampicillin This study 
pcDNA6/TR 6662 Ampicillin/Blasticidin Life Technologies 
pcDNA4/TO 5078 Ampicillin/Zeocin Life Technologies 
pcDNA4/TO 10xHBfUbb 5340 Ampicillin/Zeocin This study 
pcDNA4/TO YFPBfUbb 6053 Ampicillin/Zeocin This study 
pcDNA4/TO YFP 5804 Ampicillin/Zeocin This study 
 
Table 3 Plasmids used and generated in this study, showing size and antibiotic used for selection of 
transformants. For pcDNA6/TR and pcDNA4/TO the second antibiotic was used for selection in Caco-
2 cells.  
 
2.3 Bacterial techniques 
2.3.1 Preparation of competent cells 
 
E. coli DH5α and BL21 DE3 competent cells were purchased from New England Biolabs 
(NEB, UK). 30ml E. coli JM109 cells were chilled on ice, pelleted at 8,000xg and 
resuspended in 13.5ml ice cold 100mM MgCl2. Cells were pelleted again, resuspended in 
6ml ice cold 100mM CaCl2 and incubated on ice for 20 minutes. Cells were pelleted and 
resuspended in 1.5ml ice cold 100mM CaCl2 (15% glycerol), pelleted for a final time and 
resuspended in 6ml CaCl2 (15% glycerol). Competent cells were split into 50µl aliquots, flash 
frozen and stored at -80ºC. 
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2.3.2 Transformation of competent cells 
 
Plasmid DNA, 2µl supercoiled plasmid or 10µl ligated product, was added to 50µl thawed 
competent cells and incubated on ice for 30 minutes. Cells were held at 42ºC for 90s, then 
returned to ice for 90s. 950µl pre-warmed LB was added to the cells, which were then 
incubated at 37ºC with shaking (200rpm) for 60 minutes. 50µl of either neat culture or a 10-1 
dilution were plated onto LB amp agar. 
 
2.4 DNA techniques 
2.4.1 Plasmid purification 
 
Plasmids were isolated from bacterial culture by Miniprep (Qiagen, Netherlands) for DNA 
modification and bacterial transformation experiments, and Maxiprep (Qiagen, Netherlands) 
for tissue transfection experiments. 
 
For the Minipreps, 1.5-4.5ml bacterial culture were pelleted in microcentrifuge tubes at 
>16,000xg for 5 minutes. Pellets were resuspended in 250µl Buffer P1 (without LyseBlue 
reagent), then added 250µl Buffer P2 and mixed by inversion until the solutions became 
clear. Within 5 minutes 350µl of Buffer N3 was added and the solutions were mixed by 
inversion before being centrifuged at >16,000xg for 10 minutes. The supernatants were then 
applied to QIAprep spin columns and centrifuged at >16,000xg for 1 minute. The flow-
through was discarded and 750µl Buffer PE applied to the top of the columns, followed by 
centrifugation at >16,000xg for 1 minute. The flow-through was discarded and the columns 
centrifuged again under the same conditions to remove residual buffer. The spin columns 
were then transferred into fresh microcentrifuge tubes and 30-50µl Buffer EB added to the 
top of the columns. The columns were incubated at room temperature for 1-3 minutes and 
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then centrifuged at 16,000xg for 1 minute. Collected DNA was stored at -20°C in Buffer EB 
until use. 
 
For Maxipreps, 200-400ml overnight bacterial culture were centrifuged at 8,000xg for 15-30 
minutes at 4°C and the pellets resuspended in 10ml Buffer P1 (no LyseBlue reagent used). 
10ml Buffer P2 was added and the suspensions were mixed by swirling then incubated at 
room temperature for 5 minutes. After the lysis reaction, 10ml pre-chilled Buffer P3 was 
added and the lysate solutions were mixed by swirling then poured into a QIAfilter cartridge, 
where they were incubated at room temperature for >10 minutes. The lysate solutions were 
then filtered through the QIAfilter into 50ml falcon tubes. 2.5ml Buffer ER was added to the 
falcon tubes, the solutions mixed by inversion and then incubated on ice for 25-30 minutes. 
QIAGEN-tip 5000 columns were equilibrated with 10ml Buffer QBT. The chilled lysate 
solutions were then applied to the columns, followed by 2 x 30ml Buffer QC to wash the 
columns. The bound DNA was eluted using 15ml Buffer QN into depyrogenated 30ml 
centrifuge tubes. The solubilised DNA was precipitated by adding 10.5ml isopropanol and 
pelleted by centrifugation at 20,000xg for 30 minutes at 4°C. The supernatant was discarded 
and the pellet washed with 10ml endotoxin-free 70% ethanol, then centrifuged at 20,000xg 
for 15 minutes at 4°C. The supernatant was removed carefully so as not to disturb the pellet 
and the pellet allowed to air dry for up to 20 minutes before resuspension in <1ml Buffer TE. 
DNA was stored at -20°C in Buffer TE until use.  
 
2.4.2 Polymerase chain reaction (PCR) 
 
PCR reactions were performed using an Eppendorf Mastercycler (Eppendorf, UK) or an MJ 
Research DNA Engine PTC-200 Peltier thermocycler (Bio-Rad, USA). Mixtures typically 
contained: 2µl template DNA, 1µl forward primer, 1µl reverse primer, 10µl 10x GC buffer 
(NEB) 0.5µl Phusion polymerase (NEB, UK), 35.5µl dH2O. A standard 30 cycle protocol was 
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used: 98ºC for 1 minute, followed by 30 cycles of 98ºC for 10s, annealing temperature for 
20s, 72ºC for 30s, then 10 minutes at 72ºC. The annealing temperature was usually 2-6ºC 
lower than the lowest primer melting temperature (Table 2).  
 
2.4.3 Agarose gel electrophoresis 
 
DNA products were mixed with DNA gel loading buffer (NEB, UK) and loaded onto 1% (w/v) 
agarose gels, with 1kb or 100bp DNA markers (NEB, UK). Products were separated by 
electrophoresis at 80V for 30-60 minutes in 1x TAE buffer (40 mM Tris, 1 mM EDTA pH8, 19 
mM Glacial acetic acid). Gels were stained in 1µg/ml ethidium bromide for 20 minutes and 
destained in dH2O for 20 minutes, then imaged using a UVP VisiDoc- It Imaging System 
(UVP LLP, USA).  
 
2.4.4 DNA purification 
 
PCR products were cleaned using a QIAquick PCR Purification Kit (Qiagen, Netherlands). 
PCR reactions were transferred to microcentrifuge tubes and 5x starting volume Buffer PB 
(with pH indicator added as per kit instructions) added. Samples were vortexed then applied 
to QIAquick spin columns and centrifuged at >16,000xg for 1 minute. The flow-through was 
discarded and 750µl Buffer PE (with ethanol added as per kit instructions) was applied to the 
columns which was then centrifuged at >16,000xg for 1 minute. The flow-through was 
discarded and the columns centrifuged again under the same conditions to remove residual 
buffer. The columns were transferred into fresh microcentrifuge tubes. 20-50µl Buffer EB 
was applied to the columns which were incubated at room temperature for 1-5 minutes then 
centrifuged at >16,000xg for 1 minute. The cleaned PCR products were stored in Buffer EB 
at -20°C until use. 
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2.4.5 Gel extraction 
 
Desired bands were extracted from agarose gels using a QIAquick Gel Extraction Kit 
(Qiagen, Netherlands). Bands were cut from the gel using a scalpel under a UV lamp and 
transferred to a tared microcentrifuge tube and weighed (should be <400mg). 3x gel weight 
of Buffer QG (assuming 100mg = 100µl) was added and the sample incubated at 50°C for 
~10 minutes, with vortexing every 2-3 minutes. Once the gel slice had fully dissolved 1x gel 
weight isopropanol was added and the sample vortexed. The sample was then applied to a 
QIAquick spin column and centrifuged for 1 minute at >16,000xg. The flow-through was 
discarded and 500µl Buffer QG applied to the column, which was then centrifuged for 1 
minute at >16,000xg. The flow-through was again discarded and 750µl Buffer PE (with 
ethanol, added per kit instructions) applied to the column and flushed through by 
centrifugation at >16,000xg for 1 minute. The flow-through was discarded and the column 
centrifuged again under the same conditions to remove residual buffer. The column was 
transferred to a fresh microcentrifuge tube. 20-50µl Buffer EB was applied to the column and 
incubated at room temperature for 1-5 minutes before centrifuging at >16,000xg for 1 
minute. The purified DNA was stored in Buffer EB at -20°C until use. 
 
2.4.6 DNA quantification 
 
DNA products were quantified by applying 2µl DNA solution to a NanoDrop ND-1000 
Spectrophotometer (Thermo Scientific, USA) and performing analysis using NanoDrop 1000 






2.4.7 Restriction enzyme digestion 
 
DNA products were digested with restriction enzymes in the appropriate conditions as 
recommended by the manufacturer (NEB, UK). Single digests typically contained 5-10µl 
purified DNA product, 1µl enzyme, 2µl buffer and 7-12µl dH2O. Double digests typically 




Digested DNA was dephosphorylated to prevent religation. 1 μl of Antarctic Phosphatase 
(NEB, UK) and 5 μl Antarctic Phosphatase 1x buffer (NEB, UK) were added to the digest 
mixture and incubated at 37°C for 15 min. The enzyme was heat inactivated by incubation at 





Digested plasmids and PCR products were mixed at a ratio of 1:3 and 1:6, with 0.5µl T4 
DNA ligase (Promega, UK) and 1µl 10x reaction buffer, made up to 10µl with dH2O. Mixtures 
were incubated at 16ºC overnight before cleaning (section 2.4.4) and transformation (section 
2.3.2).  
 
2.4.10 Single colony preparations 
 
Transformant colonies were patched onto fresh LB amp agar and incubated at 37ºC 
overnight. Patches were picked and suspended in 50µl SCFS buffer (1.25% SDS, 2.5% 
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ficoll, 0.015% bromophenol blue, 10µg/ml RNase A, in 1x TAE buffer), incubated at room 
temperature for 15 minutes then centrifuged at 16,000xg for 30 minutes. The supernatant, 
containing the whole DNA of the cells, was analysed by agarose gel electrophoresis. 
 
2.4.11 Genomic DNA purification 
 
Genomic DNA was prepared from overnight B. fragilis cultures or clinical samples using a 
Wizard Genomic DNA Purification Kit (Promega, UK). 1ml samples were centrifuged at 
16,000xg for 3 minutes and the pellets were washed twice in nuclease-free water before 
being resuspended in 600µl Nuclei Lysis Solution. Resuspended samples were incubated at 
80°C for 5 minutes and then allowed to cool to room temperature. 3µl RNase Solution was 
added and the samples were vortexed and incubated at 37°C for 60 minutes. Samples were 
cooled to room temperature and 200µl Protein Precipitation Solution was added, the 
samples were vortexed and incubated on ice for 5 minutes. The samples were then 
centrifuged at 16,000xg for 3 minutes and the supernatant transferred into fresh 
microcentrifuge tubes containing 600µl isopropanol. The samples were mixed by inversion 
and then centrifuged at 16,000xg for 2 minutes. The supernatant was carefully removed and 
discarded and the pellet was washed with 600µl 70% ethanol before being centrifuged again 
at 16,000xg for 2 minutes. The wash solution was carefully removed and discarded and the 
pellet air dried for up to 30 minutes. The DNA was then rehydrated in 100µl Rehydration 
Solution overnight at 4°C. DNA was stored in Rehydration Solution at -20°C until use.  
 
2.4.12 Quantitative PCR (qPCR) 
 
Serial dilutions of B. fragilis genomic DNA and primers specific for the gyrB and ubb genes 
were used to generate calibration curves by Danny O’Connor (Patrick lab, Queen’s 
University Belfast). Genomic DNA was isolated from 47 clinical samples or pure cultures of 
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B. fragilis (section 2.4.11) and qPCR mixtures prepared by the author using a Platinum 
SYBR Green qPCR SuperMix-UDG (Invitrogen, Thermo-Fisher Scientific, USA). qPCR 
mixtures were prepared in 384-well plates, with each well containing: 25µl SuperMix, 9µl 
nuclease-free water, 2.5µl 50mM MgCl2, 1µl 1mg/ml BSA, 2µl genomic DNA, 0.2µl forward 
primer, 0.2µl reverse primer, 0.1µl ROX dye. qPCR analysis was performed by Dr. Derek 
Fairley (Belfast Health and Social Care Trust) and the number of copies of each gene in 
each sample was calculated from the calibration curves. 
 
2.5 Protein techniques 
2.5.1 Proteins 
 
rBfUbb was purified from E. coli DH5α as described below, solid state bovine ubiquitin 
(Sigma Aldrich, USA) was suspended in phosphate buffered saline (PBS) (100mM 
NaH2PO4,18mM KH2PO4, 1.37M NaCl, 27mM KCl, pH7.5), and all ubiquitin-activating and 
ubiquitin-conjugating enzymes (CalTag Medsystems, UK) (Table 4) were diluted in E2 buffer 
(20mM Tris, 150mM NaCl, 2mM β-mercaptoethanol, 1% glycerol). 
 
 
2.5.2 Expression  
 
500ml cultures were grown to OD600nm 0.4-0.6 and expression was induced with 1mM IPTG 






2.5.3 Affinity purification 
 
Induced 500ml culture was centrifuged at 8,000xg for 30 minutes and the pellet resuspended 
in 30ml loading buffer (26mM NaH2PO4, 0.5M NaCl, 20mM Imidazole, 1% PMSF) with 
protease inhibitors (Sigma Aldrich, USA). Cells were lysed using a 1.1 kW TS Benchtop Cell 
Disrupter (Constant Systems, UK) at 22kpsi and the lysate centrifuged at 50,000xg to pellet 
cell debris. The supernatant was filtered (0.45µm, Merck Millipore, Germany) and passed 
over a Ni-NTA agarose (Qiagen, Netherlands) column, then washed with loading buffer and 
eluted with elution buffer (26mM NaH2PO4, 0.5M NaCl, 0.5M Imidazole) in 1ml fractions 
(unless stated otherwise). Fractions were analysed by SDS-PAGE and coomassie staining 
and fractions containing the target protein were pooled. 
 
2.5.4 Gel filtration 
 
Pooled fractions from the affinity column were passed through a Superose 12 10/300 GL 
column (GE Healthcare, UK) and eluted with PBS (with 1mM EDTA and protease inhibitors) 
in 1ml fractions. Fractions were analysed by SDS-PAGE and coomassie staining and those 
containing pure protein were pooled and concentrated to 1-2ml in a Vivaspin 6, 5,000kDa 





Pure protein was quantified by applying 2µl homogenous sample to a NanoDrop ND-1000 
Spectrophotometer (Thermo Scientific, USA) and performing analysis using NanoDrop 1000 




2.5.6 Bradford assay 
 
Bradford reagent (Sigma Aldrich, USA) was diluted 1:4 in assay buffer (3M Urea, 0.001% 
Triton X-100). Complex protein samples were diluted in assay buffer to a final volume of 
100µl (in triplicate) then 900µl of diluted Bradford reagent was added to each sample (and a 
buffer control). Samples were incubated at room temperature for 15 minutes then the 
absorbance measured at 595nm. A standard curve was generated, using 0, 2, 4, 6, 8 and 
10µg bovine serum albumin, and used to calculate the concentration of each sample.  
 
2.5.7 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Protein samples were mixed with SDS sample buffer (NEB, UK) with 100mM DTT and boiled 
(unless stated otherwise) and loaded onto Tris-tricine gels, consisting of a stacking gel and a 
resolving gel. 
 
Stacking gel: 3.9ml dH2O, 1.55ml gel buffer (3M Tris-Cl, 0.3% SDS, pH8.45), 0.8ml 30% bis-
acrylamide, 100µl APS, 8µl TEMED 
Resolving gel: 3.5ml dH2O, 5ml gel buffer, 4.9ml bis-acrylamide, 1.6ml glycerol, 100µl APS, 
8µl TEMED 
 
Proteins were separated by electrophoresis at 120V for 60-90 minutes in tricine buffer (0.1M 
Tris, 0.1M Tricine, 0.1% (w/v) SDS).   
 
2.5.8 Coomassie staining 
 
Resolving gels were incubated in 50% dH2O, 40% (v/v) methanol, 10% (v/v) glacial acetic 
acid, 0.125% (w/v) Coomassie Blue Reagent (Thermo Fisher Scientific, UK) for 20 minutes 
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and destained 70% dH2O, 20% (v/v) methanol, 10% (v/v) glacial acetic acid for 1h. 
Coomassie stained gels were visualised with a Gel Doc XR imaging system (Bio-Rad, USA). 
 
2.5.9 Silver staining 
 
Resolving gels were stained using the Proteosilver Silver Stain Kit (Sigma Aldrich, USA) as 
per the manufacturer's instructions. After electrophoresis gels were incubated on a rocker in: 
Fixing solution (50% ethanol, 10% acetic acid) overnight, 30% ethanol for 10 minutes, 
Ultrapure water for 10 minutes, Sensitizer solution (1ml ProteoSilver Sensitizer, 99ml 
Ultrapure water) for 10 minutes, Ultrapure water for 2x 10 minutes, Silver solution (1ml 
ProteoSilver Silver Solution, 99ml Ultrapure water) for 10 minutes, Ultrapure water for 60 
seconds, Developer solution (5ml ProteoSilver Developer 1, 0.1ml ProteoSilver Developer 2, 
95ml water) until the bands started to appear. Once the bands of the gel were clearly visible 
ProteoSilver Stop Solution was added and the gel incubated for 15 minutes. The gel was 
then washed in Ultrapure water for 15 minutes before imaging. Silver stained gels were 
visualised with a Gel Doc XR imaging system (Bio-Rad, USA). 
 
2.5.10 Western blotting 
 
Proteins from resolving gels were transferred to a PVDF membrane (Life Technologies, 
Sigma Aldrich, USA) at 100V for 60 minutes in transfer buffer (25mM Tris, 192mM Glycine). 
Membranes were incubated in blocking buffer (5% (w/v) milk protein in PBS with 0.05% (w/v) 
Tween-20) for 1h then washed in PBS-T (PBS with 0.05% Tween-20). Membranes were 
then incubated in primary antibody diltued in blocking buffer (1:10,000 for anti-BfUbb and 
1:5,000 for anti-1705) for 2h, washed in PBS-T, then incubated in secondary antibody diluted 
in blocking buffer (1:20,000 anti-rabbit). The membranes were washed in PBS-T and 
visualised using Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare, 
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UK) and X-ray films (GE Healthcare, UK) exposed to the chemiluminescent blots and 
developed using an X-ray processor (Medical Index GmbH).  
 
2.5.11 Ubiquitin transfer assay 
 
rBfUbb (His-tagged) was incubated at 37ºC for 1h in 4 different conditions: 
1. 0.5mg/ml rBfUbb 
2. 0.5mg/ml rBfUbb, 200mM DTT 
3. 0.5mg/ml rBfUbb, 0.2µM E1 activating enzyme 
4. 0.5mg/ml rBfUbb, 0.2µM E1 activating enzyme, 200mM DTT 
All mixtures were prepared in E2 buffer. After the initial incubation, 10µl of each mixture was 
mixed with 10µl 0.5µM of each E2 conjugating enzyme (in E2 buffer) then incubated at 37ºC 
for a further 2h. 0.5mg/ml rBfUbb = 60µM rBfUbb, therefore the molar ratio of rBfUbb:E1:E2 
is 60:0.2:0.25 (300:1:1.25). Samples were analysed by SDS-PAGE and Western blotting. 
 
2.5.12 Pull down with His-tagged rBfUbb 
 
Caco-2 cell lysate was incubated at 37ºC with gentle shaking for 3h in 4 different conditions: 
1. 2mg/ml Caco-2 cell lysate 
2. 2mg/ml Caco-2 cell lysate, 0.2mg rBfUbb 
3. 2mg/ml Caco-2 cell lysate, 100mM DTT 
4. 2mg/ml Caco-2 cell lysate, 0.2mg/ml rBfUbb, 100mM DTT 
All mixtures were prepared in PBS. After incubation, samples were passed over a Ni-NTA 
agarose (Bio-Rad, USA) column, washed in PBS and eluted in a single fraction with elution 





2.6 Tissue culture techniques 
 
2.6.1 Culture and passage 
 
Human epithelial colorectal adenocarcinoma cell line Caco-2 cells were grown in Eagle's 
Minimum Essential Medium with Earle salts (Sigma Aldrich, USA), supplemented with 10% 
foetal bovine serum (Gibco, Thermo Fisher Scientific, UK), 1% non-essential amino acids 
(Gibco, Thermo Fisher Scientific, UK), 5mM L-glutamine (Gibco, Thermo Fisher Scientific, 
UK), 100U/ml penicillin and 10µg/ml streptomycin (as Pen-Strep, Gibco, Thermo Fisher 
Scientific, UK). Cultures were incubated at 37ºC in 5% CO2. 
 
For passage, culture medium was removed, cells were washed in PBS, and then incubated 
in 10ml 1x Trypsin (Thermo Fisher Scientific, UK) for 5 minutes. 1ml of suspended cells were 




24-well plates were seeded with 102 cells/ml in culture medium and grown for 48h. Plasmid 
DNA was mixed with Lipofectamine 2000 (Thermo Fisher Scientific, UK) in Opti-Mem 
(Thermo Fisher Scientific, UK) according to manufacturer's instructions. Culture medium was 
removed from the wells and cells were washed in Opti-Mem, then transfection mixtures were 
added. Cells were incubated at 37ºC for 18-24h then transfection mixtures were removed 
and replaced with culture media. Cells were incubated for another 24h then passaged into 
culture medium containing appropriate antibiotic (Table 3). After 1 week (replacing culture 
medium every 48h), dead cells were washed away with PBS and antibiotic resistant cells 
suspended in trypsin. 24 cells were picked under a light microscope and transferred to 
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individual wells containing culture medium with antibiotic. After ~2 weeks 8 of the 24 wells 
were used to establish cell lines containing the plasmid.   
 
2.6.3 Preparation of cell lysate 
 
Between 2 and 4 flasks (75cm2) of Caco-2 cells were suspended in 10ml trypsin each. Cells 
were pooled and centrifuged at 5,000xg then resuspended in 10ml lysis buffer (PBS with 
1mM EDTA, 0.2% Triton X-100, 1% PMSF, protease inhibitors). Cells were incubated on ice 
for 20 minutes (with intermittent inversions) then passed through a 25 gauge needle 4 times. 
Lysate was centrifuged at 16,000xg for 10 minute and the supernatant collected and used 
immediately. 
 
2.7 Preparation of periplasmic extract and concentrated supernatants  
2.7.1 Preparation of periplasmic extract 
 
1ml of late-log phase/early stationary-phase B. fragilis cell culture were centrifuged at 
16,000xg, resuspended in PBS, then centrifuged again. Pellets were then resuspended in 
150µl ice cold 20% sucrose/10mM Tric-Cl (pH7.5) and vortexed. 5µl 0.5M EDTA (pH8) was 
added after which cells were incubated on ice for 10 minutes then centrifuged at 16,000xg 
for 5 minutes at 4ºC. Pellets were resuspended in 100µl ice cold dH2O and incubated on ice 
for 10 minutes, then centrifuged at 16,000xg for 5 minutes. The supernatant was collected 







2.7.2 Preparation of concentrated supernatant 
 
400ml late log phase B. fragilis culture was centrifuged at 8,000xg and the supernatant 
filtered through a 0.45µm PVDF filter (Merck Millipore, Germany). Filtered supernatant was 
then concentrated to ~1-3ml in a Centricon Plus-70 Centrifugal Filter (Merck Millipore, 
Germany) according to the manufacturer's instructions. 
 
2.8 Isolation of OMV 
2.8.1 Tangential flow filtration 
 
5L late log phase/early stationary phase WT B. fragilis culture was centrifuged at 8,000xg 
and the supernatant filtered (0.45µm) and concentrated to ~200ml using tangential flow 
filtration at a torque setting of 400 inch-lb.  
 
2.8.2 Centrifugal filtration 
 
The ~200ml concentrated supernatant was concentrated to ~1-3ml as described in section 
2.7.2 and the concentration determined by Bradford assay. 
 
2.8.3 Density centrifugation 
 
A density gradient of Opti-Prep (Axis Shield, Sigma Aldrich, USA) was prepared in PBS. 
From bottom to top, Opti-Prep layers were: 1ml 30%, 1ml 25%, 2ml 20%, 2ml 15%, 2ml 
10%. 3mg concentrated supernatant was loaded onto the top of the gradient, which was 
then centrifuged at 30,000xg for 3h. The tube content was then fractioned (0.5ml/fraction). 
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2.8.4 Alkaline phosphatase and β-galactosidase assays 
 
For each preparation of OMV, the fractions of the Opti-prep density gradient were assayed 
for alkaline phosphatase activity (Mossner et al., 1980) and β-galactosidase activity (Zhang 
& Bremer, 1995). The arbitrary units/ml of each enzyme were calculated and the ratio of 
alkaline phosphatase units to β-galatosidase units determined. The three fractions with the 
highest ratio were pooled. 
 
2.8.5 Dynamic light scattering (DLS) 
 
50µl of 0.5mg/ml WT B. fragilis concentrated supernatant was analysed by DLS, using a 
Zetasizer APS (Malvern Instruments, UK) according the manufacturer's instructions, to 
calculate an average diameter of the OMV. BHI-S and PBS controls were analysed for 
comparison. 
 
2.9 Proteomic techniques 
2.9.1 Sample preparation 
 
1mg of the concentrated samples of OMV was precipitated using methanol and chloroform: 
to the sample was added 4x starting volume (SV) methanol, 2x SV chloroform and 2x dH2O 
(with vortexing after each addition). The sample was then centrifuged at 16,000xg for 2 
minutes, after which the top aqueous layer was removed and 3x SV methanol was added. 
The sample was vortexed and centrifuged at 16,000xg for 10 minutes. The supernatant was 
removed and discarded and the pellet was vacuum dried to remove any additional solvent 
(Le Bihan et al., 2011). The dried pellet was resuspended in a mixture of 62.5µl 8M urea, 
12.5µl 200mM DTT and 12.5µl 1M ammonium bicarbonate and incubated for 30 minutes at 
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room temperature. 12.5µl 500mM iodoactemide and 10µl 1mg/ml trypsin were added and 
the sample mixed thoroughly. The mixture was left shaking at room temperature overnight, 
after which 10µl were cleaned using Stagetips (Le Bihan et al., 2011; Rappsilber et al., 
2007). 
 
2.9.2 LTQ-Orbitrap mass spectrometry 
 
The samples were loaded onto a 1200 binary HPLC system (Agilent, USA) for capillary 
HPLC, which delivered peptides to a hybrid LTQ-Orbitrap XL (Thermo-Fisher Scientific, UK) 
for mass spectrometry. These devices were controlled using Xcalibur 2.0.7 software 
(Thermo Scientific, UK) (Le Bihan et al., 2010). HPLC-MS was performed by Dr Sarah 
Martin (Thierry lab, SynthSys, University of Edinburgh). 
 
2.9.3 Analysis  
 
Mascot (Matrix Science, USA) was used to compare experimental peptide hits with the 
pattern of predicted hits from the genome sequence of B. fragilis (NCBI) and produce a list of 
identified proteins. Progenesis (Nonlinear Dynamics, UK) was used for label-free 
quantitation and comparison of the OMV and PP samples (Le Bihan et al., 2011). Further 
protein identification was performed using protein BLAST (NCBI). 
 
2.10 OMV antibacterial assays 
2.10.1 Bacterial culture and inoculation 
 
Growth curves were prepared in triplicate in 5ml aliquots of LB without antibiotics. For the 
first experiment, aliquots were inoculated with 20µl overnight S. enterica Typhimurium 
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culture along with 500µl of either PBS, 1mg/ml WT concentrated supernatant or 1mg/ml 
Δubb concentrated supernatant. Cultures were grown at 37ºC with shaking, and at 0, 2, 4, 6 
and 8 hours after inoculation 100µl of each culture was diluted to an appropriate 
concentration (10-1-10-3) in PBS and spread onto LB agar. 5ml aliquots of LB were also 
inoculated with just concentrated supernatants or PBS and grown for 8h at 37ºC with 
shaking, after which 100µl were spread onto LB agar. Plates were incubated at 37ºC for 48h, 
after which colonies were counted and Cfu/ml was calculated based on the dilution factor. 
 
For the second experiment, aliquots were inoculated with 5µl S. enterica Typhimurium 
overnight culture then grown at 37ºC with shaking for 2h. 500µl of either PBS or 0.5mg/ml, 
1mg/ml, or 2mg/ml of concentrated supernatant from WT, WT (gent), pGB920, or Δubb B. 
fragilis was then added to the cultures. The cultures were then grown for a further 8h, and at 
2, 4, 6, 8 and 10h, 100µl were taken from each culture and serially diluted (10-1-10-6). 10µl of 
each dilution were spotted onto LB agar. Controls were set up the same as in experiment 1. 
Plates were grown at 37ºC for 48h, after which the number of colonies were counted from 
dilutions with 2-30 colonies and the Cfu/ml were calculated based the dilution factor. 
 
2.10.2 T-test analysis 
 
T-tests (Microsoft Excel 2010, USA) were used to compare 2 datasets at different time 













Patrick et al (2011) identified a gene (ubb, formerly designated BF3883) in NCTC9343, 
which shares 76% identity (151/199bp, e value of 5x10-29) with a ubiquitin-encoding gene 
from migratory grasshopper entomopoxvirus. The ubb gene encodes a 76aa protein (BfUbb) 
which shares 63% identity (48/76aa) with human ubiquitin (Ubc52) (Figure 7 A). The key 
lysines and arginines involved in interactions with E1 activating enzyme are conserved in 
BfUbb, however there are some significant differences between the primary structure of 
BfUbb and Ubc52. Firstly, BfUbb contains an N-terminal signal sequence, suggesting it is 
exported from the cytoplasm. Secondly, in place of the double glycine (GG) residues that are 
required for covalent interaction between ubiquitin and E1 activating/E2 conjugating 
enzymes, there is a single cysteine residue. Thirdly, BfUbb is missing 1 of the 7 lysines used 
in ubiquitin chain formation: K11, which is replaced with a tryptophan (W11) (Patrick et al., 
2011). A comparison of the solved structure of Ubc52 (Vijaykumar et al., 1987) and the 
predicted structure of BfUbb, created using PHYRE2 (Kelley & Sternberg, 2009), shows that 
BfUbb has a β-grasp fold with a free C-terminal tail, similar to ubiquitin. However, there are 







Figure 7 Comparisons of human ubiquitin Ubc52 and B. fragilis ubiquitin BfUbb. (A) A sequence 
comparison showing the additional periplasmic signal sequence at the N terminus of BfUbb, the lack 
of the C terminal double glycine residue, and the conservation of key arginine and lysine residues 
involved in interactions with E1 activating enzyme (bold, asterisks) (Patrick et al., 2011). (B) The 
solved 3D structure of Ubc52 (Vijaykumar et al., 1987) and the predicted 3D structure of BfUbb using 




The ubb gene in B. fragilis is believed to be the product of an interkingdom HGT and is 
located in an 11kb, low GC region of the NCTC9343 genome (Patrick et al., 2011). It is also 
present in 7 other sequenced strains of B. fragilis (NCBI) and has been identified by PCR in 
several other strains isolated from clinical samples of various abscesses, however it has not 
yet been detected in any other Bacteroides species (Patrick et al., 2011).  
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A deletion mutant of ubb (Δubb) was generated using a previously described method 
(Patrick et al., 2009), replacing ubb with an ermF (erythromycin resistance) cassette. This 
mutation did not appear to affect growth or morphology of B. fragilis in BHI-S or DM. 
Reverse transcription PCR (RT-PCR) of ubb mRNA indicated that BfUbb is transribed in 
both the exponential and stationary phases of growth (Figure 8 a). A 6xHis fusion of ubb was 
expressed from pTRC99A in DH5α and purified. This recombinant (rBfUbb) was used to 
generate antibodies against BfUbb, which were then used to probe for BfUbb in whole cell 
extracts of NCTC9343 and the Δubb mutant by Western blotting (Figure 8 b). 3 bands were 
detected in the NCTC9343 strain: a ~12kDa band consistent with the size of the pre-
processed holoprotein; a ~9kDa band, the strongest band, consistent with the size of the 
processed protein (8.6kDa); a smaller band which is believed to be a product of degradation. 
None of these bands were detected in the Δubb mutant. Cleavage of the signal sequence to 
produce a ~9kDa protein is consistent with BfUbb being exported to the periplasm. A 
smeared band the size of processed BfUbb could also be detected by Western blotting in the 
concentrated supernatants of NCTC9343 (Figure 8 c), suggesting that the protein is 








Figure 8 "Detecting expression of BfUbb. (a) Agarose gel showing transcription of ubb detected by 
RT-PCR. Lanes: 1, PCR using genomic DNA; 2–4, PCR using RNA from cultures at OD600 0.4, 0.8 
and 1.6 (indicates absence of DNA contamination); 5–7, RT-PCR using RNA from cultures at OD600 
0.4, 0.8 and 1.6. The position of ubb is indicated with an arrow. (b) Immunoblot using rabbit anti-
BfUbb polyclonal antiserum. Lanes: 1, purified 6×His-BfUbb; 2, whole-cell extract of B. fragilis 
NCTC9343; 3, whole-cell extract of B. fragilis Δ ubb. The lowest band in lane 2 represents a 
degradation product of BfUbb. (c) Immunoblot of concentrated supernatant from a culture of 
NCTC9343 grown in DM (lane 1), compared with purified 6×His-BfUbb (lane 3). Molecular mass 
markers are shown in lane 2" (Patrick et al., 2011). 
 
 
Since the deletion of ubb did not appear to affect the viability of B. fragilis it was 
hypothesised that BfUbb may act as an effector in the host cells. The ubiquitylation cycle 
was recreated using HeLa extracts and a biotinylated lysozyme substrate, and visualised by 
Western blotting against the lysozyme. When the HeLa extract and lysozyme were mixed 
directly and incubated at 37ºC for 180 minutes, the increased molecular weight of the 
lysozyme indicates ubiquitylation of the substrate. However, if the HeLa extract was 
preincubated with BfUbb, ubiquitylation does not occur (Figure 9 a). Moreover, when mixed 
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together in non-reducing conditions and incubated at 37ºC for 60 minutes, BfUbb was found 
to covalently bind with E1 activating enzyme in the absence of ATP (Figure 9 b). It is 
possible, therefore, that BfUbb acts as a suicide substrate, binding and inactivating enzymes 
of the ubiquitylation cycle, by forming a disulphide bridge between the C-terminal cysteine 
and the active site of the enzyme (Patrick et al., 2011).  
 
Unlike the species of Actinobacteria that utilise Pup as a marker for protein degradation, B. 
fragilis does not have a 26S- or 20S-like proteasome system, nor does it encode any known 
E1 activating enzymes, E2 conjugating enzymes or E3 ligases (Patrick et al., 2011). It is 
therefore unlikely that BfUbb is acting as a protein modifier within the bacterial cell. Many 
bacterial pathogens secrete virulence factors that interfere with the ubiquitin system of the 
host (Ashida et al., 2014; Munro et al., 2007); most of these are E3 ligases, deubiquitylases 
or other ubiquitin-binding proteins and usually have a specific target in a specific pathway. 
However, a bacterial homologue of ubiquitin itself, such as BfUbb, has the potential to interfere 
with any host cell process that utilises ubiquitin. In the case of B. fragilis this may be the TLR-
activated inflammatory response; B. fragilis has been shown to interact with the inflammatory 
pathways by other mechanisms (Shen et al., 2012) (section 1.1.4). Such activity could either 
contribute to inflammatory disease, such as that caused by ETBF, or protect the host against 
inflammatory disease, as observed with PSA by Shen et al (2012). Alternatively, BfUbb may 
act as a virulence factor in other diseases, or be a causative agent in autoimmune diseases, 






Figure 9 "In vitro activity of BfUbb. (a) Immunoblot of in vitro ubiquitination of lysozyme using HeLa 
cell extract in the absence (lanes 1 and 2) or presence (lanes 3 and 4) of BfUbb. Samples were taken 
at the start of the reaction (0) and at 180 min (180). Lane 2 shows the increase in molecular mass of 
the lysozyme substrate following covalent attachment of ubiquitin (+Ub). This covalent modification is 
inhibited by the addition of BfUbb (lane 4). (b) Covalent complexes between human E1 and BfUbb, 
under non-reducing conditions, were detected by immunoblotting using anti-bovine ubiquitin 
polyclonal serum. Two reactions using different concentrations of E1 are shown, with time points at 0 
and 60 min. Note there was some antibody cross-reactivity with E1 at the higher concentration" 





There is evidence that BfUbb is capable of interfering the ubiquitylation cycle of eukaryotic 
cells (Patrick et al., 2011). In order for this to occur in vivo the protein must be delivered to 
epithelial cells of the GI tract. BfUbb can be detected in the concentrated supernatant of WT 
cell culture, suggesting that it is present in OMV. B. fragilis OMV are known to be engulfed 
by DCs (Shen et al., 2012) and may interact with other cells in the gastro-intestinal 
epithelium, thus providing a mechanism for delivery of BfUbb to the host.  
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BfUbb can bind E1 activating enzyme and inhibit ubiquitylation of lysozyme in vitro (Patrick 
et al., 2011), suggesting that it can act as a suicide substrate for ubiquitylation reactions. 
However, inhibiting all ubiquitylation in the host cell would lead to necrosis (Xu et al., 2010), 
and it is more likely that B. fragilis, which exists as a commensal rather than a pathogen in 
the gut, would have retained BfUbb as a mechanism to affect a single target or pathway to 
benefit its own long term survival (and coincidentally the health of the host). Identifying 
binding partners for BfUbb, including specific E2 conjugating enzymes and E3 ligases, would 
aid significantly in determining its function.  
 
On average mammalian cells contain ~108 molecules of ubiquitin (Haglund & Dikic, 2005; 
Komander & Rape, 2012). If BfUbb is utilising the host cell ubiquitin pathway it needs to be 
able to compete with endogenous ubiquitin, however it is unlikely that the OMV can deliver 
enough BfUbb for it to match the concentration of ubiquitin in the whole cell. Therefore, 
BfUbb needs to be highly concentrated at a specific location; the OMV may deliver its 
contents directly to a location or BfUbb may interact with a chaperone or similar protein. 
Determining the subcellular localisation of BfUbb may help determine its target and function. 
Lastly, the phenotypic effect resulting from the presence of BfUbb in the host cell may the 
biggest indicator of its function in vivo. Morphological changes would suggest an alteration of 
cell cycle or cell structure, cytokine changes would indicate induction or suppression of cell 
signalling for pathways such as inflammation, whilst necrosis would suggest that all 
ubiquitylation is being inhibited. Alternatively, various clinical isolates containing B. fragilis 
can be screened for the presence of the ubb gene, potentially revealing correlations between 
the presence or absence of BfUbb and 1 or more diseases. 
 
The purpose of the following experiments was to characterise BfUbb, identify any target 
proteins/binding partners, determine its subcellular location within the host cell, and highlight 





3.2.1 Purification of rBfUbb 
 
Expression of the his-tagged, recombinant Bfubb, rBfUbb, in 500ml E. coli DH5α pTRC99A-
6xHBfUbb was induced with 1mM IPTG for 3 hours and the presence of the protein 
confirmed by SDS-PAGE and coomassie staining (Figure 10 A), after which cells were 
harvested and lysed. The lysate was filtered and passed over a nickel affinity (Ni) column, 
which was washed and then eluted with imidazole in a single fraction. The presence of 
rBfUbb in the elution fraction was confirmed by SDS-PAGE and coomassie staining (Figure 
10 B). The whole fraction was then concentrated using a centrifugal filter to ~2-3mg/ml (total 
~2ml, ~4-6mg). 0.5ml (~1-1.5mg) was passed through a Sepharose gel filtration column and 
eluted in 1ml fractions. Pure rBfUbb-containing fractions were identified by SDS-PAGE and 
coomassie staining (Figure 10 C) and pooled, then concentrated to a final concentration of 
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Figure 10 Coomassie stained gels showing the expression and purification of rBfUbb from E. coli 
DH5α pTRC99A-6xHBfUbb. (A) Whole cell extract of culture without (-) and with (+) 1mM IPTG. (B)  
Samples from the Ni affinity column: lysate prior to loading (L), the flow-through during loading of the 
column (F), the wash-off (W) and the eluted fraction (E). (C) The samples from the gel filtration 
column: eluted fraction from the Ni column (E), gel filtration fractions 1-8 and 9-16. The expected 
location of rBfUbb (9.6kDa) is indicated by an arrow on each gel. A second band, ~17kDa, can be 
seen in most lanes, which is believed to be a dimeric form of rBfUbb. 
 
3.2.2 BfUbb forms multimers in vitro 
 
When kept at 37ºC for >1 hour (or >6 months at -20ºC) in the absence of glycerol or a 
reducing agent, rBfUbb forms multimeric structures. A dimer is visible by coomassie staining 
(Figure 11 A) and up to a tetramer is visible by Western blotting (Figure 11 B). This effect is 
reproducible between different preparations of rBfUbb. The tetrameric and trimeric structures 
can be broken down by adding DTT to the sample (100mM in 0.5mg/ml BfUbb) or by boiling 
at 90ºC for 10 minutes, whilst the dimeric structure seems very stable (Figure 11 B). DTT-
sensitivity suggests that the intermolecular bonds between BfUbb residues in these 
multimers are disulphide bridges between cysteine resides. BfUbb contains 2 cysteine 
residues (C70 and C76), both in the C-terminal tail (Figure 7 A), which would allow formation 
of a unique chain (Figure 12). Interestingly, when incubated with human E1 activating 
enzyme (Uba1), pentamers and hexamers have also been observed by Western blotting 
(Figure 11 C). The E1 enzyme is not involved in ubiquitin chain formation so there is no clear 
mechanism for multimerisation involving this protein. BfUbb multimers have never been 
observed in samples extracted from B. fragilis culture (Figure 8, Figure 26), so the biological 
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Figure 11 Multimerisation of rBfUbb. Arrows indicate the number of rBfUbb molecules in the complex 
represented by each band. (A) Coomassie stain of 2 independently prepared samples of rBfUbb, 
1mg/ml, stored at -20ºC for >6 months. (B) Western blot of 0.5mg/ml rBfUbb incubated at 37ºC for 2 
hours. Lanes: 1, rBfUbb only; 2, + 100mM DTT; 3, boiled at 90ºC post-incubation; 4, + DTT and boiled 
post-incubation using rabbit anti-BfUbb primary antibodies and HRP-conjugated anti-rabbit secondary 
antibodies. X-ray film was exposed to chemiluminescent blot for 30s. (C) Western blot of 0.5mg/ml 





Figure 12 Possible structures of BfUbb dimers (A) and hexamers (B). A C70-C76 linkage (upper 
figures) would allow an elongating chain, similar to, but distinct from, those formed via lysine residues. 
Alternatively, a C76-C76 (or end-to-end) linkage would form a unique complex unseen in eukaryotic 
ubiquitin. The lack of additional cysteine residues prevents branched chain formation. Note that C70-











3.2.3 BfUbb interacts with E2 conjugating enzymes in vitro 
 
To determine whether BfUbb can form a covalent bond with E2 conjugating enzymes, as it 
does with E1 activating enzyme, rBfUbb was incubated with E1 in the absence of ATP at 
37ºC for 1 hour, after which the sample was mixed with 8 randomly chosen human E2 
enzymes and incubated for another 2 hours at 37ºC. Final mixtures were analysed SDS-
PAGE (without boiling the samples in DTT) and Western blotting (Figure 13 A). Visible in 
most lanes are bands consistent with the expected size of covalent complexes formed 
between rBfUbb and the various E2 enzymes (arrows), as well as the 3 bands representing 
the monomeric, dimeric and trimeric forms of rBfUbb. For example, a ~28-30kDa band in the 
lane containing Ube2E1 (lane "E1") is approximately the size of the enzyme (21.4kDa) 
combined with rBfUbb (9.6kDa). Similarly, a covalent complex between Ube2R2 (27.2kDa) 
and rBfUbb would be ~35.8kDa and a band of roughly this size can be seen in the Ube2R2 
sample (lane "R2"). The most striking example is the covalent complexes formed with 
Ube2Q2 (42.8kDa): a band of ~45-50kDa is consistent with Ube2Q2 combined with rBfUbb 
(lane "Q2"), however a larger band of ~90kDa can also be seen which might indicate that 2 
enzyme molecules are binding the same rBfUbb molecule. The expected molecular weight 
of that complex would be 94.2kDa. Other reactions, e.g. Ube2E3 and Ube2L3 (Figure 13 A, 
lanes "E3+U" and "A+U"), also contain multiple bands larger than the rBfUbb trimer, but 
smaller than a complex containing 2 copies of the enzyme, suggesting either that rBfUbb is 
binding the E2 enzymes in multimeric form or that E2 enzymes are binding multiple 
monomers. The most striking example of this is Ube2K (Figure 13 C). Lane "K+U" contains a 
band of ~50kDa, which is consistent with a complex formed between Ube2K (22.4kDa) and 
3 rBfUbb residues (again, whether this is trimeric rBfUbb or 3 monomers is unknown). No 
bands can be detected in any samples containing only an E2 enzyme (Figure 13 B, C), 







Figure 13 Western blots showing mixtures of BfUbb (U) incubated with E1 activating enzyme (E1AE) 
and randomly selected E2 enzymes, separated by SDS-PAGE, reacted with anti-rBfUbb polyclonal 
antisera, visualised with anti-rabbit-HRP antibody. rBfUbb was incubated with E1 activating enzyme at 
37ºC for 1h then mixed with each E2 enzyme and incubated at 37ºC for 2h in non-reducing conditions 
(alternatively, rBfUbb was incubated for 3h on its own, or single E2 enzymes were incubated for 2h in 
the absence of E1 or rBfUbb). Final concentrations were: 0.25mg/ml (30µM) rBfUbb, 0.1µM E1, 
0.25µM E2. 10µl of each sample was mixed with 5µl loading buffer and analysed by SDS-PAGE and 
Western blotting using rabbit anti-BfUbb primary antibody and anti-rabbit secondary antibody. (A) 3 
bands representing the monomeric, dimeric and trimeric forms of rBfUbb can be seen in most lanes. 
Each lane also contains at least 1 other band which corresponds to the expected size of a complex 
containing an E2 enzyme and at least 1 copy of rBfUbb. Some of these bands are indicated by 
arrows. (B) and (C) The 3 rBfUbb bands can be seen in all lanes containing rBfUbb. There are no 
bands in any lanes containing only an E2 enzyme and the E1 activating enzyme, indicating that these 
enzymes are not cross-reactive with the anti-BfUbb antibody. In these blots, bands representing E2 




To further investigate the nature of these interactions, rBfUbb was incubated with 22 E2 
enzymes (Table 4) in 4 conditions: 1, rBfUbb was incubated directly with each E2 enzyme; 2, 
rBfUbb was pre-incubated with E1 activating enzyme then incubated with each E2 enzyme; 
3, same as condition 1 but in the presence of reducing agent DTT (dithiothreitol); 4, same as 
condition 2 but in the presence of DTT. Each sample was analysed by SDS-PAGE and 








Name  Alternative 
Name  
Size (kDa)  Associated Function/Pathway 
UBA1  
 
118  Initiating Ubb transfer  
Ube2A  (Rad6A)  17.1  Post-replicative DNA repair  
Ube2B  
 
17.3  Post-replicative DNA repair  
Ube2C  UbcH10  19.7  Destruction of mitotic cyclins  
Ube2D1  Ubc5A  16.6  Cell cycle regulation 
Ube2D2  UbcH5B  16.7  Cell cycle regulation  
Ube2D3  UbcH5C  16.7  Cell cycle regulation  
Ube2D4  UbcH5D  16.6  Unknown  
Ube2E1  UbcH6  21.4  Unique N-terminal extension  
Ube2E2  UbcH8  22.3  Mediate degradation of misfolded proteins  
Ube2E3  UbcH9  22.9  Mediate degradation of misfolded proteins 
Ube2F  
 
21.1  Unknown  
Ube2G1  
 
19.5  Degradation of muscle-specific proteins  
Ube2G2  
 
18.6  Protein degradation  
Ube2H  UbcH2  20.7  Histones and cytoskeletal proteins  
Ube2I  
 
18.0  Transcription 
Ube2K  E2-25K  22.4  Apoptosis suppression  
Ube2L3  
 
17.9  p53 and NFkB degradation  
Ube2L6  
 
17.8  p53 and NFkB degradation  
Ube2M  UbcH12  20.9  Cell cycle regulation, mediates cytotoxicity 
Ube2N  Ubc13, Uev1a  17.1  Post replicative DNA repair  
Ube2Q2  
 
42.8  Cell cycle regulation 
Ube2R1  Ubc3, Cdc34  26.7  Cell cycle regulation 
Ube2R2  Ubc3B 27.2  Cell cycle regulation, cell-cell adhesion  
Ube2S  
 
23.8  Cell cycle regulation  
Ube2T  
 
22.5  DNA damage repair  
Ube2W  
 




Table 4 All E1 activating and E2conjugating enzymes used in this study, showing all known 




rBfUbb is able to form covalent complexes with some E2-conjugating enzymes when not 
pre-incubated with E1-activating enzyme (Figure 14 A, B, C). For example, the Ube2H 
(20.7kDa) and Ube2K (22.4kDa) reactions both contain a band of approximately 35-40kDa, 
whilst the Ube2R1 (26.7kDa) and Ube2R2 (27.2kDa) both contain a band of approximately 
40-45kDa. This is consistent with each of these enzymes binding 2 copies of rBfUbb, 
however these blots do not allow for differentiation between E2 enzymes binding dimeric 
rBfUbb or 2 copies of monomeric rBfUbb binding a single E2 enzyme. When pre-incubated 
with E1-activating enzyme, rBfUbb forms covalent complexes with most E2 enzymes in both 
monomeric and multimeric form, as indicated by multiple bands above 28.8kDa (the 
molecular weight of trimeric rBfUbb) (Figure 14 D, E, F). These interactions are DTT 
sensitive; there is no indication of interactions between rBfUbb and any of the E2 enzymes 
without pre-incubation with E1 activating enzyme when DTT is present (Figure 14 G, H, I). 
There are also significantly fewer detectable interactions between rBfUbb and the E2 
enzymes when pre-incubated with E1 activating enzyme in the presence of DTT (Figure 14 
J, K, L), however, some bands still appear under these conditions. A ~30kDa band can be 
seen in the Ube2M sample (red arrow) in conditions 2 and 4, consistent with Ube2M 
(20.9kDa) combined with 1 molecule of rBfUbb. This band is absent in conditions 1 and 3, 
suggesting that binding of rBfUbb to Ube2M is dependent on E1 activating enzyme. A ~40-
45kDa band can be seen in both the Ube2R1 (red asterisk) and Ube2R2 (red hash) 
samples, appearing faintly in conditions 1 and 4 and strongly in condition 2 (but not 
appearing in condition 3). This suggests that the interaction between rBfUbb and these 
enzymes is not completely dependent on E1 activating enzyme, but that E1 is able to 
partially rescue the DTT sensitivity of these complexes. Pre-incubation of E1 also enables 
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the formation of the Ube2M-rBfUbb complex in the presence of DTT. These results indicate 
that a) rBfUbb most likely forms disulphide bonds with E2 enzymes via 1 of its cysteines, and 
b) the E1 enzyme is involved in the transfer of rBfUbb to at least some E2 enzymes. This 
contradicts the previous hypothesis, that BfUbb acts as a suicide substrate, permanently 
















Figure 14 Western blots of mixtures containing rBfUbb and 22 E2 conjugating enzymes in 4 different 
conditions, reacted with rabbit polyclonal antisera raised against rBfUbb, and visualised with anti-
rabbit-HRP antibody. Condition 1 (A, B, C): rBfUbb was incubated at 37ºC for 1h then mixed with 
each E2 enzyme and incubated at 37ºC for 3h in non-reducing conditions. Condition 2 (D, E, F): 
rBfUbb was mixed with E1 activating enzyme at 37ºC for 1h then mixed with each E2 enzyme and 
incubated at 37ºC for 3h in non-reducing conditions. Condition 3 (G, H, I): same mixtures as condition 
1 but in the presence of DTT. Condition 4 (J, K, L): same mixtures as condition 2 but in the presence 
of DTT. Final concentrations were: 0.25mg/ml (30µM) BfUbb, 0.1µM E1, 0.25µM E2, 100mM DTT. 
10µl of each sample was mixed with 5µl loading buffer and analysed by SDS-PAGE and Western 
blotting using rabbit anti-BfUbb primary antibody and anti-rabbit secondary antibody. The bonds 
formed between rBfUbb and E2 enzymes are DTT-sensitive and partially E1-dependent. Some E2 
enzymes form covalent complexes with rBfUbb in the absence of E1 (A, B, C) but not if DTT is 
present (G, H, I). When pre-incubated with E1-activating enzyme rBfUbb forms complexes with most 
E2s (D, E, F). Again, these interactions are DTT sensitive (J, K, L), however some bands can still be 
detected, specifically in Ube2M (arrow), Ube2R1 (asterisk) and Ube2R2 (hash). There is a large 
amount of background noise, believed to be caused by cross-reactivity with the polyclonal antisera, 
on several of these blots, which often obscures the bands representing the monomeric (M) and 
dimeric (D) forms of BfUbb. 
 
3.2.4 No binding partners of BfUbb could be identified in vitro 
 
To identify possible binding partners of BfUbb in the host cell, rBfUbb was incubated with 
Caco-2 cell extracts, in the presence or absence of DTT. The mixtures were then passed 
over a Ni column and the eluted fractions were analysed by non-reducing SDS-PAGE and 
Coomassie staining (Figure 15 A and B). There were no bands exclusive to those samples 
incubated with rBfUbb that would be indicative of rBfUbb complexed with a binding partner. 
The samples were also analysed via Western blotting using anti-BfUbb antibody and no 
bands larger than the BfUbb monomer, dimer and trimer could be detected (Figure 15 C and 
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D) The presence of DTT did not significantly impact the results. So far, the only known 
































Figure 15 SDS-PAGE gels imaged with Coomassie (A and B) and Western blotting (C and D), 
showing Ni column fractions of Caco-2 cell extract incubated in 4 conditions. Condition 1: 10mg Caco-
2 cell lysate was incubated at 37ºC for 3h with gentle shaking. Condition 2: 10mg Caco-2 cell lysate 
was incubated with 1mg rBfUbb at 37ºC for 3h with gentle shaking. Condition 3: Same as 1 but with 
100mM DTT. Condition 4: Same as 2 but with 100mM DTT. The final concentrations were 2mg/ml 
Caco-2 cell lysate, 0.2mg/ml rBfUbb, 100mM DTT. All samples were mixed 2:1 with loading buffer 
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(but were not boiled in DTT) and analysed by SDS-PAGE and Coomassie staining or Western 
blotting. (A) rBfUbb (U), Caco-2 cell lysate (L) and the flowthrough (F), wash (W) and elution (E) 
fractions of the samples from conditions 1 and 2. Aside from the rBfUbb band, there were no bands 
present in the elution fraction of condition 2 that were not present in that of condition 1. (B) U, L and 
the F, W and E fractions of conditions 3 and 4. The presence of DTT did not significantly impact the 
samples. (C) and (D) showed the same results as (A) and (B), respectively. Western blotting was 
performed using the anti-BfUbb antibody, the exposure time was 2 minutes. The only band detectable 
in the eluted fractions for conditions 2 and 4 was BfUbb itself. No larger bands were evident. The 
apparent banding in the "L" lane in (D) was most likely due to accidental exposure of the film. 
 
 
3.2.5 Generation of a recombinant BfUbb protein with a cleavable affinity tag 
 
Native (untagged) and fluorescently tagged forms of BfUbb would allow further 
characterisation of the protein. For example, native BfUbb can be used for crystallisation and 
X-ray crystallography, and fluorescently tagged BfUbb can be used in ligand-binding assays. 
Expression plasmid pET19b (Novagen), which encodes an N-terminal 10xHis affinity tag 
followed by an enterokinase cleavage sequence, was chosen and an analytical digest of this 
plasmid was performed to confirm its identity (Figure 16 A). To create the cleavable affinity 
tagged recombinant the ubb gene was amplified from B. fragilis genomic DNA using primers 
Bfndei and Brbamhi (PCR product designated Pbfubb) (Figure 16 B). To create the 
fluorescent protein fusion, the ubb gene was amplified from B. fragilis genomic DNA using 
primers Bfx and Brbamhi (PCR product designated Pbfubbx) and the yellow fluorescent 
protein (YFP) gene, yfp, was amplified from pDL3196 using primers Yfndei and Yrx (PCR 
product designated PYx) (Figure 16 B). A crossover PCR was performed using PYx, 
Pbfubbx and primers Yndei and Bbamhi (PCR product designated PYbfubb) (Figure 16 C). 
pET19b, Pbfubb and PYbfubb were sequentially digested with BamHI then NdeI. Neither 
enzyme caused unexpected digestion of the plasmid or PCR products (Figure 16 D and E). 
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The digested products were then mixed (pET19b with Pbfubb and pET19b with PYbfubb) 
and ligated to produce pET19b-10xH-BfUbb and pET19b-10xH-YFP-BfUbb. E. coli DH5α 
was transformed with both ligations (DH5α was also transformed with the empty vector); 
transformed cells were then grown on LB ampicillin plates at 37ºC. 8 individual colonies of 
both pET19b-10xH-BfUbb and pET19b-10xH-YFP-BfUbb transformed cells were picked, 
transferred onto fresh LB agar containing ampicillin and incubated at 37ºC for a further 24h. 
DNA was isolated from each colony by single colony preparation and analysed by agarose 
gel electrophoresis and staining with ethidium bromide (Figure 16 F and G). The majority of 
selected colonies contained the ligated products.  
 
Three successful transformants containing each construct were grown in LB ampicillin and 
the plasmid DNA purified by miniprep (Qiagen). The plasmids were digested with NdeI and 
BamHI and analysed by agarose gel electrophoresis and ethidium bromide staining (Figure 
16 H and I). The change in banding pattern after digestion confirms the presence of inserts 
the size of Pbfubb and PYbfubb in the respective plasmids. The inserts in pET19b-10xH-
BfUbb and pET19b-10xH-YFP-BfUbb were sequenced (DNA Sequencing and Services, 
MRC, Dundee) and the results (Appendix II) indicate that the DNA sequence of both inserts 
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Figure 16 DNA agarose gels showing the construction of 2 plasmids, 1 encoding a form of BfUbb with 
a cleavable affinity tag (pET19b-10xH-BfUbb) and 1 encoding an N-terminal YFP-fusion of BfUbb 
(pET19b-10xH-YFP-BfUbb), visualised with ethidium bromide under UV excitation. (A) Analytical 
digest of pET19b. Lanes: pET19b digested with: 1) BamHI 2) EcoRI 3) ApaI 4) BamHI+EcoRI 5) 
BamHI+ApaI 6) EcoRI+ApaI 7) Undigested. pET19b is 5717bp - a band of this size was seen in lanes 
1-3 (there is some *activity in BamHI due to the buffer used). The double digests should give bands 
as follows: BamHI+EcoRI - 5396, 321; BamHI+ApaI - 4600, 1117; EcoRI+ApaI - 4279, 1438. Although 
the smaller bands were difficult to see, the banding patterns in lanes 4-6 matched those expected. (B) 
Initial PCR products: 1) Pbfubb, 255bp 2) Pbfubbx, 258bp 3) PYx, 734bp. All bands matched 
expected sizes. (C) Crossover PCR product. Lanes 1-6) PYbfubb, 992bp. (D) BamHI digest of 
plasmid and PCR products. Lanes: 1) Undigested pET19b, 2) pET19b+BamHI, 3) Undigested Pbfubb, 
4) Pbfubb +BamHI, 5) Undigested PYbfubb, 6) PYbfubb +BamHI. There was no obvious degradation 
of the plasmid or PCR products. (E) NdeI digest of BamHI digests from (D). Lanes: 1) Double 
digested pET19b, 2) Undigested pET19b, 3) Double digested Pbfubb, 4) Undigested Pbfubb, 5) 
Double digested PYbfubb, 6) Undigested PYbfubb. Again, there was no obvious degradation of any 
bands. (F) Plasmids seen in the single colony preparations of pET19b-10xH-BfUbb transformed cells. 
Lanes: 1-8) Single colony preparation s from 8 different colonies, 9) Undigested pET19b. Lanes 1-2 
and 4-8 contain plasmids larger than pET19b, suggesting that they carry the insert. These bands 
were faint because pET19b is a low copy number plasmid. (G) Plasmids seen in the single colony 
preparations of pET19b-10xH-YFP-BfUbb transformed cells. Lanes: 1) Undigested pET19b, 2-9) 
Single colony preparations from 8 different colonies. Lanes 2-9 all contain a plasmid larger than 
pET19b, suggesting that they carry the insert. (H) Digests of miniprepped plasmids from cells 
transformed with pET19b-10xH-BfUbb. Lanes: 1) Undigested pET19b-10xH-BfUbb, 2,4,6) pET19b-
10xH-BfUbb +BamHI, 3,5,7) pET19b-10xH-BfUbb +BamHI+NdeI. The excised bands were not visible, 
however the reduction in size in lanes 3, 5 and 7 is consistent with excision of a ~200-300bp band. (I) 
Digests of miniprepped plasmids from cells transformed with pET19b-10xH-YFP-BfUbb. Lanes: 1) 
Undigested pET19b-10xH-YFP-BfUbb, 2,4,6) pET19b-10xH-YFP-BfUbb +BamHI, 3,5,7) pET19b-
10xH-YFP-BfUbb +BamHI+NdeI. The excised bands were not visible, however the reduction in size in 




Expression of 10xH-BfUbb was induced in 500ml E. coli BL21 DE3 pET19b-10xH-BfUbb 
with 400µM IPTG for 4h, after which the cells were harvested and lysed. The lysate was 
clarified and filtered, then passed over a Ni column, washed and eluted in 8 fractions using 
imidazole. Presence of 10xH-BfUbb was confirmed by SDS-PAGE and Coomassie staining 
(Figure 17 A and B). The 10xH-BfUbb-containing fractions were pooled and concentrated to 
~3-4mg/ml (total ~2ml, 6-8mg), then 0.5ml (~1.5-2mg) were loaded onto a Sepharose gel 
filtration column and eluted in 1ml fractions. Fractions were analysed by SDS-PAGE and 
Coomassie staining (Figure 17 C). 10xH-BfUbb should have a molecular weight of 11.6kDa 
and a band of this size can be seen in lanes containing the protein, however there is also a 
smaller band (~10kDa) which was not removed by gel filtration. The origin of this band is 
unknown. Multiple attempts were made to cleave the His-tag with enterokinase, however 
none resulted in the isolation of native ubiquitin. Cleavage of the post-gel filtration fraction 
was unsuccessful (Figure 17 D), whereas cleavage of the pooled elution fraction from the Ni 
column resulted in complete degradation of the sample, suggesting that there is a protease 
present in the elution fraction (Figure 17 E). Expression of 10xH-YFP-BfUbb has also been 
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Figure 17 Gels demonstrating the expression of 10xH-BfUbb in bacterial culture samples, the 
purification of this by Ni-NTA affinity, and the result of incubation of 10xH-BfUbb with enterokinase, 
visualised by Coomasie staining. (A) and (B) Cell lysate (L), which shows overexpression of 10xH-
BfUbb, prior to loading was loaded onto a Ni column. Subsequent lanes show: flowthrough from the 
column (F); the wash-off from the column (W); rBfUbb (U); elution fractions (E1-8); rBfUbb. (C) Eluted 
fractions were pooled (E), 0.5ml loaded onto a gel filtration column and eluted in 1ml fractions (1-16). 
Fractions 7 and 8 were pooled. (D) 0.5mg 10xH-BfUbb was incubated with 5µg enterokinase in 10ml 
enterokinase buffer at 37ºC for 16h. The mixture was then passed over a Ni column, washed and 
eluted in a single fraction. Lanes: pooled eluted fractions (E); the flowthrough and wash fraction, i.e. 
cleaved BfUbb (C); the elution fraction, i.e. uncleaved 10xHBfUbb and remaining his-tags (Ni); rBfUbb 
(U). The enterokinase does not appear to have cleaved any of the protein. (E) 0.5mg/ml 10xH-BfUbb 
was incubated with 10µg enterokinase in 10ml enterokinase buffer containing Ni-Agarose at 37ºC with 
gentle shaking for 16h. The sample was then centrifuged to pellet the Ni-Agarose. The supernatant 
was collected and the Ni-Agarose pellet was incubated in imidazole-containing buffer at room 
temperature to release any bound protein. Lanes: pooled elution fraction (E); supernatant from the 
cleavage mixture (C); fraction eluted from the Ni-Agarose (Ni); rBfUbb (U). No protein was detected in 




3.2.6 Generation of BfUbb constructs for expression in mammalian cells 
 
To determine whether BfUbb has an effect on, or localises to a specific area of, a host 
epithelial cell, it was necessary to create constructs allowing the expression of an affinity 
tagged form of BfUbb, and a fluorescent protein fusion of BfUbb, in mammalian cells. The T-
REx mammalian expression system, consisting of the regulator plasmid pcDNA6/TR and the 
expression plasmid pcDNA4/TO, was used as it allows high levels of inducible expression 
(Life Technologies, 2011). Analytical digests of both plasmids (which were not sourced 
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directly from the manufacturer) were performed to confirm their identity (Figure 18 A and B). 
To create a His-tagged construct the ubb gene was amplified from B. fragilis genomic DNA 
using primers Bfhindiii and Brbamhi (PCR product designated 4bfubb) (Figure 18 C). To 
create the fluorescent protein fusion, the ubb gene was amplified from B. fragilis genomic 
DNA using primers Bfx and Brbamhi (PCR product designated 4bfubbx) and the yfp gene 
was amplified from pDL3196 using Cfhindiii and Crx (PCR product designated 4Yx) (Figure 
18 C). Crossover PCR was performed using 4Yx, 4bfubbx and primers Cfhindiii and Brbamhi 
(PCR product designated 4Ybfubb) (Figure 18 D). To create a YFP control construct the yfp 
gene was amplified from pDL3196 using Cfhindiii and Crbamhi (PCR product designated 4Y) 
(Figure 18 C). pcDNA4/TO and PCR products 4bfubb, 4Ybfubb and 4Y were digested first 
with BamHI then with HindIII (Figure 18 E and F). Digested products were mixed 
(pcDNA4/TO with each of the PCR products) and ligated. E. coli JM109 cells were 
transformed with each ligated product (and the empty vector) and cells were grown on LB 
ampicillin plates at 37ºC. The transformation efficiency of the ligations was ~2-6 
transformants/µl ligation.  
 
Patches of each ligation (8 each of pcDNA4/TO-6xHBfUbb and pcDNA4/TO-YFP-BfUbb, 
and 6 of pcDNA4/TO-YFP) were made onto fresh LB agar containing ampicillin. DNA was 
extracted by single colony preparations and analysed by agarose gel electrophoresis and 
stained with ethidium bromide (Figure 18 G, H and I). Three colonies from each 
transformation, believed to contain the correct version of the relevant plasmid, were grown in 
LB ampicillin. The plasmids were purified by miniprep, digested with BamHI and HindIII, and 
analysed by agarose gel electrophoresis and ethidium bromide staining (Figure 18 J, K and 
L). Bands the size of 4bfubb, 4Ybfubb and 4Y were excised from pcDNA4/TO-6xHBfUbb, 
pcDNA4/TO-YFP-BfUbb and pcDNA4/TO-YFP, respectively. Each plasmid was sequenced 
(Appendix IV) and confirmed to contain the expected inserts. Large (400-600ng), endotoxin-
free batches of plasmids pcDNA6/TR, pcDNA4/TO, pcDNA4/TO-6xHBfUbb, pcDNA4/TO-
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Figure 18 DNA agarose gels showing the intermediate and final products of the construction of 2 
inserts for a mammalian 2-plasmid expression system, 1 encoding a 6xH-BfUbb (pcDNA4/TO-
6xHBfUbb) and 1 encoding an N-terminal YFP-fusion of BfUbb (pcDNA4/TO-YFP-BfUbb), visualised 
using ethidium bromide excited by UV light. (A) Analytical digest of pcDNA6/TR. Lanes: 1) 
Undigested pcDNA 6/TR, 2) pcDNA6/TR digested with EcoRI, 3) BamHI, 4) NdeI, 5) PvuI. 
pcDNA6/TR is 6662bp. The digests should give bands as follows: EcoRI - 6662bp; BamHI - 5324, 
1338; NdeI - 4883, 1779; PvuI - 4570, 2092. The banding pattern in lanes 2-5 matches that expected. 
(B) Analytical digest of pcDNA4/TO. Lanes: 1) Undigested pcDNA4/TO, 2) pcDNA4/TO digested with 
XhoI, 3) EagI, 4) PvuI, 5) XhoI+EagI, 6) XhoI+PvuI, 7) EagI+PvuI. pcDNA4/TO is 5078bp, bands of 
this size can be seen in lanes 2-4. The double digests should give bands as follows: XhoI+EcoRI - 
4543, 535; XhoI+PvuI - 4041, 1037; EcoRI+PvuI - 3506, 1572. The banding pattern in lanes 5-7 
matches that expected. (C) Initial PCR products: 1) 4bfubbx, 258bp, 2) 4bfubbx, 282bp, 3) 4Yx, 
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737bp, 4) 4Y, 746. All bands match expected sizes. (D) Crossover PCR product. Lanes 1-3) 4Ybfubb, 
995bp. (E) BamHI digest of pcDNA4/TO and PCR products. Lanes: 1) Undigested pcDNA4/TO, 2) 
pcDNA4/TO+BamHI, 3) Undigested 4Y, 4) 4Y +BamHI, 5) Undigested 4bfubb, 6) 4bfubb +BamHI, 7) 
Undigested 4Ybfubb, 8) 4Ybfubb +BamHI. There is no obvious degradation of the plasmid or PCR 
products. (E) NdeI digest of BamHI digests from (F). Lanes: 1) Undigested pcDNA4/TO, 2) Double 
digested pcDNA4/TO, 3) Undigested 4Y, 4) Double digested 4Y, 5) Undigested 4bfubb, 6) Double 
digested 4bfubb, 7) Undigested 4Ybfubb, 8) Double digested 4Ybfubb. Again, there is no obvious 
degradation of any bands. (G) Plasmids seen in the single colony preparations of pcDNA4/TO -
6xHBfUbb transformed cells. Lanes: 1-8) Single colony preparations from 8 different colonies, 9) 
Undigested pcDNA4/TO. Lanes 1-8 all contain plasmids larger than pcDNA4/TO, suggesting that they 
carry the insert. The double banding is a gel artefact. (H) Plasmids seen in the single colony 
preparations of pcDNA4/TO -YFP-BfUbb transformed cells. Lanes: 1) Undigested pcDNA4/TO, 2-9) 
Single colony preparations from 8 different colonies. Lanes 2 and 4-9 all contain a plasmid larger than 
pcDNA4/TO, suggesting that they carry the insert. The double banding is a gel artefact. (I) Plasmids 
seen in the single colony preparations of pcDNA4/TO -YFP transformed cells. Lanes: 1) Undigested 
pcDNA4/TO, 2) Linearised pcDNA4/TO, 3-8) Single colony preparations from 6 different colonies. 
Lanes 5, 6 and 8 all contain a plasmid larger than pcDNA 4/TO, suggesting that they carry the insert. 
(J) Digests of miniprepped plasmids from cells transformed with pcDNA4/TO-6xHBfUbb. Lanes: 1) 
Undigested pcDNA4/TO-6xHBfUbb, 2,4,6) pcDNA4/TO-6xHBfUbb +BamHI, 3,5,7) pcDNA4/TO-
6xHBfUbb +BamHI+HindIII. Excised bands of ~200-300bp are just visible at the bottom of lanes 3 and 
7. The lack of DNA in lane 5 is most likely due to experimental error. (K) Digests of miniprepped 
plasmids from cells transformed with pcDNA4/TO-YFP-BfUbb. Lanes: 1) Undigested pcDNA4/TO-
YFP-BfUbb, 2,4,6) pcDNA4/TO-YFP-BfUbb +BamHI, 3,5,7) pcDNA4/TO-YFP-BfUbb +BamHI+HindIII. 
Excised bands of ~1000bp can be clearly seen in lanes 3, 5 and 7. (L) Digests of miniprepped 
plasmids from cells transformed with pcDNA4/TO-YFP. Lanes: 1) Undigested pcDNA4/TO-YFP, 
2,4,6) pcDNA4/TO-YFP +BamHI, 3,5,7) pcDNA4/TO-YFP +BamHI+HindIII. The reduction in size in 





The epithelial cell line Caco-2 (ATCC HTB-37) was transfected using various combinations 
of pcDNA6/TR and Lipofectamine 2000 (Life Technologies) concentrations, diluted in Opti-
Mem reduced serum medium (Life Technologies). 24-48h post-transfection, cells were 
moved into 5µg/ml blasticidin to select for stable transfectants. 10 foci (R1-10) were selected 
from a range of successful conditions, grown to confluence and aliquots stored in liquid 
nitrogen. The pcDNA4/TO-YFP plasmid would be used as a positive control to determine 
basal and inducible levels of expression from the recombinant plasmids (and therefore the 
level of expression of TetR from pcDNA6/TR). Attempts were made to transfect cell lines R1, 
2, 3 and 4 with pcDNA4/TO-YFP, pcDNA4/TO-6xHBfUbb, pcDNA4/TO-YFP-BfUbb and 
pcDNA4/TO (empty vector). None of these transfections were successful due to a large 
amount of cell death (70-80%), within 24h of transfection, prior to movement into 1mg/ml 
zeocin. This level of toxicity was not observed in cells incubated with just the plasmids or 
Lipofectamine 2000 for the same amount of time, suggesting that there is no contamination 
of either the DNA or the Lipofectamine with toxic material, such as endotoxin. It is possible 
that basal expression of BfUbb from the inserts was enough to kill the cells, however toxicity 
was also observed in cells transfected with the YFP and empty vector controls. The exact 












3.2.7 The presence of the ubb gene does not appear to correlate with any particular 
disease 
 
To determine how frequently the ubb gene occurs in clinical strains of B. fragilis, and 
whether carriage of the ubb gene correlates with any particular diseases, real time 
quantitative PCR (qPCR) was performed on a range of clinical samples from patients with B. 
fragilis-associated diseases. Genomic DNA was extracted either from bacterial cultures 
isolated from clinical samples or directly from the samples themselves, depending on the 
nature of the sample. The presence and relative quantity of B. fragilis in the samples was 
determined using a primer set specific for the gyrB gene of human-associated B. fragilis 
strains (Lee & Lee, 2010). Mixtures were prepared in triplicate and qPCR was performed by 
a lab associated with the Belfast Health and Social Care Trust, then the mean number of 
copies of each gene per sample was calculated using previously generated calibration 
curves (not shown). 54 analysed samples were found to encode gyrB, indicating that these 
samples contain B. fragilis (Table 5). Of these 54 samples, 13 are from patients with 
abscesses or bacteraemia, 14 are from patients with colonic diseases, and 13 are of 
unknown origin. The ubb gene was detected in 8 samples. Of these 8 samples, 4 are from a 
single patient with Diverticular Disease (3496ii and 3496vii from the ascending colon, 3497iii 
and 3497vi from the rectum), 1 is from an ischiorecal abscess, 1 is from a perianal abscess, 
1 is from a patient with irritable bowel syndrome and 1 is from a patient who had undergone 
a colostomy. From these data there is no obvious association between the presence of the 










Identity Infection Original 
sample 
gyrB ubb 
LS11 Abdominal Abscess Pus/blood 485446 0 
LS14 Perianal Abscess Pus/blood 12936708 0 
LS16 Ischiorecal Abscess Culture 14278 163921 
LS18 Bartholins Abscess Culture 2068 0 
LS27 Neoplasm Abscess Pus/blood 276373 0 
LS52 Perianal Abscess Culture 16652970 0 
LS54 Perianal Abscess Pus/blood 1257490 0 
LS66 Abdominal Abscess Pus/blood 11365376 0 
LS67 Perianal Abscess Culture 44228 33452 
LS75 Perianal Abscess Culture 6442 0 
LS80 Perianal Abscess Culture 4531898 0 
LS84 Diverticular Abscess Pus/blood 16.1 0 
LS98 Bacteraemia Culture 6903352 0 
 
3496 ii Diverticular Disease Culture 8063952 1558257 
3496 vii Diverticular Disease Culture 81816 201778 
3497 iii Diverticular Disease Culture 2264 1011 
3497 vi Diverticular Disease Culture 4835040 428242 
3498 vi Irritable Bowel Syndrome Culture 56.15 0 
3498 ix Irritable Bowel Syndrome Culture 1257490 0 
3498 x Irritable Bowel Syndrome Culture 858216 53.6 
3499 vi Irritable Bowel Syndrome Culture 898008 0 
3499 x Irritable Bowel Syndrome Culture 56201 0 
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3528 vii Quiescent Ulcerative Colitis 
(pancolitis) 
Culture 8222122 0 
3529 iii Quiescent Ulcerative Colitis 
(pancolitis) 
Culture 3683801 0 
3529 iv Quiescent Ulcerative Colitis 
(pancolitis) 
Culture 1171042 0 
3532 x Cancer of the Ascending Colon Culture 1009013 0 
3533 v Cancer of the Ascending Colon Culture 1772312 0 
3533 viii Cancer of the Ascending Colon Culture 455009 0 
3534 ii Quiescent Ulcerative Colitis Culture 10 0 
3535 v Quiescent Ulcerative Colitis 
(extensive) 
Culture 4893 0 
3536 i Active Ulcerative Colitis (pancolitis) Culture 3050 0 
3536 ii Active Ulcerative Colitis (pancolitis) Culture 203 0 
3536 vii Active Ulcerative Colitis (pancolitis) Culture 3254 0 
3536 ix Active Ulcerative Colitis (pancolitis) Culture 628 0 
3536 x Active Ulcerative Colitis (pancolitis) Culture 897 0 
3537 ii Active Ulcerative Colitis (pancolitis) Culture 4055 0 
LS15 Colostomy Culture 2124596 15 
 
EOC Unknown Culture 223203 0 
VH Unknown Culture 369859 0 
RS Unknown Culture 13.34 0 
AI Unknown Culture 13020743 0 
CN Unknown Culture 7.89 0 
BE1 Unknown Culture 12125616 0 
BE3 Unknown Culture 15710272 0 
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GNAB85 Unknown Culture 3707731 0 
GNAB92 Unknown Culture 1459421 0 
JC6 Unknown Culture 7223438 0 
JC17 Unknown Culture 2679.8 0 
JC19 Unknown Culture 176.6 0 
NCTC 
9344 
Unknown Culture 915622 0 
NCTC 
10583 
Unknown Culture 21.4 0 
NCTC 
10584 
Unknown Culture 11892353 0 
ATCC 
23745 
Unknown Culture 4502649 0 
ATCC 
29765 
Unknown Culture 17998473 0 
 
 
Table 5 A table showing the samples in which gyrB was detected by qPCR and whether ubb was also 
detected. Columns, from left to right: the identity of the sample; the disease with which it is 
associated; whether genomic DNA was extracted from the biological sample or from a derived 
bacterial culture; the number of copies of gyrB; the number of copies of ubb. Positive are shown in 
green (>0 copies), and negative results (0 copies) are shown in red. Full details of the samples 










3.3.1 Protein purification 
 
rBfUbb had previously been successfully expressed in E. coli DH5α pTrc99A-6xHBfUbb, and 
purified in a previous study (Patrick et al., 2011), therefore no difficulties were expected. The 
protocol described here gave a consistent yield of pure rBfUbb between 6 and 10mg/L initial 
culture. The recombinant protein is the expected molecular weight (9.6kDa) and can be 
successfully isolated by gel filtration. A second band of ~17kDa can be seen in most lanes 
containing rBfUbb which is most likely the dimeric form of ubiquitin forming post-filtration, 
since the gel filtration buffer did not contain a reducing agent. 
 
3.3.2 BfUbb multimers 
 
Dimeric rBfUbb was first observed in samples of rBfUbb that had been stored at -20ºC for >6 
months (Figure 11 A), and when the purified protein was incubated at 37ºC in the absence of 
a reducing agent multimers formed within 3 hours, detectable by Western blotting (Figure 11 
B). Whilst only dimers, trimers and tetramers were detected when rBfUbb was incubated 
alone, pentamers and hexamers could be detected when it was incubated with E1 activating 
enzyme for the same amount of time (Figure 11 C).  
 
Given that a) lysine-linked ubiquitin chain formation is ATP-dependent (Wickliffe et al., 
2011), b) rBfUbb lacks the C-terminal double glycine involved in chain formation (Figure 7 
A), and c) these interactions are DTT-sensitive (Figure 11 B), it appears that the bonds 
between rBfUbb molecules are disulphide bridges formed between cysteine residues, rather 
than lysine-C-terminal bonds. There are only 2 cysteine residues in rBfUbb, C70 and C76, 
both in the C-terminal tail, meaning that there are a limited number of chain conformations 
that can be formed (Figure 12 B). These will be distinct from any previously documented 
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ubiquitin chains, however, as eukaryotic ubiquitin has no cysteine residues and none of its 
lysines are located in the C-terminal tail.  
 
The mechanism by which E1 activating enzyme promotes multimerisation of rBfUbb is 
unclear, as this enzyme has no known role in polymerisation of ubiquitin. However, rBfUbb is 
known to associate with E1 enzyme in the absence of DTT, and it may be that the enzyme 
acts as a scaffold to bring together individual rBfUbb molecules, thus promoting formation of 
disulphide bridges.   
 
The ability of BfUbb to form unique chain structures could have implications if this occurs in 
the host cell. The chains may associate with a UBD to affect cellular pathways, or they may 
interfere with existing chains, preventing them from being recognised by their relevant UBD. 
It should be noted, however, that, since the formation of these multimers is inhibited by DTT 
and other reducing agents, it is unlikely that they will be able to form in the reducing 
conditions of the host cell cytoplasm. BfUbb would either need to be compartmentalised in a 
non-reducing environment, such as the lysosome, or assisted by other proteins in order to 
form multimers. It is also possible that the formation of multimers is an artefact of rBfUbb 
existing at unnaturally high concentrations in vitro, thus promoting the formation of disulphide 
bridges. BfUbb would likely never reach such concentrations in the host cell, or even the 
bacterial cell; in fact, no BfUbb multimers have ever been identified in whole cell extract or 
concentrated supernatants of B. fragilis. Therefore, the biological significance, if any, of 









3.3.3 BfUbb and E2 conjugating enzymes 
 
The enzymes of the ubiquitin cycle - the E1 activating enzyme, the E2 conjugating enzymes, 
and the E3 ligases - demonstrate increasing specificity (Komander & Rape, 2012; Wickliffe 
et al., 2011). rBfUbb has already been shown to form a covalent bond with the E1 enzyme 
Uba1 and to inhibit ubiquitylation of a lysozyme substrate, possibly by binding the acitve site 
cysteine of the E1 enzyme (Patrick et al., 2011). However, in order to do this BfUbb would 
have to reach a high enough concentration in the cell to out-compete eukaryotic ubiquitin. 
Additionally, cell-wide inhibition of ubiquitylation would result in necrosis (Xu et al., 2010), 
which would be disadvantageous to the host epithelium and, consequently, the commensal 
B. fragilis. It is therefore more likely that BfUbb acts on a specific pathway or protein, 
possibly other ubiquitin cycle enzymes. There are hundreds of target-specific E3 ligases, 
meaning screening them for interactions with rBfUbb via ubiquitin transfer assay would be 
impractical. Instead, SDS-PAGE and Western blotting was used to determine whether 
rBfUbb has a preference for 1 or more E2 conjugating enzymes in an effort to identify a 
potential target pathway. This method determined that rBfUbb was able to interact directly 
with several E2 enzymes in non-reducing conditions and in the absence of ATP and the E1 
enzyme (Figure 14 A, B and C). These interactions are DTT sensitive (Figure 14 G, H and I), 
and therefore the bonds are most likely disulphide bridges between cysteine residues, 
meaning rBfUbb may be binding the active site cysteine of an E2 enzyme via rBfUbb C70 or 
C76. Interestingly, the interactions between rBfUbb and most E2 enzymes become more 
common if rBfUbb is pre-incubated with the E1 enzyme (Figure 13 A, B and C; Figure 14 D, 
E and F), suggesting that the interaction between enzymes promotes the forming of a bond 
between BfUbb and an E2 enzyme. This is unexpected since BfUbb appears to covalently 
bind the E1 activating enzyme in a manner that should not allow nucleophillic attack by the 





Some rBfUbb-E2 enzyme interactions can form in the presence of DTT, if rBfUbb is pre-
incubated with the E1 enzyme (Figure 14 J, K and L). As well as confirming that the E1 
enzyme promotes rBfUbb-E2 enzyme bonds, this suggests that rBfUbb may have a 
preference for certain E2 enzymes, most notably Ube2M, Ube2R1 and Ube2R2 (arrow, 
asterisk and hash, respectively). Ube2R1 and Ube2R2 are also 2 of the enzymes with which 
rBfUbb is able to interact in the absence of the E1 enzyme. Ube2M is a Nedd8-conjugating 
enzyme, known to be involved in the S-phase DNA damage repair system which is required 
for cell cycle progression at this phase. Specifically, Ube2M is required for neddylation of 
certain cullin-RING ligases (cullins, a class of E3 ligases), mostly those involved in the DNA 
repair- associated ubiquitylation. Neddylation is essential for cullin activity (Cukras et al., 
2014; Huang et al., 2011a). The ability of the ubiquitin E1 activating enzyme to interact with 
Nedd8 E2 conjugating enzymes is not unprecedented as crosstalk between the 2 pathways 
has been documented during cellular stress and depletion of ubiquitin (Leidecker et al., 
2012). Ube2R1 (Cdc34) interacts exclusively with the cullin class of E3 ligases to promote 
degradation of cell cycle regulators via K48-linked ubiquitylation, thus allowing progression 
from G1 to S phase of the cell cycle (Ceccarelli et al., 2011; Harper & King, 2011). Ube2R2, 
which bears significant homology to Ube2R1, interacts with β-TrCP (Semplici et al., 2002), 
which associates with the SCF (Skp, cullin, F-box complex) to ubiquitylate cell cycle 
regulators for degradation, thus allowing progression from G1 to S and from G2 to M (Lau et 
al., 2012). Common to all 3 of these E2 enzymes is their role in cell cycle progression. 
Uncontrolled or rapid mitotic progression is associated with cancerous cells, and proteins 
associated with these 3 E2 enzymes are known oncogenes, e.g. p27, a degradation target in 
the Ube2R1 pathway, is a cell cycle inhibitor (Ceccarelli et al., 2011; Harper & King, 2011), 
and β-TrCP is over expressed in several forms of cancer, including colonic cancer (Lau et 
al., 2012). Inhibition of Ube2M results in extensive DNA damage, which delays progression 
of the cell cycle at S phase (Cukras et al., 2014), inhibition of Ube2R1 halts progression from 
G1 to S (Ceccarelli et al., 2011), and inhibition of Ube2R2 activity would most likely inhibit β-
TrCP/SCF-dependent cell cycle progression. In addition, Ube2M is the E2 enzyme 
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responsible for neddylation (and thus activation) of the cullin involved in the SCF (Chen et 
al., 2000), therefore inhibition of Ube2M would result in an extra level of cell cycle 
progression inhibition. If BfUbb can interact with and inhibit any or all of these 3 E2 enzymes, 
or their associated E3 ligases, it may act as an inhibitor of uncontrolled cell cycle 
progression and consequently protect against tumorigenesis. It should be noted that 
inhibition of Ube2R2 could also promote tumorigenesis as it is known to be involved in β-
catenin degradation (Semplici et al., 2002) and accumulation of β-catenin in the cytoplasm is 
associated with tumour cells (Lau et al., 2012).  
 
Preference of rBfUbb for these, or any other, E2 enzymes could be confirmed by other 
biochemical techniques. SPR was performed, using a rBfUbb/ubiquitin coated chip and the 
E1 and E2 enzymes as analyte, however a high enough concentration of E2 enzyme could 
not be reached to generate a conclusive result (Appendix I). A repeat of this assay at higher 
concentrations could determine the relative strength of the interactions between 
rBfUbb/ubiquitin and the E1/E2 enzymes. Thermal denaturation fluorescence was also used 
to study the stability of ubiquitin/BfUbb-E2 interactions, however both ubiquitin and BfUbb 
demonstrate high thermostability and melt curves could not be generated (data not shown). 
 
The fact that covalent bonds between BfUbb and the E2 enzymes are DTT sensitive 
suggests, as with the formation of multimers, that they are less likely to form in the reducing 
environment of the host cell cytoplasm without assistance. However, the ability of the E1 
enzyme to promote rBfUbb-E2 enzyme complexes indicates that rBfUbb may interact with 
the host cell ubiquitin pathway in much the same way as eukaryotic ubiquitin. rBfUbb was 
seen binding E2 enzymes in both monomeric and multimeric form (Figure 13 and Figure 14). 
E2 enzymes do not usually bind ubiquitin chains and therefore the biological significance of 
this finding is unknown. 
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3.3.4 Binding partners of BfUbb 
 
To identify host cell proteins that may act as binding partners for rBfUbb, the purified protein 
was incubated with Caco-2 whole cell extract and the results analysed by SDS-PAGE and 
coomassie staining (Figure 15). Even in the absence of DTT, no bands could be detected in 
the elution fraction of samples containing rBfUbb that were not also found in that of samples 
without rBfUbb. This was also observed by Western blotting (Figure 15), however a mass 
spectrometric analysis of both samples could confirm that they contain the same proteins. It 
is likely that, since ubiquitin, and presumably BfUbb, has a low affinity for all binding partners 
(Grabbe & Dikic, 2009), a short incubation period at these concentrations may not be 
sufficient to form detectable interactions. We know that rBfUbb is at least able to form 
complexes with enzymes of the ubiquitin cycle (Figure 13 and Figure 14), however these are 
at much lower concentrations in the cell extract and rBfUbb may be out competed by 
eukaryotic ubiquitin for the binding sites. For BfUbb to bind an E2 enzyme it would therefore 
need to be highly concentrated in a specific location where the E2 enzyme operates. This 
requirement means that even if a binding partner were identified by the method described 
here it would not necessarily mean that the 2 proteins would interact in vivo. 
 
3.3.5 10xH-BfUbb and 10xH-YFP-BfUbb: production and uses 
 
A construct was generated for the expression of BfUbb with an N-terminal, cleavable 10xHis 
tag. Initially, the results suggested the construct had been made successfully: the 
recombinant plasmid was found to contain an insert of the correct size (Figure 16 H), the 
sequence of the insert matched that expected (Appendix II), and the expression profile, and 
the Ni and gel filtration column elution fractions, contained a band of ~11kDa (the expected 
molecular weight of 10xH-BfUbb is 11.6kDa) (Figure 17 A-D). However, the gel filtration 
column elution fractions (and earlier samples) also contain a second band, ~10kDa. This is 
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unlikely to be a premature cleavage product as it was isolated in large amounts from the Ni 
column and therefore probably contains a his-tag. In addition, it is larger than rBfUbb and 
therefore too large to be native BfUbb. To resolve this, the recombinant plasmid should be 
resequenced to confirm that the original sequences of the his-tag, cleavage site and BfUbb 
are intact. The protein should then be expressed and purified again in the presence of 
enterokinase inhibitors. If the problem is recurring, mass spectrometric sequencing could 
reveal the exact nature of the smaller protein. Failing this, an alternative version of the 
cleavable his-tag could be used.  
 
Once cleaved from the 10xHis-tag, a purified, native form of BfUbb would be useful in further 
characterisation of the protein. A predicted structure of BfUbb was produced using PHYRE2 
(Figure 7 B), however in order to compare the structures of eukaryotic ubiquitin and BfUbb, 
the 3D structure of the latter will need to be solved, e.g. by X-ray crystallography. Since 
BfUbb is only 76aa long, a 6xHis tag will make a significant difference to the solubility and 
structure of the protein, therefore it is better to use an un-tagged version.  
 
 
A second construct was generated for the expression of an N-terminal YFP-fusion of BfUbb, 
also with a 10xHis-tag at the extreme N-terminus. Again, the results suggest a successful 
construct: the insert is the correct size (Figure 16 I), the sequence of the insert matches that 
expected (Appendix II), and the transformed strain expresses a protein of approximately the 
correct size (38kDa) (Appendix III). This protein has not yet been purified so it is not known 
whether there will be similar problems with additional bands or cleavage of the his-tag.  
 
A fluorescent fusion of BfUbb can be used in in vitro ligand-binding assays, thus allowing 
determination of the affinity of BfUbb for various E2 enzymes and other ubiquitin-binding 
proteins. Competition assays, specifically, could determine whether BfUbb and eukaryotic 
ubiquitin compete for the same binding sites and if so which has the higher affinity. Although 
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not a particularly large protein (238aa, 24.6kDa), YFP is >3 times the size of BfUbb and may 
affect binding or function of the smaller protein. This is something that should be taken into 
consideration when using this fusion protein. 
 
3.3.6 Expression of 6xHBfUbb and YFP-BfUbb in mammalian cells 
 
Constructs were generated for the expression of 6xHBfUbb, YFP-BfUbb and a YFP control 
in mammalian cells, using the T-REx 2-plasmid system. pcDNA6/TR expresses the 
tetracycline-associated repressor TetR, which binds the TetO2 region of pcDNA4/TO, 
preventing transcription initiation. When present, tetracycline binds TetR, causing a 
conformational change which prevents the repressor from binding TetO, therefore inducing 
expression (Yao et al., 1998). There is some basal expression from pcDNA4/TO even when 
pcDNA6/TR is present; the level of basal expression depends on the level of TetR 
expression. This can be assessed using a recombinant pcDNA4/TO containing a reporter 
gene (Life Technologies, 2011), in this case yfp.  The results suggest that the constructs 
were generated successfully: the inserts are all of the correct size (Figure 18 J, K and L), 
and the sequences match those expected (Appendix IV). Caco-2 cells (immortal colonic 
epithelial cells) were chosen as the model for the target cell. Although there is no clear 
evidence of B. fragilis OMV being endocytosed by gastro-intestinal epithelial cells, OMV are 
known to be taken up by DCs in tissue culture (Shen et al., 2012), and B. fragilis has been 
seen invading epithelial cells of patients with Crohn's disease (Swidsinski et al., 2005). It is 
not unreasonable to suggest that OMV of B. fragilis deliver their contents to these cells. 
Caco-2 cells were transfected with pcDNA6/TR and stable blasticidin-resistant cell lines 
were established. Several of Caco-2 pcDNA6/TR cell lines were then transfected for a 
second time either with pcDNA4/TO-YFP, pcDNA4/TO-6xHBfUbb, pcDNA4/TO-YFP-BfUbb 
or pcDNA4/TO (empty vector). So far no attempts at establishing a stable cell line containing 
both pcDNA6/TR and 1 of the pcDNA4/TO plasmids have been successful since the 
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transfected cells undergo necrosis in the 24h recovery period prior to the addition of zeocin 
to the culture medium. This is in spite of the fact that this procedure does not differ 
significantly from that of pcDNA6/TR transfection. Cells were also incubated with either 
Lipofectamine 2000 or plasmid DNA in conditions otherwise identical to the transfection 
conditions, to test for the presence of cytotoxic contaminating factors, such as endotoxin, in 
the reagent or the DNA. However, no necrosis was observed in these cells prior to the 
addition of zeocin, suggesting that only actual transfectants experience toxicity. Although 
there will be some basal expression of the inserts, BfUbb is unlikely to be the causative 
agent as necrosis also occurs in cells transfected with the empty vector. It may be that 
pcDNA4/TO, and recombinant plasmids, are recombining with the Caco-2 genome in a way 
that inhibits proper cell function. Linearising the plasmids prior to transfection may mitigate 
the problem. Alternatively, success may be achieved with a different cell line. 
 
Expression of 6xHBfUbb in Caco-2 cells is an important experiment for several reasons. 
Firstly, it will determine whether the presence of BfUbb in a eukaryotic cell would result in 
cell death, a distinct possibility if BfUbb is able to inhibit all ubiquitylation. Secondly, if the 
cells survive expression of the protein, they can be observed for phenotypic changes, such 
as changes in morphology (via microscopy), cytokine expression (via cytokine assay) or 
gene expression (via RNA microarray). Thirdly, the 6xHis-tag can be used to pull down 
BfUbb and any binding partners, followed by SDS-PAGE and mass spectrometry for 
identification. This expression would not be representative of delivery of BfUbb via OMV as 
the concentration of the protein in the host cell would be higher than could be achievable in 
vivo, however it may help to determine the function and potential effects of the presence of 
BfUbb in the epithelial cells. Expression of YFP-BfUbb in Caco-2 cells would allow tracking 
of BfUbb within the cells (via fluorescence microscopy), i.e. where, if anywhere, it localises 
to. Again, this would not be representative of delivery of BfUbb via OMV as the protein may 




3.3.7 Characterisation of BfUbb by qPCR 
 
Multiple clinical samples in which B. fragilis could be identified were screened for the 
presence of the ubb gene using qPCR (Table 5). Of the 54 samples in which the B. fragilis 
identifier gyrB was detected with confidence, 8 also contained the ubb gene. These samples 
came from patients with Diverticular Disease, an ischiorecal abscess, a perianal abscess, 
IBS and one who had undergone a colostomy. From this data no correlation can be made 
between the presence or absence of ubb and any particular disease (since all 4 Diverticular 
Disease samples came from the same patient). A larger scale version of this study has been 
performed (unpublished data) but still no correlation was observed. qPCR can be a powerful 
tool in the characterisation of a gene, and its application to a large number of clinical B. 
fragilis samples could confirm or deny the role of BfUbb in colonic diseases or abscess 
formation. There are some drawbacks to this approach, however, most notably that there are 
very few clinical samples (especially biopsy samples) from people without colonic diseases, 
making it difficult to compare healthy and diseased samples, and that whilst it can suggest a 
correlation it cannot determine causality, or mechanism of action. 
 
3.3.8 Future work and considerations 
 
There is much work still to do in the characterisation of BfUbb. Once 10xH-BfUbb has been 
successfully purified, the tag must be cleaved and the tag and enterokinase removed from 
the sample. The crystallisation conditions of eukaryotic ubiquitin should be used as a starting 
point for the crystallisation of native BfUbb, and the use of high-throughput methods could 
significantly speed up the process. Solving the structure of BfUbb would allow a direct 
comparison between it and eukaryotic ubiquitin, perhaps highlighting significant differences 
or similarities in their ability to interact with other proteins. Isolating the BfUbb multimers and 
BfUbb-E2 complexes of interest and solving their structure would also be of use in 
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characterising these interactions and their potential biological significance. Biochemical 
assays, such as SPR, using BfUbb/ubiquitin-coated chips, and ligand-binding assays, using 
purified YFP-BfUbb and fluorescently tagged ubiquitin, could determine the relative affinities 
of BfUbb and eukaryotic ubiquitin for various E2 conjugating enzymes. Such assays may 
confirm whether BfUbb has particular affinity for Ube2M, Ube2R1 and Ube2R2. Other 
ubiquitin-binding proteins of interest, such as E3 ligases or suspected targets from a pull-
down experiment, could also be screened by these methods.  
 
Binding partners of BfUbb could be identified by expressing 6xHBfUbb in Caco-2 cells (from 
pcDNA4/TO-6xHBfUbb) and, with or without cross-linking, passing the cell lysate over a Ni 
column to pull down BfUbb and any bound/cross-linked proteins. These proteins could then 
be identified by SDS-PAGE and/or mass spectrometry. Expression of BfUbb in Caco-2 cells 
may cause cell death or halt cell cycle progression, however it may also allow determination 
of the function of BfUbb, if any, in the host cell through the observation of phenotypic 
changes, e.g. cell morphology, cytokine or protein expression profiles. Expression of YFP-
BfUbb (from pcDNA4/TO-YFP-BfUbb) in Caco-2 cells can be combined with fluorescence 
microscopy to observe the subcellular localisation of BfUbb, using the YFP expressed from 
pcDNA4/TO-YFP as a control. Expression of BfUbb recombinants in the Caco-2 cells 
requires the successful transfection of a Caco-2 pcDNA6/TR cell line with the recombinant 
plasmids. Transfection may be achievable if the plasmids are first linearised by restriction 
enzyme digest, however it this does not help a different colonic epithelial cell line, such as 
FHC, could be used. Finally, the continued use of qPCR as a tool for the screening of clinical 
samples for the presence of B. fragilis and the ubb gene could establish a correlation, or lack 







4. The proteome of the outer membrane vesicles of B. fragilis 
 
4.1 Background 
4.1.1 B. fragilis OMV 
 
OMV are produced by commensal, clinical and environmental strains of B. fragilis 
(Domingues et al., 1997) and can be observed by electron microscopy budding from the cell 
surface (Lutton et al., 1991; Patrick et al., 1996) (Figure 19). These vesicles are usually 
between 50 and 100nm in diameter and are produced mostly by cells expressing the MC 
(Patrick et al., 1996; Shen et al., 2012). LC cells produce significantly fewer OMV and these 
appear to become entangled in the complex polysaccharide as they are released from the 
cell. Antibodies raised against specific B. fragilis CPS molecules are cross reactive with both 
the cells and the OMV of a particular culture, suggesting that the OMV carry the same 
epitopes as the cells that produce them. The OMV also have the same haemagglutinating 
and enzymatic activity as B. fragilis whole cells and therefore have the potential to adhere to 
and enymatically attack host cells (Patrick et al., 1996). 
 
The cephalosporinase CepA is associated with the surface of the OMV produced by several 
Bacteroides species, including B. fragilis and B. thetaiotaomicron. OMV derived from these 
species can protect other bacteria from the effects of cefotaxime when pre-incubated with 
the antibiotic. The OMV of B. thetaiotaomicron are also able to protect against the effects of 
β-lactams and it is therefore likely that the OMV of B. fragilis can do the same (Stentz et al., 
2015). This suggests that these OMV are able to present proteins on their surface that 






Figure 19 Electron micrographs of thin sections of B. fragilis cells, showing OMV budding from the 
cell surface (arrows) (bar:0.1µm) (Patrick et al., 1996).  
 
 
As mentioned previously (section 1.1.4), B. fragilis PSA is necessary and sufficient to 
prevent experimentally-induced colitis in GF mice (Mazmanian et al., 2008). Further 
research indicated that PSA is delivered to host cells on the surface of the OMV. When 
administered with 2-4-6-trinitrobenzene sulfonic acid (TNBS), mice experience artificial 
inflammation and associated colitis and weight loss. WT OMV were able to prevent weight 
loss in TNBS mice when administered orally and were able to prevent colitis when 
administered rectally. Additionally, when applied to a co-culture of DCs and CD4+ T-cells, 
WT OMV were actively internalised by DCs and induced expression of the anti-inflammatory 
cytokine IL-10 and the anti-inflammatory protein Foxp3 in T-cells. ΔPSA OMV were also 
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taken up by DCs but were not able to prevent colitis, weight loss, or induce expression of IL-
10 and Foxp3. These results suggest that B. fragilis OMV are important in proper immune 
development and protection from inflammation (Shen et al., 2012).  
 
B. fragilis does not encode any of the major secretion systems (TI - TV), and therefore OMV 
constitute an important mechanism by which this species interacts with its host and its 
environment.  
 
4.1.2 Proteomic studies of OMV 
 
Recently, there has been a notable increase in the number of proteomics studies focused on 
extracellular vesicles, both prokaryotic and eukaryotic (Choi et al., 2015). Proteomics is a 
powerful and important tool in biological studies as it can provide a large amount of 
information about an organism or subcellular fraction much faster and cheaper than classical 
biochemical and genetic techniques. Knowledge of the proteome of the OMV from any 
bacterial species can help to determine OMV function and mechanism of biogenesis, as well 
as support their use in biotechnological applications (Kulp & Kuehn, 2010; Lee et al., 2008). 
A variety of methods have been used in OMV proteomics studies (Figure 20, Figure 21), 
however the two most important steps are the efficient isolation of pure vesicles and the 
fractionation of proteins or peptides prior to identification (Choi et al., 2015; Lee et al., 2008). 
 
There are 3 types of OMV that can be isolated from bacterial cell culture. The first are 
detergent-extracted OMV (DOMV) - the detergent strips endotoxin from the OMV meaning 
they can be safely used as vaccines, however lipoproteins are also be stripped and DOMV 
tend to aggregate. Native OMV (NOMV) are extracted using a chelating agent which causes 
less damage than detergent, and spontaneous OMV (SOMV) are released naturally by the 
bacterial cells (van de Waterbeemd et al., 2013). Mechanically and chemically induced OMV 
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are not considered representative of naturally formed OMV (Kulp & Kuehn, 2010). Some 
early OMV proteomics studies used DOMV and therefore the data produced by these 
studies may not be reliable (Lee et al., 2008). Most studies now use SOMV concentrated 
from the supernatant of the cell culture. 
 
The first step in isolating OMV is differential centrifugation to remove whole cells (Figure 20), 
at around 6,000xg, after which the supernatant is usually filtered (0.45µm or 0.22µm) to 
remove any remaining cells. The OMV are then isolated from the supernatant via a variety of 
methods, the most common of which is ultracentrifugation at 80,000-100,000xg (Altindis et 
al., 2014; Berlanda Scorza et al., 2012; Haurat et al., 2011; Kreimer et al., 2015; Kulp & 
Kuehn, 2010; Lee et al., 2008) (Figure 20). Others have used density centrifugation on an 
Opti-Prep gradient (Bauman & Kuehn, 2006; Jang et al., 2014; Kreimer et al., 2015), 
tangential flow filtration (TFF) (Berlanda Scorza et al., 2012), centrifugal filtration (Bauman & 
Kuehn, 2006), precipitation with ammonium sulphate (Bauman & Kuehn, 2006; Mullaney et 
al., 2009), immunoaffinity pull-down (Kreimer et al., 2015) or gel filtration chromatography 
(Post et al., 2005) to isolate and concentrate OMV (Figure 20). Lee et al (2008) assert that 
ultracentrifugation is not sufficient to separate OMV from other membrane debris and large 
protein aggregates. Some studies used serial centrifugation at lower speeds (20,000-
40,000xg) to pellet larger debris prior to ultracentrifugation at high speed (150,000xg) and 
other studies used ultracentrifugation in combination with a second technique (Bauman & 
Kuehn, 2006; Jang et al., 2014; Lee et al., 2007). Gel filtration chromatography relies on size 
exclusion to isolate vesicles and can be effective, however a prerequisite is that the majority 
of OMV are approximately the same size (Post et al., 2005). Filtration methods, such as TFF 
and the use of centrifugal filters risk the loss of sample as OMV can adhere to filters. Low 
protein binding material, such as PVDF, is recommended when using filters. Precipitation 
with ammonium sulphate produces a larger number of vesicles than some other methods, 
but must be combined with another method, such as density centrifugation, to ensure purity 
(Bauman & Kuehn, 2006). Several authors agree that density centrifugation, ideally with 
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Opti-Prep, is an important step in the isolation of pure OMV (Bauman & Kuehn, 2006; Kalra 
et al., 2013; Kreimer et al., 2015; Lee et al., 2008). The proteomic contents of extracellular 
vesicles  as identified by mass spectrometry (MS) depend heavily on the isolation method 
used (Choi et al., 2015). Currently, different labs use a wide range of different methods for 
vesicle isolation (Figure 20). There is therefore an urgent need for a standardised procedure 
for vesicle isolation as proteomes of OMV prepared in different ways cannot reliably be 
compared. 
 
There are a range of proteomic techniques available in the study of OMV (Figure 21). 
Fractionation of OMV proteins and peptides can be performed before or after enzymatic 
digestion (or both before and after). Gel-based techniques use 1D or 2D gel electrophoresis 
to separate proteins. Individual bands or gel segments are then either excised and digested 
or digested in-gel prior to ionisation and MS analysis. This results in a low complexity mix of 
proteins meaning peptides can be more easily identified and also allows a more direct 
comparison of multiple proteomes. Fractionation of proteins prior to digestion has the added 
advantage of reducing interference of lipids and high abundance proteins (Kreimer et al., 
2015). Additional separation can be achieved by performing liquid chromatography (LC) after 
digestion (Aguilera et al., 2014; Berlanda Scorza et al., 2012; Choi et al., 2011; Lee et al., 
2008). One of the greatest drawbacks of gel-based approaches is that excision and analysis 
of individual bands is expensive and time consuming which means that often only certain 
bands are analysed. This leads to an incomplete proteome which is biased towards 
abundant proteins (those which constitute the strongest bands). Many early studies using 
this approach identified a total of less than 50 proteins (Choi et al., 2015; Kreimer et al., 
2015; Lee et al., 2008). 2D gels are especially unsuitable for OMV studies as vesicles are 
enriched in  hydrophobic membrane proteins, which are difficult to separate on 2D gels (Lee 




















































































































































































































Figure 20 A flow chart showing the different combinations of techniques used to isolate OMV in 9 
independent proteomics studies. Each colour of arrow corresponds to a different study as indicated at 
the bottom of the figure. Bauman (2006) and Mullaney (2014) both used 2 different isolation methods. 
Aside from differential centrifugation to remove whole cells, the most commonly used techniques are 
ultracentrifugation and density centrifugation. (Altindis et al., 2014; Bauman & Kuehn, 2006; Berlanda 
Scorza et al., 2012; Elhenawy et al., 2014; Jang et al., 2014; Lee et al., 2007; Lee et al., 2008; 
Mullaney et al., 2009; Nally et al., 2005; Post et al., 2005) 
 
 
van de Waterbeemd et al (2013) state that gel-free approaches are more compatible with the 
hydrophobic membrane proteins of OMV. The most common gel-free approach is "bottom-
up" proteomics in which the entire sample is digested, fractionated by LC or isoelectric 
focusing (IEF) and analysed by high-sensitivity MS (such as LTQ-Orbitrap) (Jang et al., 
2014; Kreimer et al., 2015). Using this high-throughput method, thousands of proteins can 
be identified in a matter of hours, however the signal of small, low abundance proteins can 
be lost in such a complex mixture. High-sensitivity methods can adjust for this, for example 
ultra-low flow (ULF) fractionation reduces the dilution effects of LC and produces smaller 
droplets which improves ionisation and increases the likelihood of detecting low abundance 
proteins (Kreimer et al., 2015). Tagging methods, such as phospho-tag (PTAG) can also 
reduce the effects of large or abundant proteins. PTAG modifies the internal peptides of 
proteins which are then removed by TiO2 affinity post-cleavage. This leaves only the N-
terminal peptide of each protein, meaning all proteins are equally represented (van de 
Waterbeemd et al., 2013). Multiple samples can be more easily compared with quantitative 
proteomics. In iTRAQ (isobaric tag for absolute quantitation) proteomics, the different 
samples are labelled with isobaric tags which have the same mass but a different mass-to-
charge ratio. The samples are then pooled and analysed together and the relative quantities 
of each peptide in the different samples is determined by measuring the relative intensities of 
each tag. Relative quantities of proteins can also be measured using spectral counts. In this 
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case, 2 samples are analysed separately and the derived spectral count for each protein is 
compared between the 2 samples. This method is cheaper and easier that those described 
previously as it is label-free, however it is considered to be the least accurate method of 
protein quantitation (Kreimer et al., 2015). Spectral counting is less likely to detect small fold 
changes in protein abundance (Li et al., 2012) and there is a greater risk of proteins going 
undetected due to the random-sampling effects of high-throughput MS (Cooper et al., 2010).  
 
Once the raw peptide sequences have been determined they are used to search databases 
of the genome/proteome of the organism of interest. Identified proteins are considered "true" 
hits if they are identified using multiple peptides and have a p or e value below a pre-
determined threshold (usually 0.05). When the whole sample is analysed, around 60-340 
proteins are typically identified in OMV (although some studies have identified more) 
(Aguilera et al., 2014; Altindis et al., 2014; Berlanda Scorza et al., 2012; Choi et al., 2011; 
Elhenawy et al., 2014; Jang et al., 2014; Lee et al., 2007; Mullaney et al., 2009; van de 
Waterbeemd et al., 2013).  
 
Characterisation of OMV extends beyond MS proteomics as the identification of proteins 
alone does not provide a complete understanding of their role in the OMV. Post-translational 
modifications (PTMs) play an important role in protein function and protein-protein 
interactions. Identification of PTMs requires a "top-down" approach, starting with the intact 
protein. The characterisation of other components of OMV, e.g. identification of lipids by 
lipidomics, can also provide information about the origin and function of OMV (Kreimer et al., 






























Figure 21 A flow chart showing the different combinations of proteomic techniques used in 9 
independent OMV proteomics studies. Each coloured arrow corresponds to a different study as 
indicated at the bottom of the figure. (Altindis et al., 2014; Bauman & Kuehn, 2006; Berlanda Scorza 
et al., 2012; Elhenawy et al., 2014; Jang et al., 2014; Lee et al., 2007; Mullaney et al., 2009; Nally et 






Only one comprehensive proteomic study of B. fragilis OMV has been published so far 
(Elhenawy et al., 2014). OMV were isolated by differential centrifugation to remove cells 
followed by 2 rounds of ultracentrifugation at 100,000xg for 2h. The sample was then 
fractionated by 1D SDS-PAGE and individual bands were excised, trypsin digested and 
analysed by LC-MS (quadrupole orthogonal acceleration time-of-flight, Q-TOF). A sample of 
isolated OM was analysed in parallel with the OMV. Proteins were identified using the 
Mascot search engine and the NCBI non-redundant database. This study identified 115 
OMV proteins and 102 OM proteins; 69 proteins were shared between the two samples. 
OMV-exclusive proteins were found to be more acidic than OM proteins, possibly indicating 
that acidic proteins are preferentially packaged into the OMV. Several potential proteases 
were identified by MS. OMV proteins were separated by SDS-PAGE and bands 
corresponding to these proteases were assayed for proteolytic activity. This confirmed the 
presence of at least 11 proteases in the OMV. Eight sugar hydrolases were found to be 
exclusive to the OMV and whole OMV possess fucosidase activity. The OMV were also 
found to be enriched in SusD-like starch-binding proteins. The enrichment of certain proteins 
in the OMV over the OM supports the active biogenesis theory of OMV in B. fragilis. The 
enrichment of sugar hydrolases in particular suggests that OMV may play a role in sugar 













The aim of this study was to characterise the OMV of B. fragilis. DLS was used to determine 
the size of OMV in concentrated supernatants of B. fragilis culture. In addition, mass 
spectrometry was used to identify the proteins present in the OMV and the periplasm of B. 
fragilis NCTC 9343, and the two samples were compared. OMV were isolated using a 
combination of the techniques described above. Whole cells were removed by differential 
centrifugation and the supernatant was concentrated, first by TFF and then by centrifugal 
filtration. Concentrated supernatants were then applied to an Opti-Prep density gradient and 
centrifuged. OMV and periplasmic proteomes were determined using a gel-free "bottom-up" 
approach; whole samples were trypsin digested and cleaned then fractionated by HPLC and 
analysed by LTQ-Orbitrap MS. The raw peptide data was used to search the NCBI non-
redundant database of all available B. fragilis strains via Progenesis LC-MS software. The 
results were further analysed to determine "true" hits, the most abundant proteins in the 
OMV, and the proteins most enriched in the two samples. Proteins of interest, including 













4.2.1 Dynamic light scattering of B. fragilis OMV 
 
DLS was used to determine the average size of WT OMV. Concentrated supernatant of WT 
B. fragilis (grown in BHI-S with 20µg/ml gentamicin) was diluted to 0.5mg/ml in PBS. 50µl of 
this dilution was analysed by DLS (Zetasizer APS, Malvern Instruments, UK). Each sample 
was measured 3 times and the average size calculated from the first 2, since the third 
reading was of low quality (not shown). A single peak in the WT concentrated supernatant 
sample represents a monodisperse solution of a globular species approximately 250nm in 
diameter (Figure 22 A). There was little consistency between readings (Appendix VI), 
possibly due to the effects of repeated asipration of the sample on the OMV. A control 
sample of BHI-S shows multiple peaks of low intensity, representing a polydisperse solution 
(Figure 22 B), most likely of the large molecules and possible precipitates formed in the 
medium. None of these peaks appear in the concentrated supernatant sample, suggesting 
that they have been successfully removed during the concentration and washing procedure. 
Additionally, the 250nm peak of the supposed OMV does not appear in the BHI-S control, 









Figure 22 Dynamic light scattering of WT B. fragilis concentrated supernatant grown in BHI-S (A) and 
a BHI-S control (B). (A) shows a monodisperse solution with a single peak ranging from 150-500nm 
with an average of approximately 200nm. (B) shows a polydisperse solution with at least 5 peaks of 
varying sizes. These most likely represent large molecules or precipitates in the BHI-S. None of the 
peaks were the same size as that seen in (A).   
 
 
4.2.2 Proteome of the OMV of B. fragilis 
 
The complete proteome of both the OMV and periplasm of WT B. fragilis was determined by 
gel-free mass spectrometry. OMV were isolated from 3 separate WT B. fragilis cultures. The 
supernatant of 5L WT B. fragilis culture was concentrated to ~200ml using TFF, then to ~3ml 
by centrifugal filtration, then 3mg of total protein were loaded onto an Opti-Prep gradient and 
ultracentrifuged to separate OMV from contaminants. The Opti-Prep gradient was unloaded 
in 1ml fractions and each fraction tested for the level of β-galactosidase (cytoplasmic) and 
alkaline phosphatase (periplasmic) activity (Table 6). The 3 fractions (those with the highest 
alkaline phosphatase/β-galactosidase ratios) in each sample were pooled. The pooled 
samples had an average concentration of ~1.77mg/ml, as determined by Bradford assay. 
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Periplasmic extract was also prepared from each bacterial culture and found to have an 
average of concentration of 3.83mg/ml. 1mg of WT OMV and 1mg of WT periplasmic extract 
(prepared in triplicate) were used for proteomic analysis. The total protein of each sample 
was precipitated using methanol and chloroform, then digested with trypsin and cleaned. 
Samples were analysed separately by HPLC-MS (LTQ-Orbitrap) and proteins identified 
using Progenesis LC-MS software.  
 
Sample A Sample B Sample C 
Fraction AP  β-G  Ratio Fraction AP  β-G  Ratio Fraction AP  β-G  Ratio 
A1 0.04 269.10 0.0001 B1  0.05 137.91 0.0004 C1 0.11 175.93 0.0006 
A2 0.02 218.52 0.0001 B2 0.03 171.72 0.0002 C2 0.11 165.81 0.0007 
A3 0.05 155.71 0.0003 B3 0.02 124.34 0.0002 C3 0.14 124.62 0.0011 
A4 0.11 124.58 0.0009 B4 0.06 77.33 0.0008 C4 0.12 82.99 0.0015 
A5 0.12 77.91 0.0016 B5 0.09 80.13 0.0011 C5 0.16 63.93 0.0025 
A6 0.22 64.20 0.0035 B6 0.15 65.26 0.0022 C6 0.21 68.52 0.0030 
A7* 0.31 41.30 0.0075 B7 0.19 60.48 0.0032 C7* 0.24 64.66 0.0037 
A8* 0.27 34.72 0.0078 B8 0.26 55.56 0.0048 C8* 0.27 32.47 0.0084 
A9* 0.25 29.74 0.0084 B9* 0.35 34.50 0.0101 C9* 0.25 47.84 0.0053 
A10 0.18 45.19 0.0041 B10* 0.33 42.78 0.0077 C10 0.19 76.25 0.0025 
A11 0.21 83.33 0.0025 B11* 0.28 52.33 0.0054 C11 0.15 64.97 0.0024 
A12 0.23 63.13 0.0036 B12 0.23 54.11 0.0042 C12 0.15 47.62 0.0031 
 
Table 6 The results of the alkaline phosphatase and β-galactosidase assays. Shown are the 
calculated units/ml of both alkaline phosphatase (AP) and β-galactosidase (β-G) in each fraction and 
the ratio of AP/β-G. The fractions which were pooled for analysis are indicated by *. 
 
 
A total of 1,009 proteins were identified by MS between the OMV and periplasmic extract 
samples. Of these, 783 were identified using 2 or more peptides. Label-free quantitation was 
performed using peptide spectra (Le Bihan et al., 2011) and used to compare the OMV and 
PP samples. To be considered enriched in a particular sample, a protein must have been 
identified using 2 or more peptides and be more than 2-fold more abundant in that sample 
with an associated ANOVA p value of <0.05. By these standards 88 proteins are considered 
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to be significantly more enriched in OMV than in the PP; these proteins will be referred to as 
OMV proteins from here (all of these proteins were also identified in the PP). Meanwhile 84 
proteins were considered to be more enriched in the PP than in the OMV (Figure 23).  
 
 
Figure 23 Venn diagram showing the proportion of proteins (those which were identified using 2 or 
more peptides) which were significantly enriched in the OMV or periplasm by abundance. Proteins are 
considered to be significantly enriched if the ratio of the mean abundance of the protein in the OMV 
(x̄ OMV) over the mean abundance of the protein in the periplasm (x̄ PP) is >2 (or vice versa) with an 
associated ANOVA p value of <0.05.  
 
Only 29% of OMV proteins could be identified as outer membrane and periplasmic proteins 
(Figure 24 A), however several proteins of unknown location are known to contain a signal 
sequence and are likely to originate from these subcellular fractions. 21% of enriched OMV 
proteins were of cytoplasmic origin. This is an unexpectedly high number and may be 
indicative of contamination during the isolation of the OMV. The presence of OM, IM and 
cytoplasmic proteins in the PP sample (Appendix VII) suggests that significant contamination 
occurred during the periplasmic extraction procedure.  
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The identity of proteins in the OMV were predicted using Mascot (Matrix Sciences, USA) or 
BLASTP (NCBI), based on a protein sequence comparison against NCBI non-redundant 
databases. The OMV proteins were of a wide range of predicted functions (Figure 24 B), the 
most common of which were metabolic and biosynthetic enzymes. 42% of OMV proteins 
remain uncharacterised. 
 
There was no enrichment of any particular function or subcellular location amongst the most 
abundant of the 783 proteins identified in the OMV (Table 7). The most commonly seen in 
these 20 proteins were metabolic or biosynthesis enzymes of cytoplasmic origin and outer 
membrane nutrient acquisition proteins. Of the 20 proteins which show the largest fold 
increase in abundance over the PP (Table 8), more than half are uncharacterised and of 
unknown subcellular origin, whilst the remaining proteins consist mainly of outer membrane 
and extracellular proteins. There are a large number of nutrient binding and acquisition 
proteins in the OMV (Figure 24), however due to the lack of characterisation it is unclear 
which functional group is actually the most enriched. For a full list of proteins enriched in the 
OMV see Appendix VII.  
 
There are 226 proteins identified in this study which cannot be considered "true" hits as they 
were identified using only 1 peptide. There are 84 which are significantly less abundant in 
the OMV than in the PP and a further 611 proteins which are not significantly enriched in the 
OMV. There are some proteins of interest in this last group, including a previously 
documented fibrinogen-binding protein (section 4.2.6). It is probable that other proteins 







Accession Number Predicted Identity Functional Group Subcellular Origin 
YP_213166.1 Xylanase Nutrient binding Extracellular 
YP_097602.1 Hypothetical protein Unknown Unknown 
YP_101476.1 Elongation factor Tu DNA/RNA Cytoplasm 
YP_099239.1 Starch-binding protein Nutrient binding Outer membrane 
YP_101460.1 Elongation factor G DNA/RNA Cytoplasm 
YP_099848.1 tRNA synthetase subunit DNA/RNA Cytoplasm 








YP_098327.1 30S ribosomal protein S1 DNA/RNA Cytoplasm 
YP_101034.1 Ketol-acid reductoisomerase Biosynthesis Cytoplasm 




YP_213038.1 Xylanase Nutrient binding Outer membrane 
ZP_07811280.1 Two component system response 
regulator 
Signal transduction Outer membrane 
YP_100507.1 Lipoprotein Unknown Outer membrane 
YP_099179.1 OmpA family protein Unknown Outer membrane 
YP_101286.1 Elongation factor Ts DNA/RNA Unknown 
YP_097970.1 Ribosome recycling factor DNA/RNA Unknown 
Table 7 The 20 most abundant proteins amongst the 783 identified using 2 or more peptides in the 
OMV sample. Included is the accession number for each protein (B. fragilis NCTC 9343), the 
predicted identity of the protein according to Mascot or a BLASTP search against all NCBI protein 





Figure 24 Pie charts showing the subcellular origin (A) and predicted function (B) of the 88 proteins 
enriched in the OMV. 
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Accession No. Predicted Identity  Functional Group Subcellular Origin 
YP_210059.1 TonB-dependent receptor Signal Transduction Outer Membrane 
YP_210687.1 Putative lipoprotein Unknown Unknown 
YP_210300.1 SusC/RagA Nutrient Outer Membrane 
YP_210172.1 Hypothetical protein Unknown Extracellular 
YP_210578.1 Hypothetical protein Unknown Unknown 
YP_211023.1 Hypothetical protein Unknown Unknown 
YP_210845.1 Hypothetical protein Unknown Unknown 
YP_212392.1 Hypothetical protein Unknown Unknown 
YP_213166.1 Xylanase Nutrient Extracellular 
YP_213613.1 OM protein Unknown Outer Membrane 
YP_213037.1 Hypothetical protein Unknown Unknown 
YP_211269.1 ATP/GTP-binding subunit Unknown Unknown 
YP_212656.1 Lipoprotein, LigD 
superfamily 
DNA/RNA binding Unknown 
YP_211022.1 Hypothetical protein Unknown Unknown 
YP_212584.1 OM protein Unknown Outer Membrane 
YP_211011.1 Alpha-2 macroglobulin Protease inhibitor Outer Membrane 
YP_213040.1 Hypothetical protein Unknown Unknown 
YP_211278.1 C10-like peptidase Protease Unknown 
YP_213780.1 TonB-dependent receptor Signal transduction Outer Membrane 
 
Table 8 The 20 OMV proteins with the largest fold increase in abundance over the periplasm, i.e. the 
ratio of the mean abundance of the protein in the OMV (x̄ OMV) over the mean abundance of the 
protein in the periplasm (x̄ PP). Included is the accession number for each protein (B. fragilis NCTC 
9343), the predicted identity of the protein according to Mascot or a BLASTP search against all NCBI 
protein databases, and the functional group and the predicted subcellular origin of each protein.  
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4.2.3 Potential proteases in the OMV of B. fragilis 
 
This study identified 7 putative proteases, by a BLASTP search against the NCBI non-
redundant database, which are enriched in the OMV (Table 9). Each of these proteases 
contains an N-terminal signal sequence, indicating that they are exported from the 
cytoplasm, and have a range of potential functions, including virulence, nutrient acquisition, 
cell wall turnover and degradation of misfolded proteins. However, these functions are 
speculative and would need to be confirmed by biochemical techniques. An additional 
protease was detected in the remaining 611 proteins, however it is not considered enriched 

























YP_211278.1 56.55 Related to Peptidase 
C10  
Virulence Yes 
YP_209856.1 45.29 Related to Peptidase 
C10 
Virulence Yes 




YP_211064.1 61.37 Related to Peptidase 
C69 
Various Yes 
YP_213364.1 48.94 Serine protease Nutrient acquisition Yes 
YP_210628.1 106.42 Related to Peptidase 
M16 
Unknown Yes 







Table 9 Potential proteases enriched in the OMV sample. Included is the accession number in NCTC 
9343, the predicted molecular weight of the protein (as determined by Artemis), the predicted identity 
(as determined by a BLASTP search against all available databases), the predicted function of these 
proteases based on their function in other bacteria, and whether they contain a signal sequence for 








4.2.4 A B. fragilis α-2 macroglobulin is present in the OMV 
 
One of the OMV proteins with a large fold increase in abundance over the periplasm, 
BF1415 (Accession no. YP_211011.1) is a putative α-2 macroglobulin (α2M), identified using 
a BLASTP search against all available databases. α2ms are large protease traps, found in 
both prokaryotes and eukaryotes (Budd et al., 2004). An α2m in the OMV of B. fragilis may 
sequester, inhibit and transport proteases either of bacterial or host origin. BF1415 shares 
75% identity (across 1734aa, e value 0.0) with an α2M from B. thetaiotaomicron. The gene 
encoding this α2m is directly adjacent to a gene encoding an OM protein, BF1416. The 
active domains of this α2M are predicted to exist on the extracellular side the OM, according 
to 3 independent transmembrane prediction servers; CBS TMHMM v.2.0 (Krogh et al., 

















4.2.5 A known fibrinogen-binding protein was detected in the OMV of B. fragilis 
 
BF1705 of NCTC 9343 (accession number YP_211343.1) is a previously characterised, 
54kDa, outer membrane fibrinogen-binding protein. A deletion mutant, B. fragilis Δ1705 was 
generated using the I-SceI-expressing plasmid pGB920 (Houston et al., 2010). BF1705 was 
identified amongst the 783 proteins identified in the OMV, however it is not significantly 
enriched in the OMV (p value of 0.178). To determine whether this is a true hit, 10µg of 
concentrated supernatant of WT, pGB920 and Δ1705 B. fragilis were analysed by SDS-
PAGE followed by Western blotting with rabbit anti-BF1705 antibodies (secondary staining 
with HRP-conjugated anti-rabbit antibodies). The Western blot shows that a 54kDa band 
present in both the WT and pGB920 concentrated supernatant is absent in the Δ1705 
concentrated supernatant (Figure 25 C). Gels stained with Coomassie blue and Silver stain 
show that neither B. fragilis pGB920 nor the Δ1705 mutation have a significantly different 





































































Figure 25 Comparison of WT, pGB920 and Δ1705 concentrated supernatant. Wells were loaded with 
10µg total protein and stained by Coomassie (A), Silver stain (B) and Western blotting (C) using 
rabbit anti-1705 primary antibodies and HRP-conjugated anti-rabbit secondary antibodies. Arrows 
indicate the expected location of fibrinogen-binding protein (54kDa). 
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4.2.6 BfUbb in the OMV of B. fragilis 
 
BfUbb is an 8.6kDa, prokaryotic homologue of ubiquitin, which has a periplasmic signal 
sequence and is believed to be packaged into OMV of B. fragilis (Patrick et al., 2011). 
However, this protein was not identified amongst the 783 proteins (those identified using ≥2 
peptides). 10µg of concentrated supernatant of WT, pGB920 and Δubb were analysed by 
SDS-PAGE followed by either Coomassie staining, Silver Staining, or Western blotting with 
rabbit anti-BfUbb antibodies (secondary staining with HRP-conjugated anti-rabbit 
antibodies). There were no significant differences in protein laddering patterns between the 
WT, pGB920 and Δubb strains in the Coomassie- and Silver-stained gels (Figure 26 A and 
B). A ~8-9kDa band could be detected by Western blotting in WT and pGB920 concentrated 
supernatant but not in Δubb concentrated supernatant (Figure 26 C). BfUbb may not have 




































































Figure 26 Comparison of WT, pGB920 and Δubb concentrated supernatant. Wells were loaded with 
10µg total protein and stained by Coomassie (A), Silver stain (B) and Western blotting (C) using 
rabbit anti-BfUbb primary antibodies and HRP-conjugated anti-rabbit secondary antibodies. Arrows 




4.3.1 OMV isolation procedure and LTQ-Oribtrap LC-MS 
 
The OMV isolation method used in this study was a combination of techniques established in 
previous OMV proteomics studies, closely based on method 1 from Bauhman and Kuehn 
(2006). Whole cells were removed from 5L of B. fragilis culture by differential centrifugation 
(6,000xg) and the supernatant was filtered (0.45µm), concentrated to <500ml by TFF, 
filtered a second time (0.45µm) and then concentrated by centrifugal filtration to <3ml. The 
concentration of the concentrated supernatant was ~14.7mg/ml, with a yield of ~5.38mg/L 
initial culture. Approximately 10mg of total protein were loaded onto an Opti-Prep density 
gradient (15-40%) and centrifuged (100,000xg). OMV-containing fractions were identified as 
those with the highest ratio of alkaline phosphatase activity (periplasmic) to β-galactosidase 
activity (cytoplasmic) and pooled. The final concentration of OMV was ~0.77mg/ml, a yield of 
1.24mg/L.  
 
This isolation method should have ensured a high concentration and purity of OMV. Starting 
with 5L and concentrating the supernatant to <3ml prior to density centrifugation resulted in 
a high concentration of protein, however, of the ~10mg of protein loaded onto the Opti-Prep 
gradient, only ~2.31mg was recovered in the OMV-containing fractions. This is a loss of 
~77% of total protein, which reduced the overall yield of pure OMV. The concentration of the 
sample at each stage of the isolation procedure is not known for this study, thus it is unclear 
whether protein was lost during the concentration of the supernatant. PVDF filters were used 
to prevent adherence during centrifugal filtration, but not during TFF. The high pressure 
exerted on the sample during TFF may also have caused lysis of some OMV.  Some 
researchers have added protease inhibitors to the supernatant after filtration to prevent 
protein degradation (Kolodziejek et al., 2013). Although samples were kept at 4ºC 
throughout OMV isolation in this study, the whole procedure took up to 48h. It is possible 
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that proteins were degraded during this time and that the addition of protease inhibitors 
would have increased overall yield. This may also account for the loss of small or low 
abundance proteins which will undergo complete degradation faster than larger and more 
abundant proteins (section 4.3.7). Opti-Prep density centrifugation is considered essential to 
the isolation of pure OMV (Lee et al., 2008), therefore its use here should ensure a certain 
level of purity. The alkaline phosphatase and β-galactosidase assays were used to 
determine which Opti-Prep fractions contain the highest proportion of OMV, on the 
assumption that OMV are enriched in periplasmic proteins and that cytoplasmic proteins are 
contaminants.  Although both alkaline phosphatase and β-galactosidase peptides were 
detected in the OMV neither were considered true hits and many other cytoplasmic proteins 
were identified in the OMV. This suggests that this approach is not sufficient to distinguish 
OMV from cytoplasmic contaminants.  
 
OMV and PP samples were analysed using a gel-free approach, as is appropriate when 
dealing with a large number of hydrophobic membrane proteins (van de Waterbeemd et al., 
2013). This approach also means that proteins are not excluded by the picking and choosing 
of particular bands (Choi et al., 2015). The disadvantage of this approach is that digestion of 
a whole sample without pre-fractionation leads to a very complex peptide mixture. Although 
peptides were fractionated by HPLC  prior to analysis there is still a risk that the signal of 
small or low abundance proteins is drowned out by that of large or high abundance proteins 
(Kreimer et al., 2015). Small proteins known to be exported to the periplasm could not be 
detected in this study (sections 4.2.5 and 4.3.7), suggesting that this effect is occurring. This 
could be countered by using high-sensitivity approaches such as ULF LC to further separate 
peptides prior to analysis (Kreimer et al., 2015). Alternatively, quantitative proteomics could 
determine the absolute abundance of proteins, e.g. by iTRAQ. Spectral counting was used 
for label-free quantitation in this study, however this is known to result in some proteins with 
low ion abundance being overlooked (Cooper et al., 2010) and other quantitative methods 
may be more representative. 
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4.3.2 Dynamic light scattering of OMV 
 
DLS is cheaper, easier and faster than electron microscopy, which is the standard technique 
used to determine the average diameter of OMV. Some proteomics studies have used DLS 
in parallel with TEM and the two methods seem to produce consistent measurements (Choi 
et al., 2011; Jang et al., 2014). In this study DLS was used to analyse concentrated 
supernatant of WT B. fragilis. A single peak was detected, suggesting a monodisperse 
solution of globular molecules with an average diameter of ~200nm (Figure 22 A). This peak 
is considered to be of cellular origin as it does not appear in a BHI-S only control (Figure 22 
B), however it indicates a diameter >100nm greater than that of B. fragilis OMV as 
determined by TEM in previous studies of B. fragilis OMV (Figure 19) (Patrick et al., 1996). 
Additionally, there was little consistency between the repeated measurements (Appendix VI). 
It is possible that repetitive aspiration by the needle of the Zetasizer APS causes turbulence 
which strips the OMV of their CPS, causing them to aggregate into clumps with a larger 
average diameter than individual OMV. Additional measurements of pure OMV or 
concentrated supernatant are required to determine whether the Zetasizer APS can 
accurately measure OMV diameter. The single peak in the concentrated supernatant sample 
suggests that the large molecules present in BHI-S are effectively removed during the 










4.3.3 The contents of B. fragilis OMV 
 
This study identified 783 OMV proteins using 2 or more peptide, 88 of which are enriched in 
the OMV (Figure 23). This is consistent with previous studies of OMV proteomes, which 
have identified around 60-340 proteins (discounting studies where only certain bands on a 
1D gel were selected). All 88 proteins were also detected in the PP. Some of the proteins 
most enriched in the OMV are nutrient-binding proteins and proteases as well as various OM 
proteins (Table 8, Figure 24). The enrichment of OM proteins in the OMV sample is to be 
expected.  
 
A significant proportion (21%) of the 88 OMV proteins are of cytoplasmic origin. Similar 
numbers of cytoplasmic proteins have been identified in other studies, despite the fact that 
most proteins are expected to be of periplasmic or OM origin (Aguilera et al., 2014; Altindis 
et al., 2014; Choi et al., 2011; Elhenawy et al., 2014). Some authors claim that if proper care 
is taken in isolating OMV from log-phase cells there should be no IM or cytoplasmic proteins 
in the sample (Berlanda Scorza et al., 2012; Kulp & Kuehn, 2010; Scorza et al., 2008). The 
OMV in this study were isolated from late log-phase/early stationary-phase cultures and may 
have been contaminated with cytoplasmic proteins from lysed cells. Some studies have 
described the formation of larger "complex OMV" which incorporate both the inner and outer 
membrane, as well as sections of the periplasm and cytoplasm. This model of OMV 
biogenesis accounts for the inclusion of proteins from all subcellular compartments, however 
it is believed to be damaging to the bacterial cell (Perez-Cruz et al., 2013) and these 
complex OMV may therefore be too rare to account for the high numbers of cytoplasmic 
proteins seen in this study. Moreover, these OMV have never been observed by TEM in B. 
fragilis culture (Lutton et al., 1991; Patrick et al., 1996; Pumbwe et al., 2007). Many of the 
cytoplasmic proteins identified in the OMV are metabolic "house-keeping" enzymes, some of 
which are thought to have alternative functions in other subcellular compartments. For 
example, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is known to accumulate of 
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the cell surface of various bacterial species, including Streptococcus spp, Staphylococcus 
spp, Neisseria spp, enteropathogenic E. coli (EPEC) and Mycobacterium avium (Espinosa-
Urgel & Kolter, 1998; Grifantini et al., 2002; Lottenberg et al., 1992; Modun et al., 2000; 
Pancholi & Fischetti, 1992; Pancholi & Chhatwal, 2003). Surface associated GAPDH is 
known to have ADP-ribosylating activity (Pancholi & Chhatwal, 2003), a feature of many 
enteric toxins, and in EPEC it is required for initiation of signalling between the bacterium 
and the host cell (Espinosa-Urgel & Kolter, 1998). One of the most abundant proteins 
identified in B. fragilis OMV in this study was a GAPDH (Table 7). This protein, presented on 
the surface of OMV, may allow B. fragilis to interact with its host. Other cytoplasmic enzymes 
have been found on the surface of bacteria, despite lacking signal sequences, including 
phosphoglycerate mutase, triosephosphate isomerase, aldolase, pyruvate kinase, alcohol 
dehydrogenase and succinyl-CoA synthetase (Pancholi & Chhatwal, 2003). All of these 
enzymes can be found amongst the total 783 proteins identified in the OMV of B. fragilis in 
this study (Appendix VII). 
 
Whilst the presence of some cytoplasmic proteins can be accounted for, others are more 
likely to be contaminants, for example, 5% of the enriched OMV proteome consists of DNA- 
and RNA-associated proteins. OMV are known to contain DNA (Kulkarni & Jagannadham, 
2014; Kulp & Kuehn, 2010), and therefore DNA-binding proteins might be expected, 
however proteins such as DNA polymerase and 50S ribosomal proteins, both of which were 
detected in the OMV (Appendix VII), likely should not. Cytoplasmic contaminants present a 
similar problem to large, abundant proteins in that they can be over represented in the 
digested sample, suppressing the ionisation and detection of small and low abundance 






17% of OMV proteins are nutrient-binding and acquisition proteins (Figure 24 Pie charts 
showing the subcellular origin (A) and predicted function (B) of the 88 proteins enriched in the OMV. 
B), such as SusC, SusD and xylanase. These also represent some of the most abundant 
proteins in the OMV (Table 7) (Appendix VII). Nutrient acquisition is believed to be a major 
function of OMV (Kulkarni & Jagannadham, 2014; Kulp & Kuehn, 2010) and a high number 
of these proteins is consistent with the known roles of Bacteroides spp in the uptake and 
degradation of complex intestinal sugars (Wexler, 2007).  
 
The majority of enriched B. fragilis OMV proteins identified by Mascot were designated 
"hypothetical proteins". A BLASTP search of each hypothetical protein against the non-
redundant NCBI database identified many of the hits, however 42% of OMV proteins remain 
uncharacterised (Figure 24 B). The lack of characterisation for a large number of entries in 
protein databases means that proteomic methods cannot be used to fully characterise any 
biological sample. In this case, the mechanism of biogenesis and all the functions of B. 
fragilis OMV are still to be determined. 
 
4.3.4 B. fragilis proteases in the OMV 
 
This study identified 7 proteases enriched in the OMV of B. fragilis (Table 9), whereas 
another study identified 11 potential proteases (Elhenawy et al., 2014). The proteases all 
contain signal sequences, range in size from 58.2-131.4kDa and may have a range of 
functions. Two of these proteases are closely related to C10 peptidases, which act as 
virulence factors in Streptococcus pyogenes, Prevotella intermedia and P. gingivalis. B. 
fragilis NCTC 9343 only encodes 2 C10 genes, BF0116 and BF1640, both of which are 
predicted to contain lipoprotein (OM anchor) sequences (Thornton et al., 2010). Both of 
these proteins are significantly more abundant in the OMV than in the PP (Appendix VII). 
BF0116 is co transcribed with 2 staphostatin-like inhibitors; BF0115 is exported to the PP, 
BF0117 is exported to the OM (Thornton et al., 2010). Neither of these were detected in the 
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OMV or PP samples, possibly due to their small size (<100aa). The function of these C10 
peptidases is unknown. Although such proteases are known to act as toxins in other 
species, B. fragilis NCTC 9343 is a non-enterotoxigenic strain and it is therefore unlikely that 
these C10 peptidases have any pathogenic function. Since NCTC 9343 does not express 
Bft, it is still unknown whether this toxin is packaged into the OMV of ETBF strains.  
 
4.3.5 B. fragilis α-2 macroglobulin in the OMV 
 
α-2 Macroglobulins (α2ms) are large (~1,500aa) protease inhibitors, found in both 
eukaryotes and prokaryotes, which form molecular traps for proteases. Usually acting as 
homotetramers, α2ms contain a small (30-40aa), flexible, solvent-exposed bait region 
containing 1 or more proteolytic cleavage sites. When a protease cleaves the bait region the 
α2m undergoes a conformational change; an exposed glutamyl links with a lysine in the 
target protease or in another part of the α2m, trapping the protease (Armstrong & Quigley, 
1999; Budd et al., 2004; Kantyka et al., 2010; Robert-Genthon et al., 2013). Trapped 
proteases can no longer cleave macromolecular substrates, however they can cleave 
smaller substrates. They are also protected from other protease inhibitors and from being 
proteolytically digested themselves (Armstrong & Quigley, 1999; Kantyka et al., 2010). 
Different α2ms are able to trap a wide range of proteases due to significant variation in the 
bait region and active domains, even between closely related species (Armstrong & Quigley, 
1999; Budd et al., 2004; Kantyka et al., 2010; Robert-Genthon et al., 2013). In eukaryotes, 
α2ms form part of the innate immune system, clearing proteases from tissue fluids post-
infection. The conformational change in the α2m results in the exposure of a C-terminal motif 
that binds blood cell surface protein CD19, resulting in endocytosis and digestion of the α2m 
and the trapped protease (Armstrong & Quigley, 1999; Budd et al., 2004). α2ms are also 
found in 14 of the 29 bacterial phyla (Kantyka et al., 2010). It is believed that an inter-
kingdom HGT occurred between eukaryotes and prokaryotes, however it is unclear in which 
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kingdom α2ms originated. The primary function of bacterial α2ms, which typically exist in the 
PP of Gram-negative bacteria, is believed to be the trapping of invading proteases during a 
breach of the OM (Budd et al., 2004; Kantyka et al., 2010; Robert-Genthon et al., 2013).  
This study identified a homologue of a bacterial α2m in the OM portion of the OMV of B. 
fragilis. This protein showed significant homology with an α2m in B. thetaiotaomicron by 
BLASTP, with an e value of 0.0 and 75% identity across 1734aa (with a total length of 
1864aa), and is considered enriched in the OMV by the parameters of this MS study. α2ms 
in Gram-negative bacteria are usually encoded near genes for PG synthesis or IM proteins 
and are usually anchored in the IM, facing the PP (Budd et al., 2004; Robert-Genthon et al., 
2013). The gene encoding the α2m identified in this study is directly adjacent to an OM 
protein and, moreover, the α2m is predicted to be exported to the OM with its active domains 
surface exposed rather than facing the PP. The presence of this protease inhibitor on the 
surface of OMV, and the ability of OMV to diffuse in the extracellular medium, suggests that 
proteases which may harm B. fragilis cells could be trapped before they reach their targets. 
This may provide protection from host or bacterial proteases in the gastro-intestinal tract or 
aid bacterial survival in the peritoneal cavity, for example, by inhibiting thrombin, the enzyme 
responsible for fibrin production, thus interfering with abscess formation.  
 
4.3.6 B. fragilis fibrinogen-binding protein in the OMV 
 
Fibrinogen is a large (350kDa), mammalian glycoprotein made up of 3 chains (α, β and γ). 
During abscess formation fibrinogen is cleaved by thrombin to produce fibrin, which then 
contributes to the fibrous network of the abscess (Henschen et al., 1983). B. fragilis cells 
have been shown to bind the β-chain of fibrinogen via a 54kDa protein, BF1705 (NCTC 
9343) (Houston et al., 2010). The binding of fibrinogen by bacteria is considered a virulence 
attribute as it sequesters the glycoprotein before it can be cleaved by thrombin, therefore 
reducing the total amount of fibrin available and slowing or preventing the formation of the 
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abscess. This, in turn, allows the bacteria to disseminate into the bloodstream resulting in 
bacteraemia. Additionally, binding fibrinogen increases clumping of bacterial cells, thus 
increasing their resistance to phagocytosis by macrophages. Concentrated supernatants of 
various B. fragilis strains also exhibit fibrinogenolytic activity (Houston et al., 2010). The 
unrergulated degradation of fibrinogen further reduces the availability of fibrin during 
abscess formation. 
 
BF1705 was detected in the OMV sample by MS, however it was not considered enriched in 
the OMV as it had an associated p value of >0.05. This lack of enrichment may be an 
artefact of OM contamination in the PP sample. Since it is a known OM protein with a 
potential role in pathogenesis, concentrated supernatant from WT, pGB920 and Δ1705 B. 
fragilis were analysed by Western blotting using anti-1705 antibodies, and BF1705 could be 
identified in the first two strains but not the latter (Figure 25 C). Whilst the protein could be 
detected by Western blotting in concentrated supernatants, it should be noted that 
concentrated supernatant is not necessarily representative of purified OMV. The presence of 
BF1705 on the surface of the OMV increases the total surface area capable of binding 
fibrinogen and thus improves the ability of the bacterium to inhibit abscess formation. 
Fibrinogen-binding by OMV may also contribute to bacterial clumping. Supernatants of B. 
fragilis are also known to have fibrinogenolytic activity, the agent of which is unknown. This 
study identified several proteases which may be capable of degrading fibrinogen (Table 9). 
 
4.3.7 BfUbb in the OMV 
 
BfUbb is a 76aa (8.6kDa), prokaryotic homologue of ubiquitin (described in more detail in 
Chapter 3). It contains a periplasmic signal sequence and has previously been detected in 
concentrated supernatants of B. fragilis (Patrick et al., 2011). It was also detected by 
Western blotting in concentrated supernatant produced in this study (Figure 26 C), however 
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it was not identified in the OMV by MS. Whilst the concentrated supernatant may not be 
representative of pure OMV it is still likely that BfUbb is present in the OMV. There is a risk 
that small proteins such as BfUbb are not detected by this particular approach to MS as they 
produce far fewer peptides than larger, more abundant proteins. Improved gel-free 
approaches, e.g. PTAG, may be required to detect such proteins by MS.  
 
4.3.8 Future work and considerations 
 
The list of 88 enriched OMV proteins in this study is most likely an incomplete proteome as it 
is missing at least 2 proteins which can be detected in the concentrated supernatants of B. 
fragilis NCTC 9343 (BF1705 and BfUbb). The list also contains an unprecedented number of 
cytoplasmic proteins. It may be that B. fragilis produces complex OMV, containing fractions 
of the IM and cytoplasm. TEM of thin sections of B. fragilis culture was used to demonstrate 
the production of simple OMV (Lutton et al., 1991; Patrick et al., 1996) and could also 
identify the production of complex OMV from this species. The cytoplasmic proteins may 
also be indicative of contamination in both the isolation of OMV and extraction of the PP. 
The OMV isolation method used in this study resulted in a significant loss of protein and may 
have led to the contamination of the sample by a large number of cytoplasmic proteins. An 
improved method might use log-phase bacterial culture rather than late log-phase/early 
stationary-phase bacterial culture to avoid contamination from lysed cells. It is also possible 
that the high pressures experienced by the OMV during TFF is causing premature lysis and 
leading to loss of proteins. Removing this step or replacing it with a technique that exerts 
less pressure on the OMV may improve the yield. An ultracentrifugation step after 
concentration of the supernatant may remove small protein contaminants and increase the 
concentration of OMV prior to density centrifugation. It is important that the concentration of 
the sample be determined at each stage to identify which techniques result in the most 
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protein loss. Finally, the addition of protease inhibitors to the filtered supernatant would 
ensure that little-to-no protein is lost due to proteolytic digestion.  
 
Comparing the OMV sample to the PP means that the proteins most enriched in the OMV 
will be OM proteins, however this may not be representative. A comparison of the OMV with 
not only the PP but the OM and whole cells of B. fragilis, using quantitative MS, would 
provide a better indication of which proteins are enriched in OMV. In this study label-free 
quantitation was performed using spectral counting, however this is not considered to be the 
most sensitive measure of protein quantitation and so the spectral counts were not 
incorporated into the analysis. Alternative tagging of multiple protein samples, as with iTRAQ 
and TMT, allows proper quantitation using the ratios of the tags for each protein (Kreimer et 
al., 2015) and would be more appropriate . Additionally, there appears to be significant 
contamination of the PP sample, which will have affected which proteins are considered 
enriched in the OMV. A different method of periplasmic extraction, e.g. by freeze-thaw, may 
be required to generate a purer sample. 
 
The presence of proteins of interest identified in the OMV must be confirmed using 
biochemical and/or genetic techniques. The generation of deletion mutants for genes of 
interest allows comparison with the WT strain, e.g. by SDS-PAGE and Western blotting with 
antibodies raised against the chosen protein. The activity of proteases can be confirmed 
without generating deletion mutants. OMV proteins could be separated by SDS-PAGE, 
followed by excision of bands which represent proteins the same size as suspected 
proteases. These bands could then be tested for various proteolytic activity. Alternatively, 
zymography can be used to determine which bands exhibit proteolytic activity. This has 
already been done for B. fragilis OMV (Elhenawy et al., 2014), however it does not indicate 
the exact nature of the individual proteases and therefore further analysis is needed. 
Armstrong and Quigley (1999) describe a series of tests which can be used to detect α2m 
activity in a sample. These tests are based on the principle that a protease trapped by an 
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α2m would not be able to cleave large peptide substrates but would be able to cleave 
smaller substrates and would also be immune to other protease inhibitors. This approach 
could be used to confirm the presence of the α2m on the surface of the OMV, on the 
assumption that an α2m in the lumen of the OMV would not confer protease inhibitor activity. 
However, the known proteolytic activity of the OMV may interfere with the assay. 
Alternatively, the band representing the suspected α2m could be excised from a gel, 
providing a less complex sample for analysis.  
 
The analysis of the proteome can be taken beyond simply producing a list of proteins. A 
systems biology approach to investigate the protein-protein interactions within the OMV and 
between OMV proteins and other bacterial and host proteins would provide a better insight 
into the function and mechanism of biogenesis of OMV (Choi et al., 2015). An alternative 
"top-down" approach to proteomics would allow characterisation of post-translational 
modifications, which can significantly impact protein function and localisation. For example, 
many of the known B. fragilis glycoproteins are OM proteins such as OmpA and TonB 
(Fletcher et al., 2011), several of which were identified in this study (Appendix VII), and 
BfUbb contains potential target sequences for glycosylation (Patrick et al., 2011). Since 
more than half of the extra-cytoplasmic proteins of B. fragilis are candidates for O-
glycosylation (Fletcher et al., 2011), it is likely that the OMV contain a large number of 
glycoproteins. Finally, the lipid profile of the OMV and OM of B. fragilis can be determined by 
lipidomics, possibly providing further information about the origin and function of OMV 









5. Anti-bacterial potential of B. fragilis OMV and BfUbb 
5.1 Introduction 
5.1.1 Antibiotic potential of OMV 
 
One of the many possible functions of OMV is the killing or inhibition of growth of competing 
bacteria (Kulp & Kuehn, 2010). The Gram-negative soil bacterium Myxococcus xanthus is 
known to selectively "prey" on other bacterial species, specifically by causing lysis upon cell-
cell contact. M. xanthus expresses a large number of hydrolytic enzymes and secondary 
metabolites with antibiotic activity, which were found to be enriched in the OMV of this 
species, along with the potentially lytic protease MepA. It may be that OMV of M. xanthus 
cause lysis of target bacteria upon contact (Berleman et al., 2014). P. aeruginosa expresses 
a murein hydrolase, an autolysin that is associated with the peptidoglycan layer of the 
periplasm and is a normal part of cell wall turnover (Li et al., 1996). Expression of this 
enzyme is closely associated with the presence of the B band species of LPS, the only 
species found in naturally formed P. aeruginosa OMV (Kadurugamuwa & Beveridge, 1995). 
These OMV are able to fuse with the surface of other bacteria, probably through electrostatic 
interactions between the LPS of the OMV and the surface polysaccharides of the target cell 
(Kadurugamuwa & Beveridge, 1996; Kadurugamuwa & Beveridge, 1999). This means the 
OMV could potentially deliver the autolysin, resulting in peptidoglycan degradation and cell 
lysis (Li et al., 1996). OMV production in P. aeruginosa is greater in the presence of sub-
lethal concentrations of aminoglycosides, such as gentamicin. Gentamicin is highly 
electropositive, and it has been hypothesised that it can disrupt the salt bridges between 
electronegative LPS molecules on the cell surface. This would cause destabilisation of the 
LPS, allowing the membrane to bleb and artificial OMV to form. Where this occurs, lesions in 
the peptidoglycan layer may lead to deregulation of autolysins and further destabilisation of 
the membrane, resulting in increased OMV production (Kadurugamuwa & Beveridge, 1997). 
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The OMV formed during this process contain gentamicin (Kadurugamuwa & Beveridge, 
1995) and are more effective than naturally formed OMV at inhibiting the growth of both 
Gram-positive and Gram-negative bacteria, presumably due to the synergistic effects of the 
hydrolases and the antibiotic (Kadurugamuwa & Beveridge, 1996). The OMV of a 
psychrotrophic strains of Pseudomonas syringae (Lz4W) can also carry antibiotics. These 
OMV are able to protect cells from the action of colistin and melilitin (but not streptomycin), 
specifically by absorbing the antibiotics into their lumen. Mass spectrometry analysis showed 
that the antibiotics are not degraded, just sequestered (Kulkarni et al., 2014), suggesting that 
they could potentially be delivered to other bacteria. OMV are of biotechnological interest as 
they have the potential to deliver a varied cocktail of antibiotic proteins and compounds, 
which could prevent the development of single-gene resistance in pathogenic target bacteria 
(Berleman et al., 2014). 
 
5.1.2 Antibiotic potential of ubiquitin 
 
Amongst its many roles, ubiquitylation is involved in the cellular responses to infection, for 
example through signalling in the inflammatory response pathway (Corn & Vucic, 2014) and 
lysosomal-based microbe killing (Alonso et al., 2007). Interestingly, ubiquitin and ubiquitin-
like proteins have also been shown to display potent antimicrobial activity in vitro. A ubiquitin 
protein isolated from a Pacific oyster is expressed as a fusion with the ribosomal subunit 
S27, and cleaved post-translation. This cleaved product was able to inhibit the growth of 
both Gram-positive and Gram-negative bacterial pathogens via a non-lytic mechanism (Seo 
et al., 2013). Pikt, a ubiquitin-like protein of the yeast Pichia anomala, is a killer toxin which is 
able to inhibit microbial growth without disrupting membrane integrity (De Ingeniis et al., 
2009). The best described ubiquitin-like antimicrobial is ubiquicidin, first identified as a post-
translational cleavage product of the protein Fau in the cytoplasm of mouse macrophages 
stimulated with interferon-γ. Ubiquicidin is 74aa long and shares 38% identity with ubiquitin, 
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and was able to inhibit the growth of intracellular pathogens Listeria monocytogenes and 
Salmonella enterica Typhimurium, as well as other Gram-positive and Gram-negative 
pathogens. This activity was found to be as potent as many mammalian defensins (Hiemstra 
et al., 1999; Howell et al., 2003).  
 
Some studies have not been able to replicate the inhibitory effects of whole ubiquitin 
(Svensson et al., 2005), however others indicate that it is peptide fragments of ubiquitin that 
are responsible for antimicrobial activity. The C-terminal peptide, Ub65-76, is a potent 
antifungal which is able to form holes in the cell wall of fungi and accumulate in the 
cytoplasm where it inhibits growth. The N-terminal peptide, Ub1-34, cannot cross the cell wall 
but can work synergistically with Ub65-76 to inhibit growth, presumably entering the cell via the 
holes made by the C-terminal peptide (Kieffer et al., 2003). Whilst whole ubiquitin was not 
able to inhibit growth of Mycobacterium tuberculosis, samples of ubiquitin pre-incubated with 
lysosomal proteinases could, suggesting that the digested products were antibacterial 
(Alonso et al., 2007). Furthermore, ubiquitin has been identified in biological fractions, 
extracted from insect cells (Svensson et al., 2005) and colonic mucus (Antoni et al., 2013), 
that demonstrate antibacterial activity. Ubiquicidin could also be identified in fractions of non-
inflammatory colonic mucosa with antimicrobial activity (Howell et al., 2003). Ubiquitin and 
ubiquicidin, as extra- or intracellular antimicrobial proteins, are therefore considered part of 
the innate immune system in animals (Hiemstra et al., 1999; Howell et al., 2003), however 
the exact mechanism of the antimicrobial activity of ubiquitin and its peptide fragments is 









B. fragilis OMV are believed to carry a homologue of eukaryotic ubiquitin (Figure 26 C) 
(Patrick et al., 2011). Since both eukaryotic ubiquitin and the OMV of various bacteria have 
been shown to exhibit antibiotic activity, it may be that the OMV of B. fragilis are able to kill 
or inhibit growth of other bacteria in a BfUbb-dependent manner. Such an action would 
benefit the bacterium in multiple ways: there would be fewer bacterial species competing for 
available nutrients, and killing or inhibiting pathogens would prevent inflammation of the gut 
or death of the host, thus preserving the environment. The following experiments were 
designed to determine whether B. fragilis OMV exhibit antibacterial activity and, if so, 


















5.2.1 Wild-type B. fragilis concentrated supernatant restricts growth of S. enterica 
Typhimurium 
 
Concentrated supernatants of WT and Δubb strains of B. fragilis were tested for their ability 
to inhibit the growth of the Gram-negative gut pathogen S. enterica serovar Typhimurium 
SL3144. 5ml aliquots of LB were inoculated with 20µl overnight culture of S. enterica 
Typhimurium and 500µl 1mg/ml concentrated supernatant (suspended in PBS) of the WT 
and Δubb B. fragilis strains. As a control, 5ml aliquots of LB were inoculated with 20µl 
overnight culture of S. enterica Typhimurium and 500µl PBS. All 3 culture conditions were 
prepared in triplicate. Cultures were then incubated at 37ºC with shaking for a total of 8h. At 
time points T0, T2, T4, T6 and T8, 100µl of each culture were used for serial dilutions (10-1-
10-3) in PBS. 100µl of an appropriate dilution was plated onto LB agar and grown aerobically 
for 48h at 37ºC, after which colonies were counted and colony-forming units (cfu)/ml 
calculated (Appendix VIII) and the averages plotted on a growth curve (Figure 27).  
 
In cultures treated with WT concentrated supernatant, S. enterica Typhimurium grew slower 
than in those treated with PBS or Δubb concentrated supernatant. One-tailed, paired sample 
T-tests (assuming unequal variances) were used to compare the cfu/ml of the experimemtal 
cultures against the control cultures at each time point, with a pre-decided critical p value of 
0.05.  This analysis indicated that between T2 and T8 the cfu/ml in the "WT OMV" treated 
cultures was ~2-4 -fold lower than that of the PBS treated cultures (p values of <0.028) 
(Appendix VIII). The cfu/ml in the "Δubb OMV" treated cultures, however, was never 
significantly lower than that in the control, the greatest fold difference being 1.24 at time 




The implication of these results is that the WT concentrated supernatant has the ability to 
inhibit the growth of other Gram-negative bacteria, and that this ability may be associated 
with the presence of BfUbb in the OMV. However, carriage of the ubb gene is not the only 
difference between WT and Δubb strains of B. fragilis. Firstly, the Δubb mutation was 
generated using the plasmid pGB920 (Patrick et al., 2011), and since the strain 
demonstrates resistance to 5µg/ml tetracycline the plasmid is probably still present. 
Secondly, in this study, the WT and Δubb strains were grown in different antibiotics: WT in 
20µg/ml gentamicin, and Δubb in 10µg/ml erythromycin. During preparation of concentrated 
supernatants, 400ml of culture supernatant was concentrated using a centrifugal 
concentrator with a 175kDa cut-off filter to a dead-stop volume of ~1.5ml. The concentrate 
was then resuspended in 30ml PBS whilst still on the filter, and centrifuged back to a volume 
of ~1.5ml. This step was repeated and the final ~1.5ml samples retrieved, both at a 
concentration of ~2mg/ml. These were then diluted to 1mg/ml for this study. Some antibiotic 
will be retained in the concentrated supernatants of WT and Δubb B. fragilis, at a final 
concentration of ~0.05µg/ml gentamicin and ~0.025µg/ml erythromycin, respectively, in the 
undiluted samples. This would result in ~0.025µg/ml gentamicin and ~0.0125µg/ml 
erythromycin in the WT and Δubb B. fragilis concentrated supernatants used in this study. 
The inhibition of S. enterica Typhimurium growth may be related to the presence of 
gentamicin rather than the action of BfUbb. Additionally, in this experiment the concentrated 
supernatants were added to stationary/lag phase bacterial cells, i.e. cells that are not 










Figure 27 Graph showing the log10 mean cfu/ml against time (with standard deviations) in cultures of 
S. enterica Typhimurium incubated with either PBS, WT concentrated supernatant (WT OMV) or 
Δubb concentrated supernatant (ubb OMV). At T0, 20µl overnight culture was added to 5ml LB along 
with 500µl of either PBS, 1mg/ml WT concentrated supernatant or 1mg/ml Δubb concentrated 
supernatant, all in triplicate. Cultures were incubated at 37ºC with shaking for 8h. At time points T0, 
T2, T4, T6 and T8, 100µl of each culture was serially diluted (10-1-10-3) in PBS and 100µl of the 
appropriate dilution was spread onto LB plates. After 48h colonies were counted and cfu/ml calculated 
(no. of colonies x 10 x dilution) and the mean and standard deviations plotted. 500µl of each test 
sample was also added to 5ml LB without S. enterica Typhimurium and grown for 8h before plating. 





























5.2.2 Antibiotic activity of B. fragilis OMV is partially dependent on BfUbb 
 
It was necessary to determine whether the ability of B. fragilis OMV to inhibit growth of S. 
enterica Typhimurium was related to the presence of the ubb gene, the pGB920 plasmid, or 
gentamicin. Concentrated supernatants were prepared of WT B. fragilis grown in the 
presence (WTg) or absence (WT) of 20µg/ml gentamicin, and of B. fragilis pGB920 (grown 
in 5µg/ml tetracycline, to maintain the plasmid) and B. fragilis Δubb (grown in 10µg/ml 
erythromycin, to prevent contamination with the WT strain). These were then diluted in PBS 
to 3 different concentrations: 0.5, 1 and 2mg/ml. 5ml aliquots of LB were inoculated with 5µl 
overnight culture (T0) and incubated at 37ºC with shaking for 2h (to allow bacteria to leave 
lag phase), after which (T2) 500µl of each test sample were added to cells in triplicate. At 
time points T2, T4, T6, T8 and T10, 100µl of each culture were used for serial dilutions (10-1-
10-6) and 10µl of each dilution was spotted onto an LB agar plate. Plates were incubated at 
37ºC for 48h, then colonies were counted and cfu/ml calculated (Appendix VIII) and the 
averages plotted on a growth curve.  
 
One-tailed, paired sample T-tests (assuming unequal variances) were used to compare the 
cfu/ml of each test culture with that of the PBS control at every time point (T2-T8), with a pre-
decided critical p value of 0.05 (Appendix VIII). Consistent with previous results (Figure 27), 
concentrated supernatant of WT B. fragilis grown in gentamicin delays growth of S. enterica 
Typhimurium (Figure 28 A). T-test analysis indicated that between T4 and T10 the cfu/ml of 
the WTg2 treated cultures was 4.9-11.4 -fold lower than that of the PBS treated cultures (p 
values of <0.009). The cfu/ml of the WTg1 treated culture was also significantly lower than 
that of the control: 1.9-3.6 -fold lower between T4 and T10 (p values of <0.044). The cfu/ml 
of the WTg0.5 treated cultures was 1.3-fold lower than that of the control by T10 (p value of 
0.02). There were 1.6-fold fewer cfu/ml in the WTg2 treated cultures at T4 than at T2 (p value 
of 0.046) suggesting that cells are being killed rather than just inhibited. The concentrated 
supernatant of WT B. fragilis grown without antibiotic also inhibits bacterial growth, but to a 
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lesser extent than those grown in gentamicin (Figure 28 B), suggesting that the antibiotic is 
responsible for some antibacterial activity. The T-test analysis showed that the cfu/ml of the 
WT2 treated cultures was 1.9-3.4 -fold lower than the control between T4 and T10 (p values 
of <0.024). The cfu/ml of the WT1 treated cultures was 1.8-fold lower and 2.2-fold lower than 
that of the control at T6 and T8, respectively (p values of <0.031), however there was no 
significant difference at T10. The cfu/ml of the WT0.5 treated cultures was not significantly 
lower than that of the control at any time point other than T4 (1.28-fold lower, p value of 
0.040). Growth was also inhibited by concentrated supernatant of B. fragilis pGB920 (Figure 
28 C). The cfu/ml of the pGB2 treated cultures was 1.7-2.3 -fold lower than that of the control 
between T4 and T10 (p values of <0.037), whilst the pGB1 treated samples had 1.3-fold, 1.5-
fold and 1.4-fold lower cfu/ml than that of the control at T4, T6 and T10, respectively (p 
values of <0.036). The cfu/ml of the pGB0.5 treated cultures was not significantly lower than 
that of the control at any time point other than T4 (1.2-fold difference, p value of 0.025). 
There was no significant inhibition of growth in cultures treated with concentrated 
supernatant from B. fragilis Δubb at any time point (Figure 28 D). The greatest difference 
between the cfu/ml of Δubb2 treated cultures and that of the control was 1.1-fold at time point 
























































































Figure 28 Graphs showing the log10 mean cfu/ml against time (with standard deviations) in cultures of 
S. enterica Typhimurium incubated with either PBS or the concentrated supernatants of WT B. fragilis 
(WT), WT B. fragilis grown in gentamicin (WTg), B. fragilis pGB920 grown in tetracycline (pGB), or B. 
fragilis Δubb grown in erythromycin (ubb), at various concentrations. 5µl overnight culture were added 
to 5ml LB and cultures were grown at 37ºC with shaking for 2h. At this point (T2), 500µl of a test 
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sample (PBS, or 0.5, 1 or 2ml/ml of WT, WTg, pGB or ubb concentrated supernatant) were added 
and the cultures grown for another 8h. All cultures were prepared in triplicate. At T2, and every 2h 
until T10, 100µl of each culture were taken and serially diluted (10-1-10-6) in PBS and 10µl of each 
dilution were spotted onto an LB plate. After 48h colonies were counted and cfu/ml calculated (no. of 
colonies x 100 x dilution) and the mean and standard deviations plotted. 500µl of 0.5mg/ml of each 
test sample were added to 5ml LB without S. enterica Typhimurium and grown for 10h before 
spotting. No growth was detected (data not shown).  
 
These results confirm that concentrated supernatant of WT B. fragilis is able to inhibit the 
growth of S. enterica Typhimurium. T-test analysis indicated that between T4 and T10 the 
cfu/ml of the WT2 treated cultures was 1.9-4 -fold lower than that of the Δubb2 treated 
cultures (p values of <0.022). This suggests that some inhibitory activity can be attributed to 
the presence BfUbb. In this study, supernatants were isolated from 800ml B. fragilis culture, 
concentrated to 1.5ml by centrifugal concentrator, then resuspended in 30ml PBS and 
concentrated back down to 1.5ml twice. Approximately 4mg total protein was retrieved in 
each sample and diluted to 2mg/ml for this experiment. The final concentrations of antibiotics 
in WTg2, pGB2 and Δubb2 samples was therefore expected to be ~0.025µg/ml gentamicin, 
~0.006µg/ml tetracycline and ~0.0125µg/ml erythromycin, respectively. The cfu/ml of the 
WTg2 treated cultures was 2.4-3.3 -fold lower than that of the WT2 treated cultures between 
T4 and T8 (p values of <0.047), indicating that additional inhibitory activity was associated 
with the presence of gentamicin at 0.025µg/ml. The greatest difference in cfu/ml in pGB2 
treated cultures and that of the WT2 treated cultures is 1.2-fold at time point T8 (p value of 
0.333). This suggests that there is no significant inhibitory activity associated either with the 
presence tetracycline at 0.006µg/ml or with the presence of the pGB920 plasmid in B. fragilis 
cells during OMV production. There was no significant inhibition of growth in the Δubb2 
treated cultures, suggesting that no inhibitory activity can be associated with either 





5.3.1 OMV-associated BfUbb demonstrates antibacterial activity 
 
BfUbb is believed to be packaged into OMV of B. fragilis (Patrick et al., 2011), via which it 
could be delivered to other bacterial cells (Kadurugamuwa & Beveridge, 1996). Given the 
potential of both OMV (Li et al., 1996) and ubiquitin homologues (Kieffer et al., 2003) to 
demonstrate antibacterial activity, concentrated supernatants of WT B. fragilis and Δubb B. 
fragilis were tested for their ability to inhibit growth of S. enterica Typhimurium compared to a 
PBS control. The initial results indicated that not only does WT concentrated supernatant 
significantly inhibit bacterial growth, but it does so in a BfUbb-dependent manner (Figure 27). 
A second experiment was performed, this time including concentrated supernatant from WT 
B. fragilis grown without antibiotics, to determine whether inhibition of growth is due to 
association with gentamicin, and B. fragilis pGB920, to confirm that loss of antibacterial 
activity is associated with the Δubb mutation rather than presence of the plasmid. These 
results showed that concentrated supernatant of WT B. fragilis grown without antibiotics was 
also able to significantly inhibit growth of S. enterica Typhimurium (Figure 28 A), as was B. 
fragilis pGB920 concentrated supernatant (Figure 28 C), whilst B. fragilis Δubb concentrated 
supernatant still showed no inhibitory effects (Figure 28 D). The level of antibacterial activity 
displayed by the concentrated supernatants of WT B. fragilis and B. fragilis pGB920 was 
concentration-dependent, suggesting a cause and effect relationship between the presence 
of B. fragilis-derived extracellular material containing BfUbb and the inhibition of growth in S. 
enterica Typhimurium. It should be noted, however, that although the total protein content of 
each sample is the same, the size, number and nature of the OMV produced by each strain 
cannot be assessed. Differences in antibacterial activity could therefore be attributed to 




The antibacterial effect of the concentrated supernatants of WT B. fragilis grown without 
gentamicin (and B. fragilis pGB920) at the highest concentration (500µl of 2mg/ml total 
protein) was only inhibitory, rather than lethal (Figure 28 A and C). This is consistent with the 
known antibacterial effects of ubiquitin and ubiquicidin, which are bacteriostatic rather than 
bacteriocidal (De Ingeniis et al., 2009; Hiemstra et al., 1999; Seo et al., 2013). Although it 
cannot be assumed that the concentrated supernatants used in these experiments contain 
only pure OMV, the samples were concentrated and washed using a centrifugal filter that 
should have prevented the accumulation of any proteins or molecules (<175kDa) that were 
not closely associated with OMV. It is therefore likely that BfUbb is OMV-associated and that 
the OMV may responsible for delivery of BfUbb to the bacterial cells. Purified ubiquitin, or at 
least ubiquitin fragments, are capable of antimicrobial activity (Kieffer et al., 2003; Seo et al., 
2013) and free BfUbb may be capable of the same effects, however the OMV provide a 
protective environment for antimicrobial proteins in the extracellular environment and allow 
localised delivery of a high concentration of protein. As with eukaryotic ubiquitin, the putative 
antibacterial mechanism of action of BfUbb against S. enterica Typhimurium is unknown, 
however the C-terminal fragment of ubiquitin is capable of inhibiting bacterial growth on its 
own (Kieffer et al., 2003). A small band, believed to be the product of proteolytic cleavage, 
can be detected by anti-BfUbb antibodies in whole cell extracts of B. fragilis (Figure 8 B) 
(Patrick et al., 2011), which suggests that fragments of BfUbb may also be exported in OMV, 
thus be able to act on other bacterial cells. It is also unknown whether BfUbb-containing 









The ability to control populations of competing bacteria is an important aspect of many 
commensal species, for example through the secretion of bacteriocins (Avelar et al., 1999). 
S. enterica Typhimurium has the potential not only to compete with B. fragilis for resources, 
but to disrupt its environment by causing diarrhoea in the host (Poppe et al., 1998), thus 
flushing out resident gut bacteria. It would therefore be beneficial to B. fragilis to 
constitutively secrete OMV containing a bacteriostatic protein capable of preventing 
colonisation of the gut by pathogenic bacteria which may cause inflammation and diarrhoea. 
 
5.3.2 Additional antibacterial activity of B. fragilis concentrated supernatants is due to 
sample-associated gentamicin 
 
Whilst BfUbb seems responsible for a certain amount of antibacterial activity in B. fragilis 
OMV, the concentrated supernatants of WT B. fragilis grown in gentamicin demonstrated 
significantly greater inhibitory activity than that of WT B. fragilis grown without antibiotics 
(Figure 28 A and B) (Appendix VIII). The minimum inhibitory concentration (MIC, the lowest 
concentration required to inhibit overnight growth) for gentamicin against various S. enterica 
strains is between 0.13 and 1µg/ml, depending on the strain (Stock & Wiedemann, 2000). 
The final expected concentration of gentamicin in the concentrated supernatants is 
~0.025µg/ml, 10-100 -fold lower than the MIC, and would still be capable of delaying growth 
of S. enterica Typhimurium, but not inhibiting it entirely. This phenomenon is not observed 
with concentrated supernatants containing erythromycin and tetracycline (Figure 28 C and 
D). The MIC for erythromycin against S. enterica Typhimurium is 16-128µg/ml, whilst the 
expected concentration of erythromycin in the concentrated supernatants of B. fragilis Δubb 
is 0.0125µg/ml. This is a 1,000-10,000 -fold difference and erythromycin is therefore unlikely 
to affect growth at this concentration. Accordingly, there is no significant difference between 
the cfu/ml of Δubb2 treated cultures and the PBS treated cultures. The concentration of 
tetracycline in the concentrated supernatants of B. fragilis pGB920 (0.006µg/ml) is 100-
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1,000 -fold lower than the MIC of tetracycline against S. enterica Typhimurium (0.5-4µg/ml). 
Again, this does not appear to be a high enough concentration to delay growth, since the 
cfu/ml of pGB2 treated cultures was never significantly lower than the WT2 treated cultures.  
  
5.3.3 Future work and considerations 
 
These results indicate a role for OMV-associated BfUbb in the control of bacterial 
populations in the gastro-intestinal tract, however the exact nature of this role is unclear. A 
repeat of the above experiments, testing the antibiotic potential of B. fragilis OMV against 
other bacterial species, both Gram-positive and Gram-negative, and both pathogenic and 
commensal, would indicate the spectrum of antimicrobial activity of this protein. Additionally, 
each species should be incubated with purified BfUbb to determine whether the protein is 
able to inhibit growth as effectively as seen here when not associated with the OMV. BfUbb 
may also have anti-fungal capability, and could be screened against fungal pathogens both 
in purified and OMV-associated form. As with eukaryotic ubiquitin, the proteolytic products of 
BfUbb may be just as effective, if not more effective, at inhibiting microbial growth than the 
whole protein. Genetic constructs allowing expression and purification of N- and C-terminal 
peptides of BfUbb could be used to test the antimicrobial activity of these products. Electron 
micrographs of the bacterial cells of the 3 strains used in this and future studies could 
determine whether there are any differences in the size, number or nature of the OMV 
formed by each of these strains. The level of BfUbb expression and packaging in all strains 
and growth conditions should also be assessed, e.g. by Western blotting or reverse 
transcription qPCR.  
 
Here, antibiotics were used in the cultures of B. fragilis from which concentrated 
supernatants were prepared: gentamicin to prevent the contamination of the WT culture with 
facultative anaerobes, tetracycline to maintain the presence of plasmid in the B. fragilis 
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pGB920 culture, and erythromycin to prevent contamination of the B. fragilis Δubb culture 
with the WT strain. To compare the antibacterial activity of just the OMV from WT, pGB920, 
and Δubb strains, concentrated supernatants should be prepared from cultures grown 
without antibiotics. The use of B. fragilis defined medium and careful culturing techniques 
should prevent contamination of the WT, a mini-prep can be used to confirm the presence of 





















6. General Discussion 
6.1 Biochemical characterisation of ubiquitin and BfUbb  
 
Some of the biochemical properties of ubiquitin and its homologues have made these 
proteins difficult to characterise. As a β-grasp fold protein it is thermodynamically stable with 
a TM >86ºC (Piana et al., 2013), and at temperatures above this, the thermally denatured 
ubiquitin monomers form aggregates (Herberhold & Winter, 2002). Melting curves are 
therefore difficult to generate for ubiquitin-like proteins, meaning the strength of 
ubiquitin/BfUbb-E2 enzyme bonds could not be analysed by thermal denaturation 
fluorescence. Ubiquitin is also problematic when used as a ligand in SPR, as it is difficult to 
conjugate to a CM-5 chip (Hartmann-Petersen & Gordon, 2005). The SPR data generated 
during investigation of BfUbb performed in parallel to this study was inconclusive due to the 
low concentration of E2 analyte (Appendix I), however there was also difficulty in generating 
enough resonance units on the CM-5 chip to elicit a response. The problems with using such 
methods are exacerbated by the fact that most UBDs have low to moderate affinity for 
ubiquitin (Kd = 2-500µM) (Grabbe & Dikic, 2009), making these interactions difficult to detect. 
Isothermal titration calorimetry (ITC) is more accurate than SPR, and has been used 
successfully in ubiquitin-binding experiments (Roth et al., 2007), however it requires much 
greater quantities of protein (Wear & Walkinshaw, 2006), making it unsuitable for this study, 
in which a limited amount of each E2 enzyme was available. Since the two techniques 
complement each other, SPR and ITC are best used in parallel to characterise specific 
protein-protein or protein-ligand interactions (Jecklin et al., 2009), and could therefore be 
applied once a specific E2 enzyme, E3 ligase or target protein has been identified.  
 
There exists a wide variety of ubiquitin transfer assays, used to determine ubiquitylation via 
a particular enzyme cascade (i.e. a specific combination of E1, E2 and E3 enzymes). The 
most common are those which use band shift (on SDS-PAGE) as an indication of 
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ubiquitylation (Berndsen & Wolberger, 2011), like the type used here (Figure 13 and Figure 
14). However, these methods are laborious and cannot quantify how much ubiquitin is bound 
to a protein. Other assays use techniques such as Förster resonance energy transfer 
(FRET) to detect interactions between ubiquitin and substrate. This requires fluorescent 
labelling of both proteins, which can interfere with the interactions (Berndsen & Wolberger, 
2011), especially with proteins as small as ubiquitin and BfUbb. This problem may also be 
encountered when using the YFP-tagged ubiquitin created in this study, for example in 
ligand-binding and competition assays. Some ubiquitin transfer assays monitor enzymatic 
activity, such as the release of AMP during ubiquitin activation (Berndsen & Wolberger, 
2011), however these methods cannot be applied in the study of BfUbb since the lack of the 
terminal glycine (Patrick et al., 2011) means that it cannot be activated or transferred as 
ubiquitin is (Wickliffe et al., 2011). Taken together, these factors of BfUbb, i.e. its small size, 
thermodynamic stability, the lack of a terminal glycine and the impracticality of high through-
put ligand-binding assays, mean that biochemical characterisation of this protein may prove 
time consuming, expensive and difficult. 
 
6.2 Ubiquitin homologues lacking a C-terminal double glycine motif 
 
Previously, BfUbb was shown to form covalent bonds with E1 activating enzyme (Patrick et 
al., 2011) (Figure 9 B) and in this study BfUbb was shown to form covalent bonds with 
various E2 enzymes (Figure 13 and Figure 14). Many of these bonds were DTT sensitive, 
indicating that they were cysteine disulphide bridges, however some were resistant to DTT, 
suggesting there may be a different interaction. BfUbb lacks the C-terminal double glycine 
(GG) motif (Patrick et al., 2011), which is considered to be essential for ubiquitin activation 
and conjugation of ubiquitin to proteins (Grabbe & Dikic, 2009; Wilkinson & Audhya, 1981). 
Ubiquitin homologues which lack this motif, and which are consequently considered 
incapable of covalent conjugation via ubiquitylation, are referred to as ubiquitin domain 
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proteins (UDPs) (Luders et al., 2003). Most bacterial homologues of ubiquitin lack the GG 
motif and could be considered UDPs. A BLASTP search using human ubiquitin against the 
bacterial taxid database identifies ~100 proteins with significant homology. Some of these 
are ULDs within larger proteins, whilst at least one, a Burkholderia gladioli protein, is an 
almost identical copy of ubiquitin (96% identity across 100% of query, e value of 10-44), and 
includes the GG motif. The rest are largely UDPs, usually trunctuated at the C-terminus and 
with N-terminal extensions. Several of these can be found in bacterial species known to 
associate closely with eukaryotes, including the resident rumen commensal Ruminococcus 
albus (88% identity across 98% of query, e value of 10-38) and the plant pathogen 
Pectobacterium carotovorum (94% identity across 94% of the query, e value of 10-43). It is 
possible that these UDPs are involved in bacterial-host interactions, however none have yet 
been assayed for their ability to interact with the ubiquitin cascade or conjugate to other 
proteins. Similarly, small proteins which are cross-reactive with antibodies against eukaryotic 
ubiquitin have been identified in Archaea such as Natronococcus occultus (Nercessian et al., 
2002), but have not been characterised. A UBL identified in Anabaena variabilis was found 
to cross-react with ubiquitin antibody and was able to conjugate to various proteins when 
incubated with A. variabilis cell extract, suggesting conjugative machinery exists within this 
species. However, only the N-terminal sequence of this protein was confirmed and 
conjugation could not be replicated (Durner & Boger, 1995). Furthermore, no proteins with 
significant homology to ubiquitin can be identified in Anabaena sp. by BLASTP search, so it 
is unclear whether A. variabilis expresses a true conjugative bacterial UBL. A bacterial UDP, 
YukD, found in Bacillus subtilis has a strikingly similar 3D structure to eukaryotic ubiquitin 
(root mean square deviation of 2.2Å) but has a 6aa C-terminal trunctuation, meaning it lacks 
the GG motif. YukD could not conjugate to any B. subtilis proteins when incubated with B. 
subtilis cell extract (van den Ent & Lowe, 2005), however it has never been incubated with 
eukaryotic cell extract and may be able to interfere with the ubiquitin cascade as BfUbb does 
(Patrick et al., 2011).  
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There is only one well documented case of a UDP acting as a protein modifier. Hub1 
(UBL5), a eukaryotic UDP which is highly conserved from yeast to mammals, shares 22% 
identity with ubiquitin (at the lower limit of accepted homology) and has a different pattern of 
conserved lysines, however it forms the same β-grasp fold. It is 4aa shorter than ubiquitin at 
the C-terminus and ends in a double tyrosine (YY) motif followed by a non-conserved amino 
acid. Multiple studies have shown that Hub1 is able to bind proteins in an ATP-independent 
and SDS-resistant manner (Dittmar et al., 2002; Luders et al., 2003). It was originally thought 
that the YY motif was required for covalent conjugation, however this was shown not to be 
the case. The bonds were also not disulphide bridges formed between cysteine residues as 
they were resistant to boiling in the presence of DTT, and it is now thought that Hub1 binds 
proteins, such as splicesosome component Snu66, in a non-covalent but SDS-resistant 
manner (Luders et al., 2003; van der Veen & Ploegh, 2012; Yashiroda & Tanaka, 2004). The 
ability of Hub1 to form attachments non-covalently presents a case for UDPs to bypass 
ubiquitin cascade-like machinery in order to affect protein function. This, rather than covalent 
binding via its C-terminal cysteine, may be how BfUbb interacts with host cell proteins. 
 
6.3 Potential roles of BfUbb in the host eukaryotic cell 
 
Although the exact mechanism of interaction between BfUbb and the E1 and E2 enzymes 
remains unknown, BfUbb may have a role in disrupting the ubiquitin cascade in the 
mammalian epithelial cells. Since BfUbb is known to inhibit ubiquitylation of lysozyme 
(Patrick et al., 2011) (Figure 9 B) its most likely role is as a suicide substrate, binding one or 
more of the enzymes of the ubiquitin cascade to prevent ubiquitin binding and transfer. 
Ubiquitin vinyl methylester (UbVME), a suicide substrate of deubiquitinating enzymes 
(DUBs), mimics ubiquitin but forms a thioether linkage rather than a thioester linkage with 
the active site, leaving the DUB enzymatically inert (Misaghi et al., 2005). The results of this 
study suggest the formation of disulphide bridges between BfUbb and the E1 or E2 enzymes 
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(Figure 14), possibly between the C-terminal cysteine of BfUbb and the active site cysteine 
of the enzyme. This would, similar to UbVME, prevent further transfer of BfUbb to the E2 and 
any eventual substrate, since this transfer requires the presence of thioester bonds (Dye & 
Schulman, 2007).  
 
In the ubiquitin transfer experiments performed in this study, BfUbb seemed to demonstrate 
a preference for Ube2M, Ube2R1 and Ube2R2 (Figure 14), all of which are involved in cell 
cycle progression (Ceccarelli et al., 2011; Cukras et al., 2014; Semplici et al., 2002). Exactly 
why BfUbb shows a preference for these enzymes is unknown. It may be that the DUBs of 
these three proteins bind more tightly to BfUbb than the DUBs of other E2 enzymes. Non-
covalent interactions via the hydrophobic patch surrounding isoleucine 44 on the surface of 
ubiquitin play an important role in the stabilisation of ubiquitin within the E2 enzyme active 
site (Wickliffe et al., 2011) and the non-covalent interactions of UBLs can be strong enough 
to resist separation by SDS-PAGE (Luders et al., 2003). Perhaps, then, the strength of the 
non-covalent interactions between BfUbb and these E2 enzymes can explain the resistance 
of these bonds to reducing environments (Figure 14).  
 
E2 enzymes involved in cell cycle progression are targets for inhibition in the development of 
anti-cancer drugs. Unregulated mitosis is a common feature in tumorigenesis, and often cells 
become cancerous as a result of uncontrolled degradation of one or more checkpoint 
proteins. The inhibition of the E2 enzymes responsible for the degradation of these 
checkpoint proteins should prevent mitotic progression and protect against tumorigenesis 
(Ceccarelli et al., 2011; Harper & King, 2011). The presence in the epithelial cell of a 
ubiquitin-related suicide substrate which preferentially binds such E2 enzymes could 
therefore protect the host from colonic cancer. Three samples containing B. fragilis from a 
single patient with colonic cancer were screened for the presence of the ubb gene by qPCR. 
The gene could not be detected in any of these samples (Table 5), however the results of 
this study are inconclusive due to the small sample size, and a larger scale screening could 
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determine whether there is a negative correlation between presence of BfUbb-expressing B. 
fragilis in the GI tract and the development of colonic cancer. The prevention of chronic 
disease in the host is believed to be beneficial to commensal and mutualistic GI bacteria 
(Huang et al., 2011b; Mazmanian et al., 2008; Wexler, 2007) and the composition of the gut 
microbiome is believed to affect the rate and severity of tumorigenesis in mice with colon 
cancer (Zackular et al., 2013). It is therefore not unlikely that a common mutualistic 
bacterium of the GI tract could express a protein that protects against the development of 
cancer in epithelial cells.  
 
One of the key differences between ubiquitin and BfUbb is that BfUbb lacks K11 (Patrick et 
al., 2011), one of the highly conserved lysines involved in chain formation. K11 linkages are 
important for inflammatory pathways (Corn & Vucic, 2014) and essential for mitotic 
progression (Jin et al., 2008). Furthermore, pre-incubation of BfUbb with E1 activating 
enzyme seemed to increase the number of bonds formed between BfUbb and most E2 
enzymes (Figure 14). It is therefore tempting to suggest a model in which BfUbb is passed 
through the ubiquitin cascade and is bound to substrates to prevent the extension of K11-
specific chains, thus inhibiting inflammation and/or cell cycle progression. However, the only 
mechanism by which BfUbb could be transferred from one enzyme to another is thiol-
disulphide exchange. This would require the deprotonation of the thiol group of the active 
site cysteine in the E2 enzyme so that it could displace the existing disulphide bond between 
BfUbb and the E1 active site cysteine (Sevier & Kaiser, 2002). This could only occur in an 
oxidising environment, which the cytoplasm of the eukaryotic cell is not, and this is therefore 
unlikely to be occurring in vivo.  
 
The theory that BfUbb acts as a suicide substrate by binding the active site cysteine of an E1 
or E2 enzyme via a disulphide bridge is problematic considering that the cytoplasm is a 
reducing environment. In order for these covalent bonds to occur, BfUbb and the target 
enzyme or substrate would need to coexist in a non-reducing compartment of the cell. 
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Additionally, in order to outcompete ubiquitin, BfUbb would need to exist at a relatively high 
local concentration. Given that the OMV are the mechanism by which BfUbb may be 
delivered to the host cell, the endosome is a likely compartment in which BfUbb could 
function. Multiple studies have shown that OMV can be internalised by mammalian cells via 
endocytosis (Bomberger et al., 2009; Chatterjee & Chaudhuri, 2011; Vidakovics et al., 2010), 
suggesting that their contents will be contained within an endosome and possibly directed to 
the lysosome (Tanno & Komada, 2013). To escape degradation in the lysosome, bacterial 
proteins must lyse the endosome or be redirected to another part of the cell (Bomberger et 
al., 2009). Ubiquitin and UBDs play an important role in the determining the fate of 
endocytosed proteins, both during normal protein turnover and during infection (Fujita et al., 
2013; Tanno & Komada, 2013). The endosome would provide a non-reducing compartment 
(Austin et al., 2005) in which BfUbb could exist at a high enough concentration to interfere 
with the ubiquitin system. BfUbb may therefore bind one or more UBDs to prevent trafficking 
and destruction of other OMV proteins. Alternatively, it may conjugate to either host or 
bacterial endocytosed proteins in the the endosome and target these proteins for destruction 
or recycling back to the plasma membrane. For direct binding to UBDs the E1, E2 and E3 
enzymes may not be required, and indeed it is worth noting that the binding of BfUbb to E1 
and E2 enzymes observed in this study may be coincidental to its actual function. Much 
more work needs to be done to determine if and how BfUbb interacts with the ubiquitin 
cascade, or any other ubiquitin-binding proteins, in vivo. 
 
There appears to be an alternative role for BfUbb outside of the host epithelial cell. OMV 
carrying BfUbb were found to delay the growth of S. enterica Typhmurium, significantly more 
so than OMV from a B. fragilis Δubb mutant or a PBS control (Figure 28). This suggests that 
BfUbb has antibacterial activity, which is consistent with the observed bacteriostatic activity 
of eukaryotic ubiquitin and other UBLs, the exact mechanism of which is unknown (Alonso et 
al., 2007; De Ingeniis et al., 2009; Howell et al., 2003; Kieffer et al., 2003; Seo et al., 2013). 
The production of antimicrobials is an almost universal trait within bacteria, and is an aspect 
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of "bacterial interference", in which one organism interferes with the biological functioning of 
another, usually to the benefit of the former (Ji et al., 1997). An antibiotic-producing bacterial 
species which has already colonised an environment can prevent invasion by a new, 
sensitive species. Conversely, an antibiotic-producing bacterial species which reaches a 
new environment can reduce the growth of existing, sensitive species, thus allowing 
colonisation. If BfUbb is as broad-spectrum an inhibitor as other UBLs (Howell et al., 2003; 
Seo et al., 2013), BfUbb-producing B. fragilis could prevent colonisation of the mucosa by 
bacterial species which would not only compete with B. fragilis for space and nutrients, but 
which may cause serious disease in the host (Berg, 1996). Additionally, the antimicrobial 
activity of multiple eukaryotic UBLs and BfUbb suggests that inhibition of bacterial growth 
may be one of the roles, if not the primary role, of ubiquitin homologues found in other 
bacteria.  
 
6.4 Characterisation of outer membrane vesicles 
 
The past few years have seen a significant increase in the number of studies which aim to 
characterise OMV of various Gram-negative bacteria using proteomics (Choi et al., 2015). 
This requires both the efficient isolation of OMV and an appropriate method for proteomic 
analysis. Although multiple authors agree that density centrifugation is an essential step in 
OMV isolation (Bauman & Kuehn, 2006; Kalra et al., 2013; Kreimer et al., 2015; Lee et al., 
2008), a wide range of methods are used by different groups (Figure 20) and it is rare for two 
studies to use the same combination of techniques. This is problematic since there is 
evidence that the method of isolation used can significantly affect the proteomic content of 
the OMV (Choi et al., 2015). Most studies favour the extraction of naturally formed OMV, 
rather than chemically-induced OMV (Figure 20), since the latter are not considered 
representative of the former (Kulp & Kuehn, 2010). However, the specific isolation 
techniques used may also affect the content of the vesicles (Tauro et al., 2012). It is 
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therefore difficult to say which method will isolate OMV that are most representative of those 
produced by the cell during undisturbed growth. Whichever combination of techniques is 
eventually used; however, it should be a standard for all proteomic studies of OMV, 
otherwise the different proteomes cannot be reliably compared. The best method of 
proteomic analysis of OMV is also still being debated (Figure 21). When taking into 
consideration the benefits and drawbacks of the approaches discussed in section 4.1.2, the 
best method would arguably be gel-free (Lee et al., 2008; van de Waterbeemd et al., 2013), 
using a tagging method for protein quantification (Cooper et al., 2010; Kreimer et al., 2015; 
Li et al., 2012), and an ultra-low flow fractionation method prior to high-sensitivity MS 
(Kreimer et al., 2015). Of course, time, cost and availability of resources will be limiting 
factors for most studies, and proteomics approaches in OMV will most likely continue to 
vary.  
 
Characterisation of OMV often includes determination of OMV size, either by TEM or DLS.   
In this study a Zetasizer APS (Malvern Instruments, UK) was used determine the average 
size of OMV in the concentrated supernatant samples (Figure 22). This technique suggested 
an average diameter of ~250nm, whereas TEM had previously indicated that OMV of B. 
fragilis were ~50-100nm (Patrick et al., 1996). When the two methods have been used in 
parallel in other studies they have been in agreement (Choi et al., 2011; Jang et al., 2014). 
In this study, aspiration through a needle during sample collection by the Zetasizer APS may 
have perturbed the capsular polysaccharide of the OMV. Whole cells of mutants lacking 
CPS aggregate in solution (Patrick et al., 2009) and aggregation of OMV would explain the 
larger average diameter and the inconsistency between readings. Certain other types of DLS 
apparatus analyse samples in cuvettes rather than aspirating the samples into a chamber, 
and this is probably more appropriate for analysis of OMV. Whilst DLS is a cheap, fast 
alternative to TEM in determining the size of the OMV it cannot provide information on the 
nature of the OMV, e.g. whether they contain one or two lipid bilayers (Perez-Cruz et al., 
2013) and, in the case of B. fragilis whether they are derived from LC-, SC- or MC-
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expressing cells (Patrick et al., 1996). It is therefore likely that DLS will continued to be used 
in parallel with, rather than instead of, TEM.  
 
Despite the continued characterisation of OMV from various species, much remains 
unknown about their formation and function. Proteomics studies, including this one, and 
mutational analysis have not yet identified a common protein or set of proteins involved in 
biogenesis (Kulkarni & Jagannadham, 2014). The lack, thus far, of a clear active mechanism 
for OMV production could be considered as support for the passive biogenesis theory, in 
which OMV are produced as a side effect of OM turnover and other regular cell processes 
(Schwechheimer et al., 2013). However, multiple studies, including this one (Table 8, Figure 
24), have reported the enrichment of proteins in OMV samples compared to OM, PP or 
whole cell samples (Elhenawy et al., 2014; Haurat et al., 2011; Kato et al., 2002; van de 
Waterbeemd et al., 2013), which supports the theory of an active sorting mechanism. 
Further studies aimed at characterisation of the OMV of Gram-negative bacteria are required 
to identify a mechanism for sorting and biogenesis (Choi et al., 2015; Lee et al., 2008). The 
presence of cytoplasmic proteins in OMV is also a contested issue, with some studies 
suggesting that efficiently isolated vesicles should not contain cytoplasmic proteins (Kulp & 
Kuehn, 2010; Scorza et al., 2008), whilst others provide precedence for their inclusion 
(Pancholi & Chhatwal, 2003; Perez-Cruz et al., 2013). As discussed in section 4.3.3, this 
study identified a large number of cytoplasmic proteins, suggesting a certain amount of 
contamination in both the OMV and PP samples. However, it is impossible to determine from 
individual proteomics studies which, if any, of these proteins occur naturally in B. fragilis 
OMV and which are contaminants. This problem could also potentially be resolved by the 
development of a standard, high purity procedure for isolation of OMV. 
Proteomics has proved to be a powerful tool in biological research, allowing the rapid, large 
scale identification and putative characterisation of proteins from any cellular or subcellular 
fraction of any species. There are limitations, however, with possibly the greatest being that 
a large proportion of proteins in the available databases are uncharacterised (hypothetical). 
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More than 40% of proteins enriched in B. fragilis OMV showed homology only to hypothetical 
proteins from other bacterial species (Figure 24 B) and previous studies also found that a 
similar proportion of the OMV proteins of other species were poorly characterised (Altindis et 
al., 2014; Bauman & Kuehn, 2006; Berlanda Scorza et al., 2012; Elhenawy et al., 2014; Lee 
et al., 2007; Mullaney et al., 2009; Nally et al., 2005). One or more of these uncharacterised 
proteins may be conserved between OMV from different species and may even play a role in 
OMV biogenesis or function, however genetic and biochemical analysis, and the 
construction of an OMV proteome database, would be required to determine this. 
Furthermore, even when function can be strongly inferred from sequence identity to known 
proteins, classical techniques are often required to confirm this function. This study, and 
others like it, demonstrate that until the function of the majority of "hypothetical" proteins has 
been determined, the power of proteomics as a tool for the characterisation of OMV, and 
other biological samples, will be limited.  
 
6.5 Potential roles of B. fragilis OMV 
 
It is likely that the OMV of any given species have multiple roles which support the survival 
and propagation of that species in its environment (Kulkarni & Jagannadham, 2014). B. 
fragilis OMV are already considered to have a role in suppression of the inflammatory 
response via the delivery of PSA, a function which benefits both bacterium and host by 
maintaining a stable environment in the GI tract (Shen et al., 2012). They also bind 
fibrinogen (Houston et al., 2010) and are known to promote haemagglutination of 
erythrocytes (Patrick et al., 1996), and may therefore play a role in opportunistic 
pathogenesis. Since the natural reservoir of B. fragilis is the GI tract the primary role(s) of B. 
fragilis OMV is most likely to promote survival in this environment rather than to contribute to 





Some of the most abundant and most enriched proteins in B. fragilis OMV in this study are 
involved in the binding and degradation of common nutrients in GI tract bacteria (Figure 24, 
Table 7, Table 8, Appendix VII). For example, several SusC and SusD proteins, which are 
sufficient for starch binding in B. thetaiotaomicron (Shipman et al., 2000) were identified, as 
well as a potential SusF, the exact function of which is unknown. SusG, which is responsible 
for starch degradation (Shipman et al., 2000), was not identified, however. Elhenawy et al 
(2014) found that several hydrolytic enzymes were enriched in the OMV of B. fragilis, 
including xylanase, which plays a role in degradation of hemicellulose (Juturu & Wu, 2012), 
α-L-fucosidase, which is involved in the processing of complex sugars (Wright et al., 2013), 
a zinc protease and a dipeptidase. All of these enzymes were identified in this study, as well 
as several other extra-cytoplasmic proteases (Table 9). OMV capable of binding and 
degrading various nutrients present in the GI tract could allow B. fragilis to remotely process 
these nutrients, increasing the extracellular concentration of smaller molecules that can be 
utilised by either the host or the bacterium. 
 
Amongst the most abundant of the 783 proteins identified in B. fragilis OMV were an 
unexpectedly high number of cytoplasmic, metabolic "housekeeping" enzymes, including 
GAPDH, alcohol dehydrogenase and succinyl coenzyme A synthetase (Table 7, Appendix 
VII). Despite lacking a signal sequence, these enzymes have been found on the surface of 
several bacterial pathogens, where they appear to act primarily as adhesins (Pancholi & 
Chhatwal, 2003). The presence of multiple adhesive proteins on the surface of both whole 
cells and OMV may serve to promote and maintain colonisation of the gut mucosa by B. 
fragilis, as well as potentially improving binding of OMV to epithelial cells.  
 
The results of this study suggest that the OMV of B. fragilis carry a surface-exposed α2m, a 
macromolecular protease inhibitor found in both eukaryotes and prokaryotes (Kantyka et al., 
2010). Depending on its protease specificity, which is determined by the bait region 
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(Sottrupjensen et al., 1989), this α2m has the potential to trap and inhibit a number of 
proteases. Periplasmic bacterial α2ms are thought to protect the cell against invading 
proteases during a breach of the OM (Kantyka et al., 2010; Robert-Genthon et al., 2013). 
This may also be the primary function of B. fragilis α2m, however if it is present on the 
surface of OMV this particular α2m could also inhibit one of the many proteases in the 
extracellular medium of the GI tract. For example, it may prevent activation of antimicrobial 
peptides by host proteases (Antalis et al., 2007), thus protecting itself from the host innate 
immune system. Alternatively, it may inhibit one of the many host and bacterial proteases 
involved in promoting the inflammatory response (Antalis et al., 2007), thus protecting the 
host from inflammation and maintaining its own environment.  
 
B. fragilis OMV are believed to carry BfUbb (Patrick et al., 2011) (Figure 26), which has the 
potential to interfere with the eukaryotic ubiquitylation pathway (section 3.3.3) and appears 
to demonstrate antibacterial activity against S. enterica Typhimurium (section 5.3.1). B. 
fragilis OMV can be engulfed by DCs (Shen et al., 2012), whilst OMV of other species can 
be engulfed by epithelial cells (Chatterjee & Chaudhuri, 2011; Kesty & Kuehn, 2004) and are 
able to fuse with other bacteria (Kadurugamuwa & Beveridge, 1996), thus the OMV of B. 
fragilis provide a mechanism by which BfUbb can be delivered to both eukaryotic and 
bacterial cells. Despite carrying a lytic murein transglycosylase (Appendix VII), an autolysin 
which could cause bacteriolysis when deregulated (Li et al., 1996), B. fragilis OMV do not 
appear to demonstrate bacteriolytic activity against S. enterica Typhimurium (Figure 28 D). 
They may have a lytic effect on Gram-positive or other Gram-negative bacteria, however. 
The combined results of this study suggest that the OMV of B. fragilis have the potential to 





6.6 Biotechnological potential of BfUbb and the OMV of B. fragilis 
 
The function or functions of BfUbb, as indicated by the results of this study, could be 
adapted for treatment or prevention of disease in the GI tract. E2 conjugating enzymes 
involved in the ubiquitin-dependent control of mitotic progression are established targets for 
anti-cancer therapies (Harper & King, 2011). If it can be determined that BfUbb is able to 
inhibit these specific E2 enzymes, it could be developed as a drug for the prevention or 
treatment of tumorigenesis. Additionally, depending on the spectrum and effectivity of BfUbb 
as an antibacterial protein, it could be considered a novel antibiotic in the treatment of 
gastro-intestinal bacterial infections. The use of OMV as vaccines is of ongoing interest in 
biotechnology as they represent a non-pathogenic alternative to using whole cells for 
delivery of antigens (Altindis et al., 2014; Kolodziejek et al., 2013; van de Waterbeemd et al., 
2013). Using B. fragilis OMV as a vector for antigen delivery would probably promote an 
immune reaction to B. fragilis itself, which would be detrimental to the health of the 
vaccinated individual colonised by the bacterium. These OMV may therefore be put to best 
use as a delivery mechanism for antibiotics and drugs targeted to the GI tract, such as 
BfUbb itself. In fact, if BfUbb acts via one or more of the mechanisms proposed in this study, 
deliberate colonisation of the GI tract with BfUbb-expressing B. fragilis may prove effective in 














This study aimed to characterise both the bacterial ubiquitin homologue, BfUbb, and the 
outer membrane vesicles of B. fragilis. BfUbb was found to multimerise spontaneously in 
vitro, most likely via the formation of disulphide bridges between cysteine residues in the C-
terminal tail. It was also found to form covalent bonds with multiple E2 conjugating enzymes 
of the eukaryotic ubiquitylation pathway. These bonds were DTT-sensitive, and therefore 
also likely to be disulphide bridges, however pre-incubation of BfUbb with E1 activating 
enzyme promoted the formation of DTT-resistant bonds between BfUbb and E2 enzymes 
Ube2M, Ube2R1 and Ube2R2 via an unknown mechanism. These three E2 enzymes are 
involved in ubiquitin-dependent progression of cell cycle checkpoints (Ceccarelli et al., 2011; 
Cukras et al., 2014; Semplici et al., 2002) and as such are targets for anti-cancer therapies 
(Harper & King, 2011). Covalent binding of BfUbb to the active site of these enzymes in vivo 
could inhibit cell cycle progression, provided BfUbb were able to accumulate and function 
within the host cells. There is no evidence for this thus far, however. Nickel affinity pull-down 
of his-tagged BfUbb incubated with epithelial cell extract did not identify any binding 
partners. So far the only proteins known to form covalent bonds with BfUbb are enzymes of 
the ubiquitylation cascade.  
 
Two plasmids were constructed which allowed the expression and purification of a native 
form of BfUbb, for use in X-ray crystallography, and a YFP-tagged form of BfUbb, for use in 
in vitro assays. Expression from both plasmids was demonstrated in E. coli, however the 
proteins have not yet been purified and utilised. Three additional plasmids were constructed 
which allow for the expression of his-tagged BfUbb, YFP-tagged BfUbb and a YFP-control in 
mammalian cells. This would allow observation of the effects of the presence of BfUbb in 
epithelial cells, as well as the subcellular localisation, if any, of the B. fragilis protein. These 
plasmids have not yet been successfully established in Caco-2 cells, however.  
198 
 
qPCR was used to screen for the presence of B. fragilis and the ubb gene in clinical samples 
from patients with abscesses or gastro-intestinal diseases. Due to the small scale of the 
study no correlation could be established between the presence or absence of BfUbb and 
the development of any particular disease. The exact role, if any, of BfUbb in the host 
epithelial cells, and its phenotypic effect on the host, has yet to be determined. 
 
The OMV of B. fragilis were isolated from culture supernatant using a combination of 
techniques that should have ensured high sample purity. Samples of OMV and periplasmic 
extract were analysed via LTQ-Orbitrap mass spectrometry and a proteome of the OMV was 
generated. Within this proteome were proteins that suggested a role for the OMV in nutrient 
acquisition, proteolysis, protease inhibition and adhesion to epithelial cells. A previously 
characterised fibrinogen-binding protein was identified but with low reliability, and BfUbb was 
not identified at all. Both proteins could be detected by Western blotting in concentrated 
supernatants of WT B. fragilis, however, suggesting that the proteomic techniques used in 
this study may have a limited capacity for accurate protein identification. Moreover, the purity 
of the sample, and consequently the efficiency of the OMV isolation procedure, was called 
into question due to the large number of cytoplasmic proteins identified, many of which are 
likely to be contaminants. There is a clear need for a standardised, efficient isolation 
procedure in the proteomic analysis of OMV from various bacterial species (Choi et al., 
2015). The mechanism of OMV biogenesis in B. fragilis, and indeed in all Gram-negative 











The antibiotic potential of B. fragilis OMV and BfUbb was tested by incubating inoculates of 
S. enterica Typhimurium with concentrated supernatants of WT and Δubb B. fragilis. BfUbb-
containing OMV were found to inhibit growth of S. enterica Typhimurium, significantly more 
so than both Δubb OMV and a PBS control, suggesting that BfUbb has some antibacterial 
activity. The secretion of antimicrobials is a feature of most characterised bacterial species 
(Ji et al., 1997) and the antibiotic activity of ubiquitin and ubiquitin-like proteins has been 
previously established (Alonso et al., 2007; De Ingeniis et al., 2009; Howell et al., 2003; 
Kieffer et al., 2003; Seo et al., 2013). BfUbb may provide B. fragilis with the ability to inhibit 
colonisation of invading bacteria in the gastro-intestinal mucosa. 
 
The results of this study suggest a variety of roles for both BfUbb and the OMV of B. fragilis. 
Interestingly, many of these putative functions would serve to benefit the host as well as the 
bacterium. B. fragilis is usually described as a commensal of the GI tract, i.e. an organism 
that benefits from its host without significantly effecting it (Wexler, 2007). However, given the 
accumulation of evidence suggesting that B. fragilis provides significant health benefits for its 
host, it seems prudent that this host-bacterial relationship should instead be described as 
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Appendix I - Surface plasmon resonance analysis of BfUbb-E2 interactions 
 
 
Approximately 200 response units of the ligand molecules, i.e. bovine ubiquitin (Sigma) or 
rBfUbb were affixed to a CM-5 chip (GE Healthcare). The analyte proteins (E1 enzyme and 
26 E2 enzymes) were diluted to a concentration of 2µM in buffer (20mM Tris; 150nM NaCl; 
2mM β-mercaptoethanol; 1% glycerol). SPR analysis was performed on a Biacore T-100 
(GE Healthcare) by Dr Martin Wear (Edinburgh Protein Production Facility and Edinburgh 
Biochemical Characterisation Facility, University of Edinburgh). Analyte was passed over the 
chip at a rate of 30µl/s with a contact time of 60s. Response rates (Figure A.I.i) were too low 
to calculate a reliable dissociation constant for most E2 enzymes, however they do appear to 
indicate that non-covalent interactions between BfUbb and E1 are greater than those 
between BfUbb and E2 enzymes. An experimental error resulted in sample 12 being twice 






Figure A.I.i Response rates (out of 200) of ubiquitin and rBfUbb interacting with E1 activating enzyme 





























Appendix II - Sequencing of constructs in pET19b 
 
 
600ng of pET19b-10xH-BfUbb was mixed with 3.2pmole of either Bfndei or Brbamhi. 600ng 
of pET19b-10xH-YFP-BfUbb was mixed with 3.2pmole of either Yfndei or Brbamhi. 
Constructs were quantified and sequenced by the Sequencing and Services Department 
(Medical Research Council, Dundee, Scotland). The returned sequences were compared 
with the expected sequence of the construct using Clustal Omega (McWilliam et al., 2013) 






























Figure A.IV.i Expected sequences of pET19b constructs compared with sequencing results. 
pET19b::10xH-BfUbb forward (A) and reverse (B) sequences. pET19b::10xH-YFP-BfUbb forward (C) 






Appendix III - Expression of 10xH-YFP-BfUbb in E. coli DH5α 
 
 
Expression of 10xH-YFP-BfUbb was induced in E. coli BL21 DE3 pET19b-10xH-YFP-BfUbb 
with 200µM IPTG for 3h. 10µl each of induced and uninduced cell culture was then mixed 
with 5µl loading buffer and 1µl DTT. The mixture was boiled at 90ºC for 10 minutes and 
analysed by SDS-PAGE and Coomassie staining (Figure A.III.i). A band the expected size of 























Appendix IV - Sequencing of constructs in pcDNA4/TO 
 
 
600ng of pcDNA4/TO-6xH-BfUbb was mixed with 3.2pmole of either Bfhindiii or Brbamhi, 
600ng of pcDNA4/TO-YFP-BfUbb was mixed with 3.2pmole of either Yfhindiii or Brbamhi., 
and 600ng of pcDNA4/TO-YFP was mixed with 3.2pmole of either Yfhindiii or Yrbamhi. The 
mixtures were sent to the Sequencing and Services Department (Medical Research Council, 
Dundee, Scotland) for sequencing. The returned sequences were compared to the expected 
sequence of the construct using Clustal Omega (McWilliam et al., 2013) (Figure A.IV.i and 
Figure A.IV.ii). The 6xH-BfUbb construct was sequenced twice, once including and once 
excluding the 6xH sequence. The combination of both sequences confirms the full correct 
sequence of the construct. Where there are mismatches on the forward sequence of the 


































































Figure A.IV.ii Expected sequences of pcDNA4/TO constructs compared with sequencing results. 
pcDNA4/TO::6xH-BfUbb with (A) and without (B) his-tag sequence. pcDNA4/TO::YFP-BfUbb forward 






Appendix V - qPCR samples and results 
 
 
Clinical samples from 37 patients with abscesses or GI diseases were screened for the presence of 
genes gyrB, psa, bft and ubb (Table A.V.i).  
Patient Identity Infection Disease Details Sample type gyrB psa bft ubb 
1 LS11 Bacteroides fragilis Abdominal abcess Pus/Blood 485446 0 0 0 
2 LS14 Bacteroides fragilis Perianal abcess Pus/Blood 12936708 0 0 0 
3 LS16 Bacteroides fragilis Ischiorecal abcess Culture 14278 0 0 163921 
4 LS18 Bacteroides fragilis Bartholins abcess Culture 2068 0 937862 0 
5 LS27 Bacteroides fragilis Neoplasm abcess Pus/Blood 276373 0 0 0 
6 LS52 Bacteroides fragilis Perianal abcess Culture 16652970 0 0 0 
7 LS54 Bacteroides fragilis Perianal abcess Pus/Blood 1257490 0 0 0 
8 LS66 Bacteroides fragilis Abdominal abcess Pus/Blood 11365376 0 0 0 
9 LS67 Bacteroides fragilis Perianal abcess Culture 44228 0 0 33452 
10 LS75 Bacteroides fragilis Perianal abcess Culture 6442 0 11955137 0 
11 LS80 Bacteroides fragilis Perianal abcess Culture 4531898 1976672 696 0 
12 LS84 Bacteroides fragilis Diverticular 
abcess 
Pus/Blood 16.1 0 0 0 
13 LS98 Bacteroides fragilis Blood culture Culture 6903352 0 2823 0 
14 3496 ii Bacteroides fragilis Diverticulitis: 
Biopsy ascending 
colon 
Culture 8063952 0 122 1558257 
14 3496 vii Bacteroides fragilis Culture 81816 0 0 201778 
14 3497 iii Bacteroides fragilis Diverticulitis: 
Biopsy rectum 
Culture 2264 0 0 1011 





15 3498 ii Bacteroides fragilis Irritable Bowel 
Syndrome: Biopsy 
ascending colon 
Culture 976869 0 0 0 
15 3498 vi Bacteroides fragilis Culture 56.15 0 0 0 
15 3498 ix Bacteroides fragilis Culture 1257490 0 2473146 0 
15 3498 x Bacteroides fragilis Culture 858216 0 4139661 53.6 
15 3499 vi Bacteroides fragilis Irritable Bowel 
Syndrome: Biopsy 
rectum 
Culture 898008 0 2808798 0 
15 3499 x Bacteroides fragilis Culture 56201 0 355654 0 




Culture 8222122 0 6443124 0 
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Culture 3683801 0 0 0 
16 3529 iv Bacteroides fragilis Culture 1171042 0 9920461 0 




Culture 1009013 0 0 0 
17 3533 v Bacteroides fragilis Cancer of 
ascending colon: 
Biopsy rectum 
Culture 1772313 0 48 0 
17 3533 viii Bacteroides fragilis Culture 455009 0 23 0 





Culture 10 0 23 0 
18 3534 vi Bacteroides fragilis Culture 0 0 0 0 




Culture 4893 0 180 0 




Culture 3050 0 11 0 
19 3536 ii Bacteroides fragilis Culture 203 0 0 0 
19 3536 vii Bacteroides fragilis Culture 3254 0 54 0 
19 3536 ix Bacteroides fragilis Culture 628 0 0 0 
19 3536 x Bacteroides fragilis Culture 897 0 9 0 
19 3537 ii Bacteroides fragilis Active Ulcerative 
Colitis (pancolitis): 
Biopsy rectum 
Culture 4055 0 7 0 
20 LS15 Bacteroides fragilis Colostomy patient Culture 2124596 0 0 15 
21 EOC Unknown Unknown Culture 223203 5841857 0 0 
22 VH Unknown Unknown Culture 369859 4596319 0 0 
23 RS Unknown Unknown Culture 13.34 0 0 0 
24 AI Unknown Unknown Culture 13020743 0 0 0 
25 CN Unknown Unknown Culture 7.89 0 0 0 
26 BE1 Unknown Unknown Culture 12125616 0 0 0 
27 BE3 Unknown Unknown Culture 15710272 0 0 0 
28 GNAB85 Unknown Unknown Culture 3707731 0 0 0 
29 GNAB92 Unknown Unknown Culture 1459421 0 0 0 
30 JC6 Unknown Unknown Culture 7223438 0 0 0 
31 JC17 Unknown Unknown Culture 2679.8 0 0 0 
32 JC19 Unknown Unknown Culture 176.6 0 0 0 
33 NCTC 
9344 
Unknown Unknown Culture 915622 0 0 0 
34 NCTC 
10583 
Unknown Unknown Culture 21.4 0 0 0 
35 NCTC 
10584 





Table A.V.i Details of clinical samples used in the qPCR study, including arbitrarily assigned patient 
number, sample ID, bacterial species, associated disease, sample type, and the number of copies of 
gyrB, psa, bft and ubb in each sample. 
 
Appendix VI - DLS measurements of WT B. fragilis concentrated supernatant 
 
 
DLS was performed as described in section 2.7.9. There was little consistency between readings 1 
(green) and 2 (red), with an apparent increase in average diameter between readings (Figure A.VI.i A 
and B). The third reading was excluded due to low quality (not shown). The intensity and mass 
distributions both indicate an average diameter of ~250nm (Figure A.VI.i C and D). 
36 ATCC 
23745 
Unknown Unknown Culture 4502649 0 9 0 
37 ATCC 
29765 























Appendix VII - Proteins identified in the OMV of B. fragilis 
 
 
188 proteins were identified in the OMV of B. fragilis (Figure A.VII.i). 88 of these proteins 
were enriched in the OMV, 84 were enriched in the PP and 16 were not significantly 















       
YP_210059.1 110.27 301.968 TonB-dependent receptor 





YP_210687.1 70.55 87.627 hypothetical protein BF1082 
[Bacteroides fragilis YCH46] 
Hypothetical 
protein 
Unknown Unknown location 
YP_210300.1 2864.27 87.186 surface membrane protein, 




Nutrient Outer membrane 
YP_210172.1 304.74 75.377 hypothetical protein BF0506 




YP_210578.1 93.54 55.293 hypothetical protein BF0965 
[Bacteroides fragilis YCH46] 
Hypoyhetical 
protein 
Unknown Unknown location 
YP_211023.1 372.56 54.761 hypothetical protein BF1363 




Unknown Unknown location 
YP_210845.1 191.74 51.398 hypothetical protein BF1209 
[Bacteroides fragilis YCH46] 
Hypothetical 
protein 
Unknown Unknown location 
YP_212392.1 320.23 45.978 hypothetical protein BF2776 
[Bacteroides fragilis NCTC 
9343] 
Hypothetical Unknown Unknown location 
YP_213166.1 3369.03 45.911 hypothetical protein BF3567 





YP_213613.1 244.2 37.548 hypothetical protein BF4211 
[Bacteroides fragilis YCH46] 
Unknown OMP Unknown Outer membrane 
YP_213037.1 229.26 35.095 hypothetical protein BF3629 
[Bacteroides fragilis YCH46] 
Hypothetical 
protein 
Unknown Unknown location 
YP_211269.1 76.27 31.486 hypothetical protein BF1616 




Unknown Unknown location 
YP_212656.1 899.09 29.364 hypothetical protein BF3042 





DNA/RNA Unknown location 
YP_211022.1 227.07 27.822 hypothetical protein BF1423 
[Bacteroides fragilis YCH46] 
Hypothetical 
protein 
Unknown Unknown location 
YP_212584.1 121.26 24.199 hypothetical protein BF3135 
[Bacteroides fragilis YCH46] 
Hypothetical OM 
protein 
Unknown Outer membrane 
YP_211011.1 145.99 23.952 hypothetical protein BF1415 






YP_213040.1 587.05 22.292 hypothetical protein BF3632 
[Bacteroides fragilis YCH46] 
Hypothetical 
protein 
Unknown Unknown location 
YP_211278.1 144.57 22.076 hypothetical protein BF1628 







YP_213780.1 326.59 21.475 TonB-dependent receptor 





YP_210306.1 1405.18 21.364 hypothetical protein BF0670 
[Bacteroides fragilis YCH46] 
Probable 
SusC/RagA 
Nutrient Outer membrane 
YP_209713.1 400.79 21.302 hypothetical protein 
pBF9343.20c [Bacteroides 
fragilis NCTC 9343] 
Hypothetical 
protein 
Unknown Unknown location 
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YP_210305.1 2159.73 21.117 hypothetical protein BF0669 




Unknown Outer membrane 
YP_210567.1 122.84 19.148 hypothetical protein BF0953 
[Bacteroides fragilis YCH46] 
Possible starch 
binding protein 
Nutrient Inner membrane, 
periplasmic side 
YP_211693.1 81.51 19.147 Na(+)-translocating NADH-
quinone reductase subunit A 




YP_210010.1 137.79 18.023 hypothetical protein BF0273 





YP_210206.1 104 17.275 conserved hypothetical protein 
[Bacteroides fragilis 3_1_12] 
Hypothetical 
protein 
Unknown Unknown location 
YP_213035.1 752.42 16.548 hypothetical protein BF3429 




Unknown Outer membrane 
YP_210964.1 111.62 15.674 hypothetical protein BF1302 





YP_211819.1 296.29 15.190 hypothetical protein BF2139 
[Bacteroides fragilis YCH46] 
Probable 
SusC/RagA, OM 
Nutrient Outer membrane 
YP_211224.1 629.55 15.125 hypothetical protein BF1567 






Transport Outer membrane 
YP_209856.1 73.68 14.849 pyrogenic exotoxin B 






YP_213132.1 261.11 14.384 biopolymer transport protein 
[Bacteroides fragilis YCH46] 
 
Transport Inner membrane 
YP_213262.1 186.13 13.948 hypothetical protein BF3899 
[Bacteroides fragilis YCH46] 
Hypothetical 
protein 
Unknown Unknown location 
YP_211519.1 250.1 13.733 hypothetical protein BF1820 
[Bacteroides fragilis YCH46] 
Hypothetical 
protein 
Unknown Unknown location 
YP_210615.1 803.5 13.218 hypothetical protein BF0922 




Unknown Unknown location 
YP_210304.1 2390.77 12.771 hypothetical protein BF0594 




Nutrient Outer membrane 
YP_210307.1 1027.72 12.414 hypothetical protein BF0597 
[Bacteroides fragilis NCTC 
9343] 
Probable SusD Nutrient Outer membrane 
YP_213235.1 195.31 12.321 hypothetical protein BF3871 
[Bacteroides fragilis YCH46] 
Hypothetical 
protein 
Unknown Unknown location 
YP_212758.1 682.82 11.901 hypothetical protein BF3306 
[Bacteroides fragilis YCH46] 
Probable SusD Nutrient Outer membrane 
YP_213039.1 476.61 11.901 hypothetical protein BF3631 
[Bacteroides fragilis YCH46] 
Hypothetical 
protein 
Unknown Unknown location 
YP_211637.1 496.34 11.013 TonB-dependent outer 
membrane protein 




YP_210296.1 917.36 10.996 hypothetical protein BF0662 
[Bacteroides fragilis YCH46] 
Possible 
lipoprotein 
Unknown Inner membrane 
YP_213818.1 901.33 10.795 hypothetical protein BF4460 
[Bacteroides fragilis YCH46] 
Probable 
SusC/RagA 
Nutrient Outer membrane 
YP_211590.1 1638.1 10.790 hypothetical protein BF1957 




Nutrient Outer membrane 
YP_211589.1 2819.92 10.494 hypothetical protein BF1894 
[Bacteroides fragilis YCH46] 
Probable 
SusC/RagA 
Nutrient Outer membrane 
YP_213038.1 1713.53 10.237 hypothetical protein BF3432 






Nutrient Outer membrane 
YP_210444.1 163.88 10.166 UDP-GlcNAc 2-epimerase 




YP_213878.1 117.35 9.692 outer membrane protein 




Nutrient Unknown location 
YP_213581.1 537.86 9.390 50S ribosomal protein L4 





YP_210073.1 102.78 9.343 hypothetical protein BF0393 




Unknown Unknown location 
YP_213149.1 328.99 9.083 hypothetical protein BF3759 
[Bacteroides fragilis YCH46] 
Probable OmpB Unknown Outer membrane 
YP_211674.1 203.73 8.448 hypothetical protein BF2045 




Unknown Outer membrane 
YP_211583.1 598.25 8.441 conserved hypothetical protein 
[Bacteroides fragilis 3_1_12] 
Hypothetical 
protein 
Unknown Unknown location 
YP_210677.1 539.6 8.348 hypothetical protein BF1073 




Unknown Outer membrane 
YP_213779.1 586.47 8.292 hypothetical protein BF4417 
[Bacteroides fragilis YCH46] 
Possible Tol-pal 
protein 
Transport Outer membrane 
YP_213865.1 362.03 7.655 peptidylprolyl isomerase 
[Bacteroides fragilis YCH46] 
 
Protein folding Inner membrane, 
periplasmic side 
YP_213819.1 787.72 7.603 hypothetical protein BF4461 
[Bacteroides fragilis YCH46] 
SusD-like Nutrient Outer membrane 
YP_210170.1 257.78 7.177 outer membrane protein 
[Bacteroides fragilis NCTC 
9343] 
 
Unknown Outer membrane 
YP_212741.1 592.26 7.095 propionyl-CoA carboxylase 




YP_212757.1 529.07 6.881 hypothetical protein BF3305 
[Bacteroides fragilis YCH46] 
Probable SusF Nutrient Extracellular 
YP_212330. 145.36 6.345 ribonucleotide-diphosphate 
reductase subunit alpha 
[Bacteroides fragilis YCH46] 
SirA DNA/RNA Cytoplasm 
YP_212258.1 427.51 5.867 hypothetical protein BF2635 







YP_213107.1 62.68 5.854 glucose-1-phosphate 
thymidylyltransferase 
[Bacteroides fragilis YCH46] 
 
Metabolic Cytoplasm 
YP_211325.1 1629.32 5.849 hypothetical protein BF1680 
[Bacteroides fragilis YCH46] 
Hypothetical Unknown Unknown location 
YP_211557.1 286.06 5.705 hypothetical protein BF1924 




Unknown Inner membrane, 
periplasmic side 
YP_210087.1 178.49 5.690 FKBP-type peptidylprolyl 
isomerase [Bacteroides fragilis 
YCH46] 
 
Protein folding Inner membrane, 
periplasmic side 
YP_211041.1 597.21 5.457 hypothetical protein BF1383 




Unknown Unknown location 
YP_213397.1 1313.04 5.015 tryptophanyl-tRNA synthetase 
[Bacteroides fragilis YCH46] 
 
DNA/RNA Cytoplasm 
YP_213328.1 85.57 4.818 conserved hypothetical protein 





Transport Inner membrane 
YP_209830.1 359.41 4.595 conserved hypothetical protein 
[Bacteroides fragilis 3_1_12] 
Hypothetical 
protein 
Unknown Unknown location 
YP_213263.1 128.6 4.558 exopolyphosphatase 
[Bacteroides fragilis YCH46] 
 
Metabolic Cytoplasm 
YP_212625.1 648.93 4.538 hypothetical protein BF3011 








YP_211146.1 427.35 4.275 hypothetical protein BF1500 




Unknown Unknown location 
YP_211327.1 357.49 4.253 major outer membrane protein 
OmpA [Bacteroides fragilis 
YCH46] 












YP_213143.1 210.31 4.080 citrate synthase [Bacteroides 
fragilis NCTC 9343] 
 
Biosynthesis Cytoplasm 
YP_210506.1 645.92 4.052 glycosylhydrolase 
[Bacteroides fragilis YCH46] 
Probable alpha-
L-fucosidase 
Metabolic Unknown location 
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YP_212164.1 97.92 3.932 cobalt chelatase [Bacteroides 
fragilis NCTC 9343] 
 
Biosynthesis Cytoplasm 
YP_213364.1 224.81 3.345 subtilisin-like serine protease 






YP_210980.1 135.16 3.102 redox-sensitive transcriptional 






YP_210999.1 79.38 2.977 acetyl esterase [Bacteroides 
fragilis YCH46] 
XynC Metabolic Inner membrane, 
periplasmic side 
YP_212189.1 287.15 2.914 hypothetical protein BF2536 
[Bacteroides fragilis YCH46] 
Hypothetical 
protein 
Unknown Unknown location 
YP_210396.1 195.61 2.881 lytic murein transglycosylase 
[Bacteroides fragilis NCTC 
9343] 
 
PG cleavage Unknown location 
YP_210628.1 2408.44 2.634 zinc protease [Bacteroides 






YP_210985.1 2411.22 2.315 formate acetyltransferase 
[Bacteroides fragilis YCH46] 
 
Metabolic Cytoplasm 
YP_212118.1 2989.98 2.237 hypothetical protein BF2494 





YP_210678.1 2677.4 2.182 hypothetical protein BF1074 
[Bacteroides fragilis YCH46] 
Hypothetical 
protein 
Unknown Unknown location 
 
 
YP_212494.1 63.9 2.127 hypothetical protein BF2880 







Table A.VII.i The 88 proteins significantly enriched in the OMV of B. fragilis. Shown is the accession 
number in NCTC 9343, the Mascot confidence score, the fold increase in OMV over PP, the identity 
of the protein as determined by Mascot, the identity of the protein as determined by BLAST, the 
predicted functional group of the protein and the predicted subcellular origin of the protein. Proteases 




Accession No. Confidence 
Score 
Mascot Predicted Identity Average 
Abundance 
YP_097602.1 971.09 hypothetical protein BF0319 [Bacteroides fragilis YCH46] 268917993.7 
YP_101476.1 3830.51 elongation factor Tu [Bacteroides fragilis YCH46] 192885908.6 
YP_099239.1 894.28 hypothetical protein BF1957 [Bacteroides fragilis YCH46] 167747374.9 
YP_101460.1 4950.24 elongation factor G [Bacteroides fragilis YCH46] 164439714.3 
YP_099848.1 1175.71 phenylalanyl-tRNA synthetase subunit beta [Bacteroides fragilis 
YCH46] 
151078016.7 
YP_100577.1 2484.25 fructose-bisphosphate aldolase [Bacteroides fragilis YCH46] 109236286.4 
YP_100610.1 6822.2 pyruvate-flavodoxin oxidoreductase [Bacteroides fragilis YCH46] 91176650.31 
YP_098251.1 2993.35 glyceraldehyde 3-phosphate dehydrogenase [Bacteroides fragilis 
YCH46] 
72189970.59 
YP_098327.1 3259.65 30S ribosomal protein S1 [Bacteroides fragilis YCH46] 61955437.23 
YP_101034.1 2672.24 ketol-acid reductoisomerase [Bacteroides fragilis YCH46] 52041183.3 
YP_101717.1 4358.11 phosphoenolpyruvate carboxykinase [Bacteroides fragilis YCH46] 40692256.84 
ZP_07811280.1 2006.14 two-component system response regulator [Bacteroides fragilis 
3_1_12] 
37039824.25 
YP_100507.1 910.2 lipoprotein [Bacteroides fragilis YCH46] 33887483.49 
YP_099179.1 1256.72 OmpA family outer membrane protein [Bacteroides fragilis YCH46] 32911486.23 
YP_101286.1 2795.66 elongation factor Ts [Bacteroides fragilis YCH46] 31652651.88 
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YP_097970.1 782.16 ribosome recycling factor [Bacteroides fragilis YCH46] 29806455.33 
YP_101472.1 771 50S ribosomal protein L1 [Bacteroides fragilis YCH46] 29563233.59 
YP_212870.1 956.07 hypothetical protein BF3256 [Bacteroides fragilis NCTC 9343] 27740151.49 
YP_213015.1 2824.92 glutamate dehydrogenase [Bacteroides fragilis NCTC 9343] 27020265.58 
YP_097891.1 3591.9 bifunctional aspartokinase I/homoserine dehydrogenase I 
[Bacteroides fragilis YCH46] 
25855278.22 
YP_100485.1 1723.63 hypothetical protein BF3206 [Bacteroides fragilis YCH46] 25474155.36 
YP_098509.1 2996.26 molecular chaperone DnaK [Bacteroides fragilis YCH46] 25191319.63 
YP_100486.1 2810.87 hypothetical protein BF3207 [Bacteroides fragilis YCH46] 24710100.22 
YP_097785.1 1513.18 outer membrane protein OmpH [Bacteroides fragilis YCH46] 24224412.94 
YP_099822.1 175.04 RNA methyltransferase [Bacteroides fragilis YCH46] 23755364.08 
YP_098935.1 1918.9 galactokinase [Bacteroides fragilis YCH46] 23547600.66 
YP_212794.1 960.38 hypothetical protein BF3181 [Bacteroides fragilis NCTC 9343] 23451753.13 
YP_099876.1 1840.64 UDP-glucose 4-epimerase [Bacteroides fragilis YCH46] 23414909.25 
YP_212720.1 3492.98 phosphoglycerate kinase [Bacteroides fragilis NCTC 9343] 23367210.12 
YP_210264.1 2551.72 TonB dependent receptor [Bacteroides fragilis NCTC 9343] 22716217.33 
YP_100395.1 2498.67 glucosamine-6-phosphate deaminase-like protein [Bacteroides 
fragilis YCH46] 
22475397.77 
YP_100698.1 1708.04 adenylosuccinate synthetase [Bacteroides fragilis YCH46] 21794176.59 
YP_100882.1 2047.16 malic enzyme [Bacteroides fragilis YCH46] 19951901.99 
YP_098481.1 774.13 50S ribosomal protein L25 [Bacteroides fragilis YCH46] 18238734.51 
YP_100330.1 1783.92 aspartokinase [Bacteroides fragilis YCH46] 17845209.3 
YP_098944.1 829.9 hypothetical protein BF1662 [Bacteroides fragilis YCH46] 17437909.67 
YP_100703.1 762.01 AraC family transcriptional regulator [Bacteroides fragilis YCH46] 16549885.51 
YP_097878.1 2352.91 aspartate aminotransferase [Bacteroides fragilis YCH46] 15829428.36 
YP_098472.1 1681.01 phosphopyruvate hydratase [Bacteroides fragilis YCH46] 14029105.33 
YP_100457.1 594.57 rubrerythrin [Bacteroides fragilis YCH46] 13729475.15 
YP_213596.1 897.71 50S ribosomal protein L10 [Bacteroides fragilis NCTC 9343] 13481312.66 
YP_212348.1 588.59 30S ribosomal protein S16 [Bacteroides fragilis NCTC 9343] 13392593.14 
YP_101232.1 1773.07 triosephosphate isomerase [Bacteroides fragilis YCH46] 13134421.53 
YP_097958.1 2514.44 anaerobic fumarate hydratase class I [Bacteroides fragilis YCH46] 12787165.12 
YP_210853.1 1104.32 hypothetical protein BF1184 [Bacteroides fragilis NCTC 9343] 12295134.73 
YP_100642.1 1194.66 aminopeptidase [Bacteroides fragilis YCH46] 12126267.38 
YP_100673.1 2772.58 molecular chaperone GroEL [Bacteroides fragilis YCH46] 12110789.09 
YP_101254.1 1914.97 malate dehydrogenase [Bacteroides fragilis YCH46] 11997683.14 
YP_101439.1 712.79 50S ribosomal protein L15 [Bacteroides fragilis YCH46] 11558038.21 
YP_101445.1 221.39 30S ribosomal protein S14 [Bacteroides fragilis YCH46] 11177089.19 
YP_100379.1 2694.75 diphosphate--fructose-6-phosphate 1-phosphotransferase 
[Bacteroides fragilis YCH46] 
11123356.69 
YP_212085.1 1567.87 8-amino-7-oxononanoate synthase [Bacteroides fragilis NCTC 
9343] 
10876505.12 
YP_099970.1 815.34 hypothetical protein BF2686 [Bacteroides fragilis YCH46] 10822073.35 
YP_101462.1 546.24 30S ribosomal protein S12 [Bacteroides fragilis YCH46] 10434522.39 
YP_101461.1 1029.25 30S ribosomal protein S7 [Bacteroides fragilis YCH46] 10400165.01 
YP_101355.1 1836.66 FKBP-type peptidylprolyl isomerase [Bacteroides fragilis YCH46] 10397056 
YP_210947.1 1132.23 outer membrane protein [Bacteroides fragilis NCTC 9343] 10101132.98 
YP_101470.1 677.61 50S ribosomal protein L7/L12 [Bacteroides fragilis YCH46] 9955730.357 
YP_101287.1 2364.85 30S ribosomal protein S2 [Bacteroides fragilis YCH46] 9512015.696 
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YP_210272.1 1138.47 threonine synthase [Bacteroides fragilis NCTC 9343] 9282428.354 
YP_101734.1 1319.27 GTP-binding elongation factor family protein TypA/BipA 
[Bacteroides fragilis YCH46] 
9277554.348 
YP_213153.1 1826.71 dihydroxy-acid dehydratase [Bacteroides fragilis NCTC 9343] 9273729.78 
YP_101598.1 1932.66 polynucleotide phosphorylase [Bacteroides fragilis YCH46] 9262494.898 
YP_100988.1 964.61 dTDP-glucose 4,6-dehydratase [Bacteroides fragilis YCH46] 9033149.954 
YP_211784.1 899.61 hypothetical protein BF2161 [Bacteroides fragilis NCTC 9343] 9013351.555 
YP_212191.1 1796.9 pyruvate phosphate dikinase [Bacteroides fragilis NCTC 9343] 8930334.66 
YP_210113.1 1376.46 aspartate-semialdehyde dehydrogenase [Bacteroides fragilis 
NCTC 9343] 
8858569.431 
YP_101454.1 257.25 30S ribosomal protein S19 [Bacteroides fragilis YCH46] 8848063.575 
YP_099847.1 703.97 hypothetical protein BF2564 [Bacteroides fragilis YCH46] 8811287.55 
YP_097854.1 264.9 hypothetical protein BF0571 [Bacteroides fragilis YCH46] 8280344.706 
YP_097855.1 361.51 hypothetical protein BF0572 [Bacteroides fragilis YCH46] 8156735.491 
YP_101311.1 2187.4 glutamine-dependent carbamyl phosphate synthetase [Bacteroides 
fragilis YCH46] 
8092319.026 
YP_101443.1 717.13 50S ribosomal protein L6 [Bacteroides fragilis YCH46] 8064922.827 
YP_101220.1 1302.15 phospho-2-dehydro-3-deoxyheptonate aldolase [Bacteroides 
fragilis YCH46] 
7987226.472 
YP_101088.1 2178.27 glucose-6-phosphate isomerase [Bacteroides fragilis YCH46] 7926799.48 
YP_099673.1 1122.54 hypothetical protein BF2390 [Bacteroides fragilis YCH46] 7881976.875 
YP_101288.1 535.76 30S ribosomal protein S9 [Bacteroides fragilis YCH46] 7727314.601 
YP_101449.1 805.75 30S ribosomal protein S17 [Bacteroides fragilis YCH46] 7466340.966 
YP_210299.1 1033.94 hypothetical protein BF0589 [Bacteroides fragilis NCTC 9343] 7438333.178 
YP_101473.1 619.7 50S ribosomal protein L11 [Bacteroides fragilis YCH46] 7288114.482 
YP_101434.1 613.65 30S ribosomal protein S13 [Bacteroides fragilis YCH46] 7216386.074 
YP_210271.1 1028.31 cofactor-independent phosphoglycerate mutase [Bacteroides 
fragilis NCTC 9343] 
7166523.793 
YP_101756.1 3070.14 hypothetical protein BF4485 [Bacteroides fragilis YCH46] 7066161.122 
YP_099485.1 1197.64 serine hydroxymethyltransferase [Bacteroides fragilis YCH46] 7007150.494 
YP_213164.1 678.39 hypothetical protein BF3562 [Bacteroides fragilis NCTC 9343] 7006715.464 
YP_101458.1 1219.8 50S ribosomal protein L3 [Bacteroides fragilis YCH46] 6996162.402 
YP_100028.1 2250.17 serine protease [Bacteroides fragilis YCH46] 6939960.761 
YP_209901.1 1099.03 cysteinyl-tRNA synthetase [Bacteroides fragilis NCTC 9343] 6781033.907 
YP_213783.1 1163.78 arginyl-tRNA synthetase [Bacteroides fragilis NCTC 9343] 6518690.219 
YP_099705.1 1526.35 magnesium chelatase subunit I [Bacteroides fragilis YCH46] 6509437.24 
YP_101432.1 939.34 30S ribosomal protein S4 [Bacteroides fragilis YCH46] 6447415.812 
YP_101038.1 922.77 acetolactate synthase large subunit [Bacteroides fragilis YCH46] 6307463.994 
YP_213085.1 1291.34 oxidoreductase [Bacteroides fragilis NCTC 9343] 6180609.854 
YP_098934.1 1971.72 transketolase [Bacteroides fragilis YCH46] 5834782.091 
YP_097845.1 1057.29 transcriptional repressor [Bacteroides fragilis YCH46] 5786197.386 
YP_212624.1 1112.99 hypothetical protein BF3010 [Bacteroides fragilis NCTC 9343] 5772189.063 
YP_210841.1 1978.32 heat shock ClpB protein [Bacteroides fragilis NCTC 9343] 5675915.003 
YP_213382.1 1065.41 beta-galactosidase [Bacteroides fragilis NCTC 9343] 5597199.198 
YP_209837.1 366.78 dipeptidyl peptidase IV [Bacteroides fragilis NCTC 9343] 5595436.493 
YP_211656.1 1490.59 hypothetical protein BF2024 [Bacteroides fragilis NCTC 9343] 5489876.415 
YP_210392.1 1792.8 alanyl-tRNA synthetase [Bacteroides fragilis NCTC 9343] 5482603.342 
YP_100269.1 996.62 NAD-dependent nucleotide-diphosphate-sugar epimerase 




YP_210849.2 992.68 recombinase A [Bacteroides fragilis NCTC 9343] 5396318.54 
YP_211991.1 1810.67 isoleucyl-tRNA synthetase [Bacteroides fragilis NCTC 9343] 5359915.042 
YP_101444.1 716.11 30S ribosomal protein S8 [Bacteroides fragilis YCH46] 5343247.123 
YP_097545.1 1286.19 transcription elongation factor NusA [Bacteroides fragilis YCH46] 5329099.065 
YP_101430.1 1083.37 50S ribosomal protein L17 [Bacteroides fragilis YCH46] 5307324.252 
YP_099909.1 655.42 small heat shock protein [Bacteroides fragilis YCH46] 5282399.637 
YP_100585.1 1048.45 hypothetical protein BF3307 [Bacteroides fragilis YCH46] 5133896.284 
YP_101365.1 604.98 3-oxoacyl-ACP synthase [Bacteroides fragilis YCH46] 5073373.238 
YP_101468.1 3206.98 DNA-directed RNA polymerase subunit beta' [Bacteroides fragilis 
YCH46] 
5056283.147 
YP_211701.1 1357.36 D-3-phosphoglycerate dehydrogenase [Bacteroides fragilis NCTC 
9343] 
5046665.14 
YP_101446.1 951.86 50S ribosomal protein L5 [Bacteroides fragilis YCH46] 5030961.295 
YP_098938.1 1088.66 mannose-6-phosphate isomerase [Bacteroides fragilis YCH46] 4943229.676 
YP_100593.1 1302.39 phosphoribosylformylglycinamidine synthase [Bacteroides fragilis 
YCH46] 
4906728.757 
YP_213165.1 383.28 hypothetical protein BF3563 [Bacteroides fragilis NCTC 9343] 4882388.143 
YP_101292.1 1035.6 asparaginyl-tRNA synthetase [Bacteroides fragilis YCH46] 4874768.656 
YP_097309.1 1366.78 coenzyme A transferase [Bacteroides fragilis YCH46] 4858928.202 
YP_212278.1 1262.39 carbamoyl-phosphate synthase large subunit [Bacteroides fragilis 
NCTC 9343] 
4844743.859 
YP_098586.1 833.99 peptidase T [Bacteroides fragilis YCH46] 4768870.292 
YP_097502.1 1397.42 3-oxoacyl-ACP synthase [Bacteroides fragilis YCH46] 4679959.367 
YP_101394.1 706.78 3-oxoacyl-ACP reductase [Bacteroides fragilis YCH46] 4677177.891 
YP_099299.1 1647.62 phosphoserine aminotransferase [Bacteroides fragilis YCH46] 4674802.849 
YP_101363.1 977 GTP-binding protein EngA [Bacteroides fragilis YCH46] 4649634.107 
YP_213196.1 1080.56 lysyl-tRNA synthetase [Bacteroides fragilis NCTC 9343] 4544546.325 
YP_101138.1 536.89 30S ribosomal protein S6 [Bacteroides fragilis YCH46] 4534846.394 
YP_101431.1 932.54 DNA-directed RNA polymerase subunit alpha [Bacteroides fragilis 
YCH46] 
4457712.757 
ZP_07811680.1 438.17 50S ribosomal protein L22 [Bacteroides fragilis 3_1_12] 4403507.307 
YP_098745.1 734.31 hypothetical protein BF1460 [Bacteroides fragilis YCH46] 4338971.307 
YP_098400.1 300.86 hypothetical protein BF1116 [Bacteroides fragilis YCH46] 4273517.385 
YP_213523.1 1074.67 hypothetical protein BF3942 [Bacteroides fragilis NCTC 9343] 4129056.842 
YP_211657.1 696.53 hypothetical protein BF2025 [Bacteroides fragilis NCTC 9343] 4127073.362 
YP_098968.1 1047.14 threonyl-tRNA synthetase [Bacteroides fragilis YCH46] 4068020.477 
YP_210692.1 1091.34 hypothetical protein BF1004 [Bacteroides fragilis NCTC 9343] 4043147.962 
YP_098483.1 246.83 nitrogen utilization substance protein [Bacteroides fragilis YCH46] 4007139.336 
YP_212087.1 1220.25 aspartyl-tRNA synthetase [Bacteroides fragilis NCTC 9343] 3979232.904 
YP_100721.1 1047.24 3-isopropylmalate dehydrogenase [Bacteroides fragilis YCH46] 3978215.349 
YP_101091.1 683.78 asparagine synthetase AsnA [Bacteroides fragilis YCH46] 3958570.115 
YP_098969.1 379.65 translation initiation factor IF-3 [Bacteroides fragilis YCH46] 3933149.458 
YP_101469.1 2170.11 DNA-directed RNA polymerase subunit beta [Bacteroides fragilis 
YCH46] 
3882545.214 
YP_099717.1 1189.04 prolyl-tRNA synthetase [Bacteroides fragilis YCH46] 3822171.828 
YP_213385.1 217.89 hyaluronidase [Bacteroides fragilis NCTC 9343] 3739191.3 
YP_100329.1 522.89 diaminopimelate decarboxylase [Bacteroides fragilis YCH46] 3669274.559 
YP_213043.1 582.68 peptidase [Bacteroides fragilis NCTC 9343] 3657512.295 
ZP_07811678.1 716.11 50S ribosomal protein L2 [Bacteroides fragilis 3_1_12] 3624734.275 
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YP_101823.1 1813.08 succinate dehydrogenase flavoprotein subunit [Bacteroides fragilis 
YCH46] 
3590469.217 
YP_098253.1 1079.51 GMP synthase [Bacteroides fragilis YCH46] 3464300.792 
YP_098319.1 780.51 thioredoxin reductase [Bacteroides fragilis YCH46] 3464116.026 
YP_101137.1 387.93 30S ribosomal protein S18 [Bacteroides fragilis YCH46] 3418332.244 
YP_213724.1 592.56 aminopeptidase [Bacteroides fragilis NCTC 9343] 3385796.651 
YP_213794.1 477.64 hypothetical protein BF4230 [Bacteroides fragilis NCTC 9343] 3355611.947 
YP_209819.1 1288.17 tyrosyl-tRNA synthetase 1 [Bacteroides fragilis NCTC 9343] 3308116.909 
YP_101289.1 350.03 50S ribosomal protein L13 [Bacteroides fragilis YCH46] 3296918.822 
YP_097586.1 619.6 cell division protein FtsA [Bacteroides fragilis YCH46] 3245833.147 
YP_097695.1 928.7 glycyl-tRNA synthetase [Bacteroides fragilis YCH46] 3172367.22 
YP_098403.1 178.29 hypoxanthine guanine phosphoribosyltransferase [Bacteroides 
fragilis YCH46] 
3164025.76 
YP_101352.1 1250.84 ATP-dependent DNA helicase RecQ [Bacteroides fragilis YCH46] 3111100.927 
YP_211065.1 2330.97 phosphoglucomutase [Bacteroides fragilis NCTC 9343] 3110032.607 
YP_212163.1 736.94 iron transport-like protein [Bacteroides fragilis NCTC 9343] 3051399.596 
YP_097846.1 281.02 50S ribosomal protein L19 [Bacteroides fragilis YCH46] 3024933.582 
YP_101442.1 479.22 50S ribosomal protein L18 [Bacteroides fragilis YCH46] 3004903.796 
YP_098294.1 356.65 50S ribosomal protein L21 [Bacteroides fragilis YCH46] 2975557.529 
YP_097304.1 518.54 rubrerythrin [Bacteroides fragilis YCH46] 2962376.963 
YP_101850.1 774.96 GTP-dependent nucleic acid-binding protein EngD [Bacteroides 
fragilis YCH46] 
2903112.351 
YP_098499.1 1123.1 hypothetical protein BF1215 [Bacteroides fragilis YCH46] 2878457.914 
YP_101477.1 475.7 sigma-54 modulation protein [Bacteroides fragilis YCH46] 2877103.75 
YP_213927.1 1111.27 leucyl-tRNA synthetase [Bacteroides fragilis NCTC 9343] 2840426.977 
YP_100822.1 827.01 O-acetylhomoserine (thiol)-lyase [Bacteroides fragilis YCH46] 2837914.702 
YP_097344.1 635.17 S-adenosylmethionine synthetase [Bacteroides fragilis YCH46] 2810792.375 
YP_098930.1 767.85 2-ketoisovalerate ferredoxin reductase [Bacteroides fragilis 
YCH46] 
2802155.714 
YP_101448.1 241.84 50S ribosomal protein L14 [Bacteroides fragilis YCH46] 2792249.134 
YP_099924.1 654.17 glycerophosphodiester phosphodiesterase [Bacteroides fragilis 
YCH46] 
2779053.429 
YP_213503.1 1232.36 hypothetical protein BF3922 [Bacteroides fragilis NCTC 9343] 2771648.311 
YP_097762.1 1199.73 acetate kinase [Bacteroides fragilis YCH46] 2722763.773 
YP_100905.1 535.31 hypothetical protein BF3628 [Bacteroides fragilis YCH46] 2721558.888 
YP_097341.1 532.92 S-adenosylmethionine:tRNA ribosyltransferase-isomerase 
[Bacteroides fragilis YCH46] 
2715462.912 
YP_100566.1 832.82 lactoylglutathione lyase and related protein [Bacteroides fragilis 
YCH46] 
2709259.675 
YP_100047.1 843.51 thiol peroxidase [Bacteroides fragilis YCH46] 2669972.119 
YP_100851.1 349.87 hypothetical protein BF3574 [Bacteroides fragilis YCH46] 2668121.939 
YP_098334.1 899.29 valyl-tRNA synthetase [Bacteroides fragilis YCH46] 2656886.809 
YP_101459.1 331.16 30S ribosomal protein S10 [Bacteroides fragilis YCH46] 2617417.188 
YP_210673.1 2085.08 preprotein translocase subunit SecA [Bacteroides fragilis NCTC 
9343] 
2610628.55 
YP_213825.1 753.43 S-adenosyl-L-homocysteine hydrolase [Bacteroides fragilis NCTC 
9343] 
2592580.993 
YP_098065.1 1287.26 aminoacyl-histidine dipeptidase [Bacteroides fragilis YCH46] 2563341.165 
YP_100725.1 1174.12 2-isopropylmalate synthase [Bacteroides fragilis YCH46] 2542971.844 
YP_210004.1 549.78 hypothetical protein BF0267 [Bacteroides fragilis NCTC 9343] 2516741.495 
YP_101452.1 658.42 30S ribosomal protein S3 [Bacteroides fragilis YCH46] 2475662.435 
YP_213182.1 683.16 peptidase [Bacteroides fragilis NCTC 9343] 2470119.717 
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YP_098780.1 548.59 hemagglutinin [Bacteroides fragilis YCH46] 2459745.5 
YP_210301.1 737.53 outer membrane receptor protein [Bacteroides fragilis NCTC 9343] 2437683.215 
YP_213213.1 969.05 ribonucleoside reductase [Bacteroides fragilis NCTC 9343] 2412895.629 
YP_100724.1 984.04 isopropylmalate isomerase large subunit [Bacteroides fragilis 
YCH46] 
2394092.727 
YP_212180.1 595.2 superoxide dismutase [Bacteroides fragilis NCTC 9343] 2375693.027 
YP_099272.1 775 ABC transporter ATP-binding protein [Bacteroides fragilis YCH46] 2367573.181 
YP_098928.1 742.03 ketoisovalerate oxidoreductase subunit VorA [Bacteroides fragilis 
YCH46] 
2327170.925 
YP_100674.1 681.18 co-chaperonin GroES [Bacteroides fragilis YCH46] 2302498.072 
YP_101313.1 481.79 major outer membrane protein OmpA [Bacteroides fragilis YCH46] 2286289.634 
YP_099519.1 580.09 hypothetical protein BF2238 [Bacteroides fragilis YCH46] 2271616.19 
YP_101483.1 1091.72 glutamyl-tRNA synthetase [Bacteroides fragilis YCH46] 2264831.634 
YP_211154.1 429.22 choloylglycine hydrolase [Bacteroides fragilis NCTC 9343] 2231305.198 
YP_213188.1 987.61 methylmalonyl-CoA mutase small subunit [Bacteroides fragilis 
NCTC 9343] 
2229108.589 
YP_099104.1 374.32 GDP-mannose 4,6-dehydratase [Bacteroides fragilis YCH46] 2185825.076 
YP_101076.1 1207.49 methylmalonyl-CoA mutase [Bacteroides fragilis YCH46] 2148034.738 
YP_210619.1 961.4 bifunctional 2-polyprenylphenol hydroxylase/glutamate synthase 
subunit beta [Bacteroides fragilis NCTC 9343] 
2136522.755 
YP_099029.1 486.98 hypothetical protein BF1748 [Bacteroides fragilis YCH46] 2066987.384 
YP_209978.1 1207.96 phosphoglyceromutase [Bacteroides fragilis NCTC 9343] 2043070.427 
YP_212115.1 2152.81 heat shock protein 90 [Bacteroides fragilis NCTC 9343] 2040197.374 
YP_097816.1 466.16 argininosuccinate synthase [Bacteroides fragilis YCH46] 2028326.428 
YP_211702.1 740.54 hypothetical protein BF2074 [Bacteroides fragilis NCTC 9343] 2009880.084 
YP_100411.1 320.4 hypothetical protein BF3132 [Bacteroides fragilis YCH46] 2005509.734 
YP_100010.1 1192.92 alpha-glucan phosphorylase [Bacteroides fragilis YCH46] 1974465.309 
YP_100498.1 613.12 bifunctional 5,10-methylene-tetrahydrofolate dehydrogenase/ 5,10-
methylene-tetrahydrofolate cyclohydrolase [Bacteroides fragilis 
YCH46] 
1945657.708 
YP_098002.1 658.62 magnesium chelatase subunit I [Bacteroides fragilis YCH46] 1941090.933 
YP_098216.1 435.81 oxidoreductase [Bacteroides fragilis YCH46] 1862165.236 
YP_098871.1 610.16 aspartate aminotransferase [Bacteroides fragilis YCH46] 1855499.658 
YP_098196.1 417.74 phosphoribosylformylglycinamidine cyclo-ligase [Bacteroides 
fragilis YCH46] 
1832128.958 
YP_101273.1 649.14 branched-chain amino acid aminotransferase [Bacteroides fragilis 
YCH46] 
1808107.407 
YP_098256.1 563.98 enoyl-ACP reductase [Bacteroides fragilis YCH46] 1777541.064 
YP_099820.1 678.82 hypothetical protein BF2537 [Bacteroides fragilis YCH46] 1712299.868 
YP_099539.1 1016.93 malonyl CoA-ACP transacylase [Bacteroides fragilis YCH46] 1659573.62 
ZP_07812042.1 479.73 succinate dehydrogenase/fumarate reductase iron-sulfur subunit 
[Bacteroides fragilis 3_1_12] 
1638879.497 
YP_101174.1 595.13 phosphoglucomutase [Bacteroides fragilis YCH46] 1599510.163 
YP_097877.1 1098.41 GTP cyclohydrolase II [Bacteroides fragilis YCH46] 1585540.537 
YP_097580.1 1343.41 DNA gyrase B subunit [Bacteroides fragilis YCH46] 1564621.336 
YP_101753.1 903.94 pyruvate kinase [Bacteroides fragilis YCH46] 1542453.339 
YP_099382.1 297.37 hypothetical protein BF2101 [Bacteroides fragilis YCH46] 1525925.235 
YP_099451.1 638.82 phosphoribosylglycinamide formyltransferase 2 [Bacteroides 
fragilis YCH46] 
1511344.053 
YP_211618.1 403.95 outer membrane protein [Bacteroides fragilis NCTC 9343] 1506943.785 
YP_101046.1 494.92 peptidyl-prolyl cis-trans isomerase [Bacteroides fragilis YCH46] 1502360.36 





YP_101736.1 377.17 transcriptional regulator [Bacteroides fragilis YCH46] 1491651.454 
YP_213729.1 1047.65 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase 
[Bacteroides fragilis NCTC 9343] 
1476632.875 
YP_100003.1 471.68 RNA-binding protein [Bacteroides fragilis YCH46] 1476408.783 
YP_210617.1 513.64 pantoate--beta-alanine ligase [Bacteroides fragilis NCTC 9343] 1467651.652 
YP_101712.1 516.19 2-oxoglutarate ferredoxin oxidoreductase subunit beta 
[Bacteroides fragilis YCH46] 
1458361.714 
ZP_07807811.1 723.95 adenylate kinase [Bacteroides fragilis 3_1_12] 1444729.378 
YP_101694.1 568.51 DNA-binding protein HU-beta [Bacteroides fragilis YCH46] 1442796.117 
YP_211643.1 528.51 hypothetical protein BF2011 [Bacteroides fragilis NCTC 9343] 1416558.172 
YP_100496.1 998.48 signal recognition protein [Bacteroides fragilis YCH46] 1408990.629 
YP_100328.1 611.64 ferritin [Bacteroides fragilis YCH46] 1404318.369 
YP_100469.1 657.78 ATP phosphoribosyltransferase [Bacteroides fragilis YCH46] 1403404.551 
YP_099459.1 580.06 ATP synthase F0F1 subunit alpha [Bacteroides fragilis YCH46] 1400913.671 
YP_210434.1 660.43 DegT/DnrJ/EryC1/StrS aminotransferase family O-antigen-like 
protein [Bacteroides fragilis NCTC 9343] 
1399071.899 
YP_099712.1 208.63 50S ribosomal protein L28 [Bacteroides fragilis YCH46] 1382255.665 
YP_212294.1 710.68 anthranilate phosphoribosyltransferase [Bacteroides fragilis NCTC 
9343] 
1369822.703 
YP_213737.1 628.25 carboxy-terminal processing protease [Bacteroides fragilis NCTC 
9343] 
1363083.833 
YP_099419.1 784.98 hypothetical protein BF2138 [Bacteroides fragilis YCH46] 1356061.906 
YP_099920.1 196.95 carbamoyl phosphate synthase small subunit [Bacteroides fragilis 
YCH46] 
1346260.078 
YP_097786.1 497.2 cationic outer membrane protein [Bacteroides fragilis YCH46] 1335493.713 
YP_211077.1 245.62 pyridine nucleotide-disulfide oxidoreductase [Bacteroides fragilis 
NCTC 9343] 
1320555.401 
YP_097777.1 302.08 ornithine carbamoyltransferase [Bacteroides fragilis YCH46] 1288469.654 
YP_098203.1 868.44 phosphoribosylaminoimidazole-succinocarboxamide synthase 
[Bacteroides fragilis YCH46] 
1261303.396 
YP_100258.1 638.62 TPR repeat-containing protein [Bacteroides fragilis YCH46] 1257812.146 
YP_098595.1 477.61 peptide chain release factor 3 [Bacteroides fragilis YCH46] 1247899.617 
YP_099934.1 265.44 tryptophan synthase subunit beta [Bacteroides fragilis YCH46] 1219983.876 
YP_212372.1 295.5 hypothetical protein BF2756 [Bacteroides fragilis NCTC 9343] 1213350.227 
YP_100544.1 310.6 phenylalanyl-tRNA synthetase subunit alpha [Bacteroides fragilis 
YCH46] 
1203816.867 
YP_097585.1 596.48 cell division protein FtsZ [Bacteroides fragilis YCH46] 1202018.251 
YP_098268.1 737.82 glucosamine-6-phosphate deaminase [Bacteroides fragilis YCH46] 1196437.485 
YP_210072.1 392.98 beta-glucosidase [Bacteroides fragilis NCTC 9343] 1188745.063 
ZP_07812118.1 504.88 phosphoribosylaminoimidazole carboxy formyltransferase 
[Bacteroides fragilis 3_1_12] 
1188647.824 
YP_101294.1 622.71 adenylosuccinate lyase [Bacteroides fragilis YCH46] 1187604.976 
YP_097552.1 404.68 aminotransferase [Bacteroides fragilis YCH46] 1171514.318 
YP_100518.1 900.9 aminoacyl-histidine dipeptidase [Bacteroides fragilis YCH46] 1164580.402 
YP_213801.1 560.52 2-oxoglutarate ferredoxin oxidoreductase subunit [Bacteroides 
fragilis NCTC 9343] 
1148950.48 
YP_101348.1 516.42 peptidyl-prolyl cis-trans isomerase [Bacteroides fragilis YCH46] 1132722.366 
YP_100492.1 350.3 transcription termination factor Rho [Bacteroides fragilis YCH46] 1130150.391 
YP_100263.1 409.79 DNA polymerase III subunit beta [Bacteroides fragilis YCH46] 1118692.916 
YP_101595.1 538.45 histidine triad (HIT) family protein [Bacteroides fragilis YCH46] 1102453.77 
YP_099936.1 290.77 anthranilate synthase component II [Bacteroides fragilis YCH46] 1091388.216 
YP_097584.1 604.82 hypothetical protein BF0301 [Bacteroides fragilis YCH46] 1079452.017 
YP_211225.1 334.38 hypothetical protein BF1582 [Bacteroides fragilis NCTC 9343] 1077223.145 
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YP_099236.1 566.49 endopeptidase Clp ATP-binding chain B [Bacteroides fragilis 
YCH46] 
1073408.041 
YP_101243.1 482.63 pyridoxine 5'-phosphate synthase [Bacteroides fragilis YCH46] 1062703.55 
YP_213287.1 452.19 hypothetical protein BF3697 [Bacteroides fragilis NCTC 9343] 1056980.422 
YP_099711.1 201.24 50S ribosomal protein L33 [Bacteroides fragilis YCH46] 1047149.606 
YP_099580.1 253.22 ATP-dependent RNA helicase [Bacteroides fragilis YCH46] 1046269.68 
YP_099547.1 458.94 thioredoxin peroxidase [Bacteroides fragilis YCH46] 1042609.896 
YP_098965.1 236.73 peptide deformylase [Bacteroides fragilis YCH46] 1039960.976 
YP_210196.1 263.09 acetylornithine aminotransferase [Bacteroides fragilis NCTC 9343] 1035406.848 
YP_213853.1 490.58 methionyl-tRNA synthetase [Bacteroides fragilis NCTC 9343] 1030644.143 
YP_211940.1 228.65 hypothetical protein BF2318 [Bacteroides fragilis NCTC 9343] 1029081.699 
YP_213285.1 443.38 nucleotidyltransferase [Bacteroides fragilis NCTC 9343] 1025390.445 
YP_097769.1 252.17 elongation factor P [Bacteroides fragilis YCH46] 1021969.428 
YP_097503.1 148.7 acyl carrier protein [Bacteroides fragilis YCH46] 1006735.361 
YP_210302.1 592.3 surface membrane protein, partial [Bacteroides fragilis NCTC 
9343] 
1000603.005 
YP_099089.1 222.88 2',3'-cyclic-nucleotide 2'-phosphodiesterase [Bacteroides fragilis 
YCH46] 
990632.1576 
YP_099720.1 494.49 protease [Bacteroides fragilis YCH46] 978863.2397 
YP_209815.1 356.28 uroporphyrinogen-III synthase [Bacteroides fragilis NCTC 9343] 977952.4079 
YP_097793.1 413.04 orotate phosphoribosyltransferase [Bacteroides fragilis YCH46] 970583.8829 
YP_213051.1 323.04 hypothetical protein BF3446 [Bacteroides fragilis NCTC 9343] 969677.7864 
YP_098943.1 304.65 short-chain dehydrogenase [Bacteroides fragilis YCH46] 965412.3004 
YP_099901.1 296.41 hypothetical protein BF2617 [Bacteroides fragilis YCH46] 962417.0045 
YP_099448.1 909.96 hypothetical protein BF2167 [Bacteroides fragilis YCH46] 935356.6685 
YP_097994.1 562 thioredoxin [Bacteroides fragilis YCH46] 934476.0514 
ZP_07809161.1 759.96 ATP synthase F1 sector subunit beta [Bacteroides fragilis 3_1_12] 925536.8536 
YP_101451.1 123.69 50S ribosomal protein L16 [Bacteroides fragilis YCH46] 892679.9243 
YP_098291.1 1014.87 seryl-tRNA synthetase [Bacteroides fragilis YCH46] 892352.3366 
YP_098927.1 579.33 ketoisovalerate oxidoreductase subunit VorA [Bacteroides fragilis 
YCH46] 
891276.5183 
YP_098250.1 487.97 peptidyl-dipeptidase [Bacteroides fragilis YCH46] 887176.7016 
YP_098754.1 271.03 nicotinate-nucleotide pyrophosphorylase [Bacteroides fragilis 
YCH46] 
870971.9104 
YP_212281.1 1024.08 asparagine synthetase B [Bacteroides fragilis NCTC 9343] 868645.1298 
YP_210526.1 577.71 orotidine 5'-phosphate decarboxylase [Bacteroides fragilis NCTC 
9343] 
866317.1541 
ZP_07809209.1 247.46 aspartate carbamoyltransferase subunit catalytic [Bacteroides 
fragilis 3_1_12] 
864312.8164 
YP_101474.1 438.35 transcription anti-termination protein [Bacteroides fragilis YCH46] 852836.2009 
YP_101735.1 161.55 30S ribosomal protein S15 [Bacteroides fragilis YCH46] 843724.5326 
YP_099113.1 614.29 phosphoenolpyruvate phosphomutase [Bacteroides fragilis 
YCH46] 
827485.9464 
YP_212110.1 533.51 dihydrodipicolinate synthase [Bacteroides fragilis NCTC 9343] 825431.0447 
YP_099025.1 390.03 ABC transporter ATP-binding protein [Bacteroides fragilis YCH46] 816177.2159 
YP_213224.1 381.48 50S ribosomal protein L9 [Bacteroides fragilis NCTC 9343] 808133.6336 
YP_210827.1 577.21 alpha-glucosidase [Bacteroides fragilis NCTC 9343] 807156.8796 
YP_099135.1 430.84 6-phosphogluconate dehydrogenase [Bacteroides fragilis YCH46] 800215.1005 
YP_098487.1 522.79 hypothetical protein BF1203 [Bacteroides fragilis YCH46] 795715.4552 
YP_101221.1 435.33 prephenate dehydratase [Bacteroides fragilis YCH46] 793648.9995 
YP_098482.1 118.33 hypothetical protein BF1198 [Bacteroides fragilis YCH46] 790572.9728 
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YP_098191.1 627.44 bifunctional UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine 
deacetylase/(3R)-hydroxymyristoyl-ACP dehydratase [Bacteroides 
fragilis YCH46] 
789699.8611 
YP_101594.1 605.63 mannose-1-phosphate guanylyltransferase [Bacteroides fragilis 
YCH46] 
781345.8086 
YP_212478.1 683.83 2-amino-3-ketobutyrate CoA ligase [Bacteroides fragilis NCTC 
9343] 
778680.2362 
YP_098837.1 347.18 DNA-binding protein HU [Bacteroides fragilis YCH46] 778460.8046 
YP_100650.1 431.07 electron transfer flavoprotein subunit beta [Bacteroides fragilis 
YCH46] 
773279.0131 
YP_211187.1 337.06 hypothetical protein BF1542 [Bacteroides fragilis NCTC 9343] 766820.8998 
YP_210815.1 343.19 hypothetical protein BF1145 [Bacteroides fragilis NCTC 9343] 764248.2292 
YP_213605.1 687.58 peptidase [Bacteroides fragilis NCTC 9343] 763218.5968 
YP_100860.1 211.35 arsenate reductase [Bacteroides fragilis YCH46] 761295.0418 
YP_211719.1 218.38 hypothetical protein BF2093 [Bacteroides fragilis NCTC 9343] 755287.312 
YP_099682.1 293.06 dihydroorotate dehydrogenase electron transfer subunit 
[Bacteroides fragilis YCH46] 
754051.633 
YP_101441.1 164.04 30S ribosomal protein S5 [Bacteroides fragilis YCH46] 751623.1435 
YP_098587.1 159.22 glycine cleavage system aminomethyltransferase T [Bacteroides 
fragilis YCH46] 
748388.0096 
YP_213898.1 171.72 hypothetical protein BF4343 [Bacteroides fragilis NCTC 9343] 747966.5041 
YP_213380.1 579.04 ribosomal large subunit pseudouridine synthase [Bacteroides 
fragilis NCTC 9343] 
747635.7772 
YP_101353.1 393.95 ATP-dependent protease ATP-binding subunit ClpX [Bacteroides 
fragilis YCH46] 
732615.9332 
YP_097737.1 775.69 glutamate decarboxylase [Bacteroides fragilis YCH46] 728343.7799 
YP_097761.1 783.1 phosphate acetyltransferase [Bacteroides fragilis YCH46] 720141.7091 
YP_100022.1 163.77 periplasmic protein [Bacteroides fragilis YCH46] 719454.2577 
YP_098274.1 232.54 aminotransferase [Bacteroides fragilis YCH46] 716989.1943 
YP_101716.1 397.53 uracil phosphoribosyltransferase [Bacteroides fragilis YCH46] 712368.2066 
YP_099585.1 547.44 ATP-dependent protease [Bacteroides fragilis YCH46] 708734.1573 
YP_098469.1 138.2 hypothetical protein BF1185 [Bacteroides fragilis YCH46] 708701.6565 
YP_097978.1 520.63 uridylate kinase [Bacteroides fragilis YCH46] 706989.5035 
YP_100529.1 379.35 fructose-bisphosphate aldolase [Bacteroides fragilis YCH46] 702664.5636 
YP_098459.1 274.62 purine nucleoside phosphorylase II [Bacteroides fragilis YCH46] 701794.4159 
YP_213284.1 237.21 nucleotidyltransferase [Bacteroides fragilis NCTC 9343] 700451.7807 
YP_099567.1 359.45 hypothetical protein BF2286 [Bacteroides fragilis YCH46] 692769.7064 
YP_100652.1 702.25 acyl-CoA dehydrogenase [Bacteroides fragilis YCH46] 691946.0561 
YP_101447.1 529.08 50S ribosomal protein L24 [Bacteroides fragilis YCH46] 689075.6584 
YP_098303.1 214.11 2-dehydro-3-deoxyphosphooctonate aldolase [Bacteroides fragilis 
YCH46] 
687865.4747 
YP_212851.1 467.59 histidyl-tRNA synthetase [Bacteroides fragilis NCTC 9343] 672518.5865 
YP_098547.1 168.05 hypothetical protein BF1263 [Bacteroides fragilis YCH46] 665136.8461 
YP_099484.1 210.36 hypothetical protein BF2203 [Bacteroides fragilis YCH46] 659611.9601 
YP_099814.1 247.89 thiamine biosynthesis protein ThiC [Bacteroides fragilis YCH46] 659014.8795 
YP_212505.1 176.95 imidazole glycerol phosphate synthase subunit HisH [Bacteroides 
fragilis NCTC 9343] 
650015.09 
YP_098529.1 654.98 catalase [Bacteroides fragilis YCH46] 647268.785 
YP_101358.1 304.58 RNA-binding protein RbpA [Bacteroides fragilis YCH46] 636353.2054 
YP_100262.1 481.85 DNA polymerase III subunit epsilon [Bacteroides fragilis YCH46] 636100.6892 
ZP_07807375.1 635.58 GTP-binding protein [Bacteroides fragilis 3_1_12] 635596.5683 





YP_211817.1 191.35 hypothetical protein BF2194 [Bacteroides fragilis NCTC 9343] 628662.087 
YP_101827.1 607.03 TonB-dependent outer membrane protein [Bacteroides fragilis 
YCH46] 
626973.7977 
YP_101025.1 411.65 6-phosphofructokinase [Bacteroides fragilis YCH46] 625020.6861 
YP_099557.1 563.97 DnaK suppressor protein [Bacteroides fragilis YCH46] 622835.1906 
YP_097546.1 871.55 translation initiation factor IF-2 [Bacteroides fragilis YCH46] 619869.0195 
YP_213484.1 208.82 GTP-binding protein Era [Bacteroides fragilis NCTC 9343] 615392.328 
YP_099927.1 182.56 L,L-diaminopimelate aminotransferase [Bacteroides fragilis 
YCH46] 
610184.0844 
YP_097515.1 471.44 nitroreductase [Bacteroides fragilis YCH46] 608799.513 
YP_100024.1 283.65 clostripain-related protein [Bacteroides fragilis YCH46] 605063.9945 
YP_211284.1 186.21 hypothetical protein BF1646 [Bacteroides fragilis NCTC 9343] 603098.5652 
YP_097758.1 347.5 hypothetical protein BF0475 [Bacteroides fragilis YCH46] 597230.6592 
YP_101351.1 229.28 inosine-5'-monophosphate dehydrogenase [Bacteroides fragilis 
YCH46] 
586824.841 
YP_211645.1 253.17 hypothetical protein BF2013 [Bacteroides fragilis NCTC 9343] 580195.6993 
YP_098478.1 104.84 hypothetical protein BF1194 [Bacteroides fragilis YCH46] 578131.9018 
YP_210861.2 222.87 tryptophan synthase subunit beta [Bacteroides fragilis NCTC 9343] 576536.9883 
YP_212441.1 427.49 dihydroorotate dehydrogenase 2 [Bacteroides fragilis NCTC 9343] 571869.7639 
YP_098172.1 328.18 hypothetical protein BF0887 [Bacteroides fragilis YCH46] 571377.2695 
YP_097367.1 897.82 phosphoribosylamine--glycine ligase [Bacteroides fragilis YCH46] 558376.5307 
YP_099902.1 258.13 hypothetical protein BF2618 [Bacteroides fragilis YCH46] 558100.7946 
YP_101253.1 420.61 Tricorn-like protease [Bacteroides fragilis YCH46] 556388.5529 
YP_098863.1 355.42 hypothetical protein BF1579 [Bacteroides fragilis YCH46] 541467.2803 
YP_099940.1 297.24 tryptophan synthase subunit alpha [Bacteroides fragilis YCH46] 533262.3508 
YP_098405.1 413.47 GTPase ObgE [Bacteroides fragilis YCH46] 531639.1953 
YP_101092.1 267.07 uracil-DNA glycosylase [Bacteroides fragilis YCH46] 525833.4216 
YP_210123.1 574.9 glutaminase [Bacteroides fragilis NCTC 9343] 525796.121 
YP_098897.1 283.86 hypothetical protein BF1615 [Bacteroides fragilis YCH46] 511492.1315 
YP_100813.1 335.55 inosine 5-monophosphate dehydrogenase [Bacteroides fragilis 
YCH46] 
511269.9082 
YP_100332.1 519.01 bifunctional phosphoribosyl-AMP cyclohydrolase/phosphoribosyl-
ATP pyrophosphatase protein [Bacteroides fragilis YCH46] 
509219.1338 
YP_100466.1 337.9 imidazole glycerol-phosphate dehydratase/histidinol phosphatase 
[Bacteroides fragilis YCH46] 
506457.4955 
YP_099291.1 217.58 aminopeptidase [Bacteroides fragilis YCH46] 504455.6695 
YP_098189.1 380.02 hypothetical protein BF0904 [Bacteroides fragilis YCH46] 504033.1645 
YP_101433.1 240.69 30S ribosomal protein S11 [Bacteroides fragilis YCH46] 502750.825 
YP_211735.1 134.65 amino acid transferase [Bacteroides fragilis NCTC 9343] 495636.5386 
YP_097605.1 533.05 hemolysin A [Bacteroides fragilis YCH46] 491832.7663 
YP_098971.1 237.96 50S ribosomal protein L20 [Bacteroides fragilis YCH46] 491125.6955 
YP_100730.1 372.05 purine nucleoside phosphorylase [Bacteroides fragilis YCH46] 490356.8602 
YP_098267.1 602.81 flavoprotein [Bacteroides fragilis YCH46] 484733.3611 
YP_097848.1 171.91 5'-nucleotidase [Bacteroides fragilis YCH46] 478339.5262 
YP_098055.1 205.27 stationary phase survival protein SurE [Bacteroides fragilis YCH46] 476184.8985 
YP_212860.1 413.4 peptidase [Bacteroides fragilis NCTC 9343] 474134.8709 
YP_211343.1 328.24 surface antigen [Bacteroides fragilis NCTC 9343] 468762.3259 
YP_098008.1 178.75 aminopeptidase [Bacteroides fragilis YCH46] 466586.4231 
YP_212245.1 206.19 hypothetical protein BF2622 [Bacteroides fragilis NCTC 9343] 463300.6083 
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YP_101861.1 357.87 quinolinate synthetase [Bacteroides fragilis YCH46] 461809.6253 
YP_101270.1 219.74 Mrp/Nbp35 family ATP-binding protein [Bacteroides fragilis 
YCH46] 
459708.4507 
YP_097609.1 200.79 hypothetical protein BF0326 [Bacteroides fragilis YCH46] 459561.9328 
YP_213145.1 720.5 aconitate hydratase [Bacteroides fragilis NCTC 9343] 455260.2405 
YP_213305.1 354.45 aminotransferase [Bacteroides fragilis NCTC 9343] 444893.1457 
YP_098840.1 90.86 single-strand binding protein [Bacteroides fragilis YCH46] 441349.6306 
YP_101787.1 578.06 transcriptional regulator [Bacteroides fragilis YCH46] 436912.1258 
YP_100382.1 167.78 hypothetical protein BF3103 [Bacteroides fragilis YCH46] 434164.7074 
YP_211962.1 211.6 oxidoreductase [Bacteroides fragilis NCTC 9343] 431006.466 
YP_100408.1 168.76 dihydroorotase [Bacteroides fragilis YCH46] 422426.6787 
YP_099921.1 513.77 amidophosphoribosyltransferase [Bacteroides fragilis YCH46] 422193.9846 
YP_212331.1 282.59 ribonucleotide-diphosphate reductase subunit beta [Bacteroides 
fragilis NCTC 9343] 
420041.8952 
YP_211451.1 295.65 beta-galactosidase [Bacteroides fragilis NCTC 9343] 419465.4729 
YP_100467.1 84.42 histidinol-phosphate aminotransferase [Bacteroides fragilis 
YCH46] 
419055.8127 
YP_099136.1 216.55 glucose-6-phosphate 1-dehydrogenase [Bacteroides fragilis 
YCH46] 
418077.4059 
YP_212885.1 314.99 bacterioferritin-like protein [Bacteroides fragilis NCTC 9343] 416500.356 
ZP_07810793.1 186.71 conserved hypothetical protein [Bacteroides fragilis 3_1_12] 411212.0593 
YP_210407.1 594.23 hypothetical protein BF0704 [Bacteroides fragilis NCTC 9343] 410732.8736 
YP_211902.1 628.07 ribose-phosphate pyrophosphokinase [Bacteroides fragilis NCTC 
9343] 
408107.2562 
YP_211660.1 193.48 aminotransferase [Bacteroides fragilis NCTC 9343] 405109.5419 
YP_209759.1 211.44 iron transport receptor protein [Bacteroides fragilis NCTC 9343] 404731.5759 
YP_213864.1 371.07 FKBP-type peptidylprolyl isomerase [Bacteroides fragilis NCTC 
9343] 
399676.9425 
YP_101479.1 189.24 30S ribosomal protein S21 [Bacteroides fragilis YCH46] 394796.1851 
YP_100723.1 478.07 3-isopropylmalate dehydratase small subunit [Bacteroides fragilis 
YCH46] 
393845.2154 
YP_101162.1 203.25 glutathione peroxidase [Bacteroides fragilis YCH46] 391986.8826 
YP_100264.1 118.43 hypothetical protein BF2982 [Bacteroides fragilis YCH46] 390111.3973 
YP_101129.1 310.37 methylglyoxal synthase [Bacteroides fragilis YCH46] 385270.056 
YP_100454.1 316.75 thioredoxin [Bacteroides fragilis YCH46] 382717.0411 
YP_100025.1 97.59 hypothetical protein BF2741 [Bacteroides fragilis YCH46] 381659.7322 
YP_099935.1 399.81 anthranilate synthase component I [Bacteroides fragilis YCH46] 379449.6725 
YP_097550.1 379.77 ABC transporter ATP-binding protein [Bacteroides fragilis YCH46] 375342.5155 
YP_210158.1 338.34 hypothetical protein BF0436 [Bacteroides fragilis NCTC 9343] 374522.1622 
YP_099444.1 353.68 3-methyl-2-oxobutanoate hydroxymethyltransferase [Bacteroides 
fragilis YCH46] 
368650.9465 
YP_101492.1 360.06 L-asparaginase II [Bacteroides fragilis YCH46] 367660.1674 
YP_209891.1 297.29 outer membrane protein [Bacteroides fragilis NCTC 9343] 362159.3925 
YP_212863.1 180.13 hypothetical protein BF3250 [Bacteroides fragilis NCTC 9343] 358945.1765 
YP_100717.1 230.79 UDP-glucuronic acid epimerase [Bacteroides fragilis YCH46] 358106.5469 
YP_101179.1 408.89 methionyl-tRNA formyltransferase [Bacteroides fragilis YCH46] 356029.3866 
YP_210204.1 391.8 malate dehydrogenase [Bacteroides fragilis NCTC 9343] 355617.0374 
YP_211257.1 203.45 adenosylmethionine-8-amino-7-oxononanoate aminotransferase 
[Bacteroides fragilis NCTC 9343] 
355586.6289 
YP_101596.1 624.03 transcription elongation factor GreA [Bacteroides fragilis YCH46] 354476.7334 
YP_101750.1 133.7 ribosome-binding factor A [Bacteroides fragilis YCH46] 344944.8212 
YP_100983.1 177.55 hypothetical protein BF3706 [Bacteroides fragilis YCH46] 343873.6974 
249 
 
YP_100731.1 186.08 thiamine-monophosphate kinase [Bacteroides fragilis YCH46] 341664.8285 
YP_099839.1 297.4 GTP-binding protein LepA [Bacteroides fragilis YCH46] 338121.8613 
ZP_07809463.1 190.36 conserved hypothetical protein [Bacteroides fragilis 3_1_12] 328781.9452 
YP_211654.1 243.19 hypothetical protein BF2022 [Bacteroides fragilis NCTC 9343] 326856.9566 
YP_209848.1 521.84 deoxyribose-phosphate aldolase [Bacteroides fragilis NCTC 9343] 312227.3473 
YP_101818.1 129.33 carboxy-terminal processing protease [Bacteroides fragilis YCH46] 309927.1642 
YP_212850.1 222.43 hypothetical protein BF3237 [Bacteroides fragilis NCTC 9343] 309264.0826 
YP_099696.1 278.57 universal stress protein UspA [Bacteroides fragilis YCH46] 306991.7818 
YP_100497.1 216.15 thiol:disulfide interchange protein [Bacteroides fragilis YCH46] 304176.7317 
YP_099024.1 383.67 heat shock protein GrpE [Bacteroides fragilis YCH46] 304006.0864 
YP_101437.1 139.95 methionine aminopeptidase [Bacteroides fragilis YCH46] 303193.4545 
ZP_07807614.1 291.89 peptide chain release factor 1 [Bacteroides fragilis 3_1_12] 302340.8378 
YP_210609.1 239.64 FNR-like protein [Bacteroides fragilis NCTC 9343] 295920.411 
YP_212290.1 539.68 alcohol dehydrogenase [Bacteroides fragilis NCTC 9343] 290527.6629 
YP_100530.1 495.86 phosphoglyceromutase [Bacteroides fragilis YCH46] 290236.9168 
YP_099545.1 238.04 phosphodiesterase I [Bacteroides fragilis YCH46] 289909.6865 
YP_100597.1 205.34 hypothetical protein BF3319 [Bacteroides fragilis YCH46] 287945.4839 
YP_101389.1 377.58 cyclophilin type peptidyl-prolyl cis-trans isomerase [Bacteroides 
fragilis YCH46] 
287625.3118 
YP_097591.1 195.95 UDP-N-acetylmuramoylalanine--D-glutamate ligase [Bacteroides 
fragilis YCH46] 
283942.8164 
YP_101036.1 223.44 acyl-ACP thioesterase [Bacteroides fragilis YCH46] 279123.3613 
YP_210148.1 340.52 alkaline phosphatase [Bacteroides fragilis NCTC 9343] 274983.2914 
YP_097607.1 111.82 deoxyuridine 5'-triphosphate nucleotidohydrolase [Bacteroides 
fragilis YCH46] 
274772.3528 
YP_212295.1 234.82 indole-3-glycerol phosphate synthase [Bacteroides fragilis NCTC 
9343] 
272129.4107 
YP_100976.1 89.91 1-deoxy-D-xylulose 5-phosphate reductoisomerase [Bacteroides 
fragilis YCH46] 
270796.9882 
YP_100397.1 195.29 xanthan lyase [Bacteroides fragilis YCH46] 270207.0626 
YP_101781.1 170.82 UDP-N-acetyl-D-mannosamine dehydrogenase [Bacteroides 
fragilis YCH46] 
269726.3932 
YP_101691.1 356.5 DNA topoisomerase I [Bacteroides fragilis YCH46] 266657.5242 
YP_098598.1 84.51 haloacid dehalogenase [Bacteroides fragilis YCH46] 265431.0795 
YP_098364.1 177.35 4-hydroxythreonine-4-phosphate dehydrogenase [Bacteroides 
fragilis YCH46] 
264675.7635 
YP_100026.1 293.08 RNA polymerase sigma factor RpoD [Bacteroides fragilis YCH46] 262749.5482 
ZP_07809230.1 664.26 ribose-phosphate pyrophosphokinase [Bacteroides fragilis 3_1_12] 261188.9022 
YP_097656.1 147.46 long-chain-fatty-acid-CoA ligase [Bacteroides fragilis YCH46] 257209.0406 
YP_100042.1 470.35 glutaminyl-tRNA synthetase [Bacteroides fragilis YCH46] 254026.2875 
YP_098602.1 227 naphthoate synthase [Bacteroides fragilis YCH46] 252769.4027 
YP_098270.1 178.05 hypothetical protein BF0986 [Bacteroides fragilis YCH46] 252181.2913 
YP_212683.1 128.93 hypothetical protein BF3070 [Bacteroides fragilis NCTC 9343] 251660.508 
YP_211281.1 146.33 hypothetical protein BF1643 [Bacteroides fragilis NCTC 9343] 251072.0645 
YP_099164.1 278.51 glycerate dehydrogenase [Bacteroides fragilis YCH46] 249910.4603 
YP_101012.1 151.17 transcriptional regulator [Bacteroides fragilis YCH46] 248847.8942 
YP_100391.1 190.19 hypothetical protein BF3112 [Bacteroides fragilis YCH46] 248398.3007 
YP_098870.1 201.17 hypothetical protein BF1586 [Bacteroides fragilis YCH46] 248202.6379 
YP_098074.1 213.37 arginine/ornithine transport system ATPase [Bacteroides fragilis 
YCH46] 
245547.0853 
YP_213028.1 113.95 DNA-binding protein [Bacteroides fragilis NCTC 9343] 243651.0846 
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YP_212572.1 133.65 hypothetical protein BF2958 [Bacteroides fragilis NCTC 9343] 240925.715 
YP_100806.1 294.2 pyruvate carboxylase subunit A [Bacteroides fragilis YCH46] 232572.2861 
YP_097811.1 239.1 acetyl-coenzyme A synthetase [Bacteroides fragilis YCH46] 228045.9193 
ZP_07811021.1 134.58 conserved hypothetical protein [Bacteroides fragilis 3_1_12] 228022.9089 
YP_099886.1 304.07 CTP synthetase [Bacteroides fragilis YCH46] 227111.5428 
YP_098286.1 544.83 glycogen synthase [Bacteroides fragilis YCH46] 223998.3584 
YP_099524.1 75.17 1,4-alpha-glucan branching enzyme [Bacteroides fragilis YCH46] 223346.187 
YP_211315.1 187.47 sulfate adenylyltransferase [Bacteroides fragilis NCTC 9343] 222567.5881 
ZP_07810591.1 84.93 thioredoxin [Bacteroides fragilis 3_1_12] 220629.1625 
YP_101234.1 178.01 hypothetical protein BF3958 [Bacteroides fragilis YCH46] 218884.8498 
YP_101068.1 130.51 chorismate synthase [Bacteroides fragilis YCH46] 217001.4318 
YP_212643.1 382.65 histidinol dehydrogenase [Bacteroides fragilis NCTC 9343] 216960.9834 
ZP_07809999.1 147.38 conserved hypothetical protein [Bacteroides fragilis 3_1_12] 214998.4943 
YP_101798.1 163.45 hypothetical protein BF4527 [Bacteroides fragilis YCH46] 214573.65 
ZP_07810468.1 124.43 imidazole glycerol phosphate synthase subunit hisF [Bacteroides 
fragilis 3_1_12] 
213209.2853 
YP_209852.1 207.37 adenine phosphoribosyltransferase [Bacteroides fragilis NCTC 
9343] 
211529.8044 
YP_098747.1 159.76 hypothetical protein BF1462 [Bacteroides fragilis YCH46] 210212.716 
YP_100036.1 146.13 riboflavin synthase subunit alpha [Bacteroides fragilis YCH46] 209760.5732 
YP_097657.1 257.33 peptide chain release factor 2 [Bacteroides fragilis YCH46] 209240.1142 
YP_101239.1 140.16 ThiJ family intracellular protease [Bacteroides fragilis YCH46] 207463.8942 
YP_211347.1 117.6 LPS-related regulatory protein [Bacteroides fragilis NCTC 9343] 206414.8975 
YP_098028.1 254.31 3-dehydroquinate synthase [Bacteroides fragilis YCH46] 199619.3458 
YP_099317.1 84.63 xylanase [Bacteroides fragilis YCH46] 198833.3266 
YP_213475.1 226.06 ATP-dependent Clp protease proteolytic subunit [Bacteroides 
fragilis NCTC 9343] 
196140.4637 
YP_210443.1 212.68 UDP-ManNAc dehydrogenase [Bacteroides fragilis NCTC 9343] 195091.847 
YP_099578.1 326.53 UDP-glucose 6-dehydrogenase [Bacteroides fragilis YCH46] 192803.8737 
YP_098192.1 113.34 UDP-3-O-[3-hydroxymyristoyl] glucosamine N-acyltransferase 
[Bacteroides fragilis YCH46] 
192495.1459 
YP_098960.1 110.85 hypothetical protein BF1679 [Bacteroides fragilis YCH46] 191708.7142 
YP_100711.1 271.55 hypothetical protein BF3434 [Bacteroides fragilis YCH46] 190882.4826 
YP_101765.1 159.04 acetyl-CoA synthetase [Bacteroides fragilis YCH46] 189818.49 
YP_101619.1 119.09 haloacid dehalogenase [Bacteroides fragilis YCH46] 189099.3613 
YP_101282.1 308.56 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase 
[Bacteroides fragilis YCH46] 
188598.9336 
YP_100471.1 179.81 hypothetical protein BF3192 [Bacteroides fragilis YCH46] 185756.5696 
YP_101635.1 131.1 glycine cleavage system protein H [Bacteroides fragilis YCH46] 183677.3365 
YP_209844.1 90.41 DNA polymerase I [Bacteroides fragilis NCTC 9343] 183371.0251 
YP_101436.1 216.21 translation initiation factor IF-1 [Bacteroides fragilis YCH46] 182245.9787 
YP_099170.1 80.65 hypothetical protein BF1888 [Bacteroides fragilis YCH46] 181497.7365 
YP_101450.1 219.41 50S ribosomal protein L29 [Bacteroides fragilis YCH46] 181483.3991 
YP_211282.1 182.47 hypothetical protein BF1644 [Bacteroides fragilis NCTC 9343] 179076.1672 
YP_213246.1 81.41 hypothetical protein BF3653 [Bacteroides fragilis NCTC 9343] 177273.8363 
YP_210140.1 105.67 hypothetical protein BF0416 [Bacteroides fragilis NCTC 9343] 176971.0191 
YP_099813.1 117.06 thiazole synthase [Bacteroides fragilis YCH46] 175917.5822 
YP_098616.1 270.65 non-specific DNA-binding protein Dps [Bacteroides fragilis YCH46] 175065.8859 
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YP_100573.1 152.25 alpha-amylase [Bacteroides fragilis YCH46] 171623.1094 
YP_211101.1 365.91 aspartate aminotransferase [Bacteroides fragilis NCTC 9343] 170324.5486 
YP_099538.1 308.92 succinyl-CoA synthetase subunit beta [Bacteroides fragilis YCH46] 168155.8285 
YP_209762.1 350.93 L-aspartate oxidase [Bacteroides fragilis NCTC 9343] 167742.3201 
YP_098177.1 179.28 bifunctional UDP-N-acetylmuramoyl-tripeptide:D-alanyl-D-alanine 
ligase/alanine racemase [Bacteroides fragilis YCH46] 
167573.0455 
YP_210416.1 186.02 hypothetical protein BF0713 [Bacteroides fragilis NCTC 9343] 167512.4643 
YP_101543.1 128.72 hypothetical protein BF4268 [Bacteroides fragilis YCH46] 166982.7073 
YP_101300.1 98.54 hypothetical protein BF4024 [Bacteroides fragilis YCH46] 165259.3923 
YP_210420.1 67.15 hypothetical protein BF0717 [Bacteroides fragilis NCTC 9343] 163543.1963 
YP_097847.1 197.84 5'-nucleotidase [Bacteroides fragilis YCH46] 160904.5772 
YP_101841.1 361.5 ribonuclease R [Bacteroides fragilis YCH46] 160697.2032 
YP_101851.1 240.4 oxidoreductase [Bacteroides fragilis YCH46] 157983.9282 
YP_098190.1 219.04 UDP-N-acetylglucosamine acyltransferase [Bacteroides fragilis 
YCH46] 
157758.5244 
YP_099102.1 176.35 long-chain-fatty-acid-CoA ligase [Bacteroides fragilis YCH46] 156840.8953 
YP_097522.1 155.23 arginine decarboxylase [Bacteroides fragilis YCH46] 155263.7435 
YP_213340.1 56.85 hypothetical protein BF3750 [Bacteroides fragilis NCTC 9343] 153576.5623 
YP_100979.1 155.94 UDP-N-acetylglucosamine 1-carboxyvinyltransferase [Bacteroides 
fragilis YCH46] 
153038.2637 
YP_213288.1 178.49 transcriptional regulator [Bacteroides fragilis NCTC 9343] 152732.0074 
YP_101659.1 237.8 hypothetical protein BF4387 [Bacteroides fragilis YCH46] 152299.3983 
YP_212755.1 226.37 hypothetical protein BF3142 [Bacteroides fragilis NCTC 9343] 151931.1229 
ZP_07807995.1 106.23 peptidase [Bacteroides fragilis 3_1_12] 146689.1382 
YP_212952.1 117.69 beta-lactamase [Bacteroides fragilis NCTC 9343] 145821.6316 
ZP_07809338.1 81.97 AMP nucleosidase [Bacteroides fragilis 3_1_12] 144870.5651 
YP_099683.1 425.49 dihydroorotate dehydrogenase 1B [Bacteroides fragilis YCH46] 144238.2852 
YP_100808.1 251.97 propionyl-CoA carboxylase subunit beta [Bacteroides fragilis 
YCH46] 
143939.1259 
YP_100018.1 113.17 ATP synthase subunit E [Bacteroides fragilis YCH46] 143723.154 
YP_211301.1 331.96 aldose 1-epimerase [Bacteroides fragilis NCTC 9343] 143048.3636 
YP_100558.1 70.59 hypothetical protein BF3280 [Bacteroides fragilis YCH46] 142083.7366 
YP_209709.1 152.31 putative ParA-related protein [Bacteroides fragilis NCTC 9343] 138595.4684 
YP_098976.1 126.76 indolepyruvate oxidoreductase subunit IorA [Bacteroides fragilis 
YCH46] 
134786.2113 
YP_097548.1 112.08 cysteine desulfurase [Bacteroides fragilis YCH46] 131284.9143 
YP_101133.1 168.27 long-chain-fatty-acid-CoA ligase [Bacteroides fragilis YCH46] 129778.3051 
YP_209950.1 280.99 L-fucose isomerase [Bacteroides fragilis NCTC 9343] 129738.1122 
YP_212985.1 196.53 bifunctional methionine sulfoxide reductase A/B [Bacteroides 
fragilis NCTC 9343] 
129714.889 
YP_211923.1 146.02 hypothetical protein BF2301 [Bacteroides fragilis NCTC 9343] 129162.1783 
YP_098332.1 157.39 nucleoside triphosphate pyrophosphohydrolase [Bacteroides 
fragilis YCH46] 
126205.4618 
YP_212043.1 203.03 hypothetical protein BF2420 [Bacteroides fragilis NCTC 9343] 125124.7239 
YP_099523.1 130.46 hypothetical protein BF2242 [Bacteroides fragilis YCH46] 119811.2226 
ZP_07811547.1 139.9 phosphoribosylaminoimidazole carboxylase [Bacteroides fragilis 
3_1_12] 
117849.6269 
YP_212681.1 118.94 hypothetical protein BF3068 [Bacteroides fragilis NCTC 9343] 117155.1426 
YP_213738.1 186.6 PfkB family carbohydrate kinase [Bacteroides fragilis NCTC 9343] 116314.9147 
YP_099497.1 123.45 hypothetical protein BF2216 [Bacteroides fragilis YCH46] 114020.5909 
YP_098317.1 205.34 DNA translocase FtsK [Bacteroides fragilis YCH46] 114011.7379 
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YP_098321.1 127.78 Crp/Fnr family transcriptional regulator [Bacteroides fragilis 
YCH46] 
113600.376 
YP_210157.1 356.54 D-alanyl-alanine synthetase A [Bacteroides fragilis NCTC 9343] 113374.8922 
YP_100981.1 157.9 glycoprotease [Bacteroides fragilis YCH46] 112265.7767 
YP_210566.1 107.82 hypothetical protein BF0871 [Bacteroides fragilis NCTC 9343] 111242.2713 
YP_209838.1 326.05 methylase [Bacteroides fragilis NCTC 9343] 111224.1477 
YP_101376.1 138.21 rod shape-determining protein MreB [Bacteroides fragilis YCH46] 108514.4387 
YP_098401.1 154.79 TonB-dependent outer membrane receptor protein [Bacteroides 
fragilis YCH46] 
108275.2122 
YP_213389.1 309.54 outer membrane protein [Bacteroides fragilis NCTC 9343] 108142.6012 
YP_098152.1 65.55 NADH dehydrogenase I chain D [Bacteroides fragilis YCH46] 107032.9538 
YP_097593.1 185.47 UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate 
ligase [Bacteroides fragilis YCH46] 
105075.0413 
YP_098284.1 88.46 alpha-amylase [Bacteroides fragilis YCH46] 104566.3082 
YP_097459.1 162.15 hypothetical protein BF0176 [Bacteroides fragilis YCH46] 102566.8001 
YP_098318.1 82.29 hypothetical protein BF1034 [Bacteroides fragilis YCH46] 100543.241 
YP_097538.1 121.77 L-fuculose-1-phosphate aldolase [Bacteroides fragilis YCH46] 100380.2362 
YP_210647.1 338.87 glutamine synthetase [Bacteroides fragilis NCTC 9343] 98857.5689 
YP_098361.1 120.21 peptidyl-prolyl cis-trans isomerase [Bacteroides fragilis YCH46] 98400.14247 
YP_098853.1 94.85 outer membrane vitamin B12 receptor protein [Bacteroides fragilis 
YCH46] 
98127.49063 
YP_210325.1 115.91 ribosome-associated GTPase [Bacteroides fragilis NCTC 9343] 96535.76674 
YP_099972.1 140.57 TonB-dependent receptor [Bacteroides fragilis YCH46] 96106.06983 
YP_213221.1 158.6 hypothetical protein BF3627 [Bacteroides fragilis NCTC 9343] 93522.93923 
YP_212044.1 198.96 hypothetical protein BF2421 [Bacteroides fragilis NCTC 9343] 93094.49102 
YP_098316.1 84.87 hypothetical protein BF1032 [Bacteroides fragilis YCH46] 91545.3986 
YP_101836.1 91.26 hypothetical protein BF4565 [Bacteroides fragilis YCH46] 90636.30743 
YP_099694.1 297.21 DNA gyrase A subunit [Bacteroides fragilis YCH46] 89362.76282 
YP_098970.1 86.29 50S ribosomal protein L35 [Bacteroides fragilis YCH46] 88887.18548 
YP_100375.1 216.84 hypothetical protein BF3096 [Bacteroides fragilis YCH46] 87337.31822 
YP_100456.1 83.64 hypothetical protein BF3177 [Bacteroides fragilis YCH46] 85784.47146 
YP_097794.1 72.69 hypothetical protein BF0511 [Bacteroides fragilis YCH46] 83899.78185 
YP_097813.1 97.11 pyrroline-5-carboxylate reductase [Bacteroides fragilis YCH46] 83373.86337 
YP_100655.1 110.71 molecular chaperone DnaJ [Bacteroides fragilis YCH46] 82283.98841 
YP_100564.1 59.58 carbonic anhydrase [Bacteroides fragilis YCH46] 82258.80689 
ZP_07809488.1 109.31 polysaccharide biosynthesis protein CapD [Bacteroides fragilis 
3_1_12] 
81215.78843 
YP_099697.1 173.52 hypothetical protein BF2414 [Bacteroides fragilis YCH46] 79442.32574 
YP_098949.1 108.44 adenylylsulfate kinase [Bacteroides fragilis YCH46] 76994.65637 
YP_211652.1 84.16 hypothetical protein BF2020 [Bacteroides fragilis NCTC 9343] 76665.64662 
YP_098525.1 106.85 endonuclease IV [Bacteroides fragilis YCH46] 75679.1021 
YP_099504.1 66.03 3-deoxy-manno-octulosonate cytidylyltransferase [Bacteroides 
fragilis YCH46] 
74694.30042 
YP_211384.1 206.1 hypothetical protein BF1748 [Bacteroides fragilis NCTC 9343] 74642.21321 
YP_101410.1 97.62 MotA/TolQ/ExbB proton channel [Bacteroides fragilis YCH46] 73910.51366 
YP_100969.1 96.63 anaerobic ribonucleoside triphosphate reductase [Bacteroides 
fragilis YCH46] 
70875.31446 
YP_101218.1 256.03 prephenate dehydratase [Bacteroides fragilis YCH46] 67886.91118 
YP_101835.1 171.57 collagenase [Bacteroides fragilis YCH46] 67681.38419 
YP_213286.1 234.39 haloacid dehalogenase [Bacteroides fragilis NCTC 9343] 67225.97775 
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YP_099441.1 150.18 phosphatase [Bacteroides fragilis YCH46] 67039.27703 
YP_100993.1 248.33 two-component system response regulator [Bacteroides fragilis 
YCH46] 
66959.86984 
YP_100707.1 94.48 cysteine synthase A [Bacteroides fragilis YCH46] 65632.14449 
YP_098950.1 78.23 sulfate adenylyltransferase subunit 2 [Bacteroides fragilis YCH46] 64555.60089 
ZP_07807931.1 59.42 amidophosphoribosyltransferase [Bacteroides fragilis 3_1_12] 61885.95312 
YP_099801.1 90.33 precorrin-3B C17-methyltransferase [Bacteroides fragilis YCH46] 60945.68473 
YP_098900.1 218.17 dihydrolipoamide dehydrogenase [Bacteroides fragilis YCH46] 60688.13863 
YP_098917.1 155.55 cytidine/deoxycytidylate deaminase [Bacteroides fragilis YCH46] 57054.54588 
YP_099818.1 79.74 thiamine phosphate pyrophosphorylase [Bacteroides fragilis 
YCH46] 
56298.97063 
ZP_07808207.1 236.4 histidine decarboxylase [Bacteroides fragilis 3_1_12] 56216.90051 
ZP_07809203.1 138.47 formate-tetrahydrofolate ligase [Bacteroides fragilis 3_1_12] 55032.19555 
YP_098987.1 58.67 N-acetylneuraminate lyase [Bacteroides fragilis YCH46] 54818.15086 
YP_100230.1 97.12 hypothetical protein BF2948 [Bacteroides fragilis YCH46] 54309.12663 
YP_098052.1 67.84 chromosome partitioning protein ParB [Bacteroides fragilis YCH46] 54075.20782 
YP_100037.1 185.64 phosphate uptake transcriptional regulator [Bacteroides fragilis 
YCH46] 
53400.62206 
ZP_07809888.1 127.58 argininosuccinate lyase [Bacteroides fragilis 3_1_12] 53110.83634 
YP_098947.1 110.5 sulfite synthesis pathway protein CysQ [Bacteroides fragilis 
YCH46] 
51824.42491 
YP_097470.1 159.54 hypothetical protein BF0187 [Bacteroides fragilis YCH46] 49837.81672 
YP_098744.1 103.07 D-lactate dehydrogenase [Bacteroides fragilis YCH46] 49711.45628 
YP_211170.1 180 hypothetical protein BF1525 [Bacteroides fragilis NCTC 9343] 49599.38495 
YP_212165.1 86.93 transport-like protein [Bacteroides fragilis NCTC 9343] 48625.96616 
YP_100473.1 134.71 hypothetical protein BF3194 [Bacteroides fragilis YCH46] 47594.56169 
YP_097781.1 232.98 gamma-glutamyl phosphate reductase [Bacteroides fragilis 
YCH46] 
46571.01868 
YP_101210.1 134.54 hypothetical protein BF3934 [Bacteroides fragilis YCH46] 46459.01545 
ZP_07811550.1 112.18 RNA polymerase sigma-54 [Bacteroides fragilis 3_1_12] 46265.74436 
YP_100331.1 114.28 ATP-binding protein involved in cell division [Bacteroides fragilis 
YCH46] 
45537.5532 
YP_211653.1 78.24 hypothetical protein BF2021 [Bacteroides fragilis NCTC 9343] 45387.8524 
YP_212176.1 162.79 hexokinase [Bacteroides fragilis NCTC 9343] 45065.77706 
YP_100260.1 129.89 DNA repair protein RecN [Bacteroides fragilis YCH46] 43454.40921 
YP_210497.1 93.87 phosphoglycolate phosphatase [Bacteroides fragilis NCTC 9343] 43100.52119 
ZP_07808299.1 171.12 ABC transporter ATP-binding protein [Bacteroides fragilis 3_1_12] 42803.32724 
YP_099137.1 96.38 6-phosphogluconolactonase [Bacteroides fragilis YCH46] 40785.26479 
YP_212116.1 132.01 negative regulator of genetic competence [Bacteroides fragilis 
NCTC 9343] 
39752.93177 
YP_100870.1 54.91 electron transport protein [Bacteroides fragilis YCH46] 37414.24777 
YP_212109.1 174.49 DNA ligase [Bacteroides fragilis NCTC 9343] 37153.25372 
YP_098213.1 170.93 hypothetical protein BF0928 [Bacteroides fragilis YCH46] 35876.53392 
YP_099447.1 112.8 GTP pyrophosphokinase [Bacteroides fragilis YCH46] 35219.89741 
YP_097375.1 206.23 octaprenyl-diphosphate synthase [Bacteroides fragilis YCH46] 34237.38566 
YP_099115.1 83.24 2-aminoethylphosphonate pyruvate aminotransferase [Bacteroides 
fragilis YCH46] 
33844.53152 
YP_098060.1 98.28 hypothetical protein BF0775 [Bacteroides fragilis YCH46] 32702.39773 
YP_098353.1 82.01 alkaline phosphatase [Bacteroides fragilis YCH46] 30878.96035 





ZP_07811952.1 117.17 propionyl-CoA carboxylase alpha polypeptide [Bacteroides fragilis 
3_1_12] 
28962.06411 
YP_097570.1 73.29 alpha-galactosidase [Bacteroides fragilis YCH46] 28930.02806 
YP_097812.1 168.73 transcriptional regulator [Bacteroides fragilis YCH46] 28193.11323 
YP_097881.1 88.11 homoserine O-succinyltransferase [Bacteroides fragilis YCH46] 27647.00789 
YP_097311.1 164.85 (dimethylallyl)adenosine tRNA methylthiotransferase [Bacteroides 
fragilis YCH46] 
27023.36075 
YP_098498.1 130.57 bacterioferritin co-migratory protein [Bacteroides fragilis YCH46] 26341.10433 
YP_101780.1 172.54 UDP-N-acetylglucosamine 2-epimerase [Bacteroides fragilis 
YCH46] 
25849.52317 
YP_212581.1 134.7 5-methyltetrahydrofolate--homocysteine methyltransferase 
[Bacteroides fragilis NCTC 9343] 
23940.97527 
ZP_07810286.1 80.35 DKI isomerase 1 [Bacteroides fragilis 3_1_12] 22775.20094 
YP_098372.1 48.71 sugar kinase [Bacteroides fragilis YCH46] 22267.16075 
YP_100994.1 76.5 ABC transporter ATP-binding protein [Bacteroides fragilis YCH46] 22253.73647 
YP_209876.1 103.53 fructokinase [Bacteroides fragilis NCTC 9343] 20499.46861 
YP_098455.1 84.36 tRNA modification GTPase TrmE [Bacteroides fragilis YCH46] 20440.81946 
YP_099918.1 55.57 thioredoxin [Bacteroides fragilis YCH46] 18985.75532 
YP_097596.1 78.2 S-adenosyl-methyltransferase MraW [Bacteroides fragilis YCH46] 17900.73237 
ZP_07811175.1 238.7 cytidylate kinase [Bacteroides fragilis 3_1_12] 17357.89166 
YP_101613.1 63.08 hypothetical protein BF4341 [Bacteroides fragilis YCH46] 16696.35234 
YP_101859.1 64.99 deoxyribonucleoside-triphosphatase [Bacteroides fragilis YCH46] 16648.71792 
YP_101834.1 77.74 hypothetical protein BF4563 [Bacteroides fragilis YCH46] 15814.77689 
YP_211896.1 68.26 hypothetical protein BF2273 [Bacteroides fragilis NCTC 9343] 14889.14793 
YP_100569.1 102.11 biotin carboxyl carrier protein [Bacteroides fragilis YCH46] 13375.1994 
YP_098275.1 65.71 O-acetylhomoserine sulfhydrylase [Bacteroides fragilis YCH46] 11203.8136 
YP_211924.1 100.36 hypothetical protein BF2302 [Bacteroides fragilis NCTC 9343] 10999.63493 
YP_098779.1 167.09 cytidine deaminase [Bacteroides fragilis YCH46] 10280.42216 
ZP_07811394.1 69.64 conserved hypothetical protein [Bacteroides fragilis 3_1_12] 10251.62692 
YP_099530.1 97.75 glutamine synthetase I [Bacteroides fragilis YCH46] 10201.95059 
YP_098022.1 86.86 3-phosphoshikimate 1-carboxyvinyltransferase [Bacteroides fragilis 
YCH46] 
10121.96353 
YP_100579.1 105.8 50S ribosomal protein L31 [Bacteroides fragilis YCH46] 9461.820064 
YP_098160.1 79.4 hypothetical protein BF0875 [Bacteroides fragilis YCH46] 9235.033125 
YP_100878.1 51.92 Cu2+ homeostasis protein CutC [Bacteroides fragilis YCH46] 6480.779946 
YP_100943.1 108.17 hypothetical protein BF3666 [Bacteroides fragilis YCH46] 5895.34273 
YP_213144.1 133.16 isocitrate dehydrogenase [Bacteroides fragilis NCTC 9343] 5748.306096 
YP_099462.1 72.68 thioredoxin [Bacteroides fragilis YCH46] 5614.987901 
ZP_07809987.1 67.73 topoisomerase IV subunit A [Bacteroides fragilis 3_1_12] 5524.645358 
ZP_07810427.1 141.77 conserved hypothetical protein [Bacteroides fragilis 3_1_12] 4608.395189 
YP_211379.1 176.87 hypothetical protein BF1743 [Bacteroides fragilis NCTC 9343] 3941.277243 
YP_099537.1 100.27 succinyl-CoA synthetase alpha chain [Bacteroides fragilis YCH46] 3769.051072 
ZP_07807476.1 105.4 GTP pyrophosphokinase [Bacteroides fragilis 3_1_12] 1677.205995 
YP_211521.1 93.38 GDP-L-fucose synthetase [Bacteroides fragilis NCTC 9343] 337.2817895 
Table A.VII.ii The 695 proteins identified using 2 or more peptides but which are not significantly 
enriched in the OMV, sorted according to abundance. Shown are the accession number, Mascot 
confidence score, Mascot predicted identity and the average raw abundance (across the 3 OMV 
samples). All of these proteins were also identified in the PP samples. 
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Appendix VIII - Growth curves of S. enterica Typhimurium incubated with B. 
fragilis OMV 
 
Growth curves were conducted as described in section 2.9.1. Cfu/ml for each sample at each time 
point, along with mean and standard deviation, are listed in Table A.VIII.i (first experiment, 5.2.1) and 
Table A.VIII.ii (second experiment 5.2.2). T-tests were used to determine the statistical significance of 
the differences between the cfu/ml of different samples at each time point. The fold difference and 
calculated p values for each comparison are listed in Table A.VIII.iii (first experiment) and Table 
A.VIII.iv (second experiment). 
 
Cfu/ml in the triplicate samples Mean Standard 
Deviation 
 
PBS 1 PBS 2 PBS 3  
  
T0 6900.00 9600.00 11800.00 9433.33 2454.25 
T2 26000.00 24000.00 33000.00 27666.67 4725.82 
T4 87000.00 104000.00 159000.00 116666.67 37634.20 
T6 320000.00 420000.00 460000.00 400000.00 72111.03 
T8 810000.00 970000.00 1120000.00 966666.67 155026.88 
      
 
WT OMV 1 WT OMV 2 WT OMV 3 
  
T0 10100.00 13500.00 9200.00 10933.33 2267.89 
T2 8000.00 11000.00 7000.00 8666.67 2081.67 
T4 29000.00 34000.00 26000.00 29666.67 4041.45 
T6 120000.00 190000.00 90000.00 133333.33 51316.01 
T8 450000.00 610000.00 320000.00 460000.00 145258.39 
      
 
ubb OMV 1 ubb OMV 2 ubb OMV 3 
  
T0 5600.00 9100.00 7700.00 7466.67 1761.628035 
T2 19000.00 29000.00 25000.00 24333.33 5033.222957 
T4 79000.00 113000.00 90000.00 94000.00 17349.35157 
T6 330000.00 520000.00 430000.00 426666.67 95043.84953 
T8 760000.00 1010000.00 840000.00 870000.00 127671.4533 
 









1 2 3 Mean SD 
2 70000 60000 100000 76666.66667 20816.66 
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4 330000 310000 360000 333333.3333 25166.11 
6 1500000 1600000 1100000 1400000 264575.1 
8 5000000 7000000 8000000 6666666.667 1527525 
10 13000000.00 11000000.00 11000000.00 11666666.67 1154701 
      
 
WT0.5 
    
 
1 2 3 Mean SD 
0 60000 50000 70000 60000 10000 
2 280000 210000 290000 260000 43588.99 
4 1400000 900000 1100000 1133333.333 251661.1 
6 7000000 3100000 5000000 5033333.333 1950214 
8 16000000 7000000 11000000 11333333.33 4509250 
      
 
WT1 
    
 
1 2 3 Mean SD 
0 80000 60000 90000 76666.66667 15275.25 
2 240000 170000 350000 253333.3333 90737.72 
4 800000 500000 1100000 800000 300000 
6 2500000 1600000 5000000 3033333.333 1761628 
8 9000000 6000000 16000000 10333333.33 5131601 
      
 
WT2 
    
 
1 2 3 Mean SD 
0 70000 70000 80000 73333.33333 5773.503 
2 160000 110000 190000 153333.3333 40414.52 
4 400000 400000 700000 500000 173205.1 
6 1800000 1400000 2600000 1933333.333 611010.1 
8 5000000 4000000 9000000 6000000 2645751 
      
 
WTg0.5 
    
 
1 2 3 Mean SD 
0 100000.00 100000.00 80000.00 93333.33 11547.01 
2 240000.00 220000.00 220000.00 226666.67 11547.01 
4 1100000.00 1400000.00 900000.00 1133333.33 251661.1 
6 4000000.00 7000000.00 4000000.00 5000000.00 1732051 
8 8000000.00 10000000.00 9000000.00 9000000.00 1000000 
      
 
WTg1 
    
 
1 2 3 Mean SD 
0 80000.00 70000.00 60000.00 70000.00 10000 
2 140000.00 90000.00 150000.00 126666.67 32145.5 
4 700000.00 320000.00 600000.00 540000.00 196977.2 
6 2100000.00 1000000.00 2500000.00 1866666.67 776745.3 
8 7000000.00 2600000.00 9000000.00 6200000.00 3274141 
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WTg2 
    
 
1 2 3 Mean SD 
0 60000.00 90000.00 100000.00 83333.33 20816.66 
2 40000.00 50000.00 60000.00 50000.00 10000 
4 160000.00 230000.00 240000.00 210000.00 43588.99 
6 350000.00 600000.00 800000.00 583333.33 225462.5 
8 1400000.00 2800000.00 3000000.00 2400000.00 871779.8 
      
 
pGB0.5 
    
 
1 2 3 Mean SD 
0 100000.00 60000.00 70000.00 76666.67 20816.66 
2 300000.00 250000.00 280000.00 276666.67 25166.11 
4 1400000.00 1200000.00 1400000.00 1333333.33 115470.1 
6 7000000.00 4000000.00 6000000.00 5666666.67 1527525 
8 15000000.00 10000000.00 11000000.00 12000000.00 2645751 
      
 
pGB1 
    
 
1 2 3 Mean SD 
0 50000.00 80000.00 90000.00 73333.33 20816.66 
2 260000.00 230000.00 290000.00 260000.00 30000 
4 900000.00 800000.00 1100000.00 933333.33 152752.5 
6 4000000.00 1900000.00 7000000.00 4300000.00 2563201 
8 9000000.00 7000000.00 10000000.00 8666666.67 1527525 
      
 
pGB2 
    
 
1 2 3 Mean SD 
0 60000.00 100000.00 70000.00 76666.67 20816.66 
2 150000.00 210000.00 190000.00 183333.33 30550.5 
4 500000.00 1100000.00 900000.00 833333.33 305505 
6 1600000.00 4000000.00 3600000.00 3066666.67 1285820 
8 3000000.00 8000000.00 4000000.00 5000000.00 2645751 
      
 
ubb0.5 
    
 
1 2 3 Mean SD 
0 110000.00 80000.00 70000.00 86666.67 20816.66 
2 370000.00 360000.00 330000.00 353333.33 20816.66 
4 1900000.00 1700000.00 1400000.00 1666666.67 251661.1 
6 7000000.00 6000000.00 4000000.00 5666666.67 1527525 
8 13000000.00 10000000.00 8000000.00 10333333.33 2516611 
      
 
ubb1 
    
 
1 2 3 Mean SD 
0 90000.00 60000.00 80000.00 76666.67 15275.25 
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2 380000.00 270000.00 320000.00 323333.33 55075.71 
4 2000000.00 1300000.00 1900000.00 1733333.33 378593.9 
6 10000000.00 6000000.00 9000000.00 8333333.33 2081666 
8 13000000.00 11000000.00 14000000.00 12666666.67 1527525 
      
 
ubb2 
    
 
1 2 3 Mean SD 
0 80000.00 50000.00 80000.00 70000.00 17320.51 
2 350000.00 280000.00 330000.00 320000.00 36055.51 
4 1600000.00 1400000.00 1400000.00 1466666.67 115470.1 
6 8000000.00 6000000.00 9000000.00 7666666.67 1527525 
8 12000000.00 10000000.00 13000000.00 11666666.67 1527525 
 







Time Mean Con Mean Exp Fold Difference 
Con/Exp 
p value Significant? 
PBS and WT 0 9433.33 10933.33 0.86 0.2403 No 
 
2 27666.67 8666.67 3.19 0.0051 Yes 
 
4 116666.67 29666.67 3.93 0.0278 Yes 
 
6 400000.00 133333.33 3.00 0.0042 Yes 
 
8 966666.67 460000.00 2.10 0.0073 Yes 
PBS and Δubb 0 9433.33 7466.67 1.26 0.1643 No 
 
2 27666.67 24333.33 1.14 0.2251 No 
 
4 116666.67 94000.00 1.24 0.2088 No 
 
6 400000.00 426666.67 0.94 0.3599 No 
 
8 966666.67 870000.00 1.11 0.2265 No 
 
Table A.VIII.iii The T-test comparison of the samples from Table A.VIII.i, showing fold difference 










Time Mean Con Mean Exp Fold Diff 
(Exp/Con) 
p value Significant? 
PBS and WTg0.5 2 76666.67 93333.33 0.82 0.1545 No 
 
4 333333.33 226666.67 1.47 0.0042 Yes 
 
6 1400000.00 1133333.33 1.24 0.1374 No 
 
8 6666666.67 5000000.00 1.33 0.1402 No 
 
10 11666666.67 9000000.00 1.30 0.0200 Yes 
PBS and WTg1 2 76666.67 70000.00 1.10 0.3264 No 
 
4 333333.33 126666.67 2.63 0.0006 Yes 
 
6 1400000.00 540000.00 2.59 0.0064 Yes 
 
8 6666666.67 1866666.67 3.57 0.0086 Yes 
 
10 11666666.67 6200000.00 1.88 0.0443 Yes 
PBS and WTg2 2 76666.67 83333.33 0.92 0.3574 No 
 
4 333333.33 50000.00 6.67 0.0004 Yes 
 
6 1400000.00 210000.00 6.67 0.0071 Yes 
 
8 6666666.67 583333.33 11.43 0.0093 Yes 
 
10 11666666.67 2400000.00 4.86 0.0003 Yes 
PBS and WT0.5 2 76666.67 60000.00 1.28 0.1517 No 
 
4 333333.33 260000.00 1.28 0.0403 Yes 
 
6 1400000.00 1133333.33 1.24 0.1374 No 
 
8 6666666.67 5033333.33 1.32 0.1603 No 
 
10 11666666.67 11333333.33 1.03 0.4557 No 
PBS and WT1 2 76666.67 76666.67 1.00 0.5000 No 
 
4 333333.33 253333.33 1.32 0.1315 No 
 
6 1400000.00 800000.00 1.75 0.0306 Yes 
 
8 6666666.67 3033333.33 2.20 0.0277 Yes 
 
10 11666666.67 10333333.33 1.13 0.3500 No 
PBS and WT2 2 76666.67 73333.33 1.05 0.4057 No 
 
4 333333.33 153333.33 2.17 0.0026 Yes 
 
6 1400000.00 500000.00 2.80 0.0057 Yes 
 
8 6666666.67 1933333.33 3.45 0.0106 Yes 
 
10 11666666.67 6000000.00 1.94 0.0244 Yes 
PBS and pGB0.5 2 76666.67 76666.67 1.00 0.5000 No 
 
4 333333.33 276666.67 1.20 0.0255 Yes 
 
6 1400000.00 1333333.33 1.05 0.3592 No 
 
8 6666666.67 5666666.67 1.18 0.2338 No 
 
10 11666666.67 12000000.00 0.97 0.4277 No 
PBS and pGB1 2 76666.67 73333.33 1.05 0.4270 No 
 
4 333333.33 260000.00 1.28 0.0165 Yes 
 
6 1400000.00 933333.33 1.50 0.0361 Yes 
 
8 6666666.67 4300000.00 1.55 0.1282 No 
 
10 11666666.67 8666666.67 1.35 0.0288 Yes 
PBS and pGB2 2 76666.67 76666.67 1.00 0.5000 No 
 




6 1400000.00 833333.33 1.68 0.0367 Yes 
 
8 6666666.67 3066666.67 2.17 0.0184 Yes 
 
10 11666666.67 5000000.00 2.33 0.0166 Yes 
PBS and ubb0.5 2 76666.67 86666.67 0.88 0.2940 No 
 
4 333333.33 353333.33 0.94 0.1753 No 
 
6 1400000.00 1666666.67 0.84 0.1374 No 
 
8 6666666.67 5666666.67 1.18 0.2338 No 
 
10 11666666.67 10333333.33 1.13 0.2346 No 
PBS and ubb1 2 76666.67 76666.67 1.00 0.5000 No 
 
4 333333.33 323333.33 1.03 0.3973 No 
 
6 1400000.00 1733333.33 0.81 0.1434 No 
 
8 6666666.67 8333333.33 0.80 0.1657 No 
 
10 11666666.67 12666666.67 0.92 0.2102 No 
PBS and ubb2 2 76666.67 70000.00 1.10 0.3462 No 
 
4 333333.33 320000.00 1.04 0.3151 No 
 
6 1400000.00 1466666.67 0.95 0.3592 No 
 
8 6666666.67 7666666.67 0.87 0.2338 No 
 
10 11666666.67 11666666.67 1.00 0.5000 No 
       
PBS and WTg2 2 and 4 83333.33 50000.00 1.67 0.0457 Yes 
       
WT2 and WTg2 2 73333.33 83333.33 0.88 0.2485 No 
 
4 153333.33 50000.00 3.07 0.0203 Yes 
 
6 500000.00 210000.00 2.38 0.0466 Yes 
 
8 1933333.33 583333.33 3.31 0.0242 Yes 
 
10 6000000.00 2400000.00 2.50 0.0659 No 
       
WT2 and ubb2 2 70000.00 73333.33 0.95 0.3884 No 
 
4 320000.00 153333.33 2.09 0.0031 Yes 
 
6 1466666.67 500000.00 2.93 0.0011 Yes 
 
8 7666666.67 1933333.33 3.97 0.0066 Yes 
 
10 11666666.67 6000000.00 1.94 0.0223 Yes 
       
WT2 and pGB2 2 73333.33 76666.67 0.96 0.4057 No 
 
4 153333.33 183333.33 0.84 0.1835 No 
 
6 500000.00 833333.33 0.60 0.0970 No 
 
8 1933333.33 3066666.67 0.63 0.1329 No 
 
10 6000000.00 5000000.00 1.20 0.3337 No 
 
Table A.VIII.iii T-test comparisons of samples in Table A.VIII.ii, including fold difference between the 
samples, calculated p values and whether or not the difference is significant.  
